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Abstract 
There is considerable policy interest surrounding the introduction of 
interventions to support self care in the UK. Advocates of these interventions 
claim that patient outcomes are improved and costs to the health service could 
be reduced. 
This thesis critically reviews the published evidence around the cost- 
effectiveness of interventions to support self care, and uses the example of the 
Expert Patients programme (EPP) to analyse the cost-effectiveness of these 
interventions. An economic evaluation conducted alongside a Randomised 
Controlled Trial (RCT) of the EPP is considered as the starting point for the 
analysis. Further potentially relevant evidence is then incorporated including 
other UK based randomised trial evidence, non UK evidence and non- 
randomised evidence. The assumptions required for each of these models, as 
well as the impact of model selection on the adoption decision and the value of 
future research is considered in an explicit framework. 
The analyses above are conducted in the extra-welfarist tradition where 
"health" is considered to be the maximand in the decision makers' objective 
function. The inclusion of other outcomes that may not be incorporated in 
"health", such as levels of isolation and process measures, such as speed of 
access to health professionals, is also considered. How these additional 
outcomes could be incorporated into a cost-effectiveness framework is 
explored. 
The strengths and weaknesses of the analyses are discussed and 
recommendations for future research are presented. 
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Chapter 1. Economic evaluation of interventions to 
support self care 
1.1 Background 
Chronic conditions account for around two-thirds of the global burden of disease, ' 
with 32% of the adult population of Great Britain suffering from a long standing 
condition. 2 There is a consequent interest by policy makers to address the 
management of these conditions. In the UK, the National Health Service (NHS) 
policy for patients with chronic conditions who are at "low risk" has been to 
encourage these individuals to "self-care", 3 and this is considered central to the 
management of these conditions. 4 The Wanless report described self care as one 
of the principal determinants of efficiency of the NHS. 5 As a consequence, interest 
in the effectiveness of interventions to support individuals in their self care has 
increased in recent years. 6 The cost-effectiveness of these interventions has 
attracted less interest, and evidence in favour of the increased use of interventions 
to support self care has been based on poorly conducted studies generating 
unreliable conclusions. 7 
Self care has been defined as `the care taken by individuals towards their own 
health and well being: it comprises the actions they take to lead a healthy lifestyle; 
to meet their social, emotional and psychological needs; to care for their long-term 
condition; and to prevent further illness or accidents'. A range of interventions are 3 
available to support individuals to self care in a variety of settings and for a range 
of conditions or ailments. 3 
The NHS Plan identified self care as an important factor in providing a "patient 
8 centred health service". More recently a Department of Health report has claimed 
that supporting self care can "improve health outcomes [and], improve patient 
satisfaction", 3 while the roll-out of self care support programmes "will improve the 
length and quality of lives"9 and "could create a generation of patients empowered 
to take action to improve their health". 10 
12 
There are many interventions available to support or enhance self care. There is 
differing quality and quantity of evidence regarding their effectiveness. However, 
in a budget constrained system such as the National Health Service (NHS), it is 
important for these interventions to promote patients' self care or self management 
to be cost-effective as well as clinically effective; otherwise scarce resources will 
be used on these interventions that could be better spent elsewhere in the system. 
The use of economic evaluation as a discipline to tackle this constrained 
optimisation problem are described in the next two chapters. The methodological 
challenges associated with the use of economic evaluation depend upon the 
context in which the decision is to be addressed. For example, "Who decides 
what interventions are cost-effective, on behalf of whom, using which evidence? " 
These issues are discussed in more detail in the next section. 
1.2 The decision problem and economic evaluation 
The decision problem addressed in this thesis is to assess whether these 
interventions provide additional benefits that are worth paying for, relative to other 
appropriate comparators, in the budget constrained system of the UK NHS. 
Economic evaluation is an explicit methodology for addressing this decision 
problem. In order to establish the relative cost-effectiveness of interventions to 
support self care, it is necessary to explicitly estimate the incremental costs and 
effects of providing these interventions compared with suitable alternatives. 
X Z. 1 Who Is the Decision maker? 
The decision problem described above appears uncontroversial. However, it 
raises the question of who is the decision maker and where he/she receives 
his/her legitimacy from? Traditional welfarist economists would not require a 
decision maker as the sum of individual utilities is sufficient to determine the "best" 
option. The use of welfarist economics in the health sector has been questioned 
and the social decision making approach using extra-welfarist (or non-welfarist) 
concepts have become standard practice in economic evaluation. Simply put, this 
approach considers that the political process delivers an entity that can either act 
as a legitimate decision maker itself or delegate power to another body which then 
has a legitimate role. 
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1.22 What evidence exists atpresent for the decision maker? 
It is feasible that there is sufficient evidence to make a decision on the cost- 
effectiveness of interventions to support self care in the literature published to 
date. The decision problem stated above may be solved by examination of the 
existing literature if that literature consisted of reliable and relevant evidence using 
appropriate measures of outcome. 
t 23 Which outcomes shouldinforn the decision? 
Economic evaluations consider incremental costs and benefits of an 
intervention(s) compared to a suitable alternative. However, to be most useful for 
a decision maker facing the decision problem above, outcomes need to be 
comparable across conditions. This requires the use of a generic measure of 
health related quality of life, such as the quality-adjusted life-year (QALY). Where 
the analysis uses a non-generic (or disease specific) outcome measure, the 
decision maker may be faced with a range of outcomes that he/she is not familiar 
with or cannot value easily. While the intervention may improve patient outcomes 
as estimated by these clinical measures, if the intervention is also cost-additive, 
decision making becomes problematic. The limitation of generic instruments is 
that all the outcomes of interest may not be picked up by the instrument, either 
because it is not a health improvement or because the instrument is not designed 
(or sensitive enough) to detect certain health dimensions. 
424 What evidence should be used? 
A recurring theme of this thesis is the inclusion of "relevant" evidence and what 
constitutes relevance. The decision problem described above is focussed on the 
UK NHS. However, it is possible (or likely) that evidence from outside the UK 
could be of interest and should be used to inform the analysis and hence the 
decision problem. 
As well as different geographical locations, studies may be of varying quality, 
using different outcome measures, in different patient populations with a range of 
conditions and severity of conditions. Depending on the definition of relevance, all 
or none of these studies could be included. 
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1.3 Objectives 
The discussion above invites a series of objectives and research questions which 
are examined in the remainder of this thesis. These objectives and research 
questions are as follows: 
Q To identify the appropriate paradigms and forms of analysis for a cost- 
effectiveness study of a specific intervention to support self care 
Q To identify and critically appraise existing economic evaluations of 
interventions to support self care and identify appropriate methodology to 
inform a cost-effectiveness study of an intervention to support self care. 
Q To assess the cost-effectiveness analysis of one well-documented 
intervention designed to support self care. 
Q To incorporate evidence from another cost-effectiveness study based on a 
randomised controlled trial (RCT) conducted in the UK. 
0 To expand the evidence base on interventions to support self care to 
include evidence from non RCT data outside the UK. 
0 To expand the measure of outcome beyond health 
Q Examine the possibility of including expanded outcomes in cost- 
effectiveness analysis. 
1.3.1 Research questions 
Q What are the appropriate paradigms for the design conduct and analysis of 
economic evaluation? 
Q Does the existing evidence base provide sufficient evidence to answer the 
specified decision problem? 
Q What lessons can we learn from the existing literature to help in the design, 
conduct and analysis of economic evaluations of interventions to support 
self care? 
Q Does the incorporation of evidence from other sources impact on the 
results, conclusions and recommendations for future research? 
Q Should health always be the outcome of interest and how does the 
expansion of the outcome measure impact on the decision problem? 
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1.4 Structure of thesis 
Chapter 2 examines the schools of thought within economic evaluation. The 
distinction between welfarist and extra-welfarist position and the influence that the 
selection of paradigm may have on the design, conduct and analysis of economic 
evaluation is examined. Other controversies with the economic evaluation 
discipline including the statistical paradigm of choice, and the use of evidence 
synthesis in economic evaluation are also discussed. 
In Chapter 3 the existing literature on economic evaluation of self care support 
interventions is identified, reviewed and appraised. The quantity and quality of this 
evidence is used to assess whether there are any studies that may inform the 
decision problem presented above. In addition, this literature may provide lessons 
or recommendations for the future use of economic evaluation in self care support 
interventions. 
Chapter 4 uses the evidence of Chapters 2 and 3 to inform the design, conduct 
and analysis of a single trial based evaluation of an intervention to support self 
care, the Expert Patients Programme (EPP). The limitations of this single trial 
based approach, in terms of ignoring potentially relevant information are then 
discussed. 
Chapter 5 then extends the analysis of Chapter 4 by incorporating individual 
patient data from another UK based randomised controlled trial (RCT) of the 
intervention used in the EPP, while Chapter 6 extends the evidence base further 
by incorporating evidence from non-UK studies, including non RCT evidence. The 
impact these additional data have on results, conclusions and recommendations 
are discussed. 
Chapters 4,5 and 6 use a generic measure of outcome, the QALY, enabling 
decision makers to make judgements that are consistent across analyses. 
However, there is concern in some quarters that the QALY may not pick up all 
outcomes of interest. For the evaluation of interventions to support self care, other 
outcomes have been postulated as being important. The relative values of these 
16 
outcomes, as compared with health related quality of life, is presented as a 
Discrete Choice Experiment (DCE) in Chapter 7. 
The final chapter, Chapter 8, presents an overview and discussion of the previous 
chapters. The principal findings of each of the chapters are summarised, together 
with their respective strengths and weaknesses. The implications of each chapter 
for the decision problem are discussed and issues arising from this thesis that may 
form an agenda for future research in this area are also be presented. 
17 
Chapter 2. Prevailing concepts in economic evaluation 
2.1 Introduction 
Chapter 1 outlined the recent policy debate and the decision problem facing 
decision makers. Economic evaluation provides a methodology that informs the 
decision problem by establishing whether interventions to support self care are 
cost-effective (or which of these interventions are cost-effective) and should 
therefore be considered as providing value for money in a budget constrained 
system. However, economic evaluation is an evolving discipline and is not free 
from controversy. This chapter aims to describe ongoing controversies and 
competing paradigms within economic evaluation and their importance in 
addressing the decision problem. Inevitably, analysts must make choices between 
paradigms. The choice of paradigms is important. The conduct of the evaluation 
and analysis of data are dependent on the paradigm selected. This influences the 
results and conclusions of any analysis. Ultimately, the recommendations for both 
the decision to adopt a strategy/intervention and the related decision of whether to 
conduct more research can depend on the choice of paradigm. This chapter also 
seeks to justify the choices made between the various paradigms that will be used 
in the remainder of this thesis. 
This chapter commences with a brief summary of the requirement for economic 
evaluations of self care support interventions. The normative foundations on 
which economic evaluation are based is then discussed (including welfarism and 
extra-welfarism) together with limitations of each approach. The historical use of 
single trial based evaluations is described, and the potential limitations of this 
approach are considered. 
Finally, the analysis and interpretation of results of economic evaluation is 
considered in both Bayesian and frequentist paradigms and the use of statistical 
inference as a decision making tool is debated. 
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2.2 Economic evaluation in health care 
Health service decision makers in the UK and elsewhere are increasingly requiring 
evidence of cost-effectiveness before making the funding decision., 1 14 While their 
use has been primarily in the assessment of the cost-effectiveness of new 
pharmaceuticals, 15' 16 economic evaluation has an important role in the 
assessment of cost-effectiveness of health promotion programmes and 
intervention S. 12 
The burden of disease associated with chronic conditions was described in 
Chapter 1. There are potentially substantial implications (both costs and benefits) 
associated with the roll-out of large programmes to treat these conditions, such as 
the Expert Patients Programme (EPP), across the NHS. Given the size of the 
target population and the potential benefits and costs of rolling out such 
programmes, it is surprising that this intervention has not been subjected to 
rigorous evaluation previously. Nevertheless, this lack of rigorous evidence 
means that there is considerable potential for economic evaluation to be 
conducted in this sphere to assess both the cost-effectiveness of these 
interventions and the value of conducting further research in this area. 
However, economic evaluation requires a theoretical framework. Without an 
appropriate framework, it is not possible to deliver a consistent and useful product 
for decision makers. There is considerable debate around the appropriate 
framework for economic evaluation, and these are discussed below. 
2.3 Normative foundations of economic evaluation 
Though there are a number of theoretical "schools of thought" amongst health 
economists working in economic evaluation, the debate between welfarists and 
extra-welfarists is perhaps the most contentious. Though there is not complete 
consensus as to the contents of either school 17 the principal characteristics of the 
two paradigms are outlined briefly below. 
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2.21 We/fare economics, we/far/sin and economic evaluation 
Positive economics, which explains causes and effects in economic variables 
(such as price and demand) makes no value judgements, but is silent on 
recommending which policy/decision shou/dbe made. In contrast, welfare 
economics is normative in nature in that value judgements are incorporated and 
therefore allows the comparison of various states of the economy (or part thereof) 
and what it should look like. Welfare (or welfarist) economics is based on four 
central beliefs, 18,19 namely that individuals maximise their utility, that individuals 
are the best judges of their own utility (individual or consumer sovereignty), that 
utility is a consequence of behaviour and that utility information on/yis relevant in 
making decisions about what is best. This final tenet is frequently termed 
"welfarism". Sen has called this the "evaluative space" '20 and the assertion is that 
only utility of individuals can contribute to welfare. This is where much of the 
confusion around definitions occurs. Welfare economics incorporates all the 
above four tenets, of which welfarism is one of the four. Later authors such as 
Culyer (1991) reduced the four tenets to two principles : 21 
a) social welfare is a function of individual utilities 
b) individual utilities are functions of the goods and services consumed by those 
individuals. 
These tenets undoubtedly generate a coherent theory that can address the issue 
of whether changes (either within the health sector or between the health sector 
and other sectors) improve social welfare. In its strictest interpretation, 
interpersonal comparisons of utility are not required or permitted. 
However, strict interpretation of this theory allows that there is only an 
improvement in social welfare if at least one person is made better off without any 
other being made worse off (a Pareto improvement). This is a restriction that 
would prevent any social decision making, as undoubtedly some are made worse 
off with any such decision. For example, the provision of improved health care 
provision for all individuals implies that either other sectors (such as education) 
would experience budgetary cuts (which would make some worse off) or there 
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would have to be an increase in taxation (or alternative mechanism) which would 
make tax-payers worse off. 
This limitation of the Pareto improvement led to the separation of the efficiency 
(the size of the cake) and distributional aspects (how the cake is divided) of social 
welfare (see for example Sugden and Williams). 22 If the distributional aspects are 
not considered, or left to political processes, a potent, /Pareto improvement exists 
where the "winners" from a change can in theory compensate the "losers" and 
remain better off than before. In practice, the Kaldor-Hicks compensation test is 
often used as the test for potential Pareto improvements and is the basis for cost- 
benefit analysis. It should be noted that all Pareto improvements would pass the 
Kaldor Hicks compensation test but that the reverse does not hold. Few examples 
of Kaldor Hicks improvements would be Pareto improvements (as someone is 
likely to be worse off). A potential problem of reversibility of this criterion (known 
as the Scitovsky paradox) is discussed in section 2.3.1.1 below. 
Allowing potential Pareto improvements permits a much broader range of policy 
options/decisions to be considered. However, the downside of this enhanced 
ability to inform decisions is that issues of equity23 (and some would argue 
morality, 24) are not incorporated. 
29>/ M81 IS ir7 the decision makers object/v8 function under eve/farisin? 
Culyer21 has suggested that the assumptions underpinning the welfarist approach 
are restrictive, and that social welfare is a function of more than individual utilities 
(for example social welfare is likely to include concepts of justice and fairness) and 
that these individual utilities are not based solely on goods and services consumed 
but also on other factors such as process utility. 25 Several commentators, see for 
example Mooney26, question the use of the individual as the appropriate unit of 
analysis. Communitarians, for example, consider the community and focus on 
social cohesion and well-being rather than the rights or utilities of individuals. In 
this approach the "community" decides what constitutes a "good" and makes 
decisions to prioritise between goods. 
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Sen, in his capabilities approach, 27 considers human well-being to be based on 
both activities and capabilities (the opportunities an individual has to achieve these 
activities, rather than purely utility). Thus the capabilities approach includes the 
capacity to exercise freedom of choice and the capacity to live to old age among 
other non-utility concepts. He considers human welfare to be multi-dimensional 
rather than based on a single concept of utility. The deprivation of these 
capabilities through oppression, poverty, ill health or other factors is considered to 
reduce "well-being". 
Sen28 is also concerned with the impact of welfarism on equity and states that 
"concern with equity must militate against the use of utilitarianism". The desire for 
equity can take many forms. Sen's paper, The Impossibility of a Paretian 
Liberal", 29 asserts that even a minimal degree of liberalism is inconsistent with the 
use of Pareto optimality as a mechanism for social decision making. This example 
is a more specific version of Arrow's Impossibility theorem. Arrow demonstrated 
that aggregating preferences of more than two members of society with a three 
choice decision cannot be achieved without the existence of unfairness or 
inconsistency. 30 More specifically aggregation of preferences with three decisions 
is not possible without contradicting one of the following: 
Q monotonicity (more of a good is preferred to less) 
Q independence of irrelevant alternatives (if A is preferred to B, the 
introduction of C should not make B preferable to A) 
0 non-dictatorship (the welfare function represents more than the welfare 
function of one individual) 
Q non-imposition (societal preferences can be ranked from the set of 
individual preferences) 
Q unrestricted domain (all preferences of all members of society should yield 
a complete ordering for all choices). 
Sen summarises these arguments. 31 He presents a classic example, showing that 
even when utility information is complete, welfarism and other utility based criteria 
could lead to a situation where torture is preferred to no torture (see example 
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below). Clearly, torture can be substituted for any other "undesirable" 
characteristic of a society. 
"Consider a set of three social states x, y and z, with the 
following utility numbers for persons I and 2 (there are 
no others). 
Xyz 
Person 1's utility 477 
Person 2's utility 10 88 
"In x person 1 is hungry while 2 is eating a great deal. In 
y person 2 has been made to surrender a part of his 
food supply to 1. While 2 is made worse off, 1 gets more 
utility, and the sum total of utility happens to be larger 
(with diminishing marginal utility). 
"It is clear that y must be judged to be better than x by 
utilitarianism (since the utility sum is larger for y), by 
the so called 'Rawlsian maximin' or its lexicographic 
extension 'leximin' (since the worst-off person's utility is 
larger in y than in x), and indeed by virtually all the 
equity criteria that have been proposed in the literature 
using utility data. Let us take y to be better than x. 
"Consider now z. Here person 1 is still just as hungry as 
in x, and person 2 is also eating just as much. However, 
person 1, who is a sadist, is now permitted to torture 2, 
who - alas - is not a masochist. So 2 does suffer, but 
resilient as he is, his suffering is less than the utility gain 
of the wild-eyed 1. The utility numbers in z being exactly 
the same as in y, welfarism requires that if y is preferred 
to x, then so must be z. But y is socially preferred to x. So 
z is preferred to x as well, thanks to welfarism. 
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"The conclusion that z can be socially preferred to x can, of 
course, be directly derived using utilitarianism, maximin, 
leximin, or some utility-based equity criterion. However, 
we might wonder whether those approaches should be used 
in the case of judging torture. But the decision to rank y over 
x by any of these criteria in a choice involving no 
judgement of torture, will readily translate into a 
preference for torture-inclusive z over x, due to 
welfarism". (reproduced from Sen). 31 
Ng has commented on this analysis. 32 He states that equity (and therefore other 
"desirable" characteristics) can be incorporated into the welfarist view. In this 
view, the goods and services described by Culyer, 21 can be extended to 
philosophical concepts such as equity, fairness and morality. Using the torture 
analogy, Ng asks why we think of torture as wrong. He argues that ultimately in 
answering this question, we will give a welfarist argument. Ng uses the example 
of someone who enjoys walking, but is unconcerned for the welfare of stones (and 
their right not to be stood on). We don't care about stones' rights because they 
have no feelings and thus suffer no disutility from being stood on. If stones did 
have feelings and therefore experienced disutility, this should be incorporated into 
the welfare of society. Clearly, this is a welfarist argument, though getting all the 
relevant utility data may be impossible. 
Thus, one reason for considering the rejection of welfarism in economic evaluation 
is because utility information is incomplete (or individuals are unlikely to, or cannot, 
reveal true values) and the opportunity cost of getting this data for each decision is 
impossibly large. This is a practical issue rather than an objection to the 
theoretical principles of welfarism, but is a key concern for ensuring that research 
itself is cost-effective. 
However, there are also theoretical problems associated with the use of welfare 
economics, such as the Scitovsky paradox, 33 whereby an allocation of goods A is 
superior to another allocation B using the Kaldor Hicks compensation test, we can 
also show that B is superior to A using the same test. This is due to the relative 
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values of the two goods changing under the new distribution. 34 So, for example, 
imagine a two person (A and B) economy with each person having one apple and 
one pear, both of which have the value 10 utils. The economy therefore has a 
total utils of 40, split equally between A and B. Now if another apple is introduced 
and given to A, he has 30 utils and can compensate B with up to 10 utils and they 
would both be better off. Clearly this would pass the Kaldor Hicks test. However, 
if the introduction of the apple caused the relative value of apples and pears to 
change such that the apples were now only worth four utils and pears worth 12, 
then clearly A would have 20 utils (two apples and one pear), while B would only 
have 16 (one apple and one pear). A movement back to the original state of the 
economy would therefore be better for B and he could compensate A with up to 
four utils and still be better off. For a more detailed exposition see Varian 
(1992). 35 
2 ,7>2 Va/uafion ofufi/rfies in the objec//ve function 
Even in instances where utility information approaches completeness there is the 
question of how utilities should be valued. One way utilities can be valued is via 
willingness-to-pay (WTP) which is derived directly from welfare economic theory, 36 
and in practice is the most common method of valuation of benefits in cost benefit 
analysis (CBA). However, in practice, WTP figures are likely to be closely related 
to ability to pay and that using this method to measure outcomes could result in a 
distribution of benefits that favour the wealthy. The aggregation of utilities 
expressed in monetary terms is clearly problematic when the income/wealth of 
individuals (and therefore the marginal utility of money) is very different (see 
2.3.2.4 below). Other problems with the use of WTP are that individuals may not 
know their WTP or that they may not state the value that they would actually be 
prepared to pay. However, this problem is not exclusive to welfare economics or 
welfarism. WTP can (and indeed is) used in the extra-welfarist tradition (see 
section 2.3.2 below) as a means of valuing health. 
More specific to the welfarist tradition is the issue of whose utility values should be 
used. As stated above, in this paradigm, individuals are the best source of their 
own utility information (consumer sovereignty). Thus in theory, utilities should not 
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be estimated by anyone other than the recipient and social decision making based 
on evaluations carried out in this sphere would be a huge undertaking. Indeed, it 
has been asserted that in the case of health, consumer sovereignty does not hold 
and that therefore techniques such as WTP that are reliant on this assumption are 
irrelevant in the case of health care decision making. 19 
Nevertheless, using these principles, and thereby generating a measure of 
societal welfare that is based on the summation of individual utilities (themselves 
based on individual valuations of the consequences on consuming goods and 
services), the welfarist approach not only allows a comparison of how resources 
should be allocated within the health care sector, but also allows a comparison of 
how resources should be allocated between health care and other activities (or 
sectors of the economy). This cannot be accomplished in the extra-welfarist 
approach described in section 2.3.2, where other characteristics such as health 
are seen as suitable maximands. These sector specific maximands have no 
substantive meaning outside the relevant sector, though trade-offs between sector 
specific maximands could, in theory, be incorporated into an assessment. 37 
2SfS The /nifia/disfcthufibn 
It is worthwhile noting that monetary valuation is not the only means of assessing 
utilities in welfarism. However, whichever metric is chosen, the potential Pareto 
improvement would require that the gainers from a change could in theory 
compensate the losers in the appropriate units. Those who have a greater 
endowment at the outset may therefore be favoured by welfarism. It is implicit 
within this paradigm that the initial distribution (of money, wealth, happiness etc) is 
at least acceptable, if not desirable. This is a value judgment that many would 
regard as incongruous with a "fair" system. 
29/4 Ofherissues with we/farism 
Sculpher et a138 and Claxton et al 37 highlight the implausibility of the assumption 
that we live in a first best world where conditions exist for free markets to operate 
efficiently. Clearly, this is not the case. The economy is characterized by many 
imperfections, such as asymmetric information between producers and 
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consumers, few producers and the existence of public goods and externalities. As 
we live in a second best world (where free markets do nofoperate efficiently to 
maximize social welfare), choosing between interventions based on prices that are 
assumed to be derived in a first best world may actually reduce social welfare. 39 
Other authors have highlighted the imperfections in the health system, and thus 
the concern with reducing social welfare by assuming a first best world may be 
particularly relevant for the health sector. 
In practice, potential Pareto improvements are not likely to be recompensed (i. e 
that winners in reality have no requirement to compensate losers). Thus, not only 
is utility information incomplete and difficult to value, but also transfers to 
recompense the losers are unlikely to occur. 
The difficulties arising from using welfare economics in economic evaluation in 
health care has led to the development of the "extra-welfarist" approach (also 
known as "non-welfarist"). This approach forms the basis of most cost- 
effectiveness analyses, in which health (typically) rather than welfare is considered 
the objective to be maximised. 
282Extra-we/fagisin andsocia/decision making 
In the extra-welfarist paradigm, the orthodox assumptions about social welfare 
described above are exchanged for another set of objectives. Richardson states 
that most would consider the main objective of health care systems to be the 
maximisation of health rather than utility. 40 In Sen's capabilities approach, 27 
health is considered to be one of the "most important conditions of human life and 
a critically significant constituent of human capabilities". 41 
In the social decision making approach, the problem of how best to allocate scarce 
resources becomes a constrained optimisation problem. There is a given social 
objective (for example, the maximisation of the health of society) which is 
exogenously defined, and a given budget constraint which is again exogenously 
defined. This approach does not allow assessment of how much should be spent 
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on health compared with other sectors, merely given this exogenously defined 
budget, how best should it be spent. 
2,72 1 l4Yhafis ire the decision makers'obiecfive function undefextra-welfarisrr, 
andhowIS// valued? 
In the extra-welfarist approach the contents of the objective function tend to be 
narrower than under welfarism, though there is no requirement that this is so. 
Indeed, the extra-welfarist position, largely initiated by Sen in his capabilities 
approach, 20,20,27 stresses the move away from the narrow concept of measuring 
individual utilities. Nevertheless, the analytic technique most commonly used in 
the extra-welfarist economic evaluation is cost-effectiveness analysis (CEA), 
where there is a single unidimensional outcome measure, such as the QALY, to 
be maximised. Most analyses conducted in the extra-welfarist paradigm (see 
Chapter 3 and Richardson et al 20057) use an outcome measure (such as the 
QALY or more narrowly a change in blood pressure or Body Mass Index) where it 
is assumed that there is no difference between individuals in the level of utility 
derived from a unit gain in outcome. That is, the value of a QALY is independent 
of the marginal utility of money, or that any differences between individuals are not 
relevant to the decision. In this "unadjusted" state, all QALYs (or change in blood 
pressure or whatever outcome is being assessed) are valued equally and 
therefore differential ability to value improvements is avoided. 
The use of a composite measure of the quality and quantity of life has become 
more common in the recent literature, in particular with the use of the QALY. 19 At 
this point it is worth commenting on different "types" of QALYs. Although QALYs 
are always the product of the time spent in a specific health state and the "quality" 
of that health state, the derivation of this quality weight has different potential 
sources. Hurley19 identifies two broad types of QALY, those where the weights 
are derived using psychometric testing (see for example Weinstein and Stason42), 
and those where the weights are derived using "utility" weights. In the former 
case, individuals are often asked to rate states on a scale of death to perfect 
health (and there is therefore no allowance for uncertainty), while in the latter 
individuals are asked to trade-off hypothetical states (where uncertainty is 
incorporated into the decision). Most QALYs used in the literature are "utility" 
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based QALYs, 19 though it does not follow that there is consensus as to the 
meaning of a QALY. To add to the confusion, Richardson and Manca43 found that 
QALYs were also calculated in different ways with a variety of assumptions, 
though later work suggests the "correct" methodology for QALY calculation. 44 
Some authors argue21 that the QALY represents a subjective assessment of 
health Hofutility, even though utility theory is used in the construction of this 
QALY, while others contend that the QALY is a measure of individual utility. 45 
Hurley19 points out that therefore the use of a utility based QALY can be used in 
either a welfarist or extra-welfarist analysis, and that the use of this instrument 
does not identify the paradigm chosen; the same author also states that the use of 
the utility based QALY is increasingly popular in economic evaluation. 
Other authors46' 47 have argued for "equity weighted" QALYs, where certain 
beneficiaries of QALYs would be valued higher than others (for example, the 
young may be favoured above the old). Other authors have argued against 
"consequentialism" in economic evaluation and that the inclusion of procedural 
preferences is important. 48,49 
While the contention of the above authors is that QALYs should be measured but 
enhanced in some manner, other authors have cautioned against the use of 
QALYs at present due to the strong assumptions required in their generation, 50 
while McGregor (2003) considers that shortcomings in the methodologies used to 
generate QALYs warrants great care in their use. 51 
Others authors dispute the usefulness of QALYs at a11,52 though the author 
appears primarily concerned with their use when there is no alternative treatment 
available for that patient group. The implications of this approach would be to 
have a higher cost-effectiveness threshold for conditions where there is no existing 
treatment, and presumably the denial of treatment (given a fixed budget) to some 
patients with complaints that are currently treatable, even though these patients 
would benefit more from treatment. This is an individual value judgment but even 
if the author's argument were accepted, there is no alternative mechanism to 
assess by how much the cost-effectiveness threshold should be raised. In 
principle a higher weight could be attached to the gains from treating patients 
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where there is no existing treatment (the argument takes a similar path to that of 
the "rule of rescue", where identifiable individuals facing death are deemed a 
treatment imperative). 
Advocates of the "QALY" approach argue that the limitations of the QALY are well 
known, and that the explicit assumptions prohibit distortion of results from those 
with a vested interest. 53 
2.? 22 Expanding the objec//ve function Of 1170 decision maker 
In the extra-welfarist approach, if health is the only consideration in the objective 
function, the only means of increasing social welfare is through increasing the 
health of society. The existence of such an objective function necessitates an 
entity with a legitimate claim to make such decisions37 based on this function. In 
addition, the methodology used in analyses should be explicit about the social and 
scientific values that are made; thus the /egifi»iafe decision maker can be seen to 
be making /egifirnafedecisions. The form of this entity is discussed in section 
2.3.2.3, where democratically elected governments and their appointed agents, 
are considered potentially appropriate decision making entities. 
The objective function of the decision making entity, and therefore the extra- 
welfarist approach, does not preclude a broader perspective than simply health. 
However, if health is the starting point, then to include other items in the objective 
function requires knowledge of the rate of substitution between health and these 
other items. 38 As a crude example, if the decision maker has individuals' 
autonomy as a desirable outcome perse, he/she would need to have some 
valuation of autonomy in terms of a QALY (e. g. a point increase in autonomy 
equals 0.1 QALY), where QALYs are the measure of health. An example of the 
potential expansion of the QALY as an outcome measure is considered in Chapter 
7. 
However, if characteristics other than health are in the objective function and are 
included as "benefits" or "costs" in the CEA, it is unclear how these should be 
viewed. For example, consider two interventions A and B with identical costs. 
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Intervention A generates 3 QALYs of health benefits and 2 QALYs (equivalents) of 
non-health benefits (assuming we know the rates of substitution and can therefore 
calculate QALY equivalents). Intervention B generates 4 QALYs of health benefits 
but zero non-health benefits. Clearly, intervention A is "better" in that it produces 
more QALY equivalents for a given sum, but if health is the maximand, B would be 
chosen. This topic has, as yet, received little attention in the literature, but is likely 
to generate more interest as the emphasis on broader outcome measures and 
cross-sectoral effects increases. However, the least that is required is that the 
perspective of the study, the exact nature of "relevant" evidence, and the 
constituents of the objective function must be stated apnb, z 
2.7 23 /nc/usion 0/0//70/" "socia//y des11ab/e °chaýacferisfics in the extra-we//mist 
paradigm 
The section above describes how other outcome measures can be incorporated 
into the extra-welfarist paradigm. While it may be feasible to obtain the MRS 
between health related outcomes and, for example, equity, this is a time 
consuming and conceptually difficult exercise. 
Others have argued that we use, as a simplifying heuristic, a series of 
rights/rules, 32 that are perceived to improve social welfare (though it should be 
noted that Ng used this in the welfarist paradigm). Nozick" (1974) has argued 
that these rules "do not determine social ordering but instead set the constraints 
within which a social choice is to be made". Government could be seen as the 
overseer of these rights and also an appropriate decision making body. The two 
roles of government are likely to be related; in, for example, providing a NHS, the 
government gives individuals in that society access to a minimum level of care, in 
providing schools, government gives individuals (the opportunity of) a minimum 
level of education and so on. This provision of goods/services may be seen as 
rights, and the level of these rights may in part determine the level of funding for 
each service. The legitimacy of government to act in this manner is gained, as 
argued by Sugden and Williams, through the political process. 22 
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Sculpher et a138 (2005) suggest that there are institutions in the UK that have been 
given authority to make decisions (about health care) on behalf of society as a 
whole. These authors go on to suggest that institutions such as the National 
Institute for Health and Clinical Excellence (NICE) provide prescriptive 
recommendations based on explicit or transparent assumptions, and that this is 
preferable to the welfarist approach where many of the assumptions remain 
implicit. 
Thus in the extra-welfarist world, a legitimate external body is seen as the 
overseer of individuals' rights and freedoms. Subsequently, this external body 
delegate responsibility to a (health care) decision maker who has a remit to 
produce the maximum amount of health for a given cost. It is argued that the 
political process delivers governments that act in a manner consistent with this 
external body and that this process gives the government a legitimacy to behave 
in this manner. Critics of the extra-welfarist approach36 contend that this approach 
simply substitutes the preferences of the decision maker or the community for 
those of individuals. While this is a valid criticism, the authors do not present an 
alternative that adequately deals with the inequity of initial distributions, as 
discussed in section 2.3.2.4 below. 
2 3.2 4 The /n//ia/disfihu/ion in extra-we/far, m 
As described above, the welfarist paradigm is not value free when considering 
distributional issues. In particular there is the controversial assumption that the 
initial distribution (of utility, however defined) is acceptable. 
In the extra-welfarist paradigm, there is no implicit assumption that the initial 
distribution is acceptable. One of the founding principles of the UK NHS was that 
access to health care should be based on capacity to benefit rather than the ability 
to pay and that there should not be differential treatment because of income. 55 
Thus it would seem reasonable to use a methodology (such as CEA) with makes 
no apfioflassumptions regarding the acceptability of the initial distribution of 
goods/services to maximise a social objective, rather than a methodology (such as 
CBA) where there is an implicit assumption that the initial distribution is acceptable 
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thereby generating results that are likely to favour those with a large initial 
endowment. 
Z.?.? Concerns with the extra-we/far/st approach. 
Sheldon56 has expressed concern that economic evaluation places too much 
emphasis on health rather than on welfare. Factors other than health may be of 
value to society and may be appropriately considered in economic evaluation. 
However, as argued above, the use of CEA with the QALY as the measure of 
benefit does not preclude the inclusion of other characteristics which may be 
important to society. Attempts have been made in the discrete choice experiment 
literature to value these other important characteristics, though none have, as yet, 
transferred these other characteristics into the QALY framework. In Chapter 7 the 
identification of these characteristics and how they might be incorporated into cost- 
effectiveness analysis is discussed more fully. 
There is also the question of what constitutes "health", assuming that health is a 
legitimate objective function for health care decision making. Some would argue 
that psychological outcomes that are not picked up elsewhere in HRQoL, should 
be included in health outcomes. Even if these outcomes are not considered to be 
included as "health", they may still be an appropriate part of a decision makers 
objective function. 57 A further problem may be the lack of meaning of the health 
maximand outside the field of health (that is as a general maximand). 17 
Nevertheless, this does not preclude extra-welfarist analyses in other spheres, 17 
and potentially the synthesis of costs and effects across different sectors. 37 
However, the desire to broaden the perspective from simply health requires that 
the Marginal Rates of Substitution (MRS) between health and the other 
characteristics to be included in the objective function are known. The discrete 
choice experiment described in Chapter 7 elicits these values for patients with 
chronic conditions enabling the relative values of health and other "important" 
outcomes to be ascertained. In principle, this methodology could be used to 
include other "socially desirable" characteristics, such as equity. 
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Birch and Donaldson36 are critical of the move away from welfare economics in the 
field of economic evaluation. They consider utility of the individual to be of 
paramount importance, rather than "health" and argue that "utility" can be 
broadened to encompass concepts such as utility derived from processes in the 
welfarist paradigm. The authors neatly encapsulate the difference between the 
paradigms using the example of smoking. In the extra-welfarist paradigm where 
health has been designated as the only outcome we are interested in, a 
programme that cuts smoking levels would be judged as "beneficial". However, in 
the welfarist world, individuals' utility may be lower through stopping smoking, and 
it is less clear whether the programme would be beneficial or not. 
The same authors are also critical of the potential paternalism within extra- 
welfarism, where the individuals' assessment of his/her own welfare (individual 
sovereignty) is replaced by that of a decision maker of the general population. 
The objective of individual sovereignty has itself been questioned. For example, 
Sen58 comments that individuals with disabilities can adjust their expectations 
down as they adapt to the disability. Hence, as utility is in part determined by the 
individual's assessment of the situation relative to their expectations, they may 
have high levels of utility. 
2.14 We/farism, extra-we/farism andthe economic evaluation of 
interventions to support self care 
Does the choice of philosophical paradigm impact on the conduct, analysis, 
results, conclusions and recommendations of an economic evaluation? Without 
conducting analyses in both paradigms, it is not possible to say whether results 
and conclusions and therefore recommendations would be affected. The conduct 
of the economic evaluation would need to be very different. Consider the outcome 
measure in the study, the extra-welfarist perspective allows the measurement of a 
variety of outcome measures, some more useful than others, as a measure of 
health. These measures are often biological measures or patient responses to a 
question (or series of questions) at various time points. This measure can then be 
expanded if required. The welfarist perspective however, requires individual 
utilities to be measured. This would require the impact of interventions on health 
and all other factors (and interactions) that may impact on individuals' utility. This 
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is a more complex task that would impact on the cost and duration of economic 
evaluations. 
2.7 5 Discussion ofnormative founo'ations ofeconoinic evaluation 
So, what are the differences between the two approaches? Brouwer et al17 
identify four principal differences. These are: 
i) the outcomes considered. Welfarism uses the utility of individuals, extra- 
welfarism can include other outcomes, though in practise, health is commonly the 
maximand. 
ii) the sources of the valuation of outcomes. Welfarism uses the individual, extra- 
welfarism can be the individual but can also be a decision maker or the general 
public. 
iii) how the outcomes are weighted. Weighting is not allowed under strict welfare 
economics criteria (as it is not certain that weightings are actually utility 
information) but are an integral part of extra-welfarism with the use of equity 
weighted QALYs for example. 
iv) interpersonal comparison of outcomes. Again this is not allowed in the strictest 
welfare economics interpretation, but is incorporated in extra-welfarism as ceteris 
, osiibus, an intervention generating 2 QALYs for individuals A and B is considered 
superior to an intervention generating one QALY for individual C. 
The similarities between the practical implementation of both approaches (which 
tend to be cost-effectiveness analysis in extra-welfarism and cost-benefit analysis 
in welfarism) has also been the subject of debate with some authors stressing the 
similarities, 59 while others dispute there is any link at all. 60 
There are drawbacks to both the extra-welfarist and welfarist paradigms. In the 
extra-welfarist approach, the absence of a legitimate decision maker could be 
considered problematic. However, the politically elected government can be 
considered to have been given a mandate to set budgets for sectors, 61 as well as 
maintaining the rights and freedom of individuals. -r4 
There are also significant problems with the use of welfarist economics in 
economic evaluation. The focus on individual utility and the incompleteness of this 
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utility data, as well problems valuing these data, are practical issues in the use of 
welfarism in economic evaluation. 
Choices need to be made between paradigms. The pragmatic advantages of the 
extra-welfarist approach, using a commonly used, understood and simple outcome 
such as the QALY are judged to outweigh the disadvantages. For the purposes of 
the following analyses, the constrained optimisation approach of extra-welfarism is 
preferable, so long as the perspective is wide enough. The implication for 
economic evaluation of interventions to support self care is that, though there are 
limitations to the use of the extra-welfarist approach in assessing the cost- 
effectiveness of interventions to support self care, for practical purposes this is the 
appropriate paradigm. 
2.4 Single trial based economic evaluation and decision making 
The choice between the extra-welfarist and welfarist approaches is not the only 
ongoing controversy in the field of economic evaluation. Economic evaluation 
within randomised controlled trials has been seen as the primary source of 
evidence of cost-effectiveness for decision making. However, just as the clinical 
evaluation field has moved towards the incorporation of other relevant information, 
using techniques such as meta-analysis, so the field of economic evaluation has 
shifted towards the synthesis of different forms of relevant evidence from sources 
outside the RCT. 
Most economic evaluations of interventions to support patients' self care have 
been conducted in the extra-welfarist tradition described above. 7 In addition, the 
majority of these economic evaluations were all based on a single trial. Where 
trial data were available, there was no attempt to use data from other sources. 
This reflects the historical use of economic evaluation alongside clinical trials as 
the primary means of assessing the cost-effectiveness of many interventions62 
including those in the self care sphere7. 
Recently it has been argued62 that, in most cases, the use of "a single RCT as a 
vehicle for economic analysis will be an inadequate and partial basis for decision 
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making", though it is acknowledged that RCTs are useful in providing an unbiased 
estimate of the relative treatment effects of comparators and ensuring that 
differences are due to the intervention. The authors consider that these single trial 
based economic evaluations have four important drawbacks that limit their 
usefulness to decision makers. Firstly, they fail to consider all the relevant 
alternatives. Secondly the time horizon of the study rarely captures all the 
outcomes of interest. Thirdly, trial based economic analyses are not always 
relevant to the decision context and finally, these analyses do not consider all the 
relevant evidence. 
While these are persuasive arguments, in certain cases there remains a case for 
presenting a single trial based analysis; it is asserted that in the evaluation of the 
EPP, presentation of a single trial based analysis is one appropriate method. 
Each of the criticisms of trial based economic evaluation is addressed below. 
2.4.1 Failure to considerailrelevantalternatives 
The Expert Patients Programme (EPP) based on the Chronic Disease Self 
Management Programme (CDSMP) is probably the only group therapy aimed at 
improving self-efficacy and ultimately health status, delivered to patients with a 
range of chronic conditions in the UK. Other self care support interventions have 
been disease specific (see the literature review in Chapter 3) or do not include 
self-efficacy as the mode of improvement. Therefore, it can be argued that in this 
instance where there are no obvious alternative treatments or management 
options for this group of patients, evaluations that consider CDSMP should be 
considered. 
In addition, the inclusion of all relevant alternatives necessitates the inclusion of 
indirect comparisons. In principle, treatment as usual could be considered a 
common comparator and links made via this treatment option. However, in this 
instance, treatment as usual may not be a constant treatment. There are 
differences in what constitutes treatment as usual with different clinical practices in 
different countries with different patient populations and a variety of conditions. It 
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is therefore a moot point as to whether treatment as usual can be used as a 
common link. 
2.42, Truncated time horizon 
Economic evaluations conducted within or alongside clinical trials are often limited 
to explore the costs and effects within the time frame of the clinical follow-up 
period. This may not be long enough to capture all the relevant costs and 
benefits of interventions and the use of such a truncated time horizon can lead to 
misleading conclusions. 62,63 In the example of the evaluation of the EPP 
presented in Chapter 4, patients were followed up six months after their 
randomisation to the intervention or the waiting list control. This may not capture 
all the effects of the intervention. The standard "within trial" estimate of cost- 
effectiveness would only consider costs and effects occurring within this period. 
This can lead to erroneous conclusions. However, simple modelling allows the 
extrapolation of effects of the intervention to periods of greater than one year. The 
effect of treatment on costs and effects after one year is unknown. Where an 
intervention provides, for example, additional survival at one year, it may be 
reasonable to assume that the intervention has no further impact and that the 
additional survival at one year generates additional QALY gains over the next 15 
years. 63 However, this assumption (effectively that survival curves are parallel after 
one year), may not be reasonable for a behavioural intervention where the effects 
may dissipate over time, 64 or where the durability of the effect is unknown. 65 
Indeed, the effect on resource use after six months is also unknown and could 
either make the intervention more or less cost-effective. Thus, a time horizon six 
months to one year is deemed appropriate, though it is acknowledged that any 
incremental costs and/or benefits of the intervention after this time period will not 
be included. 
2,4,3, Lackofre/evance to dec/c/on context 
Sculpher et al comment that the patient population considered in RCTs may be of 
limited comparability with the patient population being considered by the decision 
maker. 62 This argument can be taken to either extreme. It could be argued that 
to make the evidence most relevant to a decision context, a RCT in the same 
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population in every respect, with the same condition, using the same intervention 
is the only evidence relevant to that decision. In the case of the EPP evaluation, 
the study was driven by the decision context. The EPP evaluation was based on 
patients in the UK only, and as the jurisdiction making the decision is also UK 
based, the decision context is appropriate. The trial was multi-centred and 
designed to maximise external validity with patients from a wide variety of 
Strategic Health Authorities, so that the evaluation should be generalisable to the 
patients eligible to receive the EP p. 66 
244 Failure to incorporate a//relevant evidence 
The most fundamental criticism of economic evaluation conducted alongside a 
single trial is that not all the relevant evidence is included. Other trial evidence 
may be available estimating the relative treatment effects, but importantly, non trial 
based evidence may inform non treatment effect parameters. For example, in 
evaluating drugs for heart disease, a single trial may have a limited amount of 
evidence of quality of life after myocardial infarction, but there may be rich sources 
of data available elsewhere. Ignoring these data, it is argued, leads to "a partial or 
potentially misleading" analysis. 62 
The identification of relevant evidence and the criteria for determining relevance is 
a constant theme in this thesis. It is argued in a later chapter that there is no 
simple dichotomy between relevance and irrelevance. The concepts lie on a 
continuum, with some evidence/data/studies more relevant than others. The 
incorporation of additional evidence that is deemed relevant requires additional 
assumptions about the relationship between the treatment effect and costs and 
QALYs, and the mechanism by which costs and QALYs are affected. In essence, 
this is a debate about the structure of the model. Each representation of the cost- 
effectiveness of the CDSMP, from the single trial based analysis described in 
Chapter 4, to the evidence synthesis presented in Chapter 6, is a model. These 
models use different data and require different assumptions, but aprioriwe do not 
know which model is "correct". We therefore have a problem with "structural 
uncertainty". We do not know all the mechanisms by which the treatment impacts 
on outcomes nor whether these would be reproducible in future experiments. For 
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example, there may be a large number of intermediate or surrogate outcomes 
through which the final outcome is mediated. It may not be possible to model all 
these mechanisms (or indeed we may not be aware of all these mechanisms), or it 
may be that differences are due to truly random variation. There is a small but 
developing literature that considers the subject of the "structural uncertainty" in the 
development of economic models. 67 Structural uncertainty has been largely 
ignored as methodologists have concentrated on addressing parameter 
uncertainty 68, which often implicitly assumes that the model structure is known. 
Few papers discuss the issue, and fewer formally address the issue in their 
analysis. 67 Techniques such as scenario analysis have been used on occasion in 
the health economics literature. 69 Scenario analysis examines the impact on 
costs and outcomes of different scenarios (for example considering a male vs 
female population or a younger vs older population). Other techniques such as 
model averaging have yet to be used in the health economics field. 70 However, 
even where structural uncertainty is acknowledged, and "captured" within the 
model, this can only be conducted when we are aware that we are uncertain. It is 
an empirical question, which is addressed partly in Chapter 6, whether assuming 
that model structures that we are not aware of simply reflect "noise" influences the 
results of models. 
In the example used in Chapter 4, the single trial based evaluation of the EPP is 
essentially a scenario analysis where all other data are deemed irrelevant. This 
model is extended in later chapters to incorporate additional evidence with 
different degrees of relevance. Is it reasonable to treat one single RCT as 
providing the only evidence? In this instance, there are reasons for suggesting 
that this maybe appropriate. Many other trials of CDSMP are based outside the 
UK, 71-82 and/or use a limited study design. 71,75 
It is reasonable to argue that only UK studies that establish the effectiveness of 
CDSMP using an RCT design should be included. However, there is more than 
one trial based analysis that meets this criterion. One other trial considered the 
use of the CDSMP in the UK, but this study was based in a particular ethnic 
patient group, rather than the general population. 83 Though this study was not in a 
nationally representative population it is acknowledged that this study might be 
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considered relevant, and for this reason synthesis of this trial with the EPP 
evaluation is conducted in Chapter 5. 
More data from different locations in different settings with heterogeneous patient 
groups is added in Chapter 6. While this undoubtedly includes more evidence, the 
relevance to the UK decision context is lower than that of the single trial evidence. 
The implications of synthesising these data are discussed in terms of the impact 
on the decision and the characterisation of uncertainty. 
24 5 Discussion ofsing/e Fria/based evaluations 
The concerns with the use of single trial based economic evaluations are well 
founded. Indeed, the implications of the above critique is that, in most cases, 
single trial based economic evaluation is an incomplete analysis and should be 
supplemented with all other relevant data. The impact that expanding the 
evidence base could have on the decision problem should be clear. The results of 
one trial may well present a positive assessment of the cost-effectiveness of an 
intervention. However, the inclusion of other evidence that does not support the 
cost-effectiveness of the intervention could impact on the results and 
recommendations. Nevertheless, in certain circumstances, single trial based 
analysis remains anappropriate methodology (though not the o/7//appropriate 
methodology). In the case of the single trial based economic evaluation presented 
in Chapter 4, there are no obvious alternatives omitted, the relevant time horizon 
for such studies is ambiguous, and the decision context was the rationale for the 
trial. The inclusion of all relevant evidence is more contentious. Relevance is a 
subjective concept. The question then becomes "who defines relevance? " 
Pragmatically, relevance could be used to justify exclusion of any study not carried 
out in the jurisdiction of interest, or examining the population of interest, or does 
not use a design that is deemed appropriate. For the purposes of the evaluation 
of the EPP a sfath»gpoinffor the analysis is that only UK based trials in the 
general population are relevant to the decision problem stated in section 1.2. 
Later chapters expand the evidence base to include additional UK and non-UK 
evidence and examine the impact of their inclusion on results and conclusions. 
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Therefore, in the case of the evaluation of the EPP, the presentation of results 
based on the single trial is appropriate, while the possibility of synthesising these 
data with other available data, and the impact this would have on results and 
decisions, is considered in later chapters. 
2.5 Statistical analysis and interpretation in economic evaluation 
Z. 51 Bayesians and Frequenfisfs 
Statistical techniques used in the analysis of economic evaluations are another 
topic on which analysts are divided. Bayesians hold that probabilities represent 
the degree of belief in an event occurring. This probability can be updated as and 
when further information becomes available. This contrasts with frequentists who 
only consider probabilities as the relative frequency of events (from the sample 
space of all events) occurring in a set of random experiments. Where an 
experiment cannot be repeated numerous times, a frequentist could not assign a 
"probability" of an event occurring as the long run frequency of an event is seen as 
its probability (hence the term "frequentist") 
For CEA, the major feature of Bayesian thinking is that parameters are considered 
to have a distribution, rather than be considered as a single "true" figure as in the 
frequentist paradigm. 84 Thus for Bayesians, some values of parameters are more 
credible than others based on both the "data andprior beliefs". 85 Hence, in 
Bayesian CEA, we estimate a posterior distribution (for example of the population 
mean cost) using the available data but adjusted by our "prior" beliefs, which may 
in fact be other data from other trials, observational evidence, or other form of 
evidence. These "priors" are intended to express the beliefs we hold before we 
have had chance to observe any data. Often these "prior" beliefs are given very 
little weight so that the accumulation of a large amount of data renders them 
extraneous. 
Bayesians can talk about the "probability" of an intervention being cost-effective at 
some cut-off point given the data. Frequentists cannot make such statements. It 
has been argued that the Bayesian approach when used in economic evaluation 
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gives a natural framework for the assessment of uncertainty in decision making 
and that results are more useful to decision makers. 86,86,87 When the threshold 
value of the outcome of choice (for example the QALY) is known, Bayesian 
analysis can be used to estimate the probability that the intervention is cost- 
effective, that is to estimate the probability that the cost per QALY is below a given 
threshold. The ICER can still be presented as a measure of the relative efficiency 
of an intervention, while the probability that an intervention is cost-effective, at 
various threshold values of a QALY, can be used as a measure of uncertainty 
around the decision and the potential benefit from conducting further research. 88' 89 
The uncertainty around the decision is often portrayed graphically using the cost- 
effectiveness acceptability curve (CEAC), 88,9° while value of information 
techniques are often employed to value future research. 91' 92 As the Bayesian 
approach can incorporate new evidence as it becomes available and allows 
presentation of results in a format that is more useful for decision makers, it is 
considered the appropriate paradigm to conduct economic evaluation. 
2,5 2 The role ofinference 
Statistical inference can be used in both the Bayesian and frequentist paradigms. 
However, it is in the frequentist paradigm that inference and the use of statistical 
significance has been most prevalent. This involves setting up a hypothesis and 
then collecting data, (for example, from an experiment) to inform this question and 
subsequently either accepting or rejecting the hypothesis based on a previously 
stated "level of statistical significance". Statistical significance levels of 5% are 
commonly employed in the literature, though they are commonly misunderstood or 
misinterpreted (see for example Altman and Bland). 93 Other authors have pointed 
out the problems associated with significance testing and inference (either 
frequentist or Bayesian) and decision making. 94 Claxton points out that if we 
accept a null hypothesis (of no difference) when one treatment has a higher (but 
not significantly higher) expected net benefit, there is a cost implication of not 
implementing the intervention that can be measured in terms of benefits forgone 
by those who are not treated. 
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As an example, consider an economic evaluation of two interventions for the 
treatment of a chronic illness. The economic analysis may not be able to 
demonstrate a "statistically significant" improvement in patient outcomes, nor a 
"statistically significant" reduction in costs (possibly due to the study not having 
sufficient statistical power). In this instance, classical statistical inference fails to 
reject the null hypotheses that there is no difference in effectiveness or costs 
between two groups, and makes few recommendations for decision makers. 
In contrast comparing the incremental costs and effectiveness of an intervention, 
regardless of whether these differences are statistically significant or not, 
generates an estimated cost per QALY. Assuming that we have a decision maker 
with legitimacy (see section 2.3 above), and an exogenously defined budget 
constraint (which may come from this decision maker or another with legitimacy to 
allocate budgets between sectors), then the decision maker can compare the cost- 
effectiveness of the intervention with the threshold cost per QALY. This approach 
does not necessitate that these differences in cost or effect are "statistically 
significant", though it is common practice for analysts to present confidence 
intervals around the difference in means, from which statistical significance (or 
lack thereof) can be ascertained. 
Clearly there are implications of accepting one paradigm over the other and the 
different statistical techniques can yield different results. 95 If classical statistical 
inference is the paradigm of choice, then fewer analyses will be informative for 
decision making purposes as the requirement that differences are "statistically 
significant" is more restrictive than demonstrating the probability of an intervention 
being cost-effective. To be informative for decision making, it should not be a 
requirement that incremental costs or effects (or both) are statistically significant at 
some arbitrarily defined threshold. Incremental costs and effects can be provided 
together with estimates of uncertainty and estimates of the probability that 
interventions are cost-effective given a threshold value for the outcome measure. 
The fact that these estimates can be provided over a range of threshold values 
means that the analysis is not confined to pre-defined and arbitrary levels of 
statistical significance. For these reasons, the use of the either classical 
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statistical inference or its Bayesian equivalent are rejected in the interpretation of 
results of economic evaluations. 
25,3 Simulation in Bayesian cost-effectiveness analysis 
Bayesian methods are becoming increasingly used in CEA. 84 The posterior 
distribution, where both the data and other external evidence (or beliefs) are 
incorporated should be used to inform decision making. In some simple cases, 
this posterior distribution can be estimated using standard notions of probability. 
For example, the probability of tossing eight heads from ten tosses of a fair coin 
given that the first two tosses were heads, can be relatively simply annotated and 
calculated. Alternatively, we could write a simple programme to toss a coin ten 
times with the first two as heads. In this instance, our prior belief may be simply 
that the coin is fair and that there is therefore a probability of 0.5 of either a head 
or a tail on each toss. Replicating this procedure, say, 20,000 times would yield a 
similar estimate to the standard method above. While the former approach may 
be more appropriate when the solution is tractable (as in this example), for more 
complex problems without tractable "closed form" solutions, simulation is a 
suitable alternative. The vast majority of problems in CEA would not be tractable 
(or at least it may be necessary to make unrealistic assumptions concerning the 
distributional forms of priors so that they are "from the same family" as those of the 
likelihood/data) and simulation is a means of estimating the posterior distribution 
ss and thereby enabling a useful Bayesian solution. 
Markov Chain Monte Carlo (MCMC) is one simulation method that has proved 
particularly useful. WinBUGS is a freely available software programme that 
implements MCMC using Gibbs sampling (BUGS is an acronym for Bayesian 
inference Using Gibbs Sampling). 97 To simulate the posterior distributions (in 
effect, the final estimates, and the distributions, of the parameters of interest) of 
random variables, we first choose an initial value for each parameter. Then, 
based on this initial value, the conditional distributions we have defined and our 
prior expectations, we draw the next value. 98 Using this value and the conditional 
distributions, we draw the next value and so on until (hopefully) there is 
convergence, where continued sampling results in a stationary distribution. 
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Checks for convergence and other model diagnostics are an important 
consideration in these analyses, and they are described in more detail in a later 
chapter. 
2.6 Discussion 
This chapter has considered the schools of thought within economic evaluation, 
particularly the evaluative space (whether we consider individual's utility as the 
only contributor to social welfare), what evidence can/should be included in an 
economic evaluation and the statistical paradigm that should be implemented. 
Choices need to be made regarding the paradigms of choice, but those conducting 
analyses should be aware that these choices can impact on the results and 
recommendations for the decision problem identified in the first chapter. This 
chapter has demonstrated that though there are conflicting paradigms within which 
economic evaluation could be based, the extra-welfarist position with health as the 
maximand can be justified so long as there is an agency with legitimacy to make 
decisions to maximise health. It is argued that the democratically elected 
government forms a suitable agency and that bodies such as NICE, which are 
empowered from the democratically elected government, have a mandate to make 
decisions to maximise society's health. In this extra-welfarist perspective, societal 
health rather than (the aggregation of) individual utility is considered the 
maximand. However, the original motivation for extra-welfarism was to expand the 
outcome measure of interest. The use of health as a maximand could be 
considered a narrower maximand than utility, therefore expanding the outcome 
measure beyond that of simply health is a justifiable objective. This is considered 
in Chapter 7 where the relative value of health to other important factors is 
assessed and included in the decision problem. 
The issues around the usefulness of trial based evaluation have also been 
discussed. It is acknowledged that a single trial based analysis is only appropriate 
in certain circumstances. However, it is plausible that these circumstances are 
applicable in this instance and that a single trial based analysis may be the 
appropriate model. Therefore, a single trial based economic evaluation of the 
Expert Patients Programme is presented in Chapter 4. Extensions and variations 
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on this single trial based model are presented in Chapters 5 and 6. These 
chapters introduce additional information, firstly from another UK based evaluation 
(in Chapter 5), and then through the incorporation of non-UK based data (in 
Chapter 6). 
It has also been argued that the Bayesian statistical paradigm is appropriate for 
the analysis of economic evaluations and that the role of inference (either 
Bayesian or classical) is inappropriate for economic analysis. 
The choice of paradigms for the analysis and interpretation of the cost- 
effectiveness of one particular intervention to support self care has been 
established. However, there are many interventions designed to support self care, 
some of which have been subjected to economic evaluation. Do the existing 
economic evaluations of self care support conform to the above arguments? Do 
economic evaluations of self care support interventions use methods of evidence 
synthesis to incorporate "relevant evidence"? Do they use an outcome measure 
that is wider than simply health (or a subsection thereof)? Do they assume a 
Bayesian or frequentist approach and is decision making based on concepts of 
statistical inference? 
These issues are often implicitly included in checklists used to assess the quality 
of existing evaluations. For example, the use of relevant evidence and the use of 
a narrow outcome measure are included in the Drummond checklist, 99 via the 
questions "were all important and relevant costs and consequences identified? " 
So, the paradigms chosen are one aspect of quality assessment. Clearly, there 
are other considerations, such as the use of an appropriate perspective, the use of 
discounting and the discussion of genera Usability. How all of these issues are 
dealt with in the existing literature of economic evaluations of self care support 
interventions is discussed in the systematic review presented in the next chapter. 
2.7 Conclusion 
It has been argued in this chapter that there are several contentious issues in the 
design, conduct and analysis of economic evaluation. For the purposes of this 
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thesis, analyses use a Bayesian approach to statistical analysis, and employ an 
extra-welfarist perspective. The issue of single trial based evaluations compared 
with evaluations including more evidence is examined in detail in later chapters. 
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Chapter 3. Systematic review of economic evaluations of 
self care support 
3.1 Introduction 
Before considering new research, it is necessary to consider work that has already 
been published. Existing literature may address the decision problem, but may 
also inform the design, conduct and analysis of future research. This chapter 
examines the existing literature around interventions to support self care and 
assesses whether this literature can be used to inform the design conduct and 
analysis of the cost-effectiveness study presented in the following chapter. An 
earlier version of the review of published economic evaluations contained in this 
chapter has been published in the International Journal for Technology 
Assessment in Health Care. 7 This chapter presents an updated and extended 
version of that publication. 
3.2 Evaluating self care support 
There are well established methods for the conduct of economic evaluations and 
checklists have been designed to assess the quality of these interventions. 99 It has 
been argued that there are additional problems in conducting economic 
evaluations of self care support interventions. 7' 100 These additional problems are 
described below, and inform the checklist developed in section 3.3.4. 
Z2,1 Comparatorinfe, venfion 
Economic evaluation of any intervention requires a comparator. 99 Unfortunately, 
the comparator is often less well defined in self care support interventions than in 
other interventions where the comparator is a placebo or another intervention. 
Historically, the usual comparator in self care support interventions is no active 
intervention or usual treatment. 101 The results section below indicates that this is 
true also of economic evaluations in this sphere. This makes it more difficult to 
compare interventions against each other and hence to choose the best option. 
Comparing different interventions would require indirect comparisons with a 
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common link. In this instance, "usual treatment" could provide a common link, but 
there is little to suggest that usual care is consistent across disease groups let 
alone geographical regions. 
122 Placebo effects 
Outcomes can be affected by patient expectations and beliefs, which can lead to 
effects where at least part of any change in outcomes is attributable to there being 
anyactive intervention. 102 Where these effects are potentially present, it is better 
to compare active interventions against each other rather than against a passive 
usual care control group. This is particularly problematic in self care support 
evaluations as the comparator is usually inactive. 
In addition, studies of group based self care support interventions, do not allow for 
the potentially beneficial effect of being a member of a group of individuals with 
similar conditions. 
123 Contro/group contamination 
There may be a higher risk of control group contamination. 7 Access to the 
intervention is more difficult to prevent with self care support interventions. For 
example, with patient education materials, patients in the control group may get 
access to the materials if they are published or from members of the intervention 
group. Randomisation by centre rather than by individual can reduce the risk of 
contamination. 
3.2.4 Range of outcomes 
Self care support interventions are likely to have a wider range of outcomes since 
they are often intended both to improve patient health and to empower patients by 
giving them greater control of health affecting decisions. Hence evaluations tend to 
include a wider range of outcome measures. For example, the evaluation of the 
Expert Patients Programme described in Chapter 4 includes measures of self- 
efficacy to manage disease, a measure of communication with health 
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professionals, and subjective well being in a number of domains, in addition to a 
battery of more conventional physical and mental health measures. 103 
3.25 Patient costs 
Evaluations ideally should adopt a societal perspective and take account of costs 
wherever they fall, including on patients. 99 If some costs or benefits are excluded, 
misleading analyses can be conducted. For example, an intervention may reduce 
costs slightly in the health care sector, and taking an NHS perspective would show 
a cost saving. In reality however, these costs may be just shifted to another 
provider, such as community care, so that the real cost to society of a new 
intervention is greater. 
Patient costs, which include time off work, out-of-pocket expenses, and travel are 
often difficult to measure and for this reason are often omitted from analyses. 
Given that self care support interventions are designed to alter the way patients 
manage their conditions, patient costs are likely to be more important than in 
economic evaluations of more conventional interventions. 
The inclusion/exclusion of these costs in the single trial based economic 
evaluation is considered in sections 4.5.4 and 4.6.7 of the next chapter. 
3. Z. 6 Length of fo // o w- up 
There is some evidence that beneficial effects of interventions last for quite short 
periods. periodS. 64' 65.104. los Hence results from studies with short follow-up periods may 
not be reliable guides to long-term effects. Many self care support interventions 
involve patients with chronic conditions so that long-term consequences may be 
important. 
There are fundamental trade-offs in choosing the length of follow-up in trials of self 
care support interventions. Longer follow-up may provide information on the time 
path of effects but it increases the risk of control group contamination. In the 
absence of any barriers, control group patients may employ the same self care 
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techniques as the intervention group, thereby diluting the treatment effect. Thus a 
reduction in the difference in observed outcomes between control and intervention 
groups over time may reflect a genuine reduction in the effect of the intervention 
on the intervention group or it may reflect an improvement in the condition of 
members of the control group who adopt the same self care practices as the 
intervention group. 
3.2.7 Transferability ofresults 
The transferability of results to other settings is important. Though transferability of 
estimates of effectiveness is an issue, in studies of conventional interventions 
issues of transferability are most usually raised for cost estimates. Differences in 
unit costs of resources between countries or over time mean that disaggregated 
data (volume and unit costs for different types of resource) are more likely to be 
useful in other settings. Differences in unit costs across settings may imply that 
cost minimising input mixes may differ and so a simple recalculation of costs using 
the original study volume data but local unit costs can be misleading. 
Transferability of the treatment effect on outcomes may be more of an issue for 
self care support interventions than several other types of intervention. Because 
the interventions tend to be psychosocial in nature, cultural factors that affect 
patients' receptiveness to self care may influence both the no intervention baseline 
and the effect of an intervention. Thus it is important that the context of the 
intervention is clearly specified. 
The transferability or exchangeability assumptions made in economic evaluations 
are discussed in much greater detail in Chapter 6. 
3.3 Methods 
3.3. / Se/f care support 
For the purposes of this review, self care support was defined as interventions 
faci/rfafingpatients taking decisions intended to alter the effect of their conditions 
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on their health, via their responses to symptoms, or monitoring their condition, or 
self treatment.? The definition is broad and the range of interventions is wide, but 
the emphasis is on informing, educating or training patients to change their 
behaviour. 
.7 12 Inc/us/on cri to ri a 
Studies were included if they were considered to be full economic evaluations of 
self care support interventions, that is the intervention was compared with an 
appropriate alternative and the costs and effects of both interventions were 
considered. 99 Hence, study type was not restricted to randomised controlled trials. 
Interventions included range from facilitated education programmes for diabetes 
patients to interventions supporting self care by introducing patient requested 
consultations rather than standard follow-up at the consultants' recommendation. 
Studies of interventions where the condition is managed by the patient but did not 
involve trying to change patient behaviour were excluded. Thus, an intervention to 
enhance an asthmatic patients' ability to manage their own condition by providing 
education and support from trained personnel would be included in the review, but 
an intervention comparing asthma drug A and asthma drug B would be excluded. 
.. Z 3.? Search strategy 
A systematic literature search and review of published economic evaluations of 
self care support interventions was carried based on the above definition. Full 
details are provided in Appendix A. The search strategy is identical to that 
previously published, 7 with the exception of end date which was extended to July 
2007. 
Eleven specialist databases were searched, including NHS Economic Evaluation 
Database (NHS EED), Health Economic Evaluations Database (HEED), Database 
of Abstracts of reviews of effects (DARE), Health Technology Assessment 
database and the National Research Register. Most of these databases were 
started in 1995 but some contained studies dating from 1993. They were searched 
without date restrictions to July 2007. In addition MEDLINE was searched from 
1966-1994. 
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3.3.4 Check/ist development 
A checklist was used to assess the quality of the studies included in the review. 
The checklist is presented in Appendix B. 7 
Guidelines, checklists and criteria lists used to assess methodological quality were 
identified. 106 Chiou et al (2003) identified 19 lists after a systematic search of the 
English language literature since 1990.107 Copies of these lists were used as the 
basis for the criteria for self care evaluations. There is some agreement across the 
19 lists examined by Chiou et al (2003) 107 on the questions to be asked of 
economic evaluation studies. The general issues to be addressed in economic 
evaluations are largely the same across all types of interventions and the checklist 
presented in Appendix B reflects this. The check lists from Chiou et al (2003), 107 
Drummond et al (1997), 99 NHS Centre for Reviews and Dissemination (2001), 108 
and Forbes et al (2002) 109 were most influential in the checklist presented in 
Appendix B. In particular, a criterion was included in the checklist if it was judged 
to be either: 
a) important in assessing the quality of economic evaluations in general (for 
example the perspective of the study) 
b) particularly relevant to the evaluation of interventions to support self care 
(for instance the measurement of costs to include patients' out-of -pocket 
expenditure). 
As with the Drummond checklist, there are several sub questions under some of 
the main questions. For these questions an assessment (subjective in nature) 
was made to assess whether the paper met the quality criteria. Such subjective 
assessments are a feature of most quality assessment checklists in the economic 
evaluation literature. 
3.4 Results 
The systematic literature search produced 2,570 abstracts. Of these 157 papers 
were deemed potentially includable in the review and the full paper was ordered. 
On examination of the full papers, 53 papers were identified as full economic 
54 
evaluations of self care support interventions and were therefore considered 
suitable for review. The studies identified as full economic evaluations and the 
paper selection method is illustrated in Figure 3.1 below: 
Systematic literature search 
up to 2007 
2,570 abstracts 
157 papers obtained 
53 economic 
evaluations of support 
for self care 
2,413 excluded: apparent from the abstract 
that the study either was not an economic 
evaluation or not support for self care 
104 excluded: identified 
as not an economic 
evaluations and/or not 
self care support 
Figure 3.1 Selection of papers for assessment against criteria list 
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%Z 1> Study characteristics 
Summary tables of the characteristics of full economic evaluations identified are 
provided below in Tables 3.1 and 3.2 including details of each study including the 
origin of the data (both country and date), the type of study (both economic and 
clinical), the geographical location and clinical setting. 22 of the 53 studies (42%) 
were based in the US, with eleven from the UK (21%), nine from Scandinavian 
countries (17%), and the remainder from other countries. All the studies were 
published after 1993 and the RCT (n=33,62%) was the most common design of 
the clinical study. 
Of the 53 studies, only 21 (40%) could be considered cost-effectiveness analyses 
or cost-utility analyses. The remainder were cost consequence analyses where 
the incremental costs and outcomes were not formally synthesised and/or 
compared, 99' 110 rather a range of health (and/or other) outcomes are presented to 
decision makers. 10 
These interventions were applied across a range of (mainly chronic) conditions. 
Asthma (n=13), diabetes (n=8), arthritis (n=3) and heart disease (n=3) were the 
most commonly specified conditions, while "chronic disease" was evaluated in a 
further four studies. 
Four studies did not report the follow-up period. Of the remainder, 12 months was 
the most common follow-up period (n=25), with 13 studies having a follow-up 
period (or time horizon for models) in excess of one year. 
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142 Study conclusions and quality 
Most of the studies concluded that the self care support intervention was either 
dominant (in that costs were reduced and patient outcomes improved) or cost- 
effective (the additional benefit was judged to be worth the extra cost) (n=41,77%). 
Only four studies claimed that the intervention was not cost-effective, while the 
remainder (n=8) were inconclusive. While this may appear to be in favour of 
evidence to support these interventions, most studies had significant flaws, which 
have been previously discussed. 7 The most common flaws were: 
a) Poor costing methodology. Only 30% of studies (n=16) had a societal 
perspective. Others defined costs narrowly, for example ignoring patient 
expenditure. Several also did not present unit cost data so that replication of 
results was not possible. 
b) Inappropriate comparison group. Several studies (n=11) used a before and 
after design. There may be many reasons for changes over time in such 
studies, for example, regression to the mean may be an important factor 
where costs are high in one period and lower in the next. 
c) Inadequate handling of uncertainty. Many studies did not conduct sensitivity 
analysis (n=20) nor presented confidence intervals around mean estimates of 
cost or effect. Without these analyses/estimates, it is not possible to estimate 
the probability that an intervention is cost-effective. 
d) Missing data were either ignored or dealt with inappropriately. Few studies 
(n=8) reviewed handled missing data using recommended techniques (such 
as multiple imputation). It has been shown that results can be sensitive to 
imputation of missing data and to the choice of imputation method 
employed. 159 
e) Short period of follow-up. The majority of studies (n = 38) had a follow-up (or 
time horizon) of one year or less. The majority of clinical trials have relatively 
short follow-up periods. This "truncation of the time horizon" has been 
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discussed in more detail in section 2.3.2, but can lead to erroneous estimates 
of the treatment effect. 
f) Choice of outcome measure. Because studies often aim to demonstrate 
improvements not only in patients' health but also in empowerment, 
autonomy and control of health affecting decisions, evaluations tend to 
include a wider range of outcome. While this is not necessarily a weakness 
of the study, it is a limitation to the generalisability of the study and its 
usefulness for decision making (as these outcomes are not used in different 
conditions and are seldom valued). 
Eleven UK based studies were identified. Of these, five studies c/airnedthat the 
intervention to support self care was cost-effective, in that either the intervention 
was dominant (costs reduced and outcomes improved) or the incremental cost- 
effectiveness ratio (ICER) lay below a specified threshold value. 134,153-155,158 In one 
case this is a questionable claim, 158 as the study reported increased costs and 
improvement in outcomes, but no valuation of outcomes was performed. Three 
studies reported that support for self care was not (or was unlikely to be) cost- 
effective as the ICER exceeded a specified threshold. 116,129,148 Three studies were 
inconclusive as costs and outcomes were both increased and no valuation of 
outcomes was performed to assess whether the benefits might outweigh the 
costs . 
121,138,144 
The UK based studies were, in general, well conducted with two presenting 
uncertainty in the form of cost-effectiveness acceptability curves and dealing with 
missing data in an appropriate manner. 148,154 Clearly, the proportion of UK studies 
claiming the intervention was cost-effective (5/11,45%) was lower than that of the 
whole sample (41/53,77%). Similarly, the proportion of studies claiming that the 
intervention was not cost-effective was considerably higher in the UK sample (27% 
vs 8%), though sample sizes are too small to make any peremptory statements 
regarding cost-effectiveness of these interventions in the UK. Whether it was the 
better quality of the UK studies, or the geographical location that influenced the lack 
of cost-effectiveness is unclear given the existing evidence. 
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The evaluations of interventions based on the Chronic Disease Self Management 
Program or the Arthritis Disease Management Programme were not generally well 
conducted. Four economic evaluations of this intervention (on which the UK Expert 
Patients Programme is based) were identified. "' 75,79,80 These studies were all 
conducted in the US in patients with a range of chronic conditions. These studies 
were poorly conducted in that missing data were largely ignored rendering the 
statistical analysis largely questionable and in general had little allowance for 
uncertainty. Further c/irýica/evaluations of these interventions are reviewed in 
Chapter 6, but evidence of the cost-effectiveness of these interventions from the 
existing published literature must be considered to be unreliable. 
3.5 Discussion 
Interventions to support patient self care are very diverse and take place in many 
types of setting, so drawing general conclusions about the cost-effectiveness of 
these interventions from the existing literature is problematic. The pooling of results 
of these studies is inappropriate due to the heterogeneous nature of the studies, 
their patient populations, settings and choice of outcome measure. 
There were clear differences in the results from studies in different countries. Three 
of the four studies that showed that these interventions were not cost-effective were 
UK based, while the proportion claiming that these interventions were cost-effective 
was noticeably lower than for the whole sample. 
It is not possible to ascertain whether the contrasting conclusions generated from 
the different geographical locations of these studies is due to the different quality of 
evaluations carried out in different countries or a real difference in the relative cost- 
effectiveness of these interventions in different countries. 
The cost-effectiveness of interventions may also differ between conditions. For 
example, there were four evaluations of chronic illness, all claiming that the 
interventions were cost-effective . 
75,79,80 However, for osteoarthritis of the knee, 
there were two studies, 129.131 one of which showed equivocal results 131 the other 
demonstrating that the self care intervention was not cost-effective. 129 Similarly, the 
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type of intervention is likely to impact on effectiveness and cost-effectiveness. For 
example, groups providing training in self care may be very different in their 
effectiveness and cost-effectiveness to pharmacists providing information for 
individuals. 
Resource and unit cost data may not be readily transferable between systems. It is 
also likely that the outcome effects of these interventions may be culturally 
dependent. Some interventions concentrate on a very narrow patient population 
while others consider all chronic conditions. It is unsurprising that the conclusions of 
studies based on these diverse populations are different. There may also be more 
control group contamination in some studies than in others (for example where the 
intervention is based on a published guidebook, it may be possible for control group 
patients to access that information). These issues, particularly the transferability of 
treatment effects on costs and outcomes, are discussed in greater detail in Chapter 
6. 
Many of the studies reviewed were of poor quality, most having one or more major 
drawbacks. Many of these studies would not be of the quality required by NICE for 
use in technology appraisal. 12 This lack of quality limits their usefulness for UK 
policy. A previous review of evaluations of self management interventions was also 
critical of the methodology and of the lack of consideration of the cost-effectiveness 
of self management interventions. 160 Bower et al noted that there were no data on 
long-term clinical or cost-effectiveness for these interventions and "available 
evidence is limited in quantity and quality and more rigorous trials are required to 
provide more reliable estimates of the clinical and cost-effectiveness of these 
treatments". '61 
3.6 Conclusion 
Chapter 2 identified the various paradigms within economic evaluation. The majority 
of economic evaluations reviewed in this chapter were based in the extra-welfarist 
paradigm (either implicitly or explicitly) with the maximisation of patients' health 
outcomes (rather than changes in individuals utility), subject to an exogenously 
given budget constraint. None of the economic evaluations identified sought to 
broaden the perspective of the study beyond this approach. In addition, the majority 
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of evaluations were based on the results of a single trial/study, with little attempt to 
synthesise data. The majority of evaluations were based in the frequentist paradigm 
with few studies providing estimates of, for example, the probability of the 
intervention being cost-effective at various values of the outcome measure chosen, 
though there were exceptions to this. 148' 162 
There was no evidence of the identified studies attempting to synthesise all relevant 
evidence, to use an outcome measure that is useful for decision making purposes or 
to place a "value " on the outcomes measured. The usefulness of the studies 
described above for informing the debate over whether interventions to support self 
care are cost-effective in the UK setting is limited. To be helpful for decision makers 
to choose between interventions across a variety of conditions, results of 
evaluations should use a generic outcomes measure. 12,163 The QALY is an example 
of generic measure of health related quality of life encompassing both the quality 
and quantity of life. Chapter 4 presents an economic evaluation using the QALY as 
an outcome measure. This cost-effectiveness study is based on the results of a 
single randomised controlled trial conducted in the extra-welfarist tradition with 
maximisation of health (as measured by the QALY) as the outcome measure of 
interest. The chapter presents an evaluation of the Expert Patients Programme 
(EPP) that is now widely available in the NHS and is intended to be available to 
100,000 individuals with chronic conditions by the year 2012.1 
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Chapter 4. The Expert Patients Programme Cost- 
Effectiveness Evaluation. 
4.1 Introduction 
The previous chapter concluded that previous economic evaluations of self care 
support interventions were of limited use for decision makers in the UK, partly due to 
their poor quality and partly due to the use of outcome measures which are difficult 
to value. The decision maker's task of efficiently allocating resources is aided by the 
use of a generic outcome measure which has some commonly accepted value. 
This chapter describes the single trial based cost-effectiveness analysis undertaken 
alongside the randomised controlled trial of the Expert Patients Programme (EPP). 
The outcome measure for the economic analysis was a generic instrument (the 
QALY) which enables comparisons to be made between interventions in different 
conditions. As such, the results of an economic evaluation of EPP are directly 
relevant to the decision problem specified earlier and are therefore of interest to 
decision makers concerned with the cost-effectiveness of interventions to support 
self care. 
The chapter employs an extra-welfarist perspective and utilises Bayesian 
methodology, as described in Chapter 2, to present an analysis that is intended to 
be useful for decision makers. The review presented in Chapter 3 identified several 
drawbacks from the existing literature which the analysis presented in this chapter 
avoids. Notably, previous economic evaluations of the EPP have tended to handle 
uncertainty and missing data inappropriately, 71'73,75,7' as well as use an outcome that 
does not facilitate comparison between cost-effectiveness in differing disease areas. 
The objective of this chapter is to present the aims, design, conduct and analysis of 
the cost-effectiveness of the EPP intervention based on a single trial based 
evaluation. The uncertainty associated with this estimate is presented by estimating 
the probability that the EPP is cost-effective over a range of values of decision 
makers' threshold value of an additional quality-adjusted life-year. The contents of 
this chapter form the basis of a publication in press with the Journal of Epidemiology 
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and Community Health. 162 The cost-effectiveness results presented in this chapter 
were also included in the clinical paper previously published in the same journal. 66 
4.2 Background to the EPP 
The NHS Plan identified self care as an important factor in providing a "patient 
centred health service". 8 More recently a Department of Health report has claimed 
that supporting self care can "improve health outcomes [and], improve patient 
satisfaction", 3 while the roll-out of the Expert Patients Programme (EPP) "could 
create a generation of patients empowered to take action to improve their health". 9' 
10 The 'Expert Patients Programme' (EPP) aims to provide self care support to any 
individual with a chronic condition in England. The EPP is based on a generic 
programme developed in the US, the chronic disease self management programme 
(CDSMP). This lay led group intervention is designed to enable participants to 
develop appropriate self care skills. 66 
As asserted in Chapter 1, in a budget constrained system such as the National 
Health Service (NHS), it is important for these interventions to promote patients' self 
care or self management to be cost-effective as well as clinically effective. To 
establish whether an intervention is cost-effective in a budget constrained system 
requires that the outcome measures used are generic. 
4.3 Methods 
The EPP is an intervention designed to support patients' self care that has been 
"rolled out" across England and Wales. This analysis is conducted in the extra- 
welfarist tradition in that there is an assumed exogenously defined budget constraint 
and health as measured by the QALY is the maximand. This enables comparison 
across conditions which were not possible with many of the trials reported in the 
previous chapter. 
This cost-effectiveness analysis takes a Bayesian perspective in that the parameters 
are considered to have probability distributions and that it is not a requirement to 
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have a set of random experiments (a sample space) from which to assess the 
relative frequency of events. In this paradigm it is possible, and appropriate, to 
compute the probability of an event being effective and/or cost-effective. It was 
argued in an earlier chapter that this is a more useful technique for presenting the 
results to decision makers. 
Briefly, the EPP evaluation was a two-arm trial comparing the clinical and cost- 
effectiveness of a lay led self care support programme. The comparator was a 
waiting list control. It is acknowledged that some of the weaknesses identified in the 
literature review in Chapter 3 have been replicated in this cost-effectiveness study. 
In particular, the study has a relatively short follow-up period and the control group 
were a waiting list control rather than an active intervention. These were 
shortcomings that were unavoidable in this practical study. Nevertheless, the 
design, conduct and analysis of this study conform with accepted methodologies to 
a greater degree than did the previous studies. This is particularly the case in the 
treatment of missing data, the characterisation of uncertainty, the costing 
methodology and the choice of outcome measure. 
The EPP evaluation can be described as a "pragmatic" trial or "primary cost- 
effectiveness trial" as it was based in a real world setting and considered cost- 
effectiveness rather than cost-efficacy. 66,165 
4.1 > Pa#icipanfs 
The intervention was designed to enhance the self-efficacy of patients with a self 
defined long-term condition. Any individual with a self defined long-term condition 
could participate in the trial. Participants in the trial self reported their main condition 
on the baseline questionnaire; other co-morbidity was also recorded but analysis 
was carried out on the main condition. There were no specific inclusion or exclusion 
criteria, with recruitment carried out in all 28 Strategic Health Authorities in England. 
Recruitment was community based and used a variety of methods including posters 
in GP surgeries and media advertisements. Thus, patients were not recruited in 
clusters (such as GP practice), but individually as they put themselves forward for 
the EPP program. Characteristics of the two groups were presented in the clinical 
ss paper, and are reproduced below in Table 4.1. There was little difference between 
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the groups in types of condition. 
The most common conditions were musculo-skeletal and endocrinal and were 
closely matched in the two groups. In addition, the groups were comparable in 
terms of their age, gender, ethnicity and other socio-demographic characteristics. 
4,3.2 Intervention 
The intervention consisted of six 2.5 hour group sessions, with between 8 and 12 
individuals per group, and was held weekly. Topics within the sessions included 
relaxation, diet, exercise, fatigue, breaking the 'symptom cycle', managing pain and 
medication, and communication. Groups were led by two lay trainers or volunteer 
tutors. The lay leaders were people with lived experience of long-term conditions. 
They were trained and subject to a quality control process. 166 The intervention 
focussed on increasing participants' self-efficacy through problem solving and goal 
setting. Patients in the waiting list control could access the intervention after six 
months. While on the waiting list control, participants received treatment as usual 
and were advised to continue to manage their condition as they usually would. 
4.3.3 Outcome measures 
The outcomes used in the clinical trial reflected the objectives of the intervention. 
The mechanisms involved in the evaluation of complex interventions can be 
intricate. 167 As described in Chapter 1, the EPP is based on the Chronic Disease 
Self Management Programme that emphasises the importance of self-efficacy in the 
management of chronic conditions. Health psychology models of the CDSMP 
suggest a theoretical model where change in self-efficacy cognitions (patients' 
confidence in managing their condition) acts as a causal mechanism towards health 
status and utilisation. 168 
Individuals' level of self-efficacy was included as a measure of outcome. Self- 
efficacy is measured on a1 to 10 scale varying from "not at all confident" to "totally 
confident". In addition, the cost-effectiveness analysis used the QALY (described 
below) as a measure of outcome. 
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Table 4> Base/irre demographic andhea/fh characteristics 
Characteristic Intervent/on n= 313 Contiö/n = 316 
Age (SD) 55.5 (13.6) 55.3 (13.6) 
Gender: Female 219 (70.0%) 220 (69.6%) 
Ethnicity: White 298 (95.2%) 299 (94.6%) 
Marital status: Lives alone 82 (26.2%) 93 (29.4%) 
Lives with spouse/partner 188 (60.1%) 190 (60.1%) 
Educational qualifications: None 77 (24.6%) 61 (19.3%) 
Degree 51 (16.3%) 53 (16.8%) 
Accommodation: Owner-occupied 214 (68.4%) 214 (67.7%) 
Work situation: In paid work 58 (18.5%) 66 (20.9%) 
Unable to work due to condition 111 (35.5%) 106 (33.5%) 
Retired 110 (35.1%) 111 (35.1%) 
Self reported main long-term health condition': 
Musculoskeletal 106 (33.9%) 107 (33.9%) 
Endocrine 37 (11.8%) 37 (11.7%) 
Circulatory 20 (6.4%) 24 (7.6%) 
Myalgic encephalitis /chronic fatigue 22 (7.0%) 25 (7.9%) 
Respiratory 23 (7.4%) 17 (5.4%) 
Mental health 19 (6.1%) 19 (6.0%) 
Neurological 20 (6.4%) 18 (5.7%) 
Other 66 (21.1%) 69 (21.8%) 
Self reported general health: 
Very good/excellent 32 (10.2%) 34 (10.8%) 
Good 90 (28.8%) 92 (29.1%) 
Fair 122 (39.0%) 111 (35.1%) 
Poor 69 (22.0%) 79 (25.0%) 
Self reported baseline health characteristics: 
Self-efficacy (SD) 45.9 (21.5) 47.7 (22.3) 
Energy (SD) 32.6 (19.5) 33.3 (20.1) 
Service utilisation (SD) 8.6 (7.3) 9.1 (8.1) 
Classification of Primary Care Trust locality2: 
Predominantly rural 94 (30.0%) 93 (29.4%) 
Some rural and mixed 114 (36.4%) 118 (37.3%) 
Major and large urban 105 (33.6%) 105 (33.2%) 
Seasonal change between recruitment and follow-up3: 
Follow-up at a 'worse' month in cycle than recruitment 21 (6.7%) 18 (5.7%) 
Follow-up at a 'better' month in cycle than recruitment 31 (9.9%) 45 (14.2%) 
No difference 28 (9.0%) 24 (7.6%) 
No seasonal pattern 233 (74.4%) 229 (72.5%) 
Time between recruitment and follow-up: 219 (40.6) 209 (37.1) 
' Post-hoc classification. The classification used in minimisation was: musculoskeletal, diabetes, 
heart disease, other. 
Z Definition taken from Department of Environment, Food and Rural Affairs classification of Primary 
Care Trusts in England (September 2005). 
3 Based on informant ratings of each calendar month, collected at baseline. 
Data for all outcome measures were collected at baseline, 6 months and 12 months. 
Postal questionnaires were used for all follow-ups, non-responders were 
subsequently contacted with telephone reminders. 
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At the 12 month follow-up the control group had been offered treatment and 
therefore the analysis below considers only the six month data. 
4,3.4 Perspective 
Patients were the unit of randomisation and the unit of analysis. The trial used a 1: 1 
randomisation ratio. The analysis takes a societal perspective (including the costs to 
patients) with effects assessed in terms of health gains, measured in terms of 
quality-adjusted life-years (QALYs). An additional analysis considers the 
perspective of government agencies (health and social care). 
All costs and outcomes fell within a six month period and therefore discounting was 
not appropriate. 
4.7 5 Resource Use andiinputation 
Traditionally, economic evaluations do not collect data on resource use before the 
intervention is delivered. Thus, the mean resource use in each group is measured 
without considering whether individuals in the group were substantial users of 
resources or not. However, more recently, the importance of adjusting for baseline 
imbalance has been recognised. 44 In this trial previous resource use data were 
collected and therefore could be used as predictors of final resource use. In the 
EPP evaluation, patients were asked to estimate their use of resources over the 
previous six months (i. e before randomisation). For each item of resource use, this 
pre-baseline value was used as a covariate to adjust post-randomisation resource 
use. 
Therefore, two analyses of resource use are presented. Firstly, the analysis is 
presented in the usual manner without adjustment for previous resource use. 
Subsequently an analysis where resource use is adjusted for previous resource use 
is presented. 
Analysis of resource use data using imputed values is problematic as pre- 
randomisation resource use was used as an explanatory variable in the imputation 
of missing values and therefore there would be an element of double counting. In 
addition, where multiple imputation techniques are used (see sensitivity analysis in 
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section 4.8), several (usually five) datasets would need to be created for each 
resource use, in this case generating around 100 datasets, which are unwieldy for 
analysis. Therefore, for the resource use estimates presented in Table 4.3, the 
figures are based on the complete case analysis. 
4.4 Sources of data 
4.4,1 Resource use 
Resource use data were collected alongside clinical data during the EPP trial. 
Patient questionnaires (see Appendix G) were administered at baseline and six 
month follow-up. Patients were asked for details of visits to primary health care 
practitioners, secondary care appointments and hospital stays as well as community 
based support and individuals' out-of pocket expenditure. The medication that each 
patient received was also recorded. 
4,42 Unit costs 
Inpatient cost per day and outpatient cost per visit for attendances were both based 
on national estimates. 169 Estimates were inflated to a 2003/2004 price base using 
the Health Service Cost index. These figures are national estimates and are 
therefore appropriate for an evaluation conducted across all the SHAs in England. 
The cost of a GP visit (both home and surgery) and the cost of a practice nurse visit 
(home and surgery) were derived from Curtis and Netten estimates. 170 The unit cost 
estimate includes cost of training as well as direct care support staff and is inflated 
to a 2003/2004 price base. 
The unit cost of each medication was estimated from the British National 
Formulary. "' 
The cost of the intervention used in the trial was estimated from data on the overall 
costs of the EPP and the throughput over the period of the trial (the period April 
2003-March 2005). 172 These cost estimates include the cost of managing the 
programme, costs of training and delivery of the programme as well as the cost of 
providing facilities. 
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4 43 Health States and their value 
The EQ-5D instrument was used to measure patients' health states and to ascribe 
those states values. EQ-5D measures patient health status across five dimensions 
(mobility, self care, usual activities, pain/discomfort and anxiety/depression) with 
three possible responses (no problems, moderate problems or severe problems) for 
each dimension. 173 This locates each participant into one of 245 mutually 
exclusive health states (with the addition of death and unconscious), each of which 
has previously been valued on the zero (equivalent to dead) to one (equivalent to 
full health) valuation scale based on interviews with a sample of 3,395 members of 
the UK public. 174 The questionnaire is presented in Figure 4.1 below. 
QALYs were calculated by plotting the EQ-5D utility score at baseline and at six 
month follow-up and calculating the area under the curve. This is the appropriate 
method as it reflects the fact that the QALY is a product of both time and utility. 15 
As is common in the health economics literature, it was assumed in the absence of 
evidence to the contrary, that changes in utility score over time followed a linear 
path, 43 that is there were no higher order terms (squared, cubed etc) included in the 
change in EQ-5D scores over time. This generates a QALY gained for each patient 
over the six month time period of the study. An illustration of the QALY calculation 
for the control group in this study is presented below. More detailed examination of 
QALY calculation can be found elsewhere. 43 
The two trial groups (intervention and control) were then compared over the six 
month period to generate the estimate of mean differential QALYs between the 
groups. These estimates were then adjusted for baseline EQ-5D as recommended 
by Manca et al. 44 Gender and age were also included as covariates in order to 
adjust for any differences at baseline (whether statistically significant or not). 
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Tick one box for each group of statements. 
Mobility 
I have no problems in walking about Q 
I have some problems in walking about Q 
I am confined to bed Q 
Self-Care 
I have no problems with self-care Q 
I have some problems washing or dressing myself Q 
I am unable to wash or dress myself Q 
Usual Activities 
I have no problems with performing my usual activities Q 
(e. g. work, study, housework, family or leisure activities) 
I have some problems with performing my usual activities Q 
I am unable to perform my usual activities Q 
Pain/Discomfort 
I have no pain or discomfort Q 
I have moderate pain or discomfort Q 
I have extreme pain or discomfort Q 
Anxiety/Depression 
I am not anxious or depressed Q 
I am moderately anxious or depressed Q 
I am extremely anxious or depressed Q 
Compared with my general level of health over the past 12 months, my health 
state today is: 
Better Q 
Much the same Q 
Worse Q 
Fiaure 4.1 The EQ-5D instrument 
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E45 D 
score 
0.54 
0.47 
0 
Baseline Six months 
Figure 4.2 Calculation of a QALY 
4.5 Methods of analysis 
4,5,1 Missing data andimpufafion 
Where resource use or EQ-5D data were missing, the analyst needs to be aware of 
the pattern of missing data. There is no formal test to verify the assumption that 
data are missing at random (MAR), and this assumption is often chosen as a 
starting point when data are missing. 176 This approach was employed in this 
analysis. 
The best subset regression method was employed to impute missing data using 
Stata 8. The impute function in Stata conducts an efficient missing value 
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Utility score over time 
regression by sorting the missing data into patterns. This method determines which 
independent variables should be included in a regression model by examining all of 
the models created from all possible combinations of independent variables and 
uses R2 to check for the best model. 
Explanatory variables included in all imputations were treatment group, age and 
gender. For missing EQ-5D scores, the baseline score on that dimension was also 
employed as a covariate. For missing resource use data, the baseline value for that 
resource was included as a covariate. 
Multiple imputation, where several datasets are created with different values 
generated for each missing value in each dataset, was employed as a sensitivity 
analysis. 
4.5 2 Incremental cost-effectiveness ratios (ICERsj andnetmonetarybenefits 
The ICER is calculated from the mean difference in cost and effect between the two 
treatment options. The ICER is presented in this analysis where appropriate. 
However, because of problems interpreting ICER statistics that cover more than one 
quadrant of the cost-effectiveness plane, this analysis also uses the net benefit 
approach to cost-effectiveness analysis described below. 88' 90' "' 
Using the patient level estimates of costs and effects, it is possible to determine the 
joint density of costs and effects by re-sampling (the non-parametric bootstrap). 178 
In this instance, replicated samples were made by drawing from the original sample 
(with replacement) of 629 patients' costs and effects (313 EPP and 316 control). 
This procedure is repeated 1,000 times generating 1,000 distributions of costs and 
effects for each group. For each of these re-samples, the range of values of the 
cost-effectiveness threshold value of a QALY (henceforth represented by A) was 
applied to the mean effects (reflecting the range of values that could be placed on 
the measure of effect, in this case the QALY) , thereby generating the net benefit 
figure (for each value of A). The cost-effectiveness threshold value of a QALY is a 
matter of some debate, 61 with commonly quoted values of £20,000 to £30,000 per 
QALY. 12 Cost-effectiveness analyses commonly portray ranges of values of £0 to 
£50,000 for this threshold. 
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Thus, the value of net monetary benefit is dependent on the threshold value (X) of 
an additional QALY (as below). 
Net Monetary Benefit (NMB) = (7% * QALYs) - Cost 
If the Incremental Net (monetary) Benefit (INB) (i. e. the NMB in the EPP group 
minus the NMB in the control group) is greater than zero for that value of A, the 
treatment is judged to be cost-effective. The proportion of the samples of the INB 
estimates that are judged to be cost-effective over the range of values of threshold 
values of a QALY is then used to generate the cost-effectiveness acceptability curve 
(CEAC). 88' so 
Thus the uncertainty surrounding the NMB statistic can be used to identify the 
probability that a strategy is cost-effective using the cost-effectiveness acceptability 
curve (CEAC). The CEAC is a graphical representation of the probability of an 
intervention being cost-effective over a range of monetary values for threshold value 
of a QALY. The probability of an intervention being cost-effective differs according to 
the valuation the decision maker places on a QALY. 
As an example, imagine we have an intervention that improves QALYs but also 
costs more. It may be that if we place a value of £10,000 on a QALY, 75% of the 
replications result in a positive NMB. However, if we value gains in QALYs more 
than this, say at £30,000 per QALY, then 95% of replications result in a positive 
NMB. The CEAC portrays these estimates in graphical format. 
For this analysis the threshold value of a QALY was varied from zero to £50,000. 
The value zero is equivalent to a comparison of the groups in terms of total costs, as 
outcomes are effectively not considered (or are assumed equivalent). 
4 53 AIM horizon 
The primary results of this cost-effectiveness analysis reflect the six month period of 
the trial. Any benefit (or harm) of the intervention was measured over a six month 
period. This approach implicitly assumes that any costs and effects in the 
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intervention and control groups occurring after the six month follow-up period are 
zero, and in this instance this may represent a conservative analysis (i. e. in favour of 
the control group). A sensitivity analysis examined the assumption that patients on 
the programme maintain the same EQ-5D score at 12 months as they have at the 
six month follow-up. As the intervention has been delivered, it is assumed that the 
there is no difference in costs between the intervention and control groups in this 
hypothetical follow-up period. 
45 4 Sensitivity analyses 
Though the form of stochastic analysis described above addresses a large amount 
of uncertainty in the analysis, it is still appropriate to perform sensitivity analysis to 
allow for variability and methodological uncertainty. Four separate sensitivity 
analyses were performed; the first increasing the cost of the intervention costs to 
£450 per patient on the EPP, the second to include only costs falling on the health 
and community care sector and the third to reflect the possibility of the difference in 
utility between the groups being maintained over a longer period (in this case 12 
months). The final sensitivity analysis used an alternative method, multiple 
imputation, to impute value for data that were missing at follow-up. 
4.6 Results 
The CONSORT diagram of the trial is presented below in Figure 4.3. 
4 6.1 MLcsing data 
A total of 629 patients were recruited to the trial between April 2003 and March 
2005. There were no missing data on resource use or EQ-5D at baseline. However, 
there were missing data for both resource use and utility data at follow-up. At six 
month follow-up, 514 patients (82.0%) provided full EQ-5D responses; seven 
patients who completed the six month follow-up (as shown in the diagram above) 
did not complete the EQ-5D questionnaire. Of these 514,243 were in the treatment 
group with 271 in the control group; thus missing values were higher in the 
intervention group than in the control group (22.1% vs 14.0%). 519 (82.7%) patients 
provided full resource use data, though again there were more missing values in the 
intervention group than in the control group (21.2% vs 13.3%). 
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Potential participants 
requesting information about 
the teal (n=1260) 
Randomised (n=629) II Non-participants (n=631) 
Immediate referral to 
programme (n=313) 
Attended programme 
(n=232,74.1%) 
Attended 4+ sessions (n=187.59.7%) 
Attended all 6 sessions (n=104,33.2%) 
Completed 6 month follow- 
up (n=248,79.2%) 
Waiting list control (n=316) 
Completed 6 month follow- 
up (n=273,86.4%) 
Fiaure 4.3 CONSORT diagram of the EPP national evaluation (reproduced from Kennedy et 
al ) 
4 6.2 Resource use 
4 621 Unaodüstedresource use 
Unadjusted mean levels of resource use are presented below in Table 4.2. These 
estimates utilise resource use data estimated without the imputation method 
described above (i. e. are based on responders/completers of questionnaires). 
For the majority of resource use variables above, the EPP programme resulted in a 
reduction in resource use. Though most of these differences are small, they are 
likely to offset some of the cost of the intervention. 
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Table 4 2" Mean resource use in the two groups overfhe 6-inonih period 
Intervention 
Group 
Control 
Group 
Mean N Mean N Mean Difference 
X95% Confidence /nteiva) 
Inpatient length of stay . 80 246 1.59 272 -0.79 
(-1.75 to 0.18) 
2.73 248 2.91 273 
Number of outpatient appointments -0.18 
(-1.17 to 0.81) 
General Practitioner (at the surgery) 3.36 246 3.44 269 -0.08 
(-0.65 to 0.49) 
General Practitioner (at patient's home) . 09 247 . 18 268 -0.09 
(-0.18 to -0.01) 
Practice Nurse (at GP surgery) 1.37 247 1.59 271 -0.22 
(-0.77 to 0.32) 
Occupational Therapist (at home) 
. 06 237 . 22 264 -0.16 
(-0.32 to -0.00) 
District Nurse (at home) 
. 31 237 . 23 264 
0.08 
(-0.34 to 0.52) 
Home help 1.38 237 1.92 264 -0.54 
(-2.32 to 1.25) 
Meals on Wheels . 55 237 . 02 264 0.53 
(-0.56 to 1.61) 
Physiotherapist (at home) 
. 11 237 . 
07 264 0.03 
(-0.11 to 0.18) 
NHS Direct 
. 32 237 . 29 264 
0.02 
(-0.16 to 0.21) 
Walk-in Centre 
. 08 237 . 09 264 -. 
00 
(-0.1 to 0.09) 
Counsellor 
. 64 237 . 60 263 0.04 
(-0.46 to 0.54) 
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4622 Adüstedresource use 
In the EPP evaluation, patients were asked to estimate their use of resources over 
the previous six months (i. e before randomisation). For each item of resource use, 
this pre-baseline value was used as a covariate to adjust post-randomisation 
resource use. 
The tables below show the results of the adjusted analyses. These analyses are 
based on the analysis of responders only (i. e. complete case analysis). 
The second column of Table 4.3 replicates the analysis from Table 4.2 above. The 
third and fourth columns show analyses where the resource use estimates are 
adjusted for baseline differences. In the third column the resource use estimates 
are adjusted only for the treatment group and the relevant pre-baseline levels of 
resource use (for example GP visits are adjusted for pre-randomisation number of 
GP visits). In the final column, these are supplemented with adjustments for age, 
gender and condition. Adjusting for baseline covariates, though appropriate, has 
little impact on the results in most cases. The direction of the result changes in two 
cases, that of NHS Direct contacts and the cost of medication. In the former case, 
the unadjusted analysis showed the intervention was associated with a higher use, 
but when the estimates were adjusted for baseline covariates, the intervention was 
associated with a reduction in resource use. In the case of the cost of medication, 
the reverse is true. Initially, the unadjusted analysis demonstrated a reduction in 
drug costs associated with the intervention, but adjusting for covariates showed that 
there was in fact an increase in drug use associated with the intervention. This is 
likely to be due to the fact that treatment group is not the only factor influencing 
medication use. Thus the control group are likely to have had more "high 
medication use" individuals than the treatment group, and once this (and other 
factors) was allowed for in the analysis it becomes apparent that the effect of 
treatment group on medication is positive rather than negative. However, in 
absolute terms, both these changes are minimal and have little impact on the 
probability of the intervention being cost-effective. 
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Table 4.3: Mean resource use in the Iwo groups overfhe 6-month periodbased on 
complete case analysis 
Unadjusted Adjusted for Adjusted for 
baseline baseline resource 
resource use use, age, gender, 
condition 
Mean Difference Mean Difference Mean Difference 
(95% Confidence (95% Confidence (95% Confidence 
/nteiva// /nteiva// /nteiva/j 
Inpatient length of stay (days) -0.79 -0.75 -0.74 
(-1.75 to 0.18) (-1.71 to 0.21) (-1.70 to 0.23) 
Number of outpatient -0.18 -0.06 -0.04 
appointments (-1.17 to 0.81) (-1.01 to 0.89) (-1.00 to 0.91) 
General Practitioner (at the -0.08 -0.03 -0.02 
surgery) (-0.65 to 0.49) (-0.54 to 0.48) (-0.53 to 0.50) 
General Practitioner (at your -0.09 -0.10 -0.11 
home) (-0.18 to -0.01) (-0.18 to -0.02) (-0.19 to -0.02) 
Practice Nurse (at GP surgery) -0.22 -0.22 -0.23 
(-0.77 to 0.32) (-0.77 to 0.32) (-0.79 to 0.32) 
Occupational Therapist (at home) -0.16 -0.17 -0.18 
(-0.32 to -0.00) (-0.33 to -0.01) (-0.34 to -0.02) 
District Nurse (at home) 0.08 -0.02 -0.03 
(-0.34 to 0.52) (-0.44 to 0.38) (-0.44 to 0.38) 
Home help -0.54 -0.32 -0.37 
(-2.32 to 1.25) (-1.28 to 0.64) (-1.33 to 0.59) 
Meals on Wheels 0.53 0.54 0.53 
(-0.56 to 1.61) (-0.48 to 1.57) (-0.51 to 1.56) 
Physiotherapist (at home) 0.03 0.03 0.02 
(-0.11 to 0.18) (-0.11 to 0.18) (-0.12 to 0.17) 
NHS Direct 0.02 -0.04 -0.03 
(-0.16 to 0.21) (-0.22 to 0.14) (-0.21 to 0.15) 
Walk-in Centre -0.00 -0.00 -0.00 
(-0.1 to 0.09) (-0.1 to 0.08) (-0.1 to 0.09) 
Counsellor 0.04 0.06 0.09 
(-0.46 to 0.54) (-0.34 to 0.46) (-0.30 to 0.49) 
-23.57 -0.06 3.35 
Medication costs (£) (-174 to 127) (-108.4 to 108.3) (-104.98 to 111.68) 
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4 SV Unit costs 
Unit cost estimates and their sources used in the analysis can be found below in 
Table 4.4. 
Table 44" Uriif costs ofresources used 
Unit Cost (£ 2003/4) Source 
GP cost per surgery visit 21.00 Curtis and Netten (2004) 
GP cost per home visit 65.00 Curtis and Netten (2004) 
Practice Nurse cost per visit 9.00 Curtis and Netten (2004) 
District Nurse cost per visit 20.00 
Health Visitor cost per visit 31.00 
Home Help cost per visit 7.00 
Occupational Therapist cost per visit 48.00 
Physiotherapist cost per visit 48.00 
Counsellor cost per visit 33.00 
NHS Direct cost per visit 18.00 
Walk in centre cost per visit 25.00 
Meals on Wheels cost per meal 4.00 
Cost per Inpatient attendance Various (£203-£486) 
Cost per outpatient visit Various (£63-£364) 
Curtis and Netten (2004) 
Curtis and Netten (2004) 
Curtis and Netten (2004) 
Curtis and Netten (2004) 
Curtis and Netten (2004) 
Curtis and Netten (2004) 
National Audit Office 
Hansard 
PSSRU Discussion Paper 1427 
Netten and Curtis (2002) 
Netten and Curtis (2002) 
Cost of Intervention £250 for the primary Department of Health"` 
analysis 
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4.6.4 Heath States 
Tab/e 4 5. °o ofpafien/sin each EQ-5D dimension bygroup afbase/ine and six 
month fo/%ow-up. 
EPP Group Control Group 
ofpatients in 
health state at 
baseline 
% ofpatients in 
health state at 6 
month follow-go 
NO ofPat/ents in 
health state at 
baseline 
% ofpatients in 
health state at 6 
month follow-up 
1 2 3 123 1 23 123 
Mobility 28.4 70.6 1.0 30.0 69.3 0.6 32.3 67.1 0.6 31.0 68.4 0.6 
Self Care 59.7 38.7 1.6 62.9 36.1 1.0 61.7 36.7 1.6 56.0 42.4 1.6 
Usual 22.0 67.1 10.9 22.0 72.2 5.8 22.8 65.5 11.7 23.1 68.4 8.5 
activities 
Pain/ 12.5 64.2 23.3 12.1 65.5 23.4 13.0 63.3 23.7 12.3 62.1 25.6 
discomfort 
Anxiety/ 37.1 52.1 10.9 44.7 50.8 4.5 32.9 58.5 8.5 37.3 53.8 8.9 
depress 
For each dimension of the EQ-5D, there are 3 dimensions. 1 is the "best", and 
represents "no problems" on that dimension, while 3 is the "worst" and represents 
extreme problems. For example on the mobility dimension, 1 represents "no 
problems walking about", whilst 3 represents "confined to bed". 
While there were slight differences in the proportions in each category by group at 
baseline, none of these differences approached statistical significance, and do not 
appear to favour the intervention. 
There appears to be little impact in either group on the mobility or pain dimensions. 
However, the other dimensions exhibit some noteworthy changes. 
Both groups show an increased proportion in the least severe anxiety/depression, 
with the intervention group performing slightly better (in terms of the percentage in 
the least severe category). However, in the intervention group this is reflected by a 
reduction in the percentage in the most severely affected group, while in the control 
group, the reduction is mainly in the size of the moderately affected group. This 
demonstrates the importance of including an appropriate control group, simply 
comparing the "before and after" scores on these dimensions would overestimate 
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the treatment effect on this dimension (as individuals improved anyway without the 
intervention). 
The self care dimension shows that the intervention group improved on average 
over the period, whereas the capabilities of the control group seemed to decline 
over the period. This was the only change that would be deemed "statistically 
significant". Testing for difference in proportions shows that the proportion in 
category 2 (that is "some problems with self care") in the control group is 
significantly higher than in the treatment group (two groups are 0.37 vs 0.28, with a 
difference of 0.090 and a 95% Confidence Interval around the difference of 0.87 to 
0.93). 
The usual care dimension showed a movement from the most severely affected to 
moderately affected, and this change was most marked in the intervention group. 
Table 4 6" Mean EQ-5D score atbasellie andfo/%w-up bygroup 
Baseline 6 months 
EPP group 0.470 0.605 
Control group 
Difference 
0.474 
-0.004 
(-0.056 to 0.048) 
0.538 
0.068 
(0.015 to 0.120) (95% Cl) 
The changes shown in Table 4.5 are mirrored in the utility scores shown in Table 
4.6. At baseline, there is little difference between the groups (though the control 
group have a slightly higher utility score). However, at six month follow-up, the EPP 
show a statistically significant increase in EQ-5D score at the conventional 5% level. 
Another interesting result of this analysis is that both groups improve over the period 
of the study, which may appear surprising in a chronically ill population, again 
emphasising the importance of including a control group. 
4.6 5 Health state andse/f-efficacy 
Self-efficacy improved in both the treatment and control groups. However, the 
treatment group performed better on this measure than did the control group. 
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Individuals improved by 1.09 in the intervention group compared with 0.57 in the 
control (95% Cl around the difference in means of 0.11 to 0.94). This improvement 
in both groups reflects the improvements in utility reported for both groups above. 
The relationship between the two outcome measures is displayed in Figure 4.4 
below. 
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Figure 4.4 QALYs vs self-efficacy 
There appears to be a positive relationship between the two outcome measures. 
Positive values of self-efficacy change are associated with positive values of QALYs 
(that is, there are a large amount of data points in the upper right hand section of the 
graph). However, it is worth noting that this is far from universal. There are a 
considerable number of data points that show improvements in self-efficacy 
associated with QALY losses and vice versa. The strength of self-efficacy as a 
surrogate outcome measure for health status is questionable based on these data. 
This issue is discussed in more detail in Chapter 6. 
4.6.6 Qua/ity-ad listed/ife years (QAL Ys/ based on imputed data 
The EQ-5D score shows a difference between the groups at follow-up. Based on 
these estimates, the difference in total QALYs between the two groups can be 
estimated. The mean number of QALYs over the period is presented in Table 4.7. 
These estimates are based on data that include values imputed for missing values. 
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Tab/0 47 Unadüsfedand adüsfedmean change in QAL Ys perpafienf over 12 
month period 
Mean Difference (95% Cl) Difference allowing for 
QALY baseline characteristics* 
(95% Cl) 
Intervention group 0.276 0.0184 0.020 
Control group 0.258 (-0.004 to 0.041) (0.007 to 0.034) 
adjusted for age, gender, condition and baseline EQ-5D score 
Though these differences appear small in absolute terms, the adjusted analysis 
shows a difference that favours the EPP intervention that is equivalent to one 
addifiona/week of perfect health per year. An analysis of the complete cases (i. e. 
only considering those who fully completed baseline and follow-up data) showed 
that including the baseline value of EQ-5D score led to a similar conclusion. 
4.6.7 Total cost 
The difference in total cost between the two groups is presented in Table 4.8. 
These summary estimates include the cost of the intervention and utilise the 
resource use estimates (adjusted for treatment group and baseline resource use) in 
Table 4.3. The total costs per patient are shown in the table. 
It can be seen that when considering the impact on health care costs only, the EPP 
reduces costs considerably. However, while this may be of interest to health care 
decision makers, the societal cost is the relevant figure and this shows the EPP to 
be cost neutral. 
Table 48 Total costspe1-, oatientin the Iwo groups over 6month periodbasedon 
imputed data 
EPP group Control group 95% Cl around difference 
in mean cost 
Health care costs only £1169 £1560 -£389 
Total cost Including £1912 
patient costs with 
Intervention costed at 
(£38 to -£741) 
£1939 -£27 
(£368 to -£422) 
£250 per patient* 
* the cost of the intervention is based on estimates from Department of Health calculated by diving total cost of 
programme by throughput 
94 
There is again considerable uncertainty around these estimates and the difference 
is not statistically significant at conventional levels. Patients allocated to the EPP 
group have a slightly lower cost of providing health care (reflecting the resource use 
data presented in Table 4.2), though patient out-of-pocket costs are higher for the 
EPP group. Patient out-of-pocket expenditure included payments for alternative 
therapies, domestic help and special dietary needs as well as any home 
improvements that were necessary. 
Table 4.8 presents a summary of cost data based on the results of the imputed 
analysis. Table 4.9 presents a more detailed breakdown of the costs by category. 
(Note that figures do not tally exactly with Table 4.8, as imputation leads to slight 
differences in the total cost estimates). 
Other resource use items accounted for less than1% of total costs. 
As would be expected, these figures reflect the resource use data in Tables 4.2 and 
4.3. However, it is noticeable that while the EPP programme reduces resource use 
(and costs) in most categories, patients' out-of pocket expenditure rises in the EPP 
group. While the 95% confidence interval around the difference in mean costs 
includes zero, there is a suggestion that there may be some cost shifting from the 
NHS to individuals through improving patients' ability to self manage. 
The major part of this difference between groups is explained by "housing 
alterations" (which accounts for £65 of the £115 mean difference), though the cost of 
"special dietary needs" and "complementary therapy" were also higher in the 
intervention group. The lack of a plausible mechanism for EPP to impact on 
housing alterations means that the impact of EPP on patient costs should not be 
overstated. Nevertheless, even allowing for this there is some evidence of 
increased out-of-pocket expenditure in the EPP group. 
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7,7,61& 49 Majorcostifems bygroup 
Resource type Intervention Proportion Control group Proportion of 
group of total mean cost (E total costs 
mean cost (£ costs 2003/4) 
2003/4) 
Inpatient stay(s) 247 12.9% 561 28.9% 
Outpatient 276 14.4% 294 15.2% 
appointments 
General Practitioner 70 3.7% 72 3.7% 
visits (surgery) 
Medication costs 426 22.3% 450 23.2% 
Patient out-of 493 25.8% 378 19.5% 
pocket expenditure 
Intervention costs 250 13.1% 0 0% 
Counsellor visits 21 1.1% 20 1.0% 
Day case 87 4.6% 127 6.5% 
Subtotal* 1870 97.9% 1902 97% 
* some categories omitted as individually below 1% 
4 6.8 Incremental Cost-Effectiveness Ratio (ICER) 
The EPP group is associated with an improved QALY profile and a slightly lower 
cost. Specifically, the EPP group have a 0.020 QALY gain compared with the control 
group, and a reduced cost of around £27 per patient. EPP would therefore be 
considered dominant and calculation of the ICER is inappropriate. 
However, there is a large degree of uncertainty around these results. Therefore, to 
deal adequately with uncertainty the NMB approach was used and CEACs were 
generated. The results of these analyses are presented below. 
4.7 Net Monetary Benefits and CEAC 
The value of a QALY is open to some debate. However, the National institute for 
Health and Clinical Excellence (NICE) have suggested that interventions delivering 
a cost per QALY of under £20,000 are likely to be an acceptable use of NHS 
resources. 12 Figure 4.5 shows the CEAC curve. The cost-effectiveness threshold 
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(X) is varied between zero (where gains in QALYs are not valued at all, and amounts 
to a test for differences in costs) and £50,000. In the main analysis with imputed 
data and a cost of the intervention of £250 and patient costs included, when the 
value of a QALY is £20,000 the EPP has a probability of 94% of being cost-effective. 
Indeed, for all plausible values of willingness-to-pay for a QALY the EPP group is 
more likely to be cost-effective than the control group. Figure 4.3 shows CEAC of 
the EPP for a variety of assumptions. Figure 4.4 presents a scatter plot of the 
incremental costs and effects of the EPP. 
4.8 Sensitivity analysis 
4 8.1 Higherintenvention costs 
The results of this analysis have been transformed into a NMB framework to enable 
the results to be presented in terms of the probability of the intervention being cost- 
effective, and allowing the uncertainty around the decision to be captured. These 
results show that under the assumptions of this analysis, with the intervention 
costing £450 rather than £250, the EPP group would be more expensive than 
control, with an ICER of about £8700 (using QALY gain adjusted for baseline 
covariates). This is represented in the CEAC by the lowest of the three lines. 
However, even with this assumption, the EPP has an 84% probability (at a 
willingness-to-pay of £20,000 per QALY) of being cost-effective based on these 
data. 
4,8.2 Excluding patient costs 
Patient costs were higher in the EPP group. From a societal perspective, it is 
important to include these costs, especially in the sphere of self care support where 
there could be a shift from care provision funded by government agencies to 
patients' out-of-pocket expenditure. A sensitivity analysis shows the impact of 
excluding these costs, and confirms that the EPP would be more likely to be cost- 
effective if patient costs were excluded, with a 97% probability of being cost- 
effective at a willingness-to-pay of £20,000 for a QALY. The calculation of an ICER 
is inappropriate as the EPP intervention is dominant under this scenario. 
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488 Maintenance ofiinprovements 
As discussed above, the main analysis is based on only 6 months data. It is likely 
that benefits (or harms) achieved within this period would be maintained for a longer 
period. The duration of this "maintenance" period is an empirical question, but this 
sensitivity analysis considered the impact of maintaining the EQ-5D scores from 6 
months to 12 months. This sensitivity analysis additionally assumes that cost and 
QALY data were evenly distributed across the six month period. It is plausible that 
changes in costs or EQ-5D could have been incurred either very early or late in this 
period. However, there is no evidence to support these possibilities, and the 
assumption of equally distributed costs and EQ-5D was considered reasonable. 
Using these assumptions, the EPP group has a 97% probability of being cost- 
effective at a willingness-to-pay of £20,000 for a QALY. Again, the ICER 
calculation is inappropriate due to dominance. 
The assumption that costs would be the same between the two groups over the 
extended period is likely to be a conservative analysis as the post-intervention costs 
in the EPP group were lower than those in the control group. Therefore, extending 
the reduction in costs to 12 months would increase the probability that the EPP is 
cost-effective above 97% 
4.0 4 Mu/tip/e innputation 
Missing data were initially imputed using best subset regression. 179 However, 
multiple imputation is an alternative methodology where multiple datasets are 
generated with potentially different values for each missing item imputed and gives a 
fuller reflection of the uncertainty surrounding which value to impute. 176 Multiple 
imputation was performed using the propensity score method in the software 
package Solas. Values were imputed for each of the dimensions of the EQ-5D 
(rather than total score), and for each missing item of resource use (rather than total 
cost). Five datasets were generated in this analysis. It is not clear how multiple 
imputation techniques can be used within the non-parametric bootstrap framework 
to generate CEACs; therefore the following estimates were generated 
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parametrically. The probability that the EPP intervention was cost-effective at a 
threshold value for a QALY of £20,000 in this scenario was 94%, despite the fact 
that the treatment group were slightly more costly (difference in imputed means of 
five datasets of £45) in this analysis. The ICER generated of £2,300 per QALY 
gained would be considered acceptable. 12 
4.8.5 Ad'ustinentforcondition, age and gender 
The analysis above presents data where the costs were adjusted for pre-baseline 
differences in resource use. However, total cost data can be adjusted for many 
baseline covariates (assuming that patient level data are available). To illustrate, 
total cost data were adjusted for age, gender and condition as well as pre-baseline 
costs. In this case, the treatment group were approximately £37 less expensive 
than the control group (with a 95% Cl around the difference in mean total costs of - 
£361 to £437). This is very similar to the unadjusted analysis with EPP considered 
dominant and calculation of the ICER inappropriate. 
Of the covariates included, gender was the most influential, to the extent that if it 
were included the 9O/o Cl would not include zero. Males cost on average £393 
more than females (95% Cl -£47 to £843). 
The results of the sensitivity analyses above are presented in Table 4.10 
Table 4 >0 Sensifiuiiy analyses 
Sens/tiv/tyana/ysis Cost Difference 
(+ indicates EPP 
more cost/y) 
QALYDifference 
(# indicates EPP 
more effective/ 
/CER/£J 
Higher intervention +175 +0.02 8,700 
costs 
Exclusion of patient -140 +0.02 Dominant 
costs 
Extending time -27 +0.04 Dominant horizon 
Multiple imputation +45 +0.02 2,300 
Adjustment for -37 +0.02 Dominant 
covariates 
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4.8.6 Con ventional(classica) statistical analysis 
All of the analyses above employ Bayesian inference techniques. It was argued in 
Chapter 2 that this is the appropriate methodology for economic evaluation to inform 
decision making and results in an estimate that the EPP is 94% likely to be cost- 
effective given a threshold value of £20,000 for a QALY. A frequentist analysis 
could test for significant differences, usually at the 5% level of significance, in cost 
and effect. At these levels, there is no significant difference in cost, but a significant 
difference in effect when adjustments are made for baseline differences. Clearly, 
which variables are included in the analysis also involves a degree of subjectivity, 
but it is considered appropriate to adjust for differences in age gender, condition and 
baseline EQ-5D score. 44 In this instance, as there is no significant difference in 
costs but a significant improvement in patient outcomes, the frequentist 
interpretation would concur with the Bayesian analysis that the EPP is a cost- 
effective use of resources. 
4.9 Discussion 
The analysis above shows that, for most reasonable threshold values of a QALY, 
the EPP would be considered likely to be cost-effective when compared with 
treatment as usual. This conclusion that the EPP is cost-effective is maintained 
whether the analysis is conducted in the Bayesian or frequentist paradigm, and also 
over a range of plausible assumptions. 
The higher probability of EPP being cost-effective compared to control is due to 
there being little difference in costs and an improvement in QALY scores in the EPP 
group. Costs in both groups were similar as the increased patient costs together 
with the cost of delivering the intervention was offset by reductions in resource use. 
However, there is considerable uncertainty around the estimates of costs and 
effects in each group. This uncertainty results in a probability of between 84% and 
97% (depending on the assumptions made) that the intervention is cost-effective 
(and therefore a probability of between 3-16% that not providing EPP is cost- 
effective, as only one comparator was considered). 
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The time horizon of the study was limited to only six months (one year in a 
sensitivity analysis). Clearly, in this patient population, there is the potential for 
longer term benefits. Ideally, a longer term trial would have been conducted but 
pragmatically this was not possible. It is likely that a longer trial would have 
increased the probability of EPP being cost-effective (as shown in the hypothetical 
one year model), subject to the caveats expressed in section 4.5.3. 
The exclusion of patient costs increased the probability of the EPP being cost- 
effective. In this instance, the decision would not be changed (the EPP is likely to 
be cost-effective whether these costs are included or excluded), though this may not 
always be the case and particularly in evaluations of interventions designed to 
support self care, these costs should be included. 
The analysis above shows the potential importance of adjusting for baseline 
covariates. The direction of the results on some cost items (such as medication) 
changes from being in favour of the intervention to being in favour of the control, 
while the magnitude of the QALY difference is increased when baseline variables 
are included. 
Previous evaluations of self care support interventions were described in Chapter 3. 
The most common limitations of these trials were that they had poor costing 
methodology (often excluding patient costs), inappropriate comparison groups, 
inadequate handling of uncertainty, inappropriate methods of analysis (often not 
intention-to-treat) and usually a short follow-up period. Ideally, the problems 
encountered in previous studies should be used to inform the design of new studies. 
In this evaluation, some of these issues were addressed. In particular, the costing 
methodology was much more thorough than in most previous studies and included 
the potentially important inclusion of patient out-of-pocket expenses. The handling 
of uncertainty and the methods of analysis were also more appropriate than in some 
of the previous studies where missing data were often ignored and/or uncertainty 
around estimates was not presented. However, the control group in the EPP 
evaluation was a waiting list control. It would be preferable to have another therapy 
(such as another group therapy) where the additional effectiveness of the 
intervention could be established in isolation from the effectiveness of being in a 
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group of similar chronically ill patients. In this case, however, the intervention was 
already being rolled out across England. The potential to randomise patients to 
another intervention when the EPP was available would increase the likelihood of 
contamination. 
This evaluation of the EPP also had a short follow-up period (six months data with 
randomisation intact) due to the requirement by the funder for expeditious results. 
Additional analyses were performed to address the concerns with the short follow-up 
and to give better estimates of the long-term effects of the EPP. Extending the time 
horizon of the study may favour of the EPP intervention, though this depends on the 
timing of the costs and benefits; this is discussed in more detail in section 5.4.1.2. 
The improvements in patient outcomes as measured by EQ-5D showed that 
patient's ability to self care increased in the treatment group as compared with 
control. This is intuitively appealing as the EPP has improved individuals abilities to 
self care, and is also consistent with the theoretical model whereby improvements in 
self-efficacy (demonstrated in the clinical trial), 66 lead to an improvement in health 
status. 
The generalisability of these results is open to some debate. Around 70% of the 
sample were female (consistent with other studies of this intervention) and 95% 
were of "white" ethnicity, clearly raising the question of how cost-effective the 
intervention would be in ethnic minority (or more male) populations. Indeed, the 
other UK based trial was conducted in a population of Bangladeshi people, and the 
impact on QALYs was much less marked, and the cost-effectiveness much less 
certain. These issues are investigated in Chapter 5. 
4.10 Conclusion 
The results of this single trial based economic evaluation largely favour the 
introduction of the EPP, with a slight reduction in cost and a small but important 
improvement in QALYs. These results reflect those of the clinical trial 66 that 
demonstrated a large (and statistically significant) impact on self-efficacy, the 
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primary outcome of the clinical study. There was also a significant improvement in 
energy, which in the clinical study was used as a measure of health status. 
There are other data that could be included in the exploration of the cost- 
effectiveness of the EPP. One other economic evaluation of the EPP has been 
carried out in the UK, 83 and the synthesis of these two datasets is explored in the 
next chapter. In addition, there are previously published evaluations of CDSMP, 
performed in the US and elsewhere. These show that self-efficacy is enhanced by 
this programme, though there are limitations in the analysis of these previous 
studies. Chapter 6 extends the analysis to include the impact of these studies. 
While this chapter presents the evidence from one economic evaluation conducted 
alongside a randomised controlled trial, later chapters will synthesise the evidence 
from this trial with other "relevant" evidence. The incorporation of this additional 
evidence extends the amount of studies included, but there is a trade-off as the 
relevance to the UK decision context is reduced. In addition, the incorporation of 
additional evidence requires stringent assumptions about the relationship between 
treatment effect and outcomes to be met. This is discussed more fully in Chapter 6. 
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Chapter 5. Evidence synthesis of trials with Individual Patient Data 
(IPD) of chronic disease self management programme (CDSMP) 
5.1 Introduction 
The previous chapter presented the results of a single trial based economic 
evaluation of the Expert Patients Programme (EPP). The economic evaluation 
described in the previous chapter provides the most relevant evidence concerning 
the cost-effectiveness of the CDSMP (on which the EPP is based) for the general 
UK population. Nevertheless, there are other sources of evidence available that 
could inform the decision problem of whether the EPP should be implemented on 
cost-effectiveness grounds, and therefore the analysis presented in the previous 
chapter could be criticised as not comprehensive enough. Other criticisms of single 
trial based evaluations are that not all comparators are considered, the time horizon 
and decision context is often inappropriate and the uncertainty surrounding the 
decision is not adequately described. 
For the evaluation of the EPP, it was argued in Chapter 4 that the use of single trial 
based cost-effectiveness analysis (CEA) maybe appropriate. However, it is also 
possible that using other relevant evidence would lead to more informed decision 
making. Which of these approaches forms a "better" evidence base for decision 
making in the UK is debatable. Therefore, the next two chapters will describe the 
methods, results and implications of synthesising evidence from other sources with 
the data from the national EPP evaluation. This chapter will consider the synthesis 
of data from one additional UK based trial. 
There are two aims of this chapter. The first aim is to assess the cost-effectiveness 
of the EPP after the introduction of additional evidence from the UK. The second 
aim is to determine the most appropriate distributional assumptions and model 
structure for the evidence synthesis. These distributional assumptions and model 
structure will be assumed to be appropriate for the analysis in Chapter 6 which will 
introduce non-UK evidence. 
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5.2 Trial characteristics 
The two trials included in the analysis were the only UK based evaluations of the 
EPP. In addition, both trials had Individual Patient Data available. Both of the trials 
included in this evidence synthesis were randomised controlled trials of the EPP, 
with a waiting list control. That is, patients who were randomised to the control 
group would get the intervention at the end of a pre-specified period. This period 
differed between the trials requiring adjustments to be made; these are detailed in 
section 5.4.1.2, below. The aims of the trials were both to assess the effectiveness 
and cost-effectiveness of the EPP, though the patient groups that were targeted 
were different. Thus, the national evaluation of the EPP 66,162 targeted a sample 
that was representative of the UK population, while the Griffiths trial 83 clearly aimed 
to consider those from a specific ethnic minority. Characteristics of patients involved 
in the trials are presented in Table 5.1. 
Tab/e 5> Coinpafson ofbase% characteristics oftwo /PD trials 
Nation/evaluation of Evaluation ofEPPin UK 
EPf0'' f62 (n=629) basedBanigyadeshi 
Mean Age (standard 55.4 (13.6) 48.9 (9.9) 
deviation) 
female 70 57 
from ethnic minorities 5 100 
in employment 19 9 
Marital status (% married) 60 86 
"Main" chronic condition O/her 49 Diabetes 69 
(%) Muscu/oske%fa/34 Asthma >6 
Diabetes if Aithri/is /0 
Caroiovascu1ar5 Carnrovascu/ar 6 
Not surprisingly, as the aim of the Griffiths study was to establish the effectiveness 
of the CDSMP in a minority South Asian population, the characteristics of individuals 
in the studies were very different. The national evaluation of the EPP recruited a 
low number of individuals from ethnic minorities, though this was only slightly below 
the proportion of ethnic minorities with chronic conditions reported in the Health 
Survey for England at 5% compared with 6%. 180 Age was, on average, higher in 
the national evaluation, as was the proportion of females recruited to the study. In 
the Griffiths study sample, individuals were more likely to be married, but were less 
likely to be employed, though both studies showed that employment rates were low 
in those with chronic conditions. 
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5.2, > Trial results 
The national evaluation 66 concluded that the introduction of EPP was likely to be 
cost-effective. In summary, this evaluation showed an improvement in QALYs 
associated with the treatment group, with no additional costs. In the Griffiths study 
in a Bangladeshi population, there was little impact on either resource use or 
QALYs, though additional costs of the intervention meant that the intervention is 
unlikely to be cost-effective in this population. Both these analyses use baseline 
EQ-5D as a covariate as recommended in the literature. 44 It is interesting to note 
that this allowance for baseline EQ-5D changes the direction of the result in the 
Griffiths study. Without the baseline adjustment, the group receiving EPP performed 
slightly better than the control (generating an additional 0.006 QALY per person on 
average); however, the appropriate analysis including this covariate showed that the 
intervention group actually performed slightly worse than the control group, as 
shown in Table 5.2 below. 
Table 52 /ncremenfa/costs and QAL Ys over 12 months in the two trials 
Evaluation ofEPP Griffiths evaluation of EPP 
Incremental QALYs 0.020 -0.002 
(intervention minus (0.007 to 0.034) (-0.014 to 0.012) 
control, adjusted for 
baseline EQ-5D 
Incremental cost -£27 £146 
(intervention minus (-E422 to £368) (£65 to £223) 
control 
So the meta-analysis will synthesise evidence from two trials, one showing the 
intervention to be doininanfs6, ßs2 the other showing that it is doini»afed. 83 
5.3 IPD meta-analysis 
IPD were available for both trials and IPD meta-analysis of cost-effectiveness data 
can therefore be carried out. Performing this analysis incorporates more relevant 
information, generates a more accurate assessment of the uncertainty around the 
decision and broadens the decision context by incorporating data from less 
advantaged groups. In addition, the use of IPD meta-analysis has several 
methodological advantages compared to the use of summary statistics. In 
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particular, it enables the inclusion of patient level covariates to "adjust" for certain 
characteristics (such as age, gender, baseline utility levels) in CEA if this is 
appropriate. This is not possible with aggregate data where typically a mean and 
standard error are the only data presented. 
In addition the use of IPD meta analysis can avoid biases that can be apparent in 
meta-regression using summary statistics. 181 Potentially dangerous biases that 
have been identified in meta-regression include publication bias and ecological 
fallacy. 182 The former is known to occur due to studies with more significant, 
"interesting" results or that are of higher quality and are more likely to be 
published, 183 leading to potentially biased conclusions. Though this is an issue with 
meta-regression, it is worth noting that this is also a potential danger with IPD meta 
analysis. IPD meta-analysis involves the identification of trials and successfully 
accessing the IPD of these trials. If trials are only identified because their results 
have been published then there remains a possibility that there were unpublished 
trials with IPD available. Nevertheless, with the proliferation of trial registers this is, 
perhaps, becoming less of an issue. 
Ecological fallacy occurs where the association that is observed between aggregate 
level variables is not a reflection of the association at the level of the individual, that 
is, correlations between variables at an aggregate level may not be comparable with 
correlations between variables at an individual level. An example of this is the 
impact of age on treatment effect. Plotting the relationship between mean age and 
treatment effect from several trials may show, for example, that the treatment effect 
appears to diminish with age. However, examination of individual data within each 
trial may show that there is in fact a positive relationship and that treatment effect 
improves with age. This may be due to the fact that the trials differ in some other 
respect, for example the trials with higher average age and lower estimates of 
treatment effect may have recruited healthier individuals and it is this (confounding) 
variable that the across trial relationship detects. This has led to the 
recommendation that within trial IPD should be used to estimate the relationship 
between "treatment benefit and patient characteristics, so that confounding because 
of differences across trials is avoided". 1M 
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Another advantage of IPD meta-analysis, and one that is particularly important for 
this analysis, is that cost-effectiveness analyses can be conducted that are 
consistent across studies. 181 When synthesising data from different cost- 
effectiveness studies, there are many potential inconsistencies. For example, costs 
may be calculated using different unit cost data, different assumptions about future 
costs and benefits may be made, the perspective of the studies could be different 
(for example NHS versus society) and so on. In addition, there is some evidence 
that QALYs are not calculated consistently in cost-effectiveness analysis and that 
alternative covariates could be used in the estimation of incremental QALYs. 43 
These issues are dealt with in more detail in section 5.4. 
5.4 Methods 
Bayesian analysis is particularly useful for evidence synthesis in that it enables all 
the uncertainty (including the uncertainty arising from the existence of missing data) 
and correlation from heterogeneous trials to be incorporated. 84 Nevertheless, where 
there are obvious sources of heterogeneity, such as different follow-up periods, 
these can be adjusted before synthesis (see section 5.4.1.2). At present there are 
two trials with IPD available, and the following section describes the methods 
required to meta-analyse these data. This analysis takes a Bayesian perspective 
where it is necessary to treat parameters as random variables and generate 
posterior distributions (or final estimates) for these parameters based on: 
a) The model or estimation procedure. How samples are generated depend on the 
formulae and distributions depicted in the model 
b) The choice of initial values. 
c) The "priors" and the assumptions around them 
The models and estimation procedure are dependent on the choice of model that is 
developed in section 5.4.3 (that is, which covariates are included and the 
distributional assumptions around the costs and effect estimates). The generation 
of priors and initial values, model specification and number of required iterations as 
well as the procedures for ensuring the model has behaved appropriately are 
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described in section 5.4.3. Sensitivity analysis around the model assumptions are 
described in section 5.4.4. 
The first sections, sections 5.4.1 and 5.4.2, describe adjustments required to ensure 
that the datasets are comparable and analyses are consistent. 
5.4.1 Mal character/sf/es 
Before meta-analysis can be properly conducted, it is necessary to examine 
individual trials to ensure their comparability to enable consistent analysis to be 
conducted. The characteristics of the trials and the patients within them have been 
considered in section 5.2. 
54t/ Si»i, ia, #/es be/ween taa/s 
Full details of both trials can be found elsewhere. 66,83 Briefly, both trials were 
randomised controlled trials (RCTs) with the patient as the unit of randomisation and 
also the unit of analysis. In addition, both trials had "treatment as usual" as the 
comparator and had relatively short follow-up periods and therefore discounting was 
not appropriate as all costs within both trials fell within a one-year period. 
54>. 2 Ensuring to is are comparable and analyses are consistent 
Despite some similarities, there were differences between the methodologies 
employed in the trials. Specifically, the Griffiths trial83 used the perspective of 
primary and secondary care services within the NHS, while the EPP national 
evaluation employed a wider perspective including community care costs (such as 
district nurse visits, NHS direct contacts, physiotherapist and occupational therapist 
contacts), drug costs and patient out-of-pocket expenditure. In addition, the Griffiths 
trial had 4 months follow-up, while EPP national trial had 6 months follow-up. 
To ensure comparability of the two studies, the costs not directly estimated in the 
Griffiths study were estimated (by group) from the EPP national trial and then simply 
added to the Griffiths data. Clearly this makes the assumption that these costs are 
exchangeable. However, in the absence of any evidence to the contrary or any 
110 
better estimates of the additional expenditure, this is considered more appropriate 
than excluding costs which may be relevant to the decision. 
Also, to ensure the follow-up period was comparable and that analysis was 
consistent, the data from the former trial were extrapolated from four to six months 
by multiplying both QALYs gained and costs by 1.5. These "new" cost data were 
then appended to the EPP trial data 66 using the statistical package Stata 8. This 
makes the additional assumption that the cost and QALY data were evenly 
distributed across the trial period. While there is no evidence to contradict this 
assumption, it is plausible that costs (or resource use) could have been incurred 
mainly in the first few weeks and that the extension of the trial period from 4 to 6 
months would have little impact on overall costs. Similarly, it is plausible that the 
QALYs generated were distributed largely in the first part of the follow-up period. In 
the absence of evidence to support or refute any of these possibilities, the decision 
to assume an equal distribution of costs and QALYs across the follow-up period was 
considered reasonable. 
54.2 Meta ana/ysis of/PD 
There are several methods available for the meta-analysis of IPD. Simmonds et al 
reviewed published methodologies in the meta-analysis of IPD and identified three 
strategies: 181 
i) "Mega-trial". Data are analysed as if they were from a single trial 
ii) Stratified analysis. Trial identifier is included in the model using either a fixed or 
random effects model. 
iii) Two-stage approach. Summary statistics of each trial are produced and then 
combined as in a standard meta-analysis. 
Each of the above methods was considered. The software package WinBUGS 97 
was employed for all meta-analyses. 
5 42 > "Mega-hvW' 
In this approach, data are treated as though they were from the same trial. 
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This approach assumes perfect exchangeability between trials (after adjustment for 
the above methodological differences). 
Clearly, the mega-trial approach is a crude approach to synthesising IPD. The 
underlying assumption of this approach is that the data are perfectly transferable. 
For effectiveness data in the same geographical area using patients with similar 
characteristics, there may be some merit in this approach, though it is unlikely to be 
a correct assumption for cost data. This simple model can be extended by using 
patient level covariates as explanatory variables. However, due to the crudity of the 
approach and the necessary loss of useful data, this method was not considered 
further. 
54 22 Fixed effect aria/ysis 
A preferable approach to the meta-analysis of IPD uses the trial identifier in the 
model. This allows differences between trials to be included and is more realistic 
than the mega-trial presented above. These "stratified" analyses can be performed 
either using a fixed effect or random effect. With the fixed effect model, each trial 
within the model has a different baseline. Essentially there is a relative treatment 
effect common to both trials but each trial has a specific constant (equivalently the 
estimated regression line for each trial is raised/lowered by a specific amount). 
Fixed effects models are extended in the analysis below by incorporating patient 
level covariates in the analysis. Random effects models were deemed inappropriate 
in this analysis as there were only two datasets of IPD. Attempting to establish a 
distribution around the differences between trials in the treatment effect based on 
two observations is futile. 
5423 Two-stage approach 
The two-stage approach essentially creates aggregate estimates of costs and 
effects for each trial and then uses standard meta-analysis techniques on these 
aggregate estimates. In this methodology, there is less scope for using individual 
patient characteristics as covariates. Where IPD data are available, this form of 
analysis excludes relevant information. 185 In this instance, as IPD were available, 
this analysis was not conducted. 
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5.4.3 /Node/ling assumptions 
Models were run using the statistical package R, and the simulation package 
WinBUGS. Full details of the code in both packages are presented in Appendix C. 
54 31 Cost otinfervenfion 
The intervention cost in the EPP national trial was £250 and included a full costing 
including volunteer time, hiring of venues and equipment as well as the costs of 
running the programme. The Griffiths trial estimated a lower intervention cost of 
£123. The intervention cost used in this analysis is a simple weighted mean 
(weighted by sample size in each trial) of the two estimates. 
543.2 Fixed effectmode/s 
Section 5.4.2 described alternative model structures using a mega-trial approach, 
the two stage approach, or the preferable fixed effect model where differences 
between the two trials are acknowledged. The analysis concentrated on fixed 
effects models which can be represented as: 
C=a + ßc TTx + ßc sstudy + ßc _x 
X; + F. Eq 1 
Q=a + ßa_1Tx + ßo_sstudy + ßa x Xi+ c Eq 2 
where Tx is treatment group 
pc 
_T 
and PQ 
_T 
is the effect of treatment on costs and QALYs respectively 
Pc s and ß4s is the effect of study on costs and QALYs respectively 
Rc x and PO _x 
is the effect of other variables on costs and QALYs respectively 
and c is the error term 
In addition, it is plausible that the covariates identified above may have different 
impacts in the two studies. Thus study specific covariates were also considered. If, 
for example, baseline EQ-5D was included as a covariate in the cost regression, but 
that the relationship between costs and baseline EQ-5D might differ between 
studies, the models would then be represented as: 
C=a + Rc TTx + Rc sstudy + pintstudy*EQ-5D + (3c x Xi+ E Eq 3 
where Pint is the study specific impact of EQ-5D on costs 
Clearly, a similar approach can be used for QALY estimation. The inclusion of 
specific study effects is different from the inclusion of covariates. In the latter case 
we have little or no apaonexpectations of the impact these covariates have on 
costs and/or effects. However, in the case of study level effects we do have reason 
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to believe that costs (particularly) and effects may differ between geographical area 
with different accounting methods and in different patient populations. The other 
covariates that may be appropriate for inclusion are discussed below 
5 4,?,? Choice ofccvariafes 
The importance of allowing for baseline differences between treatment and control 
groups is becoming increasingly recognised. 44 However, it is necessary to 
determine which covariates should be included in models. Ideally, models with and 
without particular covariates could be run in WinBUGS and subsequently assessed 
for model fit. Unfortunately, running such models is time consuming, so at present it 
is necessary to simplify the model structure by identifying the appropriate covariates 
for inclusion using the regression techniques described below. The regressions 
were run in R. Subsequently, WinBUGS is used to identify the appropriate 
distributional assumptions of costs and benefits within the model (see section 
5.5.3.3). 
For the purposes of this analysis, we were interested in the effect of treatment on 
the outcomes of interest (costs and QALYs). Additional differences between 
treatment and control groups may have been influenced by a number of candidate 
covariates. These included age and gender of participants, their baseline levels of 
self-efficacy and their baseline health related quality of life as measured by EQ-5D. 
Unlike the study effects discussed in section 5.4.3.2, there was no ap/7ocireason for 
any of these covariates to be given precedence over the others in that all have a 
plausible link with both costs and QALYS. All of these variables were therefore 
included in a regression model. Thus the initial models for costs and QALYs in the 
fixed effect framework were as follows: 
C=a + Rc TTx + Pc sstudy + Rc nage + 3c cgender+ Rc SESE +3c EEQ-5D +E Eq 4 
Q=a + ßQ TTx + Ra sstudy + 13Q_nage + RQ cgender+ RQsESE +Ra EEQ-5D +E Eq 5 
where Tx is treatment group, SE is self-efficacy 
Pc 
,T and 
{3Q T is the effect of treatment on costs and QALYs respectively 
Rc s and (3Q s is the effect of study on costs and QALYs respectively 
Pc_A and PQA is the effect of age on costs and QALYs respectively 
Pc c and PQ_G is the effect of gender on costs and QALYs respectively 
Rc sE and PQ SE is the effect of self-efficacy on costs and QALYs respectively 
Pc 
-E 
and PQ_E is the effect of EQ-5D on costs and QALYs respectively 
and E is the error term 
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Stepwise regression with backward selection was performed in R using these 
regressions separately for costs and QALYs. This involves starting the model with 
all potential covariates included. The variables are then tested individually for 
statistical significance and the variable that is the least significant is removed. 
The model was then re-run until the only variables remaining were those with a 
statistically significant coefficient. The resulting model was judged as appropriate. 
The Akaike Information Criteria (AIC) was also monitored. The AIC improves as 
goodness of fit improves, but there is also a penalty for increasing the number of 
parameters in the model. Thus a model which explains more of the variation in the 
data may be worse (on AIC) if it uses more parameters to explain this variation. The 
lower the AIC value, the better is the model on this criterion. 
54 S4 Dis fi ib ufi on a/ a ss urrmp fi bns 
The use of log normal distributions in the software package WinBUGS is more 
computationally time consuming than using normal distributions. Therefore, where 
data are approximately normal this is the most efficient choice of distribution. 
However, cost data are rarely normally distributed. Examination of the plots below 
shows that a log normal distribution on costs may be a more appropriate assumption 
than normally distributed costs. Using log normal distributions requires that there 
are no zero values. In this instance, only one patient incurred a zero cost and this 
was altered to a cost of £1 to enable simulation to proceed (as the log of zero is 
undefined). 
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Figure 5.2. Histogram of (natural) log costs 
The distribution of QALYs is presented in Figure 5.3 below. Though the data are 
skewed slightly to the right, a normal distribution was deemed appropriate in the 
analysis. 
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Figure 5.3 Histogram of distribution of QALYs from the 2 datasets combined 
5435 Correlation between costs and efi`ects 
The correlation between costs and effects can be incorporated into the simulation 
model in Win BUGS with the addition of a further variable in either the cost or QALY 
simulation. Thus, for example, the cost equation (in a fixed effect framework with 
study specific EQ-5D as above) could be represented as: 
C=a + ßc_TTX + ßc_sstudy + ßi, tstudy*EQ-5D + ßc_x X; + QALY +E Eq 6 
In this example, absolute QALYs are included as a covariate for costs to 
encapsulate the correlation between costs and effects. Where correlations are 
large, these covariates are likely to have greater impact. The inclusion of correlation 
between costs and effects and the impact on model fit and on the conclusions are 
considered. 
5436 Missing data 
It was assumed for this exercise that there was an ignorable missing data 
mechanism. Specifically, it was assumed that missing data were "missing at 
random", that is that another variable(s) available in the dataset can explain whether 
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the data are missing or not. This enables the specification of distributions for 
variables which include missing data and WinBUGS simulates values for missing 
data points based on this specified distribution and other parameters. 
54 97 /nifia/ va/ties 
Initial values are required in the estimation process. Initial values were chosen at 
random using appropriate distributions (for example, variances must be positive and 
were therefore taken from a uniform distribution). Initial values for the impact of 
treatment group on both costs and outcomes were set at zero, as were values for 
the impact of age and gender. 
5498 Pri or pro b ab i/ifi es 
Prior probabilities or, more commonly simply "priors", express the uncertainty about 
an event happening before we have the data. Priors were assigned to be 
uninformative (or vague) with zero mean and very high variance. Note that in 
WinBUGS, normal and log normal distributions require the mean and precision as 
arguments rather than the mean and variance, thus a uninformative prior would 
have a very low second argument, for example dnorm (0,0.0000001) 
5439 Nurrmberofiferafions and bum-, » 
There is no consensus as to the ideal number of iterations for a MCMC for Bayesian 
inference. Cooper et al considered that a 5,000 burn-in (where the results of these 
simulations are discarded) was sufficient for convergence, with their analysis based 
on a further 15,000 iterations. 96 Following this example, 20,000 iterations were 
conducted with the first 5,000 discarded. Checks for convergence and other 
diagnostics were performed as detailed in the section below. 
5 4,7 >0 Assessing the model 
Models were assessed for convergence using history/trace plots to show that the 
successive samples move around the modal value. Kernel density was also 
monitored as non-convergence can manifest itself with a kernel plot that is multi- 
modal (more than one local maximum) 
Autocorrelation, where sequential samples are correlated, can be problematic, and 
this was also examined using plots. 
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The models were assessed for their ability to fit the data using the Deviance 
Information Criterion (DIC) function in WinBUGS which is used to assess model 
complexity and compare different models. 97 
5.4.4 Sensitivity analyses 
54 4> /nfervenfion costs 
The national evaluation of EPP estimated the cost of the intervention as £250. 
However, Griffiths et al used a less exhaustive methodology and estimated the cost 
at only £123. This figure is employed as a sensitivity analysis. 
54 42 1171»a/ va/ues 
The choice of initial values should not impact on the posterior distribution. However, 
in order to test this assumption, initial values were varied to assess the impact on 
results. This is commonly done using more than one "chain" and setting different 
initial values for each chain. If the chains converge, the impact of different initial 
values is limited. 
5.5 Results 
5 5. #Y Choice of covariafes forthe mode/ 
551f QAL Ys 
The model potentially contained all the covariates described in section 5.4.3.3. The 
results of the stepwise regressions are presented below. 
Tab/e 53 Regression ofpofenfia/exp/arnatoiy variab/es on QAL Ys 
Estimate StandardError p-value 
Constant 0.276 0.0098 0.000*""' 
Treatment effect 0.011 0.0048 0.152* 
Baseline EQ-5D 0.362 0.0072 0.000'"`* 
Study dummy 0.002 0.0055 0.716 
Age 0.000 0.000 0.5185 
Gender 0.003 0.005 0.601 
Self-efficacy 0.001 0.001 0.226 
baseline 
AIC -2436.3 
indicates statistically significant at 0.1% level 
indicates statistically significant at 1% level 
indicates statistically significant at 5% level 
'. ' indicates statistically significant at 10% level 
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Deleting non-significant variables in a one-by one (stepwise) deletion of the least 
significant yields the model displayed in Table 5.4. The treatment effect, though not 
statistically significant, has been retained in the model as it is the variable of interest. 
Table 54 S/epwise ollInI17a11on mode/for QAL Ys 
Estimate StandardEr, vr p-value 
Constant 0.281 0.0040 0.000""" 
Treatment effect 0.012 0.0048 0.167* 
Baseline EQ-5D 0.362 0.0070 0.000*** 
Study dummy 0.001 0.0049 0.771 
AI C -2446.5 
The study dummy variable above represents the use of a fixed effects model, where 
there is a fixed treatment effect on costs and QALYs, but each trial has a study 
specific intercept. The regression shows that the treatment has a positive effect on 
QALYs (of about 0.012 QALY) which, predictably lies between the estimates of the 
two included trials. The only significant covariate is baseline EQ-5D, and this was 
therefore included in the models used in WinBUGS to determine the appropriate 
distributional assumptions. Note that the AIC has been reduced in moving from the 
comprehensive model to the simplified model. This reflects the fact that fewer 
variables have been included in the regression. 
55 7.. 2 Costs 
EQ-5D baseline score was a significant predictor of total costs, and when backward 
stepwise regression was performed, no other potential covariate reached 
conventional levels of statistical significance in the final model. Though the simple 
model with baseline EQ-5D only as a covariate had a slightly higher (i. e. worse) AIC 
score than the model that included all covariates, the differences were small and this 
simpler model saved considerable time and computational effort in WinBUGS, and 
was therefore deemed appropriate. 
It is asserted therefore that the following specifications include appropriate 
covariates to model cost and QALY data: 
C=a + Rc_TTX + Rc sstudy + Pc EEQ-5D +E Eq 7 
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Q=a + R4_TTx + PQ sstudY + RQ EEQ-5D +E Eq 8 
Where: 
Where Tx is treatment group, SE is self-efficacy 
Rc_T and PQ_T is the effect of treatment on costs and QALYs respectively 
Rc s and PO -s 
is the effect of study on costs and QALYs respectively 
Rc E and ßo_E is the effect of EQ-5D on costs and QALYs respectively 
and s is the error term 
These specifications were then fed into WinBUGS and alternative distributional 
assumptions were assessed as described in the next section. 
S. &f. 2 Dis Crib u t/o n a/ ass uinp ti ons 
The software package WinBUGs was used for the following MCMC simulations to 
ascertain the most appropriate distributional assumptions. 
55 21 Cost dis fiib ut, bn 
Section 5.4.3.3 displayed the distribution of costs in the two trials. It was argued 
that a log-normal distribution for costs may be more appropriate. If this is the case 
we would expect that the DIC score (see 5.4.3.10) would improve (have a lower 
value) when we fit a log normal rather than a normal distribution on costs. For 
illustration therefore, costs with a normal distribution are represented and compared 
with a log normal distribution. 
Table 55 Comparison ofalternative distiibutiona/assumptions on mode/fit 
Incremental Incremental ICER DIC* 
cost (including QALY 
intervention 
cost) 
Normal costs (with 207 0.0088 23523 36251 
no covariates) 
Log normal costs 262 0.0084 29633 34729 
(with no covariates) 
'/owerscore reflects bellet"mode/fit 
Thus, the DIC indicates that the log normal costs are a better representation of the 
data than using the normal distribution. This is consistent with examination of the 
distributions presented earlier. 
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5522 /nc/usion ofstudyspecific covarrafes and come/afion 
Section 5.5.1 presented the results of the regression analysis to identify some 
important covariates and showed that baseline EQ-5D was an important covariate. 
The previous section, 5.5.2.1 demonstrated that a log normal distribution for costs 
was appropriate. Now, we can consider whether the EQ-5D baseline adjustment 
should be based on a study specific value and whether correlation between costs 
and effects is important. The results of these analyses are presented in Table 5.6. 
The first row, for comparison, repeats the final row of Table 5.5. Log normal 
distributions on costs offer a "better" explanation of the data than normal 
distributions. In turn, adding a generic EQ-5D covariate and subsequently a study 
specific EQ-5D covariate show a very slight improvement in the model. However, 
the inclusion of the correlation between costs and effects actually makes no sizable 
difference to the model fit. 
Tab/e 56 Compansorn ofinode/s inc/udi»q covaiiafes 
Incremental cost Incremental ICER DIC* 
(incl. intervention QALY 
cost) Log normal costs 262 0.0084 29633 34729 
(no covariates) 
Log normal costs 263 0.0088 29864 34727 
with generic EQ- 
5D covariate 
Log normal costs 262 0.0088 29838 34682 
with study specific 
EQ-5D covariate 
Log normal costs 261 0.0087 29843 34687 
with study specific 
EQ-5D covariate and 
correlation 
*10werscore reflects ; 6effer'1node1fit 
553 Cost-effectiveness 
Table 5.6 also presents the results of the cost-effectiveness analysis in terms of the 
costs and QALYs generated and the resulting ICER. Each of the log normal cost 
models gives similar results in terms of costs and QALYs generated and the ICER 
while the model using a normal distribution for costs result in a slightly lower (better) 
ICER and higher probability of being cost-effective, but does not fit the data as well. 
Two log normal cost CEACs are presented as the lower two lines in the graph 
below, while normal costs are shown as the highest of the lines. This CEAC 
illustrates the result that using two datasets with different conclusions leads to a 
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more ambiguous solution. At a cost-effectiveness threshold of £30,000 there is only 
a 50% probability that the intervention is cost-effective, while at £20,000 per QALY, 
the probability is only around 20%. There is considerably more uncertainty around 
the decision using two datasets of IPD, than there was based on the single trial 
based analysis presented in Chapter 4. 
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Figure 5.4 Cost-effectiveness acceptability curves with two datasets with alternative 
distributional assumptions 
5.5.4 Sensitivity analysis 
The reduction of the cost of the intervention to £123 as estimated in the Griffiths 
study, not surprisingly improves the likely cost-effectiveness of the intervention. 
Using the model that "best" describes the data, that is the model with study specific 
EQ-5D covariate but no correlation, yields an incremental cost of £185 with the 
same incremental QALY of 0.0088. This generates an ICER of £21,000 and a 
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probability of the intervention being cost-effective at £30,000 of around 70% (and 
around 45% at £20,000 per QALY). The results were not sensitive to the choice of 
alternative initial values. 
555 Checks for convergence and auto-correlation 
Section 5.4.3.10 described checks that should be carried out on each of the models. 
While it is not possible to present all the checks and plots for each analysis, history 
plots, density plots and autocorrelation plots for the fixed effects model with 
covariates are presented below. All models exhibited these characteristics 
indicating convergence and no auto-correlation. 
History plots: 
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Plot of Kernel density 
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5.6 Discussion 
The above analysis shows that for a range of assumptions about the type of model, 
there is considerable uncertainty around the cost-effectiveness of the intervention. 
This result is not entirely surprising. The larger of the studies, the national 
evaluation of the EPP based on the CDSMP, showed that the intervention was very 
likely to be cost-effective at commonly used cost-effectiveness thresholds. 
However, the Griffiths study, with a smaller number of participants, showed 
increased costs and slightly worse QALY profile. 
Meta-analysis of IPD is an appropriate analysis to perform where these data are 
available. However, meta-analysis is clearly limited to the number of studies 
available. In this instance, two studies provide limited evidence for a meta-analysis 
(and hence for decision makers). Nevertheless, it can be argued that this provides a 
more realistic assessment of the EPP than the single trial evaluation of the EPP. 
The analysis above suggests that using a lognormal distribution is appropriate for 
this meta-analysis, and that the use of this distribution has a negative impact on the 
likely cost-effectiveness of the intervention. Including study specific EQ-5D scores 
improves the model appreciably, though the subsequent addition of a correlation 
term between costs and effects adds little to the model in terms of the ability to 
explain the data. Nevertheless, correlation between costs and effects has been 
included as a means of allowing for correlated error terms between costs and effect 
equations using the same data. 186 
Using Bayesian techniques enables the analyst to assess the impact of employing 
alternative models on the probability of the intervention being cost-effective. The 
concept of "probability of cost-effectiveness" is meaningless in a frequentist 
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paradigm that can only establish probability as long run frequency. The flexibility of 
the Bayesian approach in using simulation to generate posterior distributions 
enables alternative distributional assumptions to be incorporated into the analysis. It 
has been demonstrated that these functional forms can change the magnitude of 
results. Changes in the magnitude of incremental cost-effectiveness ratio (ICER) 
can impact on the recommendation to decision makers. In this example, due to 
uncertainty around the exact threshold value of the QALY, the policy implications 
are unclear. If the threshold value of a QALY were either £20,000 or £30,000, the 
recommendation would not alter with the distributional assumptions and the use of 
covariates. In the former case, the intervention would be deemed no/cost-effective 
(as the ICER exceeds £20,000 per QALY), while in the latter the intervention would 
be deemed cost-effective. However, at a threshold value of £25,000, changes in 
distributional assumptions would alter the conclusions of the analysis. Using the 
normal distribution for costs the intervention would be deemed cost-effective, whilst 
using a log normal distribution the intervention would not be considered cost- 
effective. Thus, in terms of implications for policy, the distributional assumptions 
employed in the model are of critical importance. 
5.7 Conclusion 
The meta-analysis described above demonstrates the importance of employing the 
appropriate distributional assumptions and covariates. While meta-analysis of IPD 
may be appropriate in this instance, it is also limited in that there may be more data 
available on the effectiveness of this intervention, which could be used to give a 
better estimate of the uncertainty around the adoption decision. The identification of 
this evidence and their subsequent synthesis with existing data is considered in the 
next chapter. 
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Chapter 6. Evidence synthesis of IPD and summary 
statistics of surrogate outcomes 
6.1 Introduction 
The previous chapter extended the single trial based analysis to incorporate 
evidence from another UK based randomised controlled trial. However, in this 
instance, the inclusion of this additional evidence was unlikely to reduce the 
uncertainty around the decision over the adoption of the intervention. Indeed, at 
commonly quoted threshold values of a QALY, the uncertainty around the adoption 
decision was markedly increased. These two trials present the only evidence from 
UK based RCTs of the CDSMP intervention. 
However, we know from Chapter 3, that there are other studies outside the UK that 
may provide relevant evidence to inform the adoption decision. As it is frequently 
stated that economic evaluation should incorporate all relevant evidence, 38,62,84,187, 
188 it is reasonable to consider their inclusion in the analysis to inform the decision. 
Indeed, decision makers in the UK12 and other jurisdictions" provide guidance 
advising the desirability of the inclusions of a//relevant data. 
There is not, however, a simple dichotomy between relevant and irrelevant 
evidence. "Relevance" is context specific and involves a value judgement, ideally 
based on some scientific criteria. However, in conducting evidence syntheses, it is 
necessary to define what is included and what is excluded. Relevant evidence may 
vary not only across geographical regions and different conditions, but also 
according to who is making the decision on behalf of whom. 
At one extreme, in the case of the CDSMP, the single trial based analysis reported 
in Chapter 4 could be considered to contain the only relevant information, as this 
was the only trial of the CDSMP that was based on a representative sample of the 
UK public. 66' 162 However, one could also argue that another trial of the CDSMP in 
the UK, 83 albeit in a minority population, could also be considered relevant. The 
evidence base for the decision is therefore extended in Chapter 5 by synthesising 
the two trials. 66' 83,162 
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We could go a step further. Studies showing the effectiveness of the CDSMP in 
other countries, in different populations, in various conditions, over different time 
periods using alternative outcome measures with different trial designs could be of 
interest. The extent to which these studies are relevant is open to discussion. We 
know from Chapter 3 that there are studies that estimate the effectiveness of the 
CDSMP, but using non-generic outcome measures. However, these studies, and 
any others that may be identified by the search strategy (described later), are 
pofenfia//y relevant. How they might be included, the assumptions that this 
necessitates, and the impact on the results, conclusions and recommendations of 
the analysis are the focus of this chapter. 
The previously identified studies have different outcome measures from the generic 
one used in Chapters 4 and 5. These outcome measures can be considered to be 
surrogate (or intermediate) outcomes that are linked to health and are affected by 
the intervention (CDSMP). By treating these outcomes as surrogates and 
establishing the link between the surrogate and final outcome (in this instance 
health, as measured by the QALY), we can incorporate this evidence into the 
decision problem. 
As well as the use of surrogate outcomes, individual patient data are not available 
for inclusion in the analysis. Synthesising these different data types (IPD from the 
two trials used in Chapter 5 with aggregate data from the published literature) 
requires the use of additional modelling techniques and concepts and these are now 
described. 
The objectives of this chapter are three-fold. Firstly, to develop a framework for 
synthesising published (aggregate) data with the trial based data presented in the 
previous chapter. Secondly, to identify any other potentially relevant studies that 
may fit into this model and improve the analysis of the decision problem. Finally, to 
examine the impact that choice of evidence and what constitutes relevance may 
have on the adoption decision and the decision to conduct further research. A 
version of this chapter has been presented at Health Economics Study Group. 189 
128 
6.2 Modelling concepts 
6.2f Synthesising/PD andAD 
Chapter 5 described the IPD trial data available for inclusion in the model. However, 
the review in Chapter 3 indicated that there were other published data examining the 
effectiveness of the CDSMP. These data were available as aggregate data (AD) 
rather than IPD, therefore, to include these data requires some form of synthesis of 
IPD and AD. While there is some guidance in the literature as to the preferred 
conduct of an IPD meta-analysis, ' 81,190 surprisingly, there is little literature around 
combining AD and IPD. 
A similar scenario occurs in IPD meta-analysis which has been described as the 
gold standard of evidence synthesis. 191 In IPD meta-analysis, any studies that do 
not provide IPD essentially require a decision about how to incorporate AD within 
the IPD meta-analysis. The usual approach in IPD evidence synthesis has been to 
exclude these studies where "sufficient" IPD are available and to consider the 
impact that omitted results may have in a sensitivity analysis. 192,193 Clearly, both of 
these approaches do not make use of all the available evidence and also it is not 
clear how analysts should proceed when the level of IPD is insufficient (or, indeed, 
what level constitutes "sufficiency"). While this is unlikely to be an issue in 
specialties where there is a well developed network with an established history of 
synthesising evidence, such as in the cancer field, in other areas where these 
networks are not developed this may provide a sizable problem. 
The only paper identified that explicitly examined the synthesis of IPD and AD is the 
paper by Sutton et al, where the authors consider a meta-analysis where 12/37 trials 
provided usable IPD with 25/37 only having AD available. 194 An additional 
complication of this study was that a sub group of both the IPD available studies and 
the AD available studies were clustered trials. In essence the authors used a meta- 
analysis model that allows the incorporation of evidence from different study 
designs. We used a similar methodology (described below) though there were 
differences due to the nature of the data (our data were not binary outcome data) 
and the fact that the outcome used in the synthesis below was a surrogate outcome 
measure. The issue of surrogacy is discussed in the following section. 
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6.22 The use of surrogate outcomes and the assumption of conditional 
independence 
Surrogate outcomes have been defined as "outcome measures that are not of direct 
practical importance but are believed to reflect outcomes that are important". 195 For 
example, we may build a model for drug A in treatment of heart disease, but have 
only data of the effectiveness of drug A in lowering levels of cholesterol or 
hypertension. In this instance, cholesterol level or hypertension is a surrogate for 
the final outcome measure (which may be life expectancy or QALYs, for example). 
It is assumed that these surrogates would impact on final outcome. Perhaps more 
importantly it is assumed that on/ythese surrogate outcomes impact on final 
outcome. This requirement is the assumption of condifiorna/independence, such 
that once we know the value of a surrogate, the treatment effect no longer has any 
impact on outcomes. Formally, 
P(AC) = P(AIB, C) 
Where A is (for example) QALYs, B is treatment group and C is level of autonomy. 
The knowledge of B (treatment group) imparts no further knowledge of the value of 
A, given that we know the level of autonomy. 
However, there are examples from the surrogate literature where there are direct 
treatment effects that have been ignored and the surrogate has subsequently been 
discredited. 196 A frequently quoted example is that of CD4+ counts in HIV trials, 
where CD4+ count may be improved by the introduction of certain drugs. While 
CD4+ count is a good measure of survival, and the drugs have a positive impact on 
CD4+ count, other adverse effects of the drugs may actually reduce survival. 197 
This example demonstrates the potential dangers of assuming conditional 
independence, as not all of the important impact on final outcomes was picked up 
via knowing the CD4+ status. Nevertheless, the use of surrogates in the economic 
evaluation literature is common as shown in the review in Chapter 3, where the 
majority of studies used an outcome measure that (it was hypothesised) acted as a 
surrogate for the final outcome of interest (for example, health). 
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There is a considerable literature on the subject of surrogate outcomes. Much of 
this literature is concerned with hypothesis testing rather than on estimation, which 
is the primary aim of this chapter. However, recent reviews of the literature have 
identified a range of methods of testing for the suitability of surrogates as a "true" 
marker for final endpoints. 198' 199 Unfortunately, these methods, whilst yielding a 
numerical estimate of the validity of markers as surrogates, have no guidance as to 
what figure is required to achieve validity, or whether there is an absolute level that 
should be met across all conditions. It could be argued that complex interventions, 
where the "active ingredient(s)" is/are less easy to specify, 167 may have more 
mechanisms impacting on final outcome than simple interventions (such as a drug 
for asthma). Does this suggest (or allow) that the level of validity of a single 
surrogate amongst many could or should have a lower threshold for acceptability 
than one where we are more certain of the (biological) mechanism? This reduces to 
a question about our beliefs about the structure of the model and whether it is 
correct. If we believe the model is structured appropriately, and that everything 
goes through the single surrogate, then the fact that it is a "poor" surrogate may not 
be so important, we just might not be very good at measuring it. If however, we 
believe that the reason it is a "poor" surrogate is due to the exclusion of other 
important covariates or mechanisms, then we are unsure of the structure of the 
model and may require more evidence that the structure is appropriate. 
There are a number of measures of the adequacy of surrogates. One of the most 
commonly used measures to assess the suitability of a surrogate is the "proportion 
of treatment effect explained" (PTE) method, where PTE is defined as: 
PTE = 1- (ta U adjusted/ta U unadjusted) 
Where tauadjusted is the treatment effect adjusted for the surrogate and 
tauunadjusted is the treatment effect unadjusted for the surrogate 
As stated previously, there is little guidance as to what might be an acceptable 
figure in this example, though previous authors have suggested that values "close 
to" zero would indicate an invalid surrogate, 200,200,201 while a value of 1 indicates a 
perfect surrogate. 199 However, PTE has been criticised on the grounds that it is not 
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bounded by zero and 1 and is therefore difficult to interpret. 199 This is a developing 
area in biostatistics, but at present there is no consensus as to the appropriate 
method for validating a surrogate outcome. However, for the purposes of this 
analysis we are more interested in estimation as oppose to hypothesis testing. That 
is, we wish to estimate (or predict) a value with a suitable measure of uncertainty, 
rather than test whether a certain value is likely or not (subject to some pre- 
determined level). It was argued in Chapter 2, that hypothesis testing is not 
particularly suited for decision making. In this case, there may be additional 
variables that aid estimation or prediction; ideally these should not be excluded 
simply due to their lack of statistical significance. 
62V Exchangeabi/ify 
The concept of exchangeability in economic evaluation encompasses both the likely 
exchangeability of both the relative treatment effect on costs and the relative 
treatment effect on outcome data. The assumption of exchangeability between two 
trials requires that there are no apaorireasons for expecting a systematically 
different (higher or lower) estimate of the relative treatment effect on costs and/or 
effects between the two trials. 202, tos 
As with relevance, exchangeability can be represented on a continuum ranging from 
"not exchangeable" to "totally exchangeable" via "partially exchangeable". 204 
Exchangeability, again like relevance, will depend on the context. For example, a 
UK decision maker may decide that evidence from both the UK based RCTs is 
relevant and exchangeable. However a decision maker with responsibility for rolling 
out the EPP in a Bangladeshi population in London, may feel that the national 
evaluation (based across the whole of the UK with few minorities represented) has 
less relevance and that the treatment effect on costs and QALYs are not 
exchangeable. Extending this argument, it should be apparent that there is no clear 
dichotomy between exchangeable and not exchangeable, that is, there may be 
degrees of exchangeability, so that some evidence is considered to be more 
exchangeable than other evidence. In particular there is often a distinction made 
between the exchangeability of the treatment effect on cost data and the 
exchangeability of the treatment effect on outcomes data. 205 
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623. > Exchangeabilityofcosts vs exchangeabil#yofoutcomes 
It is plausible that the exchangeability of the relative treatment effect on costs may 
differ from the exchangeability of relative treatment effect on outcome evidence. It 
has been assumed in some analyses that for cost data this is not exchangeable, 206- 
208 while the relative treatment effect on outcomes is exchangeable. It is necessary 
to be explicit when setting out the decision problem and address issues of relevance 
and exchangeability at the outset. For the purposes of this analysis, both datasets 
of IPD are UK based using a common unit cost base and a common perspective 
and adjusted for differential timing. In this instance, and for these data, it is 
assumed that both the relative treatment effect on cost data and outcome data are 
exchangeable. 
Intuitively it is plausible that the relative treatment effects on cost and outcome data 
are at least as exchangeable as the relative treatment effects on self-efficacy, as the 
relative treatment effects on self-efficacy are measured in different populations, in 
different settings. For the purposes of the analysis below, it is assumed that the 
treatment effect on cost data from the two UK trials is exchangeable, and the 
relative treatment effect on outcomes from the UK and elsewhere are exchangeable. 
62 -7 2 Exchar7geabi/i/yofoutcoine measures at diffedng firne points 
Studies supplying aggregate data only, had differential follow-up periods. An earlier 
chapter referred to the adjustment made to QALYs in one trial (with IPD) to ensure 
compatibility with the other trial. This is a requirement for QALYs as by definition 
QALYs are time dependent (being a product of utility score associated with a state 
and the time spent in that state). It is not clear apaoiiwhether self-efficacy is time 
dependent, or if it is time dependent, what the nature of that relationship is. The 
relationship is not simply one that increases/decreases monotonically with time as 
some studies with shorter follow-up demonstrate greater changes in self-efficacy. If 
data were available that considered self-efficacy scores at different time points, it 
may be possible to model the impact of time on self-efficacy. Unfortunately, such 
data are not available, and differences in the levels of self-efficacy across studies 
are equally likely to be a result of different characteristics of the study population, 
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the study design or other factor. Therefore, for the purposes of this analysis, an 
assumption is made that self-efficacy is time independent. 
6.2.4 Fix edand ra n do in e ffe cf in o de is 
As described in Chapter 5, meta-analysis of IPD should use a trial identifier in the 
model. This allows differences between trials to be included and is more realistic 
than simple pooling of the data without this identifier (effectively treating the data as 
though it were from one large "mega-trial"). The analysis is then a "stratified" 
analysis (stratified by trial) and we have the choice between conducting a fixed 
effect or random effect model. With the fixed effect model, each trial within the 
model has a different baseline level of costs and QALYs. The treatment effect (the 
effect of CDSMP on either costs or QALYs) is considered common to all trials but 
each trial has a specific constant (equivalently the estimated regression line for each 
trial is raised/lowered by a specific amount), for both costs and QALYs. In contrast, 
a random effects model assumes that differences in the relative treatment effects on 
either costs or QALYs between trials are drawn from a distribution of random 
disturbances. 
Again, there is no consensus as to whether fixed effects or random effects are 
preferable. In this instance we have a small number of studies for the meta- 
analysis. With such a small number, creation of a distribution around these 
estimates is impractical, and for the purposes of this analysis therefore, a fixed 
effects model was chosen. 
625 Uncertainfyin economic evaluation 
Cost-effectiveness acceptability curves (CEACs) have been described in an earlier 
chapter. Briefly CEACs display in graphical format the probability that an 
intervention is cost-effective for a given threshold value of a QALY. In practise, 
there is always some level of uncertainty around the cost-effectiveness of an 
intervention, so that there is some possibility of mistakenly considering an 
intervention cost-effective at a particular threshold, when in reality it is not cost- 
effective at that threshold. This is due to the uncertainty around the input parameter 
estimates which are explicitly included in probabilistic sensitivity analysis, the 
134 
currently recommended technique89 to "reflect the combined implications of 
uncertainty in parameters". 12 If we have perfect information, equivalent to there 
being no parameter uncertainty, the correct decision will always be made. As stated 
above, this will not happen in practise and expected value of perfect information 
(EVPI) is a methodology that enables us to place a monetary value on the 
consequences of making a wrong decision (at various threshold values of a QALY) 
and represents the maximum value of further research that would eliminate 
uncertainty from the decision to be made, given /he current/eve/ofevidence. 209 As 
with CEACs, the EVPI can be plotted against threshold values of the QALY and 
provides a necessary but not sufficient condition for the conduct of future research 
(the EVPI must exceed the cost of conducting the research). The analysis below 
assesses the impact of different model structures on the likely cost-effectiveness of 
the CDSMP intervention, but also uses the EVPI to assess how alternative structural 
assumptions may yield different estimates of the value of conducting further 
research. 
6.3 Model development 
Section 6.2 described the modelling concepts required to allow using both IPD and 
AD in a model. These methods enable the use of alternative data types that are 
available for this analysis. In summary we have six potential types of data for use in 
the analysis, namely, IPD linking treatment and costs/QALY directly, IPD linking 
treatment to self-efficacy, IPD linking self-efficacy and QALY, or aggregate data 
(AD) for any of these relationships. 
The analysis below allows IPD and AD from different sources with different outcome 
measures. A graphical representation of the analysis is presented below in Figure 
6.1. While this chapter describes a specific example of synthesising IPD of final 
outcome and surrogate outcome AD, the model and the code are transferable to any 
of the following: 
i) synthesis of IPD surrogate and IPD final outcome 
ii) synthesis of AD surrogate and AD final outcome 
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iii) synthesis of IPD surrogate and AD final outcome 
1. Cost, QALYsITreatment 
Costs 
Treatment and QALYs 
2. Surrog 
Surrogate 
outcome 
3. Cost, QALY ISu rrogate 
Figure 6.1 Potential mechanisms for CDSMP to impact on costs/QALYs 
In this representation, there are two mutually exclusive ways that treatment may 
impact on costs and QALYs and one that is a hybrid of these two. The direct 
method, which is common to most trial based evaluations (labelled 1 above), simply 
estimates the impact of treatment effect on outcomes (costs and QALYs). The 
indirect method considers the impact of treatment on surrogate outcome and then 
the impact of surrogate outcome on final outcome (this is the product of 2 and 3 
above). The "mixed" method combines both the direct and indirect model to 
incorporate both direct evidence of treatment effect on final outcomes and the 
indirect effect which works via the surrogate. 
In the specific example considered in this chapter, the CDSMP is the treatment and 
self-efficacy is the surrogate outcome. Using the graphical representation above, 
the IPD trials described in Chapter 5 provided direcfevidence of the impact of the 
CDSMP intervention on QALYs (labelled 1 above). However, these trials also 
measured treatment effect on self-efficacy and the effect of self-efficacy on final 
outcome (QALY) and therefore they also contribute to the estimates 2 and 3 above. 
Thus these trials provide i»th ecfevidence via self-efficacy (that is treatment group 
impact on self-efficacy which impacts on QALY). 
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We know from the review in Chapter 3 that there are other sources of evidence that 
use self-efficacy as an outcome measure. These studies, and any others like them 
that are identified in the search below, inform the link between treatment (CDSMP) 
and surrogate outcome (self-efficacy) which is labelled 2 in the representation 
above. These studies did not include QALYs as an outcome measure and can 
therefore only contribute indirect/yvia the effect of CDSMP on self-efficacy 
(relationship 2 in the above graph). Thus, in this instance, they do not contribute to 
the direct evidence, though in principle at least, such data could be incorporated 
subject to satisfying certain assumptions (if we had AD for a study using CDSMP 
and measuring QALYs and costs). 
In addition, though in this example it is only the IPD that contribute to relationship 3 
(between self-efficacy and QALYs), this is due to a lack of identifiable evidence from 
other sources. The assumptions associated with each model are described in more 
detail below. 
6.1 1 The "direct"model. 
The direct trial based analysis estimates the effect of treatment group on final 
outcomes, costs and QALYs. Thus in a regression framework, treatment group 
would be used as an explanatory variable for the outcomes of interest (costs and 
QALYs). The model developed in Chapter 5 is considered appropriate. 
This model allows evidence to be incorporated on/ywhere the treatment is CDSMP 
and the outcomes measured are costs and QALYs. In this example, the only direct 
evidence we have linking treatment (CDSMP) to costs and QALYs is the IPD from 
two clinical trials. 56,83 No indirect evidence via self-efficacy is admissible in this 
model, but the model does not require additional conditional dependence 
assumptions to be satisfied. 
For ease of analysis, and as there were only two sets of data available (only IPD 
data informed the direct relationship), a fixed effect rather than a random effect 
model was used, see above. The assumptions in this model are that the cost and 
QALY data from both of these trials are completely independent (in that if we 
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observe costs (QALYs) in one trial, the costs (QALYs) in the second trial are the 
same as if we had not observed the first). However, an additional assumption is that 
the costs and QALYs from these trials are exchangeable. As both trials for which 
IPD were available were UK based and a common costing framework was 
employed, this is deemed a reasonable assumption for costs. The exchangeability 
of the relative treatment effect between two UK based trials is less controversial and 
is a commonly accepted methodology. However, a degree of caution should be 
exercised in this instance as the data from one of the trials was in a specific ethnic 
population which may reduce the degree of exchangeability of the relative treatment 
effect. A graphical representation of this model is presented below. The relationship 
between costs/QALYs and the treatment is represented by the expression over the 
arrow, Costs, QALYsITx (Costs and or QALYs, conditional on treatment group). 
Cost, QALYsITx 
Treatment 
Figure 6.2 The "direct" model 
Costs and 
QALYs 
6.3.2 The `indirect"mode/ 
In this model, we consider an indirect analysis using effect of treatment group on 
self-efficacy and then self-efficacy on QALY as the mechanism, that is, we consider 
self-efficacy as a surrogate for the final outcome measure which in this instance is 
cost or QALY. No direct mechanism is considered in this model. In essence, this 
model is similar to many decision analytic models in the health field where there are 
no data linking treatment and final outcome directly, merely an intermediate or 
surrogate outcome that, it is asserted, "predicts" final outcome. As described in 
section 6.2.2, a requirement of these models is that of conditional independence. In 
this example, we can state that given the value of self-efficacy, the measure of 
treatment effect is independent of treatment choice. Equivalently, we can say that 
the treatment has no impact on costs and QALYs, ofhei-ihan the effecfvia self- 
efficacy. 
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In addition to this strong assumption is that of exchangeability of relative treatment 
effect on outcomes. That is, the impact of the CDSMP intervention on self-efficacy 
is similar in patient groups with differing characteristics in different settings. These 
trials were conducted in different countries (US, UK, Australia, China) and the 
assumption is that these trials supply exchangeable estimates. While it is commonly 
assumed that treatment effects on outcomes are transferable, 210 this is largely in 
conditions where there is a "hard" outcome measure such as mortality in heart 
disease. It is less clear whether a "psychological" outcome such as self-efficacy 
(which is defined as confidence in ability to manage condition) is as robust to 
international and inter-ethnic exchangeability as harder measures of outcome. The 
direct analysis (in section 6.3.1 above) also assumes a common relative treatment 
effect. 
6. Z3 The `in/xed"mode/ 
The third model again extends the direct and indirect models to include both direct 
and indirect mechanisms. That is, the direct effect of treatment group on QALYs is 
considered in the analysis and the indirect analysis where QALYs are affected via 
the impact of treatment group on self-efficacy and the impact of self-efficacy on 
QALYs. 
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Figure 6.3 The "indirect" model 
Again, both IPD and AD can be used to inform this model in principle. In this 
example, IPD informs the direct relationship as there were no other sources linking 
CDSMP treatment directly to QALYs, as well as the relationship between self- 
efficacy and QALYs for the same reason. IPD and AD inform the relationship 
between CDSMP treatment and self-efficacy. 
Clearly, this model is a hybrid of the previous models in that it uses both direct and 
indirect mechanisms. A consequence of this is that the mixed model requires both 
the assumptions associated with both the direct and indirect models 
6.34 Mode/estimates 
The three models, with their assumptions are presented in Table 6.1. This table 
also shows the coefficients we are interested in for estimation purposes and how the 
model estimates costs and QALYs. 
The table describes the three models in regression terms. In the direct model, we 
estimate the impact of treatment group on costs (QALYs) with a study specific 
constant, as we have used a fixed effect model indicating a common treatment 
effect on costs but a different baseline value for each study. An error term is also 
included to capture the effects of any omitted variable. The coefficient of interest, 
the effect of the treatment on costs (or QALYs) is represented by PCT (or IQT). This 
model used only the IPD available as no other data directly linking CDSMP and 
costs (QALYs) were identified. 
The indirect model requires estimates of the effect of treatment group on self- 
efficacy and subsequently, the impact of self-efficacy on costs (QALYs). The 
treatment group effect on self-efficacy is represented by PST, while the effect of self- 
efficacy on costs (QALYs) is represented by ßcs (pas). Thus if, the effect of 
treatment group on self-efficacy and then self-efficacy on costs (QALYs) is large, the 
impact of treatment group on costs (QALYs) via self-efficacy (the indirect estimate) 
will also be high. This is represented by the product of the two coefficients, that is, 
PCS. ST (for costs) or ßQS. ßsr (for QALYs). 
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The mixed model combined both direct and indirect evidence. Not surprisingly, the 
estimate of interest is the sum of the direct and indirect models, that is, ßCS13ST"+PCT 
for costs and ßQS. PST. +RQT for QALYs. The first term in these expressions PCs-PST 
(or ßQS. ßsT) is the indirect via self-efficacy of treatment group on costs (or QALYs), 
while the second term PCT (or ßQT) shows the direct relationship of treatment group 
on costs (or QALYs). 
6.15 S111n1na1Yo1M7e models 
In summary, three models were developed. The models use different types of data 
from different sources using different endpoints. All models incorporate evidence 
that is potentially relevant. While it is important that economic evaluations 
incorporate "relevant" evidence, there is not a simple dichotomy between relevant 
and irrelevant evidence. The choice of model (direct, indirect, mixed) will influence 
what constitutes relevant evidence and alternative structures allow the incorporation 
of different types of evidence. There is a small but growing literature on the subject 
of structural uncertainty in the use of decision analytic models with suggestions as to 
how this may be addressed. 67,211,212 Of course, the model used is also dependent 
on the evidence available. It is accepted that if there is no evidence linking 
treatment to costs and QALYs direct/y, then other structures have to be employed. 
However, analysts should be aware of the assumptions made within these models 
and the potentially different estimates of cost-effectiveness and valuation of future 
research that these different analytical approaches can yield. 
6.4 Methods 
6.4,1 Mode/assumption 
One aim of Chapter 5 was to assess potential covariates and distributional 
assumptions. The conclusions of the chapter were that lognormally distributed costs 
were appropriate, while study specific EQ-5D should be used as a covariate. The 
addition of a term capturing the correlation between costs and effects had little 
impact on the "fit" of the model, but was deemed appropriate as previous authors 
have stressed the importance of including this correlation. 186 
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Thus the base case model assumed that the cost data were lognormally distributed 
and used baseline (study specific) EQ-5D as a covariate where this was available. 
Correlation between costs and effects was also included in the base case analysis. 
Any study that provided evidence of the effectiveness of CDSMP was included in 
the base case to address the decision problem more fully by informing the 
relationship 2 in figure 6.1 (the effect of treatment on self-efficacy). Studies were 
identified using methods described in 6.4.2 below. 
6.42 Search methods 
A literature search was conducted (see Appendix D for search strategy) to identify 
all trials that may provide data linking the treatment (CDSMP) to the (hypothesised) 
surrogate outcome, self-efficacy. Briefly, any trial that reported self care, self help, 
self-efficacy or similar term was targeted in the search strategy. Thus any paper 
informing the relationship labelled 2 in the representation below should have been 
identified. In addition, studies that may inform the third relationship (between self- 
efficacy and QALYs were also searched). This strategy is presented in Appendix D. 
S. 4.7 Software 
As in the previous chapters, this analysis takes a Bayesian perspective, with 
parameters treated as random variables to generate posterior distributions for these 
parameters based on the model or estimation procedure, the choice of initial values 
and the priors assigned. As asserted previously, Bayesian techniques using 
commonly available software are relatively easy to conduct and allow a range of 
distributional assumptions to be incorporated into the model, whilst retaining an 
intuitive meaning that is useful for decision making. 
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Each of the models described below has been run in the software package 
WinBUGS with 15,000 iterations and a burn-in of 5,000. As in previous analyses 
these burn-in results are discarded. Initial values were set as in section 5.4.3.7 and 
subjected to sensitivity analysis as in section 5.4.4.2. Subsequent calculation of 
Incremental net benefit and generation of cost-effectiveness acceptability curves 
were conducted in the free software programme R. Full WinBUGS and R code are 
presented in Appendix E 
6.5 Results of search for relevant clinical trial literature 
The search strategy targeting the link between CDSDMP and self-efficacy yielded 
2325 abstracts after de-duplication (as a number of databases were searched). 
After examining these abstracts, 18 papers were ordered. Together with the two 
studies already included there were 20 studies. Some papers examined a variant of 
the CDSMP, while others used a non randomised design. Other papers presented 
too little detail to enable the effectiveness of the intervention to be established. The 
studies that were included in the analysis are described below. The search strategy 
targeting the link between self-efficacy and QALYs retrieved no usable data to 
inform this relationship. Therefore, data from the two sets of IPD were the only 
evidence available providing evidence of this relationship for the models. 
6.5.1 Inclusion and exclusion ofstudies 
This analysis included papers using the CDSMP, or an earlier version the ASMP, as 
the intervention, which were presented in suitable format (that is a mean effect of 
treatment over control with a measure of dispersion was either presented or 
derivable from data presented), and the measure of outcome was not a restricted 
version of self-efficacy (such as "pain self-efficacy"). A number of "potentially" 
relevant studies were excluded from the base case for the following reasons: 
1) the intervention was an arthritis specific version of the CDSMP, the Arthritis 
Self Management Programme (ASMP), 74' 77.213-216 or variant of the CSMP or 
ASMP, 73' 78 or an alternative self management programme, 156 and did not use 
overall self-efficacy as the outcome measure. 
2) IPD data were available and were already included in the model. 66' 83 
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3) Published papers were not identified (only abstracts with minimal data 
presented). 217,218 
4) data were not presented in a manner that enabled the effect of treatment on 
self-efficacy to be established, 219.220 for example baseline data were not presented. 
6.52 Review ofincluded studies 
Two studies were available that provided IPD to inform the models described in 
section 6.4.66,66,83 These studies have been described in detail in the previous 
chapter. Additional papers supplied evidence for the models described in section 
6.4, and these papers are reviewed below. 
6 52 / Papers supp/yirigAD ir7c/udedin ana/ysis 
Five papers were identified that provided evidence of the effectiveness of the 
CDSMP. 75.76,79.81,82 All of these papers measured the effectiveness in terms of 
impact on self-efficacy. 
Lorig (2001 a), compared the effectiveness of the CDSMP with "usual care". 79 The 
intervention was delivered, as is usual, by peer instructors who had been trained in 
the delivery of the intervention following a "highly structured manual". The study 
was conducted in a community based setting in the United States (US) with a 
population of 489 adults (over 18) with one or more chronic conditions. The average 
(mean) group size was 9.4 with a range from 4 to 18. There was no discussion of 
the impact of group size on outcomes. The study was not randomised, rather a 
before and after design was employed. The mean age of the population was 62.2, 
the majority were married (64%), female (73%) and non-Hispanic white (83%) with 
an average of 2.3 chronic conditions and 15 years of education. 
The results are similar to a randomised trial conducted by the same authors, 80 
though the latter study did not report self-efficacy as an outcome. The former 
study79 showed a "statistically significant" increase in self-efficacy over 12 months, 
with a mean increase of 0.5 on the 10 point self-efficacy scale (with a standard 
deviation around the changed score of +/- 2.4). 
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Clearly, the design of this study means that there is a potential for confounding (a 
variable that impacts on the outcome that has not been allowed or controlled for). It 
is unclear whether this intervention is wholly or partly responsible for the 
improvement in self-efficacy. Nevertheless, given that improvement in self-efficacy 
is a primary objective of the intervention, this is not unlikely. 
Lorig (2001b) again considered the CDSMP delivered by trained peer leaders using 
a structured manual based in a community setting in the US. 75 The characteristics 
of the study population were broadly similar to the study above in that the majority 
were female (65.4%), married (55.8%), non-Hispanic white (90.8%) with a mean age 
of 65.3 and an average 2.2 chronic conditions and 14.3 years of education. The 
average size of the group was not reported. The study design was originally a 
randomised controlled trial, but results from the study were published as a one and 
two year longitudinal follow-up (without preserving randomisation). The study 
reported an increase in self-efficacy of 0.31 (SD 1.67) at one year and this was 
included in the models below. Again, the study lacked a control group and the 
results may be questioned due to the potential for confounders. 
Three further papers provided evidence of the effectiveness of CDSMP in terms of 
self-efficacy based on randomised evidence. 76,81' 82 Fu et al reported the CDSMP in 
five urban communities in Shanghai, China. 81 The comparator was a waiting list 
control and patients were randomised either to immediately receive the intervention 
or receive it in six months. Age, gender, marital status and number of condition 
characteristics were similar to the studies above (mean age 64.21,73.3% female, 
82.3% married, 2.09 chronic conditions), but all participants were of Chinese 
ethnicity. Baseline education levels were slightly different between the groups (9.48 
treatment and 9.88 control), but this was adjusted for in the analysis. Baseline 
levels of self-efficacy was higher in this group (7.36 intervention 7.23 control), and 
the intervention improved self-efficacy (0.22 over 6 months), while the control 
groups' self-efficacy level fell (-0.41 over 6 months), providing evidence that the 
intervention was effective at improving self-efficacy in this patient population. 
Siu et al, examined the effectiveness of CDSMP in Hong Kong compared to a Tai- 
Chi class. 82 The potential benefits of CDSMP could be expected to be lower in this 
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study as an active comparator is introduced. As with the studies described above, 
the study participants were all adults (aged 18 and over) with at least one chronic 
condition. The design of the study was randomised but in an unorthodox manner. 
Patients were initially pooled into groups of 20-30 individuals then matched 
according to age, gender, history of disease and duration of illness and then 
randomised to CDSMP or Tai-Chi using a coin toss. Presumably this was to ensure 
approximately the same size groups (which were aimed to be 12-15 for CDSMP and 
25-30 for Tai-Chi), though the rationale is not stated. Details of the make-up of 
treatment and control groups were that participants were mainly female (75%), 
married (72%) and educated to secondary level (54.1 %). The exact make-up of age 
and history/duration of disease was not stated explicitly, but was reported as "not 
significantly different" between groups. 
Lorig (2003) used a randomised design to explore the effectiveness of the CDSMP 
in a Hispanic population resident in the US. 76 The participants were Spanish 
speakers with a diagnosis of heart disease, lung disease or type 2 diabetes. The 
control was a waiting list control and both groups were evaluated at 4 month follow- 
up. As with other studies of this intervention the majority of participants were female 
(79%) and married (55%). Education level was lower than previous studies by the 
same author at 7.6 years and mean age and number of conditions were also 
somewhat lower at 57 years and 1.9 conditions. 75,79 8° Groups were comparable at 
baseline in all these variables. A majority of both groups (65% intervention and 64% 
control) were born in Mexico with a small percentage (6% intervention and 5% 
control) born in the US). Both groups showed improved levels of self-efficacy at 4 
month follow-up with the intervention group performing better on this outcome 
measure. 
All these studies showed an improvement in self-efficacy scores in those given 
CDSMP, though the lack of randomisation in two studies makes the results 
questionable. 
In addition, two papers reported overall self-efficacy from an ASMP intervention, 71.73 
while one paper reported overall self-efficacy from the CDSMP delivered via the 
internet. 78. The ASMP intervention was the forerunner of the CDSMP, and provides 
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evidence of the link between a lay led self management program and overall self- 
efficacy. The first paper examined the ASMP in a population of patients suffering 
from arthritis, again in a sample where the majority were female (79%), and a 
relatively high level of education (14 years). The study showed the intervention 
improved self-efficacy, though the before and after design limits confidence in the 
results. The other study examined the ASMP using a randomised design and again 
found improvements in self-efficacy, while another study examined the effectiveness 
of CDSMP delivered via the internet also showed an improvement in self-efficacy. 
Due to doubts over study design and the transferability of results from ASMP 
studies, the latter three studies were excluded in a sensitivity analysis to assess 
their impact on the results. 
A summary of the results of these studies is presented in Table 6.2. 
6,5.3 C//n/ca/f/a/suininary 
Two studies with IPD were available. 66,66,83 The search strategies above identified 
several trials that provided AD available linking CDSMP with self-efficacy. 71' 73.75' 76. 
78,79,81,82 No data were available (other than that available from the two studies with 
IPD available), linking self-efficacy with QALYs or utility. Therefore, in summary we 
have 4 sources of evidence: 
>) /PD /inking CDSMPaI, d QAL Ydi1ecf/y 
2) /PD k»ki»g CDSIWP 817d SE 
3) /PD /king SE and QAL Y 
4) AD//nki»g CDSMPand SE 
These sources of evidence can be used in different ways to "model" the relationship 
between the treatment (CDSMP) and costs (QALYs). These different models 
structures were described in detail in section 6.3, while the results of the different 
models are presented below in section 6.6. 
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Table 62 Summaryofs/udiesinc/udedin the analysis 
Study Date Intervention Mean SD N Type of 
effect data 
size available 
Kennedy" 2006 CDSMP 0.52 0.21 629 IPD 
Griffiths83 2005 CDSMP 0.23 0.13 476 IPD 
Lorig79 2001 CDSMP 0.50 2.40 489 AD 
Lorig75 2001 CDSMP 0.31 1.67 430 AD 
Long" 1993 ASMP 1.41 2.53 177 AD 
Siu$ 2007 CDSMP 0.57 0.39 148 AD 
Fu81 2003 CDSMP 0.63 0.21 954 AD 
Long" 2003 CDSMP 0.44 0.30 327 AD 
Lorig73 1999 ASMP 1.14 0.31 286 AD 
Lorig78 2006 Internet 0.21 0.14 780 AD 
CDSMP 
6.6 Model Results 
Results from the three models are presented below in Table 6.3 
Table 63 Results from three modeis with 95% confidence infeiva/s where 
appropriate 
Direct Model Indirect Mixed 
(usina IPD onlv) 
Cost (E) 263 193 258 
(217 to 306) (188 to 198) (214 to 294) 
Qaly 0.009 0.004 0.011 
(0.003 to 0.018) (0.001 to 0.007) (0.001 to 0.019) 
CDSMP effect 65 N/A 66 
on costs (ßcT) 
CDSMP effect 0.009 N/A 0.007 
on QALYs (POT) 
Impact of self- N/A -11 -11 
efficacy on 
costs (ßcs) 
Impact of self- N/A 0.009 0.009 
efficacy on 
QALYs (pas) 
CDSMP effect N/A 0.474 0.473 
on self-efficacy 
(Psr) 
23454 
The results are of considerable practical interest. The decision to adopt the 
intervention may be influenced by the choice of model. The direct estimate using 
the IPD only estimates an Incremental Cost-effectiveness Ratio (ICER) of £29,222. 
Current National Institute of Health and Clinical Excellence (NICE) guidance states 
that interventions delivering a cost per QALY under £20,000 are likely to be an 
acceptable use of NHS resources, those with an ICER between £20-30,000 per 
QALY may be cost-effective depending on other considerations, while those with an 
ICER over £30,000 are unlikely to be cost-effective without strong additional 
evidence. 12 The direct model, with an ICER of over £29,000 is clearly close to the 
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accepted maximum, while the indirect model is well above the maximum at almost 
£50,000 per QALY. The mixed model using all the available evidence produces the 
lowest ICER at around £23,000. Clearly, the adoption decision based solely on the 
indirect model would be to reject the intervention as it is unlikely to be cost-effective. 
Using the direct model with evidence limited to the two UK based RCTs would lead 
to less certain evidence for the adoption decision, and may be judged cost-effective 
depending on other factors that may be accounted for. The mixed model has the 
greatest uncertainty at the threshold values of a QALY currently recommended. 
The cost-effectiveness acceptability curves (CEACs), described earlier in Chapters 
2 and 4, present a graphical representation around the adoption decision. The 
CEACs for these models are presented below. These results were similar in the 
sensitivity analysis where the ASMP studies and the single internet study were 
excluded. When these studies, which demonstrated an impact of treatment on self- 
efficacy were excluded, the ICER on the indirect model increased to £48,617. The 
change is relatively small as the impact of self-efficacy on QALYs is limited. 
Similarly, excluding the studies with non randomised designs also had limited 
additional impact, partly due to the aforementioned weak relationship between self- 
efficacy and the QALY and partly due to two of the three non randomised designs 
being included in the first sensitivity analysis. The ICER remained at over £48,000 
per QALY. 
It is interesting to note that the indirect model using the surrogate mechanism via 
self-efficacy shows the greatest level of certainty at commonly used threshold 
values of a QALY. This shows that we would be virtually 100% certain (at a cost per 
QALY of £20,000), that the intervention was rno/cost-effective. Using the other two 
models, which incorporate the IPD from two UK trials, shows a much greater degree 
of uncertainty at commonly employed threshold values of a QALY. In fact, the 
mixed model which incorporates the most evidence is the most equivocal with a 
30% chance of the intervention being cost-effective at £20,000 per QALY. At values 
of £30,000 per QALY, the indirect analysis still shows almost 100% certainty that the 
intervention is not cost-effective, while the direct model and the mixed model both 
show that the probability of the intervention being cost-effective exceeds 50%. 
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Figure 6.4 CEACs for models using alternative mechanisms 
The CEACs demonstrate that there is a clear ordering of the models in terms of the 
relative cost-effectiveness of the intervention. The indirect model always portrays 
the intervention to be less cost-effective than the direct model which in turn always 
portrays the intervention to be less cost-effective than the joint model. Intuitively, we 
might expect the joint model to lie between the direct and indirect models, but that 
does not reflect the additive nature of the models. In this instance, the joint model 
allows information from both direct and indirect sources to impact on costs and 
QALYs. As there is a positive relationship between treatment and self-efficacy and 
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self-efficacy and QALYs, in this instance adding the indirect results will lead to the 
intervention being more cost-effective than simply using the direct results. 
Also of interest is the valuation of future research. The valuation of future research 
as estimated by the EVPI (Expected Value of Perfect Information) is defined as the 
difference between expected value given perfect information and the expected value 
given current information. The concept has been described in more detail in section 
6.2.5. 
The EVPI for each of the models plotted against the threshold values of a QALY are 
presented below. Again, the three models are illustrated to show the different 
recommendations to conduct future research. 
Note the level of certainty implied by the indirect model and the implication that 
follows from this is that there is little value in conducting further research. Contrast 
this with evidence from the IPD trials (the direct model) which, it could be argued, 
provide the most relevant evidence. Using the direct evidence, with the implication 
of assuming that treatment may impact on QALYs in a mechanism other than 
through self-efficacy (i. e. we break the assumption of conditional independence), 
results in a far greater EVPI than with the indirect models. Why should there be this 
apparently huge difference between the models? The graphs below show the 
distribution of costs and effects for the direct and indirect models. 
With the direct model, there does not appear to be any strong correlation between 
costs and effects. Contrast this with the indirect model, where the assumption of 
conditional independence has induced a very strong correlation between self- 
efficacy and QALYs, so that if the value of self-efficacy is high, costs and QALYs are 
likely to be high also. The issue becomes whether this strong correlation is 
justifiable. It could be argued that as long as this correlation is justified, the indirect 
model has reduced "noise" (for example it would exclude any unrelated costs and 
effects that happen to occur in the treatment groups). Alternatively, if the direct 
effects of treatment on costs, QALYs or both are not equal to zero, we have 
overstated the certainty. 
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With the data we had available for these models, we have been able to show that 
the different models generate different values of the ICERs as well as different 
probabilities of being cost-effective at various thresholds. More importantly, these 
models may give differing recommendations for both the adoption decision and the 
decision whether to conduct further research. This difference in the models is 
attributable to the differing data used in the models and the assumptions made in 
the models. In particular, if conditional independence is a valid assumption then the 
use of the indirect models is possibly appropriate. 
However, what constitutes validity in this field is not known. At present, it is a value 
judgement. The literature in the field of surrogates is not well developed in the area 
of estimation (as oppose to hypothesis testing) and offers little insight perhaps other 
than to refute the use of surrogates in these situations. 
6.7 Discussion 
This chapter aimed to provide a framework for incorporating aggregate data into 
evidence synthesis and to explore how including these data, identified through a 
systematic review, might impact on the results and conclusions of analyses. Three 
models were developed to examine a range of potential mechanisms through which 
the intervention, CDSMP, might influence final outcomes (in this case, QALYs). The 
first model, the direct model, examined the effect of treatment (CDSMP) on costs 
and final outcomes directly, as with a trial based analysis. Secondly, the indirect 
model examined the impact of treatment on costs and final outcomes indirectly, that 
is, where all the effects were through the surrogate outcome, self-efficacy. Finally, 
the third model incorporated both of these mechanisms into the "mixed" or joint 
model. The alternative models made differing assumptions, but also allowed the 
use of data from different sources. 
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The indirect and mixed models both had a wider relevant evidence base than the 
direct models in that they included more studies in different geographical areas. The 
indirect model produced the most certain estimates and lowest expected value of 
perfect information. The indirect structure is likely to produce lower estimates of 
uncertainty but requires the assumption of conditional independence. 
The most appropriate model structure may also be context specific, whether we 
have enough data to use a random effects model will depend in part upon our 
definition of "relevant". When conducting evidence syntheses, it is necessary to 
define what constitutes relevant evidence. Relevant evidence may vary not only 
across geographical regions and different conditions, but also according to who is 
making the decision on behalf of whom. In the literature around self care support 
interventions in general and the CDSMP in particular, there are many issues around 
the relevance of types of evidence. These are briefly described below and have 
been described in an earlier paper. 7 
0 Geographical location 
Most of the original studies were carried out in the US, and the more recent 
AD is from China and Australia. Whether this should be considered relevant 
to the UK decision maker is a moot point. 
0 Design/quality of study 
Earlier studies were of poorer quality, for example lacking correct 
randomisation. Again, some commentators may exclude studies based on a 
perceived lack of quality. 
0 Condition considered 
Some studies are in specific conditions, particularly arthritis. Whether the 
results of such studies are transferable to other conditions, or to "chronic" 
conditions as a whole, are questionable. 
0 Delivery of intervention 
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The intervention is usually evaluated in a face-to-face group setting. 
However, one study delivered the intervention over the internet. This may or 
may not constitute a different "intervention". 
0 Population evaluated 
The CDSMP has been evaluated across a range of ethnic subgroups. The 
transferability across these subgroups may be limited. 
Each of these may be used as reasons to include or exclude evidence as being 
relevant. For the purposes of this synthesis however, any trial where the CDSMP 
was evaluated in terms of self-efficacy was considered. 
In addition, all studies supplying aggregate data of CDSMP use a hypothesised 
surrogate outcome measure (self-efficacy) rather than a final outcome measure 
(such as QALYs) in their analysis. From a decision making viewpoint, it can be 
argued that all outcome measures other than life expectancy adjusted for quality 
(as, for example, QALYs) can be considered as "surrogates", as even "hard" 
outcomes such as survival must be extrapolated to life expectancy and then either 
implicitly or explicitly assign a "quality" score to this expectancy. Thus the example 
of self-efficacy in this analysis can easily be transferred to other economic 
evaluations with a surrogate outcome. 
The relevance and availability of data dictate which model is chosen. In this 
instance, model choice influences both whether the intervention is likely to be cost- 
effective and whether it is worth conducting future research. The results are 
particularly interesting when the different models are compared with each other 
and/or contrasted with previous chapters. After the single trial based analysis 
presented in Chapter 4, it may have been reasonable to conclude that this 
intervention was very likely to be cost-effective at commonly used threshold values 
of a QALY. However, the evidence presented in Chapter 5 weakened this 
conclusion, while the recommendations of this chapter are even more equivocal and 
are entirely dependent on the definitions of relevance of information and the 
appropriateness of assumptions made. In the absence of the UK trial based 
analyses, the model using only indirect data would be used. This model would 
reject the adoption of the intervention and also, crucially, any further research. 
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Given the evidence we have from the UK based trials, the indirect model 
understated the uncertainty around the adoption decision and the decision to 
conduct more research. This is largely due to the assumptions of the indirect model 
that the intervention worked through self-efficacy. The trial results showed that this 
model structure was limited and that the intervention influenced costs and QALYs 
through a mechanism other than self-efficacy. 
Though it is accepted that when there are no direct trial based data available, 
indirect models using surrogates need to be used, care should be taken in their 
interpretation. If the surrogate is poor, however that is defined, there is likely to be a 
misrepresentation of uncertainty and potentially misleading evidence on both the 
adoption decision and the future research decision. 
There is no suggestion as to which model is "correct" in the preceding analysis. The 
correct model is ultimately dependent on our beliefs about the correct structure of 
the model. The use of model averaging techniques is a potential methodology for 
examining structural uncertainty. This approach "parameterises" the structural 
uncertainty and places it directly into the model. 67 Thus if we have three potential 
models (as in this case), essentially this approach averages results across the three 
studies. Results can also be weighted according to their plausibility, 67 though this 
requires the valuation of the plausibility of each model. This approach is a 
promising area for future research. 
The analysis provided in this chapter, and the previous two chapters, considered 
evaluating a specific intervention to support self care using a generic, preference 
based instrument, the QALY. While this is a commonly used tool, with well 
understood limitations, 61 163 it has been argued that it does not encapsulate all 
outcomes (health or non-health) that may be of interest to decision makers. 12' The 
following chapter examines the potential for expanding the outcome measure and 
explores the impact this may have on the cost-effectiveness of the intervention. 
6.8 Conclusion 
Chapters 4 and 5 demonstrated that the inclusion of additional evidence can impact 
on results and conclusions. This chapter reinforces this conclusion. Developing 
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additional models to incorporate additional information requires further assumptions 
to be made. Using these additional data and assumptions can lead to differing 
conclusions. 
Results and recommendations of the analysis of cost-effectiveness of the CDSMP 
are sensitive to the type of model chosen and the data that are included. Analysts 
should be explicit about their choice of model and the assumptions required for that 
model. Care should be taken when using surrogate or intermediate outcomes as 
certainty around the decision may be overstated and the value of future research 
understated as these models require the assumption of conditional independence, 
which is frequently overlooked. 
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Chapter 7. What outcomes do patients value? A discrete 
choice experiment 
7.1 Introduction 
The previous three chapters have expanded the evidence base in the evaluation of 
the cost-effectiveness of the EPP from a single UK trial based analysis to an 
analysis incorporating evidence from a variety of sources and geographical 
locations. All these analyses considered the outcome of interest to be the QALY. 
This is a common outcome measure in economic evaluation, though this restricted 
perspective is not a requirement of economic evaluation in the extra-welfarist 
paradigm. However, as discussed in Chapter 2, some authors have expressed 
concern about the use of the QALY as the measure of benefit. 50,50,52 Other authors 
have argued that the QALY does not capture all outcomes of interest, 221 nor does it 
adequately allow for patient preferences. 
Extending the analysis to include other outcomes that are important to patients 
could potentially impact on the results and conclusion of the analysis. This chapter 
expands the outcome measure from a simple health related quality of life measure, 
to a wider measure encompassing other outcomes that patients have stated are 
important to them and examines the impact that this has on the probability of the 
EPP intervention being cost-effective. A shorter paper describing the experiment 
conducted in this chapter is currently in submission with Value in Health. 222 Results 
from the experiment have been presented at Cochrane colloquia, 223.224 and Health 
Economics Study Group (HESG). 225 
Z 1.1 Background 
Recent policy has targeted self care as a means to improve patient outcomes and 
reduce costs. 3.226 A recent study demonstrated that an intervention designed to 
enhance patients' ability to self care was effective at improving the self-efficacy of 
patients, that is, their confidence in their ability to manage their condition. 66 A 
separate paper, which also forms the basis of Chapter 4 of this thesis, based on the 
same clinical trial generated QALY gains for these interventions using the EQ-5D 
instrument. 162 The EQ-5D instrument measures health related quality of life, across 
five dimensions namely mobility, ability to self care, ability to perform usual activities, 
level of pain/discomfort and level of anxiety/depression. QALYs generated in this 
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analysis did not explicitly include outcomes such as self-efficacy, which was 
included as an outcome measure in the clinical study, or other important outcomes 
as described by patients in previous work. 
Therefore, while QALYs have a commonly expressed value, 12 they may not 
incorporate all the outcomes that are of interest. In contrast, while there are other 
outcomes of interest, we have no knowledge of their "value". This leads to problems 
of interpretation as decision makers cannot assess the relative merits of self-efficacy 
compared to health related quality of life. This chapter aims to address this issue by 
valuing other "important" outcomes in terms of health related quality of life. 
Z 42 Aims and objectives 
One technique that can be used to establish the relative merits of outcomes of 
interest is the discrete choice experiment (DCE). These experiments are based on 
individuals stated (rather than revealed) preferences as there is commonly no 
market for the characteristic of interest to reveal preferences. Individuals are 
typically asked to respond to a series of hypothetical questions with a number of 
attributes set at differing levels. For example, a simple question in a simple discrete 
choice experiment may present an individual with two options A and B. Both have 
two attributes, for example, access to GP and GPs knowledge of the presenting 
condition. As an example, option A may be to see the GP immediately but he/she is 
not very knowledgeable. Option B may be to see the GP in three days time, and the 
GP is reasonably knowledgeable about the presenting condition. The responder is 
asked whether he/she prefers A or B. Increasing the number of attributes and levels 
increases the complexity of the experiment but allows the analyst to gain a fuller 
idea of the relative merits of the attributes. 
This chapter describes a discrete choice experiment conducted to examine the 
relationship between health related quality of life and other outcomes which may be 
important to patients with long-term conditions. In addition, the estimation of rates of 
substitution between the QALY and these other outcomes enable decision makers 
to include other outcomes in their assessment of cost-effectiveness. 
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The use of the DCE methodology enables the valuation of important outcomes in 
terms of QALYs and allows us to "adjust" QALYs to allow for other important 
measures of outcome (in this example, self-efficacy is chosen). This enables 
interventions, such as the EPP, to be assessed in terms of both the QALY and also 
the QALY adjusted for self-efficacy. Ultimately, these additional effects can be 
incorporated into the cost-effectiveness acceptability curve (CEAC) to demonstrate 
the impact on the probability of the EPP, in this case, being cost-effective for a 
range of decision makers threshold value of a QALY. This chapter has a series of 
aims/objectives which are listed below: 
1) Can DCEs be used to assess the value of non-health outcomes that can be 
incorporated into CEA? 
2) How important are interaction terms in the DCE? 
3) What problems are encountered using DCEs in CEA and do these impact on the 
appropriate estimation technique? 
4) What impact do the results have on the cost-effectiveness of interventions to 
support self care and what are the policy implications? 
5) What are implications for DCE in CEA? 
7.2 DCEs in the health care evaluation literature 
Economic evaluation is conducted because resources are scarce and the demand 
for the resources will always outstrip the supply. To assess cost-effectiveness, the 
measure of outcome chosen is some measure of health related quality of life such 
as the QALY. However, discrete choice experiments have been used as a means of 
either expanding the measure of outcome or incorporating factors other than health 
outcomes. 221 Discrete choice experiments are a stated preference method used to 
establish the important constituent parts of a good or service, and are based on the 
premise (expanded below in section 7.4), that the benefits associated with 
healthcare interventions can be expressed in terms of: 
162 
a) the a#ribules orchacacfell, ýficsof that intervention, 227 and 
b) the affrrbufes orcharacferrstics of the person valuing them. 228,228,229 
For example, speed of access to health care, who provides that health care and 
where it is provided, are often considered as important aspects of health care that 
may not be captured by a measure of HRQoL. 221 DCEs, or similar techniques, have 
also been used to generate WTP for QALY, 230 and to generate values for health 
states for use in economic evaluation. 231.232 
DCEs have also been used to estimate preferences in miscarriage management, 233 
management of prostate cancer"' as well as a variety of other conditions and 
setting s. 235-246 
DCEs have also been used to estimate willingness-to-pay (WTP) values for a QALY 
in a Danish population. 230 The estimated WTP of 88,000 Danish Kroner 
(approximately £8,000) appears low and the authors suggest that this might be due 
in part to the upper limit presented to respondents being set at too low a level. 
Doward et al compared the values of health states using DCE and time trade off 
(TTO) and found that while the ordering of health states was similar between the two 
methods, actual values were significantly different. 231 The authors also found that 
there was much greater variation within TTO responses and much less 
understanding of the exercise. Bala and Mauskopf used DCE to estimate the loss 
function associated with drug treatment for acute myocardial infarction. 232 These 
authors used welfarism as their theoretical basis and consequently rather than 
expressing the loss function as a function of QALYs, it is expressed as a monetary 
amount. 
There are few examples in the published literature of DCEs being used to establish 
marginal rates of substitution between health states and other attributes for inclusion 
in a multi-attribute utility measure. In this instance, the use of self-efficacy is justified 
by the importance of this concept in the psychological literature, 168,247' 248 where it is 
an important outcome that would not be wholly encapsulated within a QALY 
framework. 
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Similarly, most DCEs in the literature use a limited main effects design (that is, they 
do not allow for the possibility of significant interaction terms). This analysis 
considers the importance of the interactions between attributes in the DCE. An 
example of interaction terms in this discrete choice experiment is presented in 
section 7.6.2. 
The published DCEs in the health economics literature make a number of 
assumptions about the econometric estimation technique that should be used when 
analysing these experiments. It is far from clear that previous examples use the 
correct methodology, and therefore this chapter considers several alternative 
estimation techniques. 
7.3 Design of DCE 
Historically, most DCEs in the health care literature have used a limited number of 
attributes and a simplistic main effects design. 249 When relevant attributes, or 
interaction between attributes, are omitted, biased parameter estimates are likely as 
respondents may unknowingly assign those values. 
. Z2> Fu//factor/a/andfractiona/factor/a/designs 
A full factorial design represents the full range of combinations of attributes and their 
levels. For example if we had 4 attributes with 3 levels each (as in the DCE 
described below), this would require 34 or 81 scenarios (or profiles) would be 
generated. Such designs are practical only for experiments with limited numbers of 
attributes and attribute levels. 250 Full factorial designs for large numbers of 
attributes/levels would present considerable cognitive burden on respondents. As 
with previous DCEs in health and other disciplines, a fractional factorial design was 
chosen. Fractional designs select a subset of the full factorial, but allow the 
relatively efficient estimation of the coefficients around attributes. 250 These designs 
inevitably lose some information when compared with the full factorial design, but 
reduce the cognitive burden for respondents. 
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7 3,2 Prop erii esofD CE de sig qn 
Orthogonality, level balance, utility balance and minimal overlap are considered to 
be appropriate characteristics of DCEs. 249 Orthogonality describes the property that 
each level of an attribute should appear the same (approximately) number of times 
with each other level of each other attribute. For example, health state level 1 
should not appear solely in the same choice set with confidence level one, but 
should appear equally distributed with confidence levels 1,2 and 3. Level balance 
implies that the levels each attribute should appear with equal frequency, while 
minimal overlap implies that the instances where the attribute level is the same in a 
given choice set should be minimised (thus for example, if option A has health state 
1, option B should ideally not have health state at level 1). Utility balance implies 
that each choice set option should have similar utility and therefore similar 
probability of being chosen. A trade-off exists with this characteristic as clearly 
making choices more difficult may increase the cognitive burden and reduce 
response rate. 
To ensure the most efficient statistical design, the number of levels of each attribute 
should be multiples of each other. That is, if we have 4 attributes, we could have 3 
with 4 levels and 1 with 2 levels, or even 1 with 8 levels. We should not, however, 
have some attributes with 2 levels and others with 3. The practical implication for 
this DCE is that there should be 4 attributes each with 3 levels (as having three 
levels for each clearly satisfies the above requirement). Not only is this statistically 
most efficient, but it also enables some 2 way interactions to be included in a 27 
question design (see 7.3.3 below). 
From the orthogonal design described above, choice sets (such as the one 
presented in Figure 7.1) can be created using the "foldover" technique. Consider a 
4 attribute 3 level experiment such as the one described in this chapter. Using a 
catalogue design, 251,251,252 numerous scenarios can be developed. The first scenario 
generated may have affiibufe fat /eve/ > a&70,11e 2at /eve/2, af%ibufe 3at /eve/2 
and at/iibu/e Oat /eve/3. We can represent this as 1223. This profile would be one 
scenario in the choice set. To generate the comparison, which responders will 
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choose between, levels are "folded over". Thus, for example, level 1 becomes level 
2,2 becomes 3 and 3 becomes 1. Therefore, 1223 becomes 2331 when folded 
over. The comparator then becomes a&17bufe fat /eve/2, affiibufe 2at /eve/3, 
affrrbufe Sat /eve/3, and a&17bufe Oat level 1(or 2331). This creates one choice 
set. The procedure is repeated for the number of questions to be asked to create 
the full questionnaire. 
7.73 Interaction terns andlength of questionnaire 
In recent years the DCE literature has seen more emphasis on the design of 
experiments. Issues addressed include the statistical efficiency of the designs, 249 
responder efficiency, 249 completeness of preferences and the use of simplifying 
heuristics , 
253,254 and the meaning of willingness-to-pay (WTP) measures in 
DCEs. 255 258 The structure of the choice model has received less attention. Most 
experiments have used a linear additive model due to the additional complexity and 
cognitive burden for responders of including many attributes and allowing for 
interaction terms. This is justified by the frequently quoted result that between 70 
and 90% of explained variance can be accounted for by main effects models, 259 that 
is, models that do not allow for interactions between attributes. However, these 
results are dated and should not preclude the inclusion of two way interaction terms, 
particularly where there is an a, oabriexpectation that interactions may be important. 
Kocur et al list three consequences of assuming interaction terms are negligible 
namely: these interactions remain undetected, experimental error is increased and 
incorrect conclusions may be drawn about significance of certain attributes. 251 
Louviere et al suggest the use of an endpoint design to allow for interaction terms; 250 
unfortunately, the use of this technique requires that the levels within the attributes 
are on an interval scale i. e. that the movement from health state 1 to health state 2 
is identical from the move from 2 to 3; with the health state dimension in this study, 
this is unlikely to be the case. Movements from 2 to 3 are associated with much 
greater utility decrements than movements from 1 to 2. 
Some authors have examined the use of interactions (between attributes) within a 
DCE. 260 Typically allowing for interaction terms increases the number of scenarios 
the responder has to answer several times. For example, a DCE with only 3 
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attributes each with 3 levels would require only 9 questions if interaction terms are 
ignored. However, to include all the interaction terms requires 27 questions. As the 
number of attributes and levels increases the complexity of a DCE including 
interactions increases. However, there is no consensus as to the "correct" number 
of questions to ask individuals, with previous work in the DCE field suggesting that 
length of questionnaire has little impact on response rate. 260 
While there is little evidence of the importance of interactions in this field, it was felt 
that interactions between particular attributes could be important and therefore, this 
DCE used a design enabling the estimation of interaction terms for a subset of the 
sample. 
7.4 Theoretical basis for DCEs 
The standard economic model of discrete choice experiments is based on Random 
! /fi/rfy Theovy(RUT) and the Lancasters characfenstics theory of value, whereby the 
indirect utility of consuming a good is a function of the characteristics or attributes of 
that good and also the individual's characteristics. That is, the utility of good A to 
individual i is dependent only on the characteristics of good A (XA) and the 
characteristics of the individual (s; ), or more formally UA; =U(xA; s, ). This function is 
then decomposed in to a potentially observable deterministic component of utility VA, 
and a random element s4 such that U,,; =VAj+CAl. 
For simplicity V(. ) is often assumed to have a simple additive linear functional form, 
such that VAS =A +/31x14 +... + , 
8NxNA + 70 + y1Si, +... +YMS., . Where x,, A is the value of 
the nth characteristic of good A and sm, is the value of the nth characteristic of 
individual i ß,, and y. are the individual invariant (unobserved) parameters related 
to x,, 4 and s, ,, which 
transform the characteristics of the services and the individual 
into a utility of that service to that individual. The objective of the DCE is to obtain 
estimates for the vector of unknown parameters, (ßo, ß,,..., ßN) (the part-worth 
utilities). The ratio of any two of these parameters gives the rate of substitution 
between the variables to which they are associated. Thus if say , ß5 is the parameter 
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associated with a cost dimension (money, time or distance) and A, is the parameter 
associated with a higher health state, then A represents the relative rate of 
s 
substitution between the two and therefore may be used to value variables in terms 
of a cost. cA; is assumed to be the standard unobservable error term with the usual 
properties i. e a random draw from a defined distribution with a mean of 0 and a 
constant but unknown variance (i. e. homogenous). The error terms are also 
assumed to be independent of the observed characteristics. 
In a DCE where I individuals are asked to make Jdiscrete choices between paired 
profiles A and B, the paired profiles consists of two goods or services completely 
described by the vector of variables xj, and xjB . The levels and values of the 
characteristics of the profiles are varied in each choice according to some 
experimental design in order to create sufficient variation. Any possible omitted 
variable or characteristic of each profile is explicitly stated to be constant across all 
profiles, such that all differences between profile A and profile Bin choice fare 
observed and captured by differences between the vector of variables xJA and XJB. 
In each choice the rational respondent will choose the option that yields the highest 
level of utility to them and so in choice jindividual Twill choose B over A if UJB; > UJA;. 
From the construction of these indirect utility functions it can be shown that the 
difference in utility is due to the difference in attributes between option A and Bin 
choice fand the error term. 
Yý- jBýj4l - jBi - ý; a: 
_ (1o +/31)(B +... +/. ýivt'NB +Vo fV>s>i f ... +yßMi f£jBJ- 
(13p 13>Xjq '1' ... 'f 
13A1'Njq # YO +Y 
, 431i 
+ 
... 
+ YMsMi # £jAl) 
ýidX>+... 
+13AAXN+EjBi -Ejsli 
+ß, VX, j #Eji 
where x>; =x>; B-x q andcj; = (Eiß;. E; A/I 
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As specification individual characteristics appear in equal measure on both sides of 
the difference equation, they simply difference out and hence the decision to choose 
A over B or B over A is independent of individuals' observable characteristics. 
7.5 Econometric estimation techniques for DCE 
The independent variables were the differences in the levels of the variables. The 
independent variables were dummy coded, with the "best" level of each attribute the 
omitted category. "Best" in this instance refers to a priori expectations that higher 
levels of health status and confidence would be preferred to lower levels, more 
frequent visits from friends/relatives would be preferred to fewer and that quicker GP 
access would be preferred to slower. Table 7.1 shows each attribute and its levels. 
The omitted level in each case was level one (only health problem is moderate 
pain/discomfort, totally confident, can see GP tomorrow and see friends/relatives 
daily). The results described below and in Table 7.4, show decrements in utility 
associated with movements from level one of the attribute to levels two and three. 
The dependent variable y. is unbounded and continuous, it may be positive 
indicating a preference for B over A, or negative indicating a preference for A over 
B. It may also be zero which would indicate indifference between the two choices. 
However the analyst does not observe this latent variable but instead observes the 
outcome, y; J -a binary outcome equal to 1 if option B is chosen and 0 if A is chosen. 
Thus; 
_ 
f1ify'*v>0 
y' 
0 otherwise 
Taking the previous equation and substituting in for y* , then y;; =1 if 
EIX+e>0 
i. e. yj =1 if E, 3X > -s. And so the probability that option B is chosen is given by: 
prob(y, =1) = prob() ßX > -6). 
In order to estimate such a model some assumption is required about the 
distribution of s and different assumptions about this distribution define the logit and 
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probit models. For example if we assume the error term is iid - N(0,1), 
(independently and identically distributed with a mean of zero and a constant 
variance) a draw from the standardised normal distribution, then the probit model is 
assumed. Given an assumption on the behaviour of the error terms, a set of values 
Xand a set of 1 or 0 outcomes, theß's may be estimated. For example, suppose 
we had 1000 observations, split evenly 500 ones and 500 zeros, then the estimated 
constant term would be ßo = 0. 
Returning then to the context of the DCE, suppose we give an individual a choice 
between two identical options A and B, then we would theoretically expect the 
individual to be indifferent between them i. e. a 50/50 chance of choosing B over A or 
vice versa. Thus we would clearly expect, ßo =0 (or at least not significantly different 
from zero). Any value other than zero, indicates a systematic preference for A over 
B (ßa < 0) or B over A (, ßo > 0) all other things being equal. In practice, since on a 
paper questionnaire, B appears on the right hand side and A on the left, it is 
plausible that a predominantly right handed population may well systematically 
choose B over A and give a positive non-zero constant term. However, remember 
that the /3's may be compared to each other to establish relative values and trade- 
offs between dimensions. Thus a relatively large constant term implies respondents 
are willing to trade substantive benefit for not having to exert the extra effort to tick a 
left sided box. In other words you would expect there to be a lexicographic 
preference for all attributes over the constant term. That is, that improvement in any 
of the attributes should not be outweighed by the constant term. Evidence to the 
contrary suggests there is something suspect about the underlying premise of the 
exercise. 
The role of the constant term raises its head again when dealing with the fact we 
observe many observations/choices from individuals. This causes issues with the 
assumption of independent error terms and the standard response to this in health 
economics appears to be implementation of a random effects model. However, 
random effects models account for correlation by allocating each individual their own 
choice-invariant constant term. Thus random effect models simply allow for 
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heterogeneous preferences for choosing B over A all other things being equal. Thus 
it is a rather curious solution to a problem as it is inconsistent with the underlying 
theory and hence it is arguably more of a specification test than a genuine solution. 
To summarize the above, it is argued that: an empirically significant constant term is 
inconsistent with the underlying theory and is a cause for concern and could be 
evidence of model misspecification and thus, far from being a solution to correlated 
error terms, significant random effects simply imply a heterogeneous rejection of the 
underlying model. 
We illustrate these arguments with our empirical models following the methods 
section. 
7.6 Methods 
DCE, a questionnaire based stated choice method, was used to explore the 
attributes (or characteristics) that are most valued by patients. There are several 
stages to conducting a DCE, and these stages are described below. 261 
7.6.1 Denning attributes and theIr levels 
Qualitative interviews and focus groups carried out alongside a randomised 
controlled trial of the Expert Patients Programme (EPP) and reviews of the 
published literature were used to identify the attributes that patients valued. Based 
on these sources, three outcomes were selected for inclusion into the study; access 
to General Practitioners, level of social isolation and level of self-efficacy (patients' 
confidence in their ability to manage their condition). In addition, because the 
rationale of the study was to assess the importance of these other outcomes relative 
to HRQoL and examine whether such outcomes could be included in cost- 
effectiveness analysis, a measure of HRQoL was included. As it is frequently used 
in economic evaluation and has previously been used in DCEs'230, las the EQ-5D 
was used as the basis for measuring HRQoL. EQ-5D measures patient health 
status across five dimensions (mobility, self care, usual activities, pain/discomfort 
and anxiety/depression) with three possible responses (no problems, moderate 
problems or severe problems) for each dimension. This locates each participant 
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into one of 245 mutually exclusive health states (with the additional states being 
death and unconscious). Clearly, including this number of levels of an attribute is 
impractical. Three states were selected as levels for this attribute to maintain the 
statistical efficiency of the experiment. The three states showed a clear ranking 
between them and were all levels that were considered plausible for this patient 
group. 262 The attributes and levels identified from this process are presented in 
Table 7.1. 
Table 7> A//ribu/es and/eve/s usedin the DCE 
Attribute I Levels 
Health Related Quality of Life 1 No problems with mobility, usual 
activities, self care or anxiety/depression. 
Moderate pain/discomfort 
2 No problems with usual activities, self 
care or anxiety/depression. Some 
problems with mobility and moderate 
pain/discomfort 
3 No problems with usual activities. 
Some problems with mobility and self 
care. Also moderate pain/discomfort and 
moderate anxiety/depression 
Level of confidence 1 Totally confident in ability to manage 
condition 
2 Moderately confident in ability to 
manage condition 
3 Not at all confident in ability to manage 
condition 
Access to General Practitioner 1 GP appointment tomorrow 
2 GP appointment in one week 
3 GP appointment in 3 weeks 
Level of isolation 1 See friends/relatives daily 
2 See friends/relatives every few days 
3 See friends/relatives rarely 
As described in section 7.3.2, the number of levels in each attribute should be 
multiples of each other. 250 Having more than three levels for each attribute 
increases the number of questions responders are asked and therefore increases 
the cognitive burden considerably. 
Z 6.2 Questionnaire methods 
Two questionnaires were developed to test for both differential response rates and 
to allow for interactions between attributes. The longer questionnaire contained 28 
172 
questions and allowed for interactions on 3 of the 4 attributes, but posed a 
considerably larger cognitive burden on responders. The shorter questionnaire 
consisted of 10 questions, but only considered main effects (i. e. it did not allow for 
estimation of interactions between attributes). Both questionnaires are presented in 
Appendix F. 
Therefore, the use of differential lengths of questionnaires allowed us to test for 
differences in response rate but primarily to assess the impact of interaction effects 
between attributes. For example, if the interaction effects are ignored, bad health 
and low confidence each account for a reduction in utility, but it is possible that 
these two combined reduces utility by more than the sum of the two. For example, 
being in a bad health state may reduce an individuals' utility by 0.2 and having low 
levels of confidence may reduce utility reduces by 0.1. However, having both bad 
health and low confidence may result in a drop of utility greater than 0.3. Most 
DCEs ignore interactions as they add to complexity and to the cognitive burden for 
respondents. 
Hypothetical choice sets (i. e. a comparison of alternatives) were created using a 
fractional factorial design with foldover. As described above in section 7.3.2, the 
first scenario was generated from a catalogue of designs252 and had health state at 
level 1, self-efficacy at level 2, GP access at level 2 and isolation at level 3. This 
can be represented as 1223 and would form one scenario in the choice set. 
Foldover, as described in section 7.3.2, was then used to generate the comparator. 
The original scenario (1223) and the comparator (2331) form one choice set which 
appears as one question in the questionnaire. This procedure was repeated to 
generate the full questionnaire. This design is commonly used in DCEs in health 
and other disciplines, as it allows for a relatively efficient estimation of the 
coefficients around attributes. 250 These designs inevitably lose some information 
when compared with the full factorial design250 (where the full range of combinations 
of attributes and their levels are presented), but reduces the cognitive burden for 
respondents. 
Each choice set required the respondent to select one of the unlabelled options A or 
B (i. e. it was a "forced choice"). Some authors, 263 have suggested that additional 
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options should be included (such as an opt out clause) so that the experiment is not 
a forced choice, while others '264 have claimed that this may increase the number of 
neutral responses and thereby the "power" of the study. Pilot work on this study 
indicated that neutral responses were likely in this DCE and a forced choice was 
chosen as appropriate. 
The design of both questionnaires was orthogonal, but no attempt was made at 
utility balance as this increases the complexity for responders (and also requires a 
pl7oriknowledge of individual preferences). An example of the questions facing 
patients is presented in Figure 7.1. 
Z 63 Consistency 
One question in each questionnaire (short and long) was replicated to check for 
consistency in responses. Where the responder gave different answers to the same 
question, this was considered "irrational", for the purposes of this analysis. There is 
a large literature on testing for rationality of responses in DCEs (see for example 255 
265-269) 
, and a degree of controversy over what constitutes "irrationality", how to test 
for rationality and how to proceed with "irrational" responses. 
As there is a lack of consensus on testing for, and the appropriate method for 
dealing with, "irrational" responses, 265,268,269 analyses including and excluding these 
"irrational" responses were conducted. 
When this additional check for consistency was added to the questionnaires, the 
short questionnaire contained 10 questions (9 different), while the long 
questionnaire contained 28 questions (27 different). 
174 
Imagine that you can have either option A or option B, which would you choose? If 
you would choose the option where you have moderate pain or discomfort, are not 
confident that you can manage your condition but you can have a GP appointment 
tomorrow and you see friends or relatives daily (i. e. everything in column A) then 
choose option A. 
However, if you would prefer the option where you have moderate pain or 
discomfort as well as having some problems with walking, but you are totally 
confident that you can manage your condition with a GP appointment in 3 days 
time, but you rarely see friends or relatives (i. e. everything in column B), then 
choose option B. 
A 
Q You have 
no problems walking about 
no problems with self care 
no problems with usual activities 
moderate pain or discomfort 
no anxiety or depression 
Q You are not confident you can 
manage your condition 
Q You can have a GP appointment 
tomorrow 
c You see your friends or relatives 
daily 
P/ease fick one box. " 
B 
Q You have 
some problems walking about 
no problems with self care 
no problems with usual activities 
moderate pain or discomfort 
no anxiety or depression 
Q You are totally confident you 
can manage your condition 
Q You can have a GP appointment 
in 3 days' time 
You rarely see friends or 
relatives 
OR 
Choice AQ Choice B 
Figure 7.1 Example question from discrete choice experiment 
F7 
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Z61 Pilots AltYjY 
Questionnaires were tested via a pilot study. Issues of interest included whether 
patients understood the questionnaire, whether the attributes were traded, whether 
one attribute dominated the others, and whether the responses were internally 
consistent. For the pilot study, 27 individuals with a chronic health problem 
completed a questionnaire and were then telephone interviewed. In general, 
patients understood the exercise, though the hypothetical nature of the experiment 
was not emphasised sufficiently. The hypothetical nature of the study was stressed 
more for the main study questionnaire. Several responders felt that the long 
questionnaire was repetitive, but most patients agreed with the choice of attributes. 
Some responders identified other attributes which they felt may be important such 
as continuity of care and the quality of the interaction with health professional(s). 
Several responders stated that they would have opted out of the choice where there 
was little perceived difference between the options offered, if they had been given 
an opt out option. These respondents were ultimately able to make a choice 
between the options, and for this reason the opt-out was excluded from this 
questionnaire. The disadvantage to the omission of the opt-out is that there is a 
possibility of overstating the importance or relative weight of attributes in the DCE. 
Z 6.5 Main study 
Postal questionnaires were posted to a sample of 511 chronically ill people (255 
short questionnaires, 256 long questionnaires). Patients were randomly allocated 
to receive either a short or a long questionnaire and a freephone number was 
provided for any questions patients might have had. Patients who did not respond 
after two weeks received a written reminder. 
Z 6,6 Maie study sample 
Patients who were involved in the randomised controlled trial of the Expert Patients 
Programme described in Chapter 4 and elsewhere, 66,162 and had not indicated that 
they would prefer not to receive any more questionnaires, were included in the 
study. Thus the study sample was patients with a (self defined) chronic condition. 
There were no exclusion criteria and patients from all 28 Strategic Health Authorities 
were included. 
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Z 6.7 Mode/ estimation 
The DCE was analysed by treating each choice between pairs as a single 
observation. Participants therefore provided either 10 observations if they 
completed the short questionnaire or 28 observations if they completed the longer 
questionnaire. The participants' response to each question (i. e. A or B) was 
included in the model as the binary dependent variable. The independent variables 
were the differences in the levels of the variables. "Correct" standard errors, 
allowing for correlation between observations from the same individual were 
included by clustering on patient identification number. 
In the first instance, a standard probit model with constant was used. Subsequently, 
a random effects probit model with constant was employed with clustering to allow 
for multiple responses from the same participant. The inclusion of constant terms is 
a violation of the theoretical basis of the model (see above), but can be used as a 
notional misspecification test. 
The continued identification of a significant constant term lead to other models being 
considered. There is little guidance in the health economics literature on the 
procedures for dealing with a significant constant; the problem seems to be largely 
ignored. 
Z S.. 8Incorporating the estimates ofthe value ofself-ehicacyinto the CEAC 
The methodology described above can be used to generate values for any of the 
outcomes in the DCE in terms of EQ-5D scores. Health states 1,2 and 3 are 
associated with utility scores of 0.796,0.727 and 0.552 respectively, from the EQ- 
5D tariff. 174 Thus the difference between one year spent in health state 1 compared 
to one year in health state 3 is 0.244 of a QALY. Using the example of self-efficacy, 
we can see that the coefficient around the movements between health states and 
self-efficacy levels can be compared (i. e. a marginal rate of substitution (MRS) can 
be calculated) and applied to this figure to estimate the additional impact of self- 
efficacy. Thus if the coefficient around the movement from self-efficacy level 1 to 
self-efficacy level 3 were 0.2 and that around the movement from health state 1 to 
health state 3 were 0.4, then crudely, health state movement is valued twice as 
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highly as self-efficacy (MRS=2), and the value of spending a year in self-efficacy 
level 1 over self-efficacy level 3 can be estimated as 0.122 (that is, 0.244/2). 
Using the data from the EPP trial, patients were categorised into low, moderate or 
high self-efficacy. Scores of one, two and three on the self-efficacy outcome 
measure were considered "low", while four, five and six were considered moderate, 
with scores of seven to ten considered "very confident". Thus movements from 
"low" to "very" confident (and all other combinations), could be categorised. These 
movements between self-efficacy categories can be valued in terms of QALYs (as 
above). Then, assuming that self-efficacy and QALYs are completely independent, 
the effectiveness of interventions can be adjusted for the impact of self-efficacy by 
simply adding this additional amount. While this is a crude adjustment, this estimate 
reflects the maximum impact that self-efficacy could have, as it is likely that there 
will be some overlap between QALYs and self-efficacy, this analysis assumes that 
this overlap is zero. 
Z 6,9 SensifiVifyanalyses 
A number of sensitivity analyses were conducted. While the majority of the health 
economics literature has excluded "irrational" responses, this has been questioned 
by some authors265,268' 269 who suggest that there may be a number of alternative 
explanations for these responses. Therefore, a standard random effects probit was 
employed to test whether the inclusion of these responses altered the results or 
conclusions. 
Two questionnaires were administered. It is possible that responses to the two 
questionnaires were systematically different. Thus a standard random effects probit 
was used on both questionnaires to identify any potential differences. 
7.7 Results 
511 patients who had participated in the RCT of the EPP were sent a postal 
questionnaire. Of these 367 (71.8%) completed and returned one of the 
questionnaires. Responders were, on average, slightly younger, more likely to own 
there own home and be in paid employment compared to non-responders. The 
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characteristics of patients who responded compared with non-responders to the 
questionnaire are presented in Table 7.2. Response rate among those who were 
sent the shorter questionnaire was higher than for the longer questionnaire (73.7% 
vs 69.9%), though not substantially so. The characteristics of those returning both 
types of questionnaire are also presented in Table 7.2. 
Patients' whose responses were inconsistent (in that they gave different answers to 
the repeated question) were excluded from the primary analysis (n=98,26.7%). 
Surprisingly, there were more inconsistent responders to the short questionnaire 
(n=64,34.0%), than the long questionnaires (n=34,19.2%). The remaining 269 
responses were considered in the primary analysis. 
Variables are dummy coded, with the "best" level of each attribute the omitted 
category. "Best" in this instance refers to apabriexpectations that higher levels of 
health status and confidence would be preferred to lower levels, more frequent visits 
from friends/relatives would be preferred to fewer and that quicker GP access would 
be preferred to slower. 
Tab/0 72 Characfensfics ofnon cespondecs andresponders type. 
Non- 
responders 
n=144 
Responders 
(n=367/ 
averse 
Responders 
ßn=188) 
short quest 
Responders 
(n=179) 
/on quest 
Characteristic 
Age 52.5 57.5 56.9 58.0 
% female 72.9 68.7 73.9 63.1 
Accommodation 
status" 
Owner occupied 57.6 74.4 72.9 76.0 
Rented from LA 31.9 18.0 18.1 17.9 
Rented privately 8.3 6.0 6.4 5.6 
Other 2.1 1.6 2.7 0.6 
Condition: 
Musculoskeletal 31.9 37.6 39.9 35.2 
Endocrine 13.2 11.2 10.1 12.3 
Circulatory 8.3 6.5 4.8 8.4 
ME 6.3 7.4 6.9 7.8 
Other 40.3 37.3 38.3 36.3 
Employment 
status, 
Employed 16.0 20.4 18.1 22.9 
Retired 33.3 39.8 36.7 43.0 
Unable to work 36.8 31.6 37.8 25.1 
Unemployed 6.3 3.5 4.3 2.8 
Other 7.6 4.6 3.2 6.1 
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7.7.1 Interaction terms 
The design of the long questionnaire permitted the estimation of interaction terms 
between attributes. The results of this analysis are presented in Table 7.3. Several 
interaction terms were dropped due to collinearity. Few of the remaining interaction 
terms had a substantial impact on the results. Three of the "significant" results were 
interactions between GP access and health. It is not clear apab which direction 
these should take, though it is perhaps surprising that these are all negative, thereby 
implying that speedy GP access even in relatively poor health states is not very 
important. Noticeably, the interaction between health level 3 and self-efficacy is 
positive, indicating that if patients are in a relatively poor health state, improving their 
level of confidence improves their level of utility. 
Tab/e 7.7 Interaction feirns in the DCE 
Attribute/interaction I Coefficient Standard Error 
Health 2 -0.084 0.042 Health 3 -0.496 0.074 
Self-efficacy 2 -0.081 0.029 Self-efficacy 3 -0.452 0.048 
Isolation 2 -0.016 0.025 Isolation 3 -0.497 0.051 GP access 2 -0.080 0.022 GP access 3 -0.267 0.039 Interactions 
Health 1/self-efficacy 1 -0.041 0.035 Health 1/self-efficacy 2 0.034 0.028 
Health 2/self-efficacy 3 -0.033 0.026 
Health 3/self-efficacy 1* 0.050 0.029 
Health 1/GP access 1* -0.065 0.025 Health 2/GP access 1* -0.099 0.034 Health 2/GP access 2** -0.080 0.030 
Health 3/GP access 3** 0.084 0.022 
Self-efficacy 1/GP access 3 -0.005 0.030 
Self-efficacy 2/GP access 2 0.000 0.022 
Self-efficacy 3/GP access 1 0.017 0.026 
Self-efficacy 3/GP access 3 0.015 0.033 
* significant at 10%, ** significant at 5% 
Z Z2 Standardprobitmode/ with constant term 
Results from this analysis are presented in Table 7.4. The coefficients of each 
attribute are based on the short and long data combined and represent the impact of 
a unit increase of each attribute on the probability of getting one outcome (with all 
the other variables at their mean), and thus the relative importance (marginal rates 
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of substitution) of each attribute can be estimated by dividing one coefficient by 
another. 
The coefficients reflect the disutility associated with moving from one state to 
another and are intuitively appealing in that the coefficients move in the anticipated 
direction. The only exception is the movement from isolation level one ("friends and 
relatives visit daily") to isolation level 2 ("friends and relatives visit every few days"), 
where the latter is preferred. This movement is not statistically significant and is 
also plausible in that many individuals with chronic illness would find daily visits 
burdensome. 
As expected, the movement from level one to level three is also greater than 
movement from level one to two for all attributes. 
The coefficients around health status, self-efficacy (confidence) and, to a lesser 
extent isolation, are of similar magnitude. In particular, the results indicate that 
patients value a movement from health state one (moderate pain, but no problems 
on other dimensions) to health state three (moderate pain, moderate 
anxiety/depression, some problems with self care and some problems with mobility, 
no problems with usual activities) as approximately the same as a movement from 
confidence level one ("totally confident in ability to manage condition") to confidence 
level three ("not at all confident in ability to manage condition") (as the ratio of 
confidence level 3 to health state 3 is 1.013). 
A difference in "utility" between health states one and three of 0.244 can be 
generated from the EQ-5D tariffs. Thus the movement from not at all confident to 
totally confident would equate to a gain of 0.25 QALYs if maintained for one year 
(and assuming that we can ascribe utility values from patient generated responses 
rather than those of the general public). 
Separate analyses for short and long questionnaires were consistent with the 
combined analysis. 
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Notice that the constant term included in this model is significant. This constant has 
no substantive meaning in an unlabelled experiment. In essence, this result implies 
that responders prefer A to B, even accounting for differences in the scenarios 
presented to them. Indeed, the size of the coefficient around the constant leads to a 
more worrying conclusion. If scenarios A and B are identical except that B has 
health state at level 1 (the "best" health state) and scenario A has health state at 
level 2 (the moderate health state), A would still be chosen as the coefficient around 
the constant is greater than that of hl2 (the movement from health 1 to health 2). 
Table 74 Probitmode/with consfanffeim 
Attribute Coefficient Standard Error 
Health level 2 -0.079 0.033 
Health 3 -0.462 0.057 
Confidence 2 -0.081 0.024 
Confidence 3 -0.468 0.038 
GP access 2 -0.072 0.018 
GP access 3 -0.254 0.032 
Isolation 2 0.001 0.021 
Isolation 3 -0.462 0.040 
Constant -0.120 0.017 
where 
health /eve/2 is movement from health state one to health slate 2 
health 3is movement from health state one to health state 3 
confidence 2 is movement from confidence /eve/one to confidence /eve/2 
confidence 3 is movement from confidence /eve/one to conf/dence /eve/ 3 
isolation 2is movement from isolation /eve/one to isolation /eve/2 
isolation 3is movementfrom isolation /eve/one to isolation /eve/3 
GP access 2, s movement from GP access/eve/one to GPaccess/eve/2 
GP access 3/s movement from GP access/eve/one to GPaccess /eve/3 
H13/h12 = 5.848 
c13/h13 = 1.013 
ZZS Random effectsprobif 
Table 7.5 shows the results of the random effects probit with constant model. The 
results are very similar to those from the standard probit model in terms of the 
magnitude and direction of the coefficients for attributes. The similarity is not 
surprising as the random effects are attached to individuals and picking up omitted 
individual characteristics. However, as questionnaires were randomly allocated, 
there should be no correlation between individuals' characteristics and 
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characteristics appearing in the regression model; therefore omitted variable bias 
should not occur. Again however, notice that the constant term is significant. 
The health 3 to health 2 ratio in this model was 5.728, while the confidence 3 to 
health 3 ratio was 1.041, indicating the individuals considered a drop in confidence 
(from level 1 to 3) as marginally worse that a drop in health state (from 1 to 3), which 
again, is similar to the results of the standard probit model. 
Table 75 Random effectprobifrrmode/with Cons/OW/ierm 
Attribute Coefficient Standard Error 
Health level 2 -0.081 0.033 
Health 3 -0.464 0.057 
Confidence 2 -0.107 0.024 
Confidence 3 -0.483 0.038 
GP access 2 -0.055 0.018 GP access 3 -0.284 0.032 
Isolation 2 0.024 0.021 
Isolation 3 -0.426 0.040 
Constant -0.148 0.017 
H13/h12 = 5.728 
c13/h13 = 1.041 
Z Z4 Genera/isedLinearandLatentMixedMode/s (GLLAhMMJ 
As stated above, we would not expect a constant term to be significantly different 
from zero. However, in this instance, and in previous evaluations in the health 
economics literature, the constant term is significantly different from zero. In a 
labelled experiment, for example where scenario A is always based in a hospital 
setting, while B is in a home setting, this constant can be argued to reflect the 
preference for the "label" (in this example a preference for home over hospital or 
vice versa, other things equal). In an unlabelled experiment, the constant has no 
meaning and should be zero. The results of a GLLAMM model are presented in 
Table 7.6. A basic exploratory latent class model was estimated allowing for 
heterogeneous preferences across the population. The idea behind the latent class 
model is that there may be systematic groups who have a systematic set of different 
preferences. The objective of the latent class regression model is to not only 
estimate these preferences but also to estimate the proportion of these classes 
within the population and assign a probability of membership for each individual. 
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In this example, individuals are in two classes. The majority of individuals have a 
higher probability of being in class one (78%) rather than class two. It is noticeable 
that those in class one exhibits the same direction of values of attributes as the 
previous models (good health is preferred to bad and so on), though the size of 
these coefficients is larger than previously estimated. For this class of responder, 
the health 3 to health 2 ratio in this model was 3.285, while the confidence 3 to 
health 3 ratio was 0.793, indicating that the individuals in this class considered a 
drop in health state (from level 1 to 3) as considerably worse than a drop in 
confidence (from 1 to 3). 
Tab/e 76 GLLAMMrrodel 
Variable 
Health level 2 
Health level 3 
Confidence level 2 
Confidence level 3 
GP Access level 2 
GP Access level 3 
Isolation level 2 
Isolation level 3 
Constant 
P(class) 
Latent Class > Latent Class 2 
Coefficient Sto=errors 
-0.288 0.039 
-0.946 0.058 
-0.243 0.038 
-0.750 0.049 
-0.017 0.035 
-0.240 0.044 
0.015 0.036 
-0.649 0.040 
-0.219 0.028 
0.7 84 
Coefficient Std-erro 
0.511 0.071 
0.651 0.094 
0.160 0.063 
-0.022 0.067 
-0.174 0.058 
-0.440 0.072 
0.119 0.064 
-0.063 0.098 
-0.025 0.045 
0.2 16 
H13/hl2 (class 1)= 3.285 
cl3/hl3 (class 1)= 0.793 
hl3/hl2 (class 2)= 1.274 
cl3/hl3 (class 2)= -0.034 
However, there are a sizable minority (approximately 22%) who have counter- 
intuitive values particularly for health state. This latent class appear to value 
decrements in health states whilst still valuing GP access (the other 2 attributes 
appear much less important to this group). 
Health state 3, which is the 'worst' health state is preferred to health states I and 2. 
Although this raises some doubts about whether the responders who may be 
classified as class 2 responders have understood the exercise, it is this class that 
does not have a significant constant term. This raises the question of what to do 
with the preferences of this second class - do they genuinely represent odd 
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preferences or are they evidence that a subsection of responders has 
misunderstood the questionnaire? 
In the event that it is the second reason, the effects of miss-responders in the 
homogeneous model are to weight the preferences of the population towards zero. 
Note how the ratio of moving down health states and confidence in the ability to 
manage condition increase relative to GP access (the level which is apparently 
unaffected by the latent class specification). 
It should be noted that even though a significant term in a labelled experiment can 
be explained away by preferences for one or other label, this is not necessarily the 
only explanation. Heterogeneity of preferences could also explain part of this 
effect. 
Z Z5 Random effects clustered on question number 
A further possibility that we wished to explore was whether individuals adopted 
simple heuristics when options were closely matched. The notion being that if 
difficult trade-offs were required the respondent may adopt a simple heuristic of 
choosing right over left. This could be potentially picked up by running a probit 
model with random effects for each individual question. This will give each of the 38 
questions their own specific constant term, a preference for B over A, after allowing 
for the differences between B and A. The results of this analysis are presented in 
Table 7.7. 
Table 77Randoin effects on question number 
Variab/e Coefficient Std-errors 
Health level 2 -0.087 0.046 
Health level 3 -0.472 0.047 
Confidence level 2 -0.109 0.046 
Confidence level 3 -0.493 0.046 
GP Access level 2 -0.052 0.044 
GP Access level 3 -0.294 0.049 
Isolation level 2 0.029 0.047 
Isolation level 3 -0.414 0.046 
Constant -0.154 0.033 
h12/h13 = 5.425 
c13/h13 = 1.044 
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The ratio of health level 2 to health level 3 is 5.425 and confidence level 3 to health 
state 3 is 1.044, indicating that a loss of confidence to manage their own condition is 
worse than a reduction in health state. 
Unlike the random effects model which clustered results on individuals, the random 
effects model clustered on question number indicates that the random effects do 
indeed explain some of the variation (only a small amount) and that the standard 
deviation of the question specific constant terms differs from zero. Thus after 
allowing for what the options contain, some questions are more likely than others to 
have systematic preferences for B or A. 
Given the preferences estimated, the model shows that questions 7 (59% chose B), 
1 (57% chose B) and 21 (79% chose B) of the large questionnaire demonstrate an 
above average and increasing tendency for B to be chosen given the respective 
levels in A and B. Questions 13 (12% chose B) and 26 (81 % chose B) of the large 
questionnaire and question 7 (76% chose B) of the short questionnaire have an 
increasing tendency to choose A despite the relative variables in both. 
The `middle' questions, i. e. those questions with average random effects are 
questions 4 (27%) and 6 (64%) of the short questionnaire and question 9 (13%) of 
the long questionnaire. 
7.7.6 Sensitivity analyse s 
Two questionnaires were administered and the majority of the analysis above is 
based on the merged data from both questionnaires. However, a random effects 
probit model was performed on each questionnaire to identify potential differences in 
responses. The results of this analysis are presented in Table 7.8. Though the 
direction of the results is the same for all attributes, the magnitude of the effects is 
very different for several of the attributes. The interaction terms described above 
may have some impact on these findings, though other effects, such as learning 
effects may also be responsible. 
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Tab/0 78 Responses to short and/ong questionnaires 
Short Short SE Long Long SE 
questionnaire questionnaire 
coefficient coefficient 
Health level 2 -0.234 0.058 -0.064 0.048 
Health 3 -0.064 0.101 -0.429 0.082 
Confidence 2 -0.186 0.047 -0.081 0.033 
Confidence 3 -0.762 0.079 -0.434 0.054 
GP access 2 -0.021 0.042 -0.068 0.024 
GP access 3 -0.475 0.072 -0.277 0.043 
Isolation 2 0.115 0.050 0.006 0.027 
Isolation 3 -0.118 0.049 -0.475 0.059 
The impact of including "inconsistent" responses is presented in Table 7.9. Most of 
the attributes, with the exception of GP access level 2, maintain the same direction. 
The GP level 2 attribute becomes positive, implying that responders prefer to see 
their GP in one week's time rather than in one day's time. The magnitude of the 
coefficients around the other attributes is altered when compared with the 
"consistent" responses analysis, though the relative impact of self-efficacy compared 
to health status remains similar. 
Table 79 /nc/usion of "inconsisfenf"responses 
Attribute Coefficient Standard Error 
Health level 2 -0.080 0.026 
Health 3 -0.286 0.043 
Confidence 2 0.097 0.026 
Confidence 3 -0.232 0.037 
GP access 2 0.021 0.020 
GP access 3 -0.114 0.029 
Isolation 2 0.122 0.022 
Isolation 3 -0.180 0.040 
Constant -0.150 0.016 
7.7.7 Impact ofinc/usion ofse/f-ehicacyin the CEAC 
The additional impact of self-efficacy on QALYs from the EPP depends on the 
numbers moving from one state of self-efficacy (low, moderate or very confident). In 
this crude analysis, there is no QALY benefit associated with a movement within 
category (for example a movement from 8 to 10 on the self-efficacy question), nor is 
there disbenefit associated with drops within categories. Individuals only receive 
additional QALY benefit (disbenefit) if they improve (reduce) their category. The 
numbers moving between categories by group (intervention vs control) is displayed 
in Table 7.10. More individuals in the intervention group than in the control group 
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improved from the worst self-efficacy state to the best, while more in the control 
group recorded disbenefits in that they moved to a lower category. 
Tab/0 7 /0 Numbersrrmouingbe/ween se/f-ebicacycafegoiybygýoup. 
Intervention group control Group 
Improved from worst self- 22 10 
efficacy to best 
Worst to moderate 18 28 
Moderate to best 46 42 
Best to worst 14 
Moderate to worst 15 23 
Best to moderate 103 109 
Figure 7.2 illustrates the effect of including self-efficacy as an additional outcome on 
the results of the EPP national evaluation presented in Chapter 4. Interventions that 
impact positively on self-efficacy will, other things equal, be more cost-effective 
when these outcomes are included (so long as there is a positive relationship 
between HRQoL and the chosen outcome). In this instance, the EPP intervention 
originally generated 0.020 QALYs compared with the control group and had a 
probability of 94% of being cost-effective at a threshold value of £20,000 for a 
QALY. The inclusion of the additional impact of self-efficacy increases the QALYs 
gained to 0.025 and increases the probability of the intervention being cost-effective 
to 96% at a threshold value of £20,000 for a QALY. 
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Figure 7.2. Impact of including self-efficacy on probability of EPP being cost-effective 
7.8 Discussion 
A response rate to a postal questionnaire of over 70% indicated that patients were 
willing to complete the DCE. The length, and therefore the cognitive burden of the 
questionnaire, had little impact on the response rate. Whichever model was chosen, 
the responses to both questionnaires were largely consistent with apriori 
expectations. The results of this DCE indicate that self-efficacy is an important 
outcome measure, and patients were willing to trade decrements in HRQoL for 
improvements in self-efficacy, and that this rate of trade-off was broadly similar 
across all models. Using a crude additive model, these estimates of the importance 
of self-efficacy can be included in the cost-effectiveness analysis. Their inclusion 
has no impact on the costs, but increases the QALYs gained from 0.020 to 0.025 
per person per year. These estimates are derived from the valuation of movements 
between levels of confidence and the numbers making these moves. Thus, a 
movement from not at all confident to totally confident is approximately the same as 
a movement from health state 3 to health state 1. As the latter movement is valued 
at approximately 0.25 QALY, so the movement from not at all confident to totally 
confident is valued similarly. However, from Table 7.10, only a minority of patients 
make this change, and the impact on results is not large. The associated CEAC 
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shows that the probability of the EPP being cost-effective increases from 94% to 
96% at £20,000 per QALY. 
Interaction terms were in general non-significant in this analysis, supporting the 
contention that a main effects model is adequate for this purpose. The values of 
interaction terms were, in general, very low and often in contrast with apaior 
expectations. 
The existence of a significant constant term is concerning and the issue of latent 
classes may be the subject of future work. The use of random effects probit models 
may not be the solution to the problem of a significant constant term. One 
implication of this analysis is that for unlabelled experiments, more work is required 
to explain the existence of a significant constant. However, a wider implication is 
that even for labelled experiments, the existence of a significant constant term is 
worrying. While this has previously been treated as simply a preference for the label 
(e. g. home over hospital), it is possible that this is not the only explanation. 
A further concern is the number of responders who exhibited either a tendency to 
give inconsistent responses and/or responses that were counter-intuitive (such as 
valuing "worse" health states higher than "better" health states). Around 27% of 
responders gave inconsistent responses. Of the remainder, 22% gave counter- 
intuitive values for health states. While the direction and magnitude of the 
coefficients around the attributes lend weight to the assertion that the DCE was 
broadly understood and answered correctly, there remains a suspicion that a 
relatively large number of responders did not understand the exercise. Different 
DCEs use alternative methods to assess rationality and/or consistency. San 
Miguel269 found that depending on the definitions employed, between 1 and 35% of 
patients could be described as irrational, in that they failed to select a dominant 
option. 
Typically, economic evaluations employ the QALY as a measure of HRQoL. QALYs 
generated from the EQ-5D instrument do not include self-efficacy explicitly and thus 
QALYs generated in this manner may omit the importance of self-efficacy. Including 
self-efficacy in the CEA would increase the probability, cetecispaabus, of 
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interventions that improve self-efficacy being cost-effective. DCEs are one 
methodology that allows the inclusion in the QALY. 
However, there are a number of caveats. Firstly, it is not clear whether self-efficacy 
is a health outcome; if it is not then should it be included in the objective function of 
a decision maker working within a budget constrained health system? Should these 
outcomes be considered? Decision makers need to be clear aproriabout the 
maximand and not use vague statements about other factors that may be taken into 
account. 
Secondly, self-efficacy may simply be a measure of process in that patients want 
self-efficacy as they perceive that this will improve their long-term health status. 
The study surveyed people with chronic conditions and it is likely that these 
valuations of self-efficacy will be different from those of the general public. Thus, a 
limitation of this study is that these patients' values may overstate the importance of 
self-efficacy, and thus make interventions that improve self-efficacy appear more 
cost-effective. This is a problem whenever stated preference techniques are used in 
non market situations. If we are interested in getting patient valuations of outcomes, 
then we need to be aware that patients may give higher values than they would truly 
be willing to pay. 270 
Thirdly, it is conceivable that changes in self-efficacy (or part of those changes) are 
already incorporated into the QALY, through one or more of the dimensions of the 
chosen instrument. 
Though self-efficacy has been identified as important to patients, it is likely that in 
different patient groups other outcomes would be valued and traded for HRQoL. 
These "important" outcomes should be identified before commencing the study and 
appropriate techniques should be used to ascertain the rate of substitution between 
these outcomes and HRQoL. 
Finally, it is acknowledged that the use of DCEs may not force responders to focus 
on the real opportunity cost sacrifice to health by presenting a direct trade-off 
between health outcome and self-efficacy. This is likely to result in a greater chance 
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of over-stating the relative value of the self-efficacy. Cookson demonstrated that 
individuals expressed larger relativities when trade-offs were expressed in monetary 
terms rather than lives saved - similarly in this instance trading-off self-efficacy may 
be more palatable and therefore result in higher valuations than if individuals were 
asked to reduce (for example) life expectancy. 271 
So what implications does the analysis in this chapter have for economic analysis on 
interventions to support self care? The arguments around the perspective of studies 
and whose values should be used were discussed in Chapter 2. At present, 
government appointed decision making bodes, such as NICE, use general 
population values for health states. Some authors argue for inclusion of patient 
valuation of health states (rather than valuation by the general population), 272 while 
others encourage the assessment of other outcomes that are important to 
patients. 221 While the patients' role in identifying and valuing outcomes may 
become more important as we move to a more "patient centred" service, the choice 
of outcomes and the methodology used to derive their values needs to be explicitly 
stated and the caveats and assumptions implied by this choice should be 
emphasised. 
7.9 Conclusions 
The above analysis has demonstrated that individuals are prepared to answer 
questionnaires with a large cognitive burden. However, a large minority may have 
difficulty understanding the questionnaire and this is not dependent on the length of 
questionnaire. 
Self-efficacy is valued in this patient population, and can be incorporated into the 
QALY estimates relatively easily, though caution should be exercised in doing so. 
Other outcomes were also valued by patients and in principle, these could be 
incorporated into the analysis also. 
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Chapter 8. Discussion 
Self care and support for self care have become important policy objectives. This 
thesis has examined whether this objective is justified on cost-effectiveness 
grounds. 
8.1 Summary of individual chapters 
Chapter 1 outlined the decision problem of whether interventions to support self care 
provide additional benefits that are worth paying for in the budget constrained 
system of the UK NHS. It was argued that economic evaluation provides an explicit 
methodology for addressing this decision problem, by establishing the relative cost- 
effectiveness of interventions compared with suitable alternatives. 
However, economic evaluation encompasses a range of opinions and is not free 
from controversy. The choice of paradigm can affect the design conduct, analysis, 
results and recommendations of an economic evaluation. It is important that the 
analyst is explicit in the choice of paradigms and the assumptions that these choices 
imply. 
In Chapter 2, common controversies within economic evaluation were examined. 
Historically, most economic evaluations have been conducted within or alongside 
clinical trials (typically RCTs), and these "single trial based analyses" dominated the 
literature. More recently, it has become acknowledged that there are limitations to 
this approach. Single trial based economic evaluations (and indeed single clinical 
trial analyses) suffer from a number of defects that relate to the exclusion of relevant 
information (all four of the deficiencies noted in Chapter 2 can be simplified to 
"ignoring information that may be relevant to the decision problem"). Nevertheless, 
there are occasions when a single trial based analysis may be the most appropriate 
evidence to inform the decision problem, such as instances where the data come 
from a very different population or the other studies were poorly conducted. 
The distinction between the Bayesian and frequentist schools was also discussed in 
Chapter 2. Bayesians consider probabilities to be reflections of a degree of belief 
and that this probability can be amended as more evidence becomes available. 
This enables Bayesians to make statements about the "probability" of an 
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intervention being cost-effective that are partly dependent on "prior beliefs". 
Frequentists cannot make such statements as probabilities are simply a function of 
the frequency of events in a much repeated experiment. It was argued that the 
Bayesian approach is more useful for informing the decision problem but that care 
should be taken around the elicitation and influence of the priors. 
Chapter 2 also provided a detailed explanation of the key differences between the 
welfarist and extra-welfarist perspectives. It was asserted that the distinctions 
between the two schools are often confused, and there are few definitive guides to 
welfarism and extra-welfarism. Welfare (or welfarist) economics assumes that 
individuals maximise their utility, that individuals are the best judges of their own 
utility (individual or consumer sovereignty), that utility is a consequence of behaviour 
and that utility information on/yis relevant in making decisions about what is best. 
The last named is frequently termed "welfarism". The practical problems of 
collecting this utility information, plus the restrictions placed on the sources of these 
valuations (must be the individual), the weights attached to them (it is unclear 
whether weights are allowed) and the lack of interpersonal comparisons mean that 
for the purposes of this thesis, the extra-welfarist approach was deemed 
appropriate. Extra-welfarism allows information outside individual utilities (hence the 
"extra"). Paradoxically, extra-welfarist analyses have tended to adopt narrower 
perspectives by measuring a single health related outcome. Some analyses 
consider overall health by using measures such as the QALY, while others use 
much narrower measures such as reduction in blood pressure. 
It is important to stress that the choice of paradigms may impact on the cost- 
effectiveness study and how the results of these analyses inform the decision 
problem. The published literature on self care support interventions is examined in 
a systematic review presented in Chapter 3. This chapter presented the first review 
of economic evaluations of self care support interventions. The chapter described 
the paradigms which have been used in previously published economic evaluations 
and also to assess whether any lessons could be learned for the design, conduct 
and analysis of future evaluations. 
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Studies identified for inclusion in the systematic review presented in Chapter 3 
included numerous disparate interventions for a range of conditions, in a range of 
settings and geographical locations. The results of the systematic review showed 
that all the identified studies were based in the extra-welfarist paradigm, with 
patients' health outcomes as the measure of interest. Studies were rarely 
synthesised with other relevant data, either in a narrative or quantitative manner, to 
address the decision problem more comprehensively. The majority of studies were 
poorly conducted and/or analysed, though the conclusions were mainly in favour of 
the intervention to support self care. The studies in general were of limited use in 
addressing the decision problem. Disease specific outcome measures, or 
behavioural/psychological outcome measures, were frequently employed without 
considering the value of these outcomes. Thus comparisons of cost-effectiveness 
across conditions were problematic. The chapter concluded with a call for the use 
of generic outcome measures in economic evaluations to allow decision makers to 
compare the cost-effectiveness of interventions across conditions. 
Chapter 4 presented an original single trial based economic evaluation using a 
generic instrument as a measure of outcome, the QALY. This economic evaluation, 
which is currently in press, was conducted alongside the national evaluation of the 
Expert Patients Programme (EPP), and represents the first economic evaluation of 
the EPP in the UK. 6s. 162 This study is set in the extra-welfarist paradigm and 
employs Bayesian techniques to assess the probability that the EPP intervention is 
cost-effective at a variety of threshold values of a QALY. The main analysis 
showed that the EPP based solely on this study was approximately 94% likely to be 
cost-effective at a threshold value of a QALY of £20,000 when compared with a 
waiting list control. There were a number of limitations to this study. Firstly, the 
comparator was in effect a usual care alternative. Individuals in the control group 
would receive the intervention at the end of the six month period, but until then 
received the care they had previously received. This is a limitation because it is 
plausible in this study that the effects of being in a group of individuals with similar 
conditions may itself have improved patient outcomes. It is difficult to separate the 
effect of the lay led delivery of advice from the effect of being in a group of similar 
individuals. In addition, the follow-up period is relatively short. It is possible that in 
the longer term the benefits of the EPP may be maintained or may dwindle and the 
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long-term cost-effectiveness is therefore debatable. Extrapolating the results to one 
year in a simplistic sensitivity analysis showed an improved probability of EPP being 
cost-effective at commonly used threshold values of a QALY, but is based on the 
simplifying assumption that costs and outcomes were equally distributed over the six 
month period. Other distributions are plausible and these would affect the 
conclusions. 
While these are important limitations, the main criticism of the evaluation presented 
in Chapter 4, is that it may not consider all information of relevance to the decision 
problem. At the time of writing, there was one other RCT of the EPP based in the 
UK, 83 and several other trials and experiments based outside the UK using 
interventions identical or similar to that used in the EPp. 71,75,76,78-82 This potential 
criticism of single trial based analyses was addressed in Chapters 5 and 6. 
Expanding the evidence base initially to two RCTs based in the UK, as in Chapter 5, 
could clearly impact on the decision problem. Using Individual Patient Data (IPD) 
from both these trials enabling a more complete meta-analysis including the impact 
of individual characteristics and avoiding the pitfalls commonly associated with 
meta-analysis of aggregate data. Though these two trials considered the same 
intervention and comparison, they were very different in terms of the populations 
recruited and the results obtained. The national evaluation, with a target population 
designed to be representative of the UK general population demonstrated an 
improved QALY profile at slightly reduced cost. The study of EPP in a UK based 
Bangladeshi population showed different direction of results. QALY profiles were 
negative (after the appropriate adjustment for baseline EQ-5D score) with an 
increase in costs. While the direction is different for both costs and effects, the 
incremental costs and incremental QALYs reported in both studies were small. 
The two studies were of comparable size (629 in the national evaluation, 476 in the 
Griffiths study), and were both judged to be of equal weight in the analysis. The 
cost of the intervention was estimated as a weighted mean of the intervention costs 
in the two trials (weighted by sample size). Using these estimates of costs and 
effects and the log normal distribution that best fitted the data, the EPP intervention 
generated an ICER of around £30,000 and a corresponding probability of being 
cost-effective of 50% (at the £30,000 threshold value of a QALY). At lower 
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threshold values of a QALY, say £20,000, the EPP intervention is unlikely (at only 
20%) to be cost-effective. 
The QALY difference between the intervention and control arms becomes very small 
when performing this synthesis. With such small values for the denominator 
(incremental QALYs), the ICER becomes very sensitive to small changes in costs. 
The cost of the intervention in the national evaluation was estimated at £250, and if 
this were replicated, the intervention is unlikely to be cost-effective (with an ICER of 
£41,500), while using the estimate from the Griffiths study yields an ICER of 
£20,333 which is potentially cost-effective. A limitation of the synthesis, and the two 
trials that make up the synthesis, is the lack of a measure of uncertainty around the 
cost of the intervention. For the purposes of the preceding analysis, the intervention 
cost is considered as a point estimate. It is relatively common in economic 
evaluation to consider unit costs as point estimates and subject them to sensitivity 
analysis to establish their impact on results. However, given the sensitivity of results 
to this variable, future work should consider the possibility of establishing the 
uncertainty around the point estimate of the unit cost of the intervention. 
As well as the limitation of the use of a point estimate for the unit cost of the 
intervention, the analysis presented in Chapter 5 could also be criticised for not 
incorporating all relevant information or evidence. Though both RCTs based in the 
UK using the EPP intervention on a range of individuals with a range of chronic 
conditions were included, other evidence from outside the UK could be useful to 
inform the decision problem. 
Since the other studies did not use QALYs as the outcome measure, but rather 
surrogate or intermediate outcomes such as self-efficacy, it was necessary to 
examine methods to incorporate evidence from outside the UK that used a 
surrogate measure of outcome. This is considered in Chapter 6. This chapter used 
systematic searching to identify evidence of the impact of the EPP intervention on 
costs and outcomes. No other trials were identified that measured the outcomes in 
terms of QALYs. However, a further eight trials were identified that presented data 
(in aggregate form) of an alternative outcome measure, self-efficacy. For the 
purposes of this analysis, self-efficacy was interpreted as a predictor of health state. 
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Data recorded in the two UK trials of EPP described in Chapter 5 included costs, 
QALYs and self-efficacy. Thus a link between the EPP intervention and costs and 
QALYs could be estimated indirectly using self-efficacy as a surrogate or 
intermediate outcome. This "indirect" link was employed in Chapter 6 to assess the 
impact of introducing the eight additional non-UK studies to inform the decision 
problem. Utilising this link enables three models to be developed. The "direct" 
model where the indirect evidence is not incorporated into the analysis is 
considered. The "indirect" model is then examined where only evidence utilising the 
link between treatment and Costs/QALYs viaself-efficacy is considered. Finally, the 
"mixed" or' joint" model, where both forms of evidence are admitted, is analysed. 
Each of the eight studies included in the meta-analysis of IPD and Aggregate Data 
(AD) presented data on the effect of the intervention on self-efficacy. Each showed 
a positive relationship between the intervention and the level of self-efficacy (that is 
self-efficacy improved in those receiving the intervention). Given this positive 
relationship incorporation of these studies would improve the estimates of the 
effectiveness of the intervention as long as there was a positive relationship 
between self-efficacy and QALYs. While this relationship, estimated from the two 
UK studies, was positive it was not particularly strong. Thus although the estimate 
of effectiveness increased with the inclusion of this additional evidence, the impact 
on the ICER was limited. Interestingly though, because of the small differences in 
costs and QALYs described earlier, even small changes in either costs or effects 
can influence the decision. This is the case in this instance where the decision may 
be influenced as the ICER falls from around £30,000 per QALY to around £23,000. 
While these differences may be important, the difference between the indirect and 
other models is perhaps of more concern. The indirect model utilised only evidence 
linking the treatment to cost and QALY changes via the surrogate outcome self- 
efficacy. The decision not to implement the intervention would be made with virtual 
certainty at commonly used threshold values of a QALY, while further research 
would be deemed unnecessary (again with virtually no benefit to conducting the 
research). This is because using this model, we are very confident that the ICER 
lies above reasonable threshold values of a QALY. This is in contrast with the 
largely equivocal results from the direct analysis and the positive results from the 
single trial based analysis presented in Chapter 4. 
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So, the decision is sensitive to the choice of model. Which model is "correct"? This 
depends on what evidence is available and what evidence is considered relevant. 
The indirect model described above may be a practical choice if there is no other 
evidence available and a decision has to be made. However, this decision should 
be made in the knowledge that the structural assumptions of the model have not 
been tested in any way and that uncertainty in the adoption decision and the 
decision to conduct future research may be understated. 
Where more data are available in the form of IPD from randomised controlled trials, 
these should be used to inform the decisions. However, this does not sidestep the 
issue of relevance. Is an RCT in the US relevant to a UK decision maker? It may 
be argued that it is somewhat relevant, but not as relevant as a UK trial in a 
representative population. So what weight should it be given? Half? Quarter? Who 
decides how relevant the trial is and on what basis? Is it the responsibility of the 
analyst to present analyses that allow the decision maker to select the appropriate 
model given his/her definition of "relevant", or should the analyst be more 
affirmative? Inevitably, the analyst will be required to make some choices in the 
representation of results and recommendations, otherwise decision makers will be 
faced with unwieldy analyses. Nevertheless, as argued in Chapter 2, the 
democratic process is deemed an appropriate mechanism to appoint legitimate 
decision makers. While they cannot be expected to consider every possible 
alternative, the analyst should provide them with scenarios examining the influence 
of pivotal variables or data. Thus the analyst has influence over the analyses 
presented but the decision as to which analysis influences policy is left to the 
legitimate decision maker. 
In this instance, a reasonable question from a policy maker would be "given all these 
potentially different models, datasets and assumptions, what is the recommendation 
for policy based on existing evidence? ". As highlighted throughout this thesis, there 
is no definitive answer to this question. Intuitively though, it is appealing that the 
national evaluation with a representative sample of the population should present 
the best evidence of the cost-effectiveness of the EPP in a UK setting. Where the 
comparison is treatment as usual, it is reasonable to conclude that the EPP is a 
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cost-effective use of resources at commonly employed threshold values of a QALY. 
The inclusion of other comparators may alter this conclusion 
The discussion above has centred on the relevance of data from outside the UK 
using alternative measures of outcome. The implicit assumption is that the only 
outcome of interest is "health" and that this is adequately captured by the QALY. 
However, it is plausible that there are other outcomes that may be considered 
relevant to the decision problem. Indeed, as argued in Chapter 2, the extra-welfarist 
paradigm has its foundations in a movement away from the narrow concept of utility. 
It may be that decision makers are interested in either a broader concept of health 
(including some psychological outcomes), or that we wish to go beyond health and 
introduce measures such as isolation. In the field of self care support, the concept 
of self-efficacy has attracted much attention since the 1970's. However, it is not 
clear from the published literature how a decision maker could use this outcome to 
inform the decision problem as it is not widely used outside the self care support 
field and importantly, has not been subjected to valuation. Chapter 7 addresses this 
problem by using a discrete choice experiment to value self-efficacy compared to 
health, as measured by the QALY, and other outcomes that were assessed as being 
important to patients with chronic conditions. Individuals who completed the 
questionnaire valued self-efficacy and in principle, these valuations can be 
incorporated into cost-effectiveness analysis. This is the first attempt to value this 
outcome measure and should allow a more useful assessment of treatments where 
this is the outcome measure of choice. 
8.2 What could have been done differently? 
Most of the evaluations in the published literature consider the comparison of an 
intervention with treatment as usual. In many cases, this is the comparison of 
interest and directly addresses the decision problem. However, in other cases, 
particularly the use of group therapy for chronic conditions, the decision problem 
may be wider and require information on a range of potential comparators. For 
example, the Chronic Disease Self Management Programme may be shown to be 
cost-effective when compared to treatment as usual, but how does it compare with 
other group based interventions that may be available for the same population? The 
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evaluations of CDSMP presented in the literature and in Chapter 4 have, largely for 
practical reasons, limited the comparison to treatment as usual. Thus the analyses 
inform a more limited decision problem. However, the analyses presented in 
Chapter 6, provides a framework for including additional comparators. This is 
discussed in the section below on recommendations for future research. 
The studies included in the analyses presented in Chapters 3-6 had a limited follow- 
up period. Again, this is likely to be for practical reasons, but the longer term impact 
of these interventions remains uncertain. While analyses in Chapters 4 and 5 
extended the follow-up period to a longer time frame, this was based on reasonable, 
but unsubstantiated, assumptions. It is not certain when the additional costs and 
effects of the interventions occur. This could certainly impact on the cost- 
effectiveness of the interventions not only for extending the time frame but also for 
the existing analysis. For example, QALYs are calculated as a product of time in a 
given state and the "health" of that state. Typically, health is measured using a 
generic health related quality of life instrument such as EQ-5D. The instrument is 
usually employed at baseline and follow-up(s), and a linear relationship between 
EQ-5D scores at these time points is invariably assumed. 43 In the absence of 
evidence to the contrary this may be a reasonable assumption. However, in reality, 
the benefit of the intervention may not be distributed evenly and may, for example, 
occur at the beginning of the period with the effect dissipating over time. Thus the 
effectiveness of the intervention would be understated, if the short-run benefits are 
not acknowledged as they fall between follow-up points. Similarly, the intervention 
may have little impact on health until it is completed, that is, most of the benefit will 
occur at the end of the intervention (near the follow-up measurement). Linear 
interpolation of the EQ-5D scores will overstate the benefit of the intervention. 
Given the small beneficial effects of the intervention evaluated in Chapters 4-6, the 
distribution of effects (and costs) could be pivotal. 
The search strategies developed in Chapters 3 and 6 to review existing economic 
evaluations and to populate the models respectively could have been susceptible to 
publication bias. In particular, the results of the searches in Chapter 6 only identified 
studies that reported a positive influence of the intervention on the (surrogate) 
outcome. The majority of studies identified in the review of economic evaluations 
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considered in Chapter 3 and the review of studies to populate the decision model in 
Chapter 6, were of low quality. The conduct, design, analysis and reporting of 
results varied considerably between studies. The analyses in this thesis made no 
attempt to weight studies according to quality as it is unclear what would be 
appropriate weights to give to studies of different quality. Nevertheless, a simple 
sensitivity analysis excluding poor study designs showed little impact on the ICER, 
and no effect on the likely results, conclusions and recommendations of the 
analysis. 
The analyses used in Chapters 4,5 and 6 employed a generic outcome measure of 
health, the QALY, which it has been argued is most useful in addressing the 
decision problem. The QALY in this instance was calculated using the EQ-5D 
instrument whose scores were then "valued" using a sample of the UK general 
public. This is considered the appropriate methodology for current decision 
12 but is not universally accepted. 2'2.2'3 makers, There is concern that the QALY 
does not capture all outcomes of interest (whether they are health outcomes or not) 
and that patients' may give the most reasonable values for the health states of 
which they have experience. In Chapter 7, both of these issues were examined 
using a discrete choice experiment. The sample population consisted of a 
convenience sample of patients who had been offered the EPP intervention and 
were asked to value self-efficacy compared to health related quality of life and other 
important outcomes. This patient group appeared to value the concept of self- 
efficacy, and were prepared to trade-off improvements in self-efficacy for 
decrements in health related quality of life. However, while these results suggest 
that self-efficacy has some value, the fact that the patient population had been 
trained in the concept during the EPP, means that the estimate of the relative worth 
of self-efficacy may be overstated compared to the value of self-efficacy in a more 
general chronically ill population (those who had not been on the EPP). In order to 
estimate more plausibly the value of self-efficacy, it would be appropriate to conduct 
the experiment in a less biased group. 
The analyses presented in Chapters 4,5 and 6 used a point estimate of the cost of 
the intervention. Uncertainty around unit cost data is not always considered in cost- 
effectiveness analyses as unit costs tend to be estimated from tariffs or previous 
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publications that only present point estimates. However, in this instance, the results 
of the analyses are particularly sensitive to the cost of the intervention. While 
standard univariate sensitivity analysis has been employed, obtaining a distribution 
around the point estimate of the cost of the intervention would be preferable. This 
should be achievable given that number of attendees of each group, for example, 
could be easily recorded. 
8.3 Recommendations for future research 
The limitations to the analyses presented above form the basis of the 
recommendations for future research. 
The cost-effectiveness of interventions to support self care is questionable in 
general. In particular, the cost-effectiveness of the EPP depends on the 
assumptions we make about the relevance of evidence. However, the analyses 
presented above compare the EPP to treatment as usual rather than an active 
comparator such as another group therapy. The latter comparison is more useful in 
addressing the decision problem as it informs not only whether a specific 
intervention is cost-effective compared with treatment as usual, but also which 
intervention(s) are likely to be most cost-effective compared with each other. While 
this thesis has not sought to introduce a network of evidence comparing many 
alternatives, the framework presented in Chapter 6 allows just such analyses to be 
performed. This is a key area for future research in this field. 
The analyses performed in this thesis have been conducted with the benefit of two 
datasets with individual patient data and a sizable published literature. It has been 
shown that the single trial based analysis presented in Chapter 4 may generate 
different recommendations for the cost-effectiveness of the EPP than do the 
analyses presented in Chapters 5 and 6. The latter chapters introduced other 
potentially relevant evidence, and it is this additional evidence which potentially 
alters the results and conclusions. It is necessary to state at the outset what 
evidence, and sources of evidence, will be considered potentially relevant to the 
decision problem. The direct, indirect and mixed models employ differing 
assumptions and mechanisms. It is unclear which model is appropriate for decision 
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making purposes, where more than one form of data is available. More research is 
required to assess whether the unexplained variation in the direct model reflects 
genuine variation or is simply noise that we can safely ignore. 
Future economic evaluations of these interventions should also collect information 
that quantifies the uncertainty around the distribution of the cost of the intervention. 
This will allow a more accurate representation of the uncertainty around the 
decision. 
8.4 Conclusion 
This thesis has developed the existing evidence to inform the decision problem of 
whether self care support interventions in general, and the EPP in particular, are 
cost-effective. This thesis presents the first (and to date, the only) single trial based 
economic evaluation of the EPP in the UK. The evidence base is expanded to 
include other trial data and published literature using techniques that have not 
previously been reported. The findings are equivocal. Whether these interventions 
are cost-effective or not depends on 
" choice of paradigm 
" concept of relevance 
" distributional assumptions 
" choice of comparison 
Different concepts will generate varied results with alternative recommendations for 
decision makers. The concern with the use of single trial based analyses as a 
vehicle for informing the decision problem is illustrated by comparing the results of 
this analysis with analyses using more evidence. However, the single trial based 
analysis presented in this thesis presents the most relevant evidence and the results 
suggest that the EPP is a cost-effective use of resources when the comparator is 
treatment as usual. Whichever model is chosen as the basis for the assessment of 
cost-effectiveness, analysts need to be explicit about the assumptions required by 
the analysis. Failure to do so may lead to an underestimation of the uncertainty 
around the decision to adopt the technology as well as an understatement of the 
value of conducting future research. 
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Appendices 
Appendix A. Search strategy 
NHSEED 1995 f4 09 
Accessed via CAI IRS T system 
Searched 16.4.03 
NHS EED 2003-31.08.05 (160 records) 
Accessed via CAIRS T system 
Searched 31.08.05 
S self(w)care 
S self(w)manag$ 
S self(w) monitor$ 
S self(w)help 
S self(w)treat$ 
S (self(w)administer$ andnot (self (w)administer$ (2w)questionnaire$ or 
self(w)administer$(2w)interview$)) 
S self(w)medicat$ 
S self(w)diagnos$ 
S group$(w)support$ 
S peer(w)support$ 
S expert(w)patient$ 
S ((pharmacist$ or pharmacy or pharmacies) (2w) support$) 
S ((pharmacist$ or pharmacy or pharmacies)(2w) assist$) 
S ((pharmacist or pharmacy or pharmacies)(2w) (advice or advise$)) 
S pharmaceutical(w)care 
S sl or s2 or s3 or s4 or s5 or s6 or s7 or s8 or s9 or s10 or sl 1 or s12 or s13 or s14 
or s15 
S@2005SEP1: 2007APR3 
S s16 & s17 
NHS EED 01.09.05-03.04.07 (169 records/ 166 after de-duplication) 
Accessed via CAIRS T system 
Searched 03.04.07 
S self(w)care 
S self(w)manag$ 
S self(w) monitor$ 
S self(w)help 
S self(w)treat$ 
S (self(w)administer$ andnot (self (w)administer$ (2w)questionnaire$ or 
self(w)ad min ister$(2w) interview$)) 
S self(w)medicat$ 
S self(w)diagnos$ 
S group$(w)support$ 
S peer(w)support$ 
S expert(w)patient$ 
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S ((pharmacist$ or pharmacy or pharmacies) (2w) support$) 
S ((pharmacist$ or pharmacy or pharmacies)(2w) assist$) 
S ((pharmacist or pharmacy or pharmacies)(2w) (advice or advise$)) 
S pharmaceutical(w)care 
S s1 or s2 or s3 or s4 or s5 or s6 or s7 or s8 or s9 or s10 or s11 or s12 or s13 or s14 
or s15 
S@2005SEP1: 2007APR3 
S s16 & s17 
DARE 199516 4 03 
Accessed via CAIRS T system 
Searched 16.4.03 
DARE 2003-31.08.05 (records) 
Accessed via CAIRS T system 
Searched 31.08.05 
S self(w)care 
S self(w)manag$ 
S self(w) monitor$ 
S self(w)help 
S self(w)treat$ 
S (self(w)administer$ andnot (self (w)administer$ (2w)questionnaire$ or 
self(w)administer$(2w)interview$)) 
S self(w)medicat$ 
S self(w)diagnos$ 
S group$(w)support$ 
S peer(w)support$ 
S expert(w)patient$ 
S ((pharmacist$ or pharmacy or pharmacies) (2w) support$) 
S ((pharmacist$ or pharmacy or pharmacies)(2w) assist$) 
S ((pharmacist or pharmacy or pharmacies)(2w) (advice or advise$)) 
S pharmaceutical(w)care 
S sl or s2 or s3 or s4 or s5 or s6 or s7 or s8 or s9 or s10 or s11 or s12 or s13 or s14 
or s15 
S econom$ or cost or costs or costly or costing or price or prices or pricing or 
pharmacoeconomics 
S expenditure$ andnot energy 
S value (1w) money 
S budget$ 
S s17 or s18 or s19 or s20 
S s16 and s21 
DARE 01.09.05-03.04.07 (30 records/ 25 after de-deuplication) 
Accessed via CAI RS T system 
Searched 03.04.07 
S self(w)care 
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S self(w)manag$ 
S self(w) monitor$ 
S self(w)help 
S self(w)treat$ 
S (self(w)administer$ andnot (self (w)administer$ (2w)questionnaire$ or 
self(w)administer$(2w)interview$)) 
S self(w)medicat$ 
S self(w)diagnos$ 
S group$(w)support$ 
S peer(w)support$ 
S expert(w)patient$ 
S ((pharmacist$ or pharmacy or pharmacies) (2w) support$) 
S ((pharmacist$ or pharmacy or pharmacies)(2w) assist$) 
S ((pharmacist or pharmacy or pharmacies)(2w) (advice or advise$)) 
S pharmaceutical(w)care 
S s1 or s2 or s3 or s4 or s5 or s6 or s7 or s8 or s9 or s10 or s11 or s12 or s13 or s14 
or s15 
S econom$ or cost or costs or costly or costing or price or prices or pricing or 
pharmacoeconomics 
S expenditure$ andnot energy 
S value (1w) money 
S budget$ 
S s17 or s18 or s19 or s20 
S s16 and s21 
S@2005SEP1: 2007APR3 
S s22 & s23 
Health TechaologyAssessmenfDatabase 
Accessed via http: //aqatha. york. ac. uk/welcome. htm 
Searched 17.4.03 
self-care or self-help-groups/Subject Headings Exploded 
OR self(s)care or self(s)manag or self(s)monitor or self(s)help or self(s)treat or 
self(s)administer or self(s)medicat or self(s)diagnos or group(s)support or expert 
patient or pharmaceutical care/All fields 
OR ((pharmacist or pharmacy or pharmacies) (s) (support or assist or advice or 
advise))/All fields 
Health Te ch n o%oqy Asses sm ent Database Of 09.0-'--03 04 07 (> 7 re c of ds /f 5a )7e r de - 
dup//catiodj 
Accessed via CAI IRS B system 
Searched 03.04.07 
S self(w)care 
S self(w)manag$ 
S self(w) monitor$ 
S self(w)help 
S self(w)treat$ 
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S (self(w)administer$ andnot (self (w)administer$ (2w)questionnaire$ or 
self(w)administer$(2w)interview$)) 
S self(w)medicat$ 
S self(w)diagnos$ 
S group$(w)support$ 
S peer(w)support$ 
S expert(w)patient$ 
S ((pharmacist$ or pharmacy or pharmacies) (2w) support$) 
S ((pharmacist$ or pharmacy or pharmacies)(2w) assist$) 
S ((pharmacist or pharmacy or pharmacies)(2w) (advice or advise$)) 
S pharmaceutical(w)care 
S sl or s2 or s3 or s4 or s5 or s6 or s7 or s8 or s9 or s10 or sl 1 or s12 or s13 or s14 
or s15 
S@2005SEP1: 2007APR3 
S s16 & s17 
National Research Register Issue 1 2003 
Accessed via CDROM 
Searched 22.4.03 
National Research Register Issue 3 2005 
Accessed via Internet 
Searched 31.08.05 
Not possible to limit by date 
SELF-CARE*: ME 
SELF-HELP-GROUPS: ME 
(SELF next CARE) 
(SELF next MANAG*) 
(SELF next MONITOR*) 
(SELF next HELP) 
(SELF next TREAT*) 
(SELF next ADMINISTER*) 
(SELF next MEDICAT*) 
(SELF next DIAGNOS*) 
(GROUP* next SUPPORT*) 
(SUPPORT* next GROUP*) 
(PEER next SUPPORT*) 
(EXPERT next PATIENT*) 
(((PHARMACIST near SUPPORT*) or (PHARMACY near SUPPORT*)) OR 
(PHARMACIES NEAR SUPPORT*)) 
(((PHARMACIST near ASSIST*) or (PHARMACY near ASSIST*)) OR 
(PHARMACIES NEAR ASSIST*)) 
(((PHARMACIST near ADVISE*) or (PHARMACY near ADVISE*)) OR (PHARMACIES NEAR ADVISE*)) 
(((PHARMACIST near ADVICE) or (PHARMACY near ADVICE)) OR 
(PHARMACIES NEAR ADVICE)) 
(PHARMACEUTICAL next CARE) 
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(((((((((((((((#1 or #2) or #4) or #5) or #6) or #7) or #8) or #9) or #10) or #11) or #13) 
or #14) or #15) or #16) or #17) or #18 or #19) 
ECONOMICS: ME 
COSTS-AN D-COST-ANALYS I S*: ME 
ECONOMIC-VALUE-OF-LIFE*: ME 
ECONOMICS-DENTAL: ME 
ECONOMICS-HOSPITAL*: ME 
ECONOMICS-NURSING: ME 
ECONOMICS-PHARMACEUTICAL: ME 
(#21 or #22 or #23 or #24 or #25 or #26 or #27) 
((((((((ECONOM* or COST) or COSTS) or COSTLY) or COSTING) or PRICE) or 
PRICES) or PRICING) or PHARMACOECONOMIC*) 
(EXPENDITURE* or BUDGET*) 
(VALUE next MONEY) 
(#29 or #30 or #31) 
(#28 or #32) 
(#20 and #33) 
National Research Register Issue 1 2007 (373 records/ 345 after de- 
duplication) 
Accessed via Internet 
Searched 17.04.07 
Not possible to limit by date 
#1. SELF CARE explode tree 1 (MeSH) 397 
#2. SELF-HELP GROUPS single term (MeSH) 61 
#3. (self next care) 486 
#4. (self next manag*) 370 
#5. (self next monitor*) 98 
#6. (self next help) 348 
#7. (self next treat*) 27 
#8. (self next administer*) 362 
#9. (self next medicat*) 34 
#10. (self next diagnos*) 9 
#11. (group* next support*) 43 
#12. (support* next group*) 321 
#13. (peer next support*) 42 
#14. (expert next patient*) 94 
#15. (((pharmacist near support*) or (pharmacy near support*)) or (pharmacies near 
support*)) 43 
#16. (((pharmacist near assist*) or (pharmacy near assist*)) or (pharmacies near 
assist*)) 12 
#17. (((pharmacist near advise*) or (pharmacy near advise*)) or (pharmacies near 
advise*)) 9 
#18. (((pharmacist near advice) or (pharmacy near advice)) or (pharmacies near 
advice)) 15 
#19. (pharmaceutical next care) 60 
#20. (#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 
or #14 or #15 or #16 or #17 or #18 or #19) 2028 
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#21. ECONOMICS explode all trees (MeSH) 2546 
#22. COSTS AND COST ANALYSIS explode all trees (MeSH) 2156 
#23. ECONOMIC VALUE OF LIFE explode all trees (MeSH) 0 
#24. ECONOMICS DENTAL explode all trees (MeSH) 2 
#25. ECONOMICS HOSPITAL explode all trees (MeSH) 30 
#26. ECONOMICS NURSING explode all trees (MeSH) 3 
#27. ECONOMICS PHARMACEUTICAL explode all trees (MeSH) 3 
#28. (#21 or #22 or #23 or #24 or #25 or #26 or #27) 2546 
#29. ((((((((econom* or cost) or costs) or costly) or costing) or price) or prices) or 
pricing) or pharmacoeconomic*) 10459 
#30. (expenditure* or budget*) 815 
#31. (value next money) 77 
#32. (#29 or #30 or #31) 11104 
#33. (#28 or #32) 11375 
#34. (#20 and #33) 373 
HEED (Hea/ih Economic Eva/u8/ions Da/abase) 19952003IFeb 
Accessed via CDROM. 
Searched 22.4.03 
HEED (Health Economic Eva/uafions Database) 2003-2005/Aug (190recoids) 
Accessed via CDROM. 
Searched 31.08.05 
Ax= 'self care' 
Ax= 'self help' 
Ax= 'self manage' 
Ax= 'self managing' 
Ax= 'self management' 
Ax= 'self monitor' 
Ax='self monitoring' 
Ax= 'self help' 
Ax= 'self treat' 
Ax= 'self treatment' 
Ax= 'self administer' 
Ax= 'self administration' 
Ax= 'self medicate' 
Ax= 'self medication' 
Ax= 'self diagnose' 
Ax= 'self diagnosis' 
Ax= 'group support' 
Ax= 'support group' 
Ax= 'peer support' 
Ax= 'expert patient' 
Ax= 'pharmacist support' 
Ax= 'pharmacist advice' 
Ax='pharmacy 
Ax= pharmacies 
Ax= 'pharmaceutical care' 
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HEED (Health Economic Eva/uations Database) 20052007/Apri/(131 reco, rls/ 113 aflerde- 
dup&afion) 
Accessed via CDROM (April 2007). 
Searched 17/04/07 
Date restriction limited to year only. 
Ax= 'self care' 
Ax= 'self help' 
Ax= 'self manage' 
Ax= 'self managing' 
Ax= 'self management' 
Ax= 'self monitor' 
Ax='self monitoring' 
Ax= 'self help' 
Ax= 'self treat' 
Ax= 'self treatment' 
Ax= 'self administer' 
Ax= 'self administration' 
Ax= 'self medicate' 
Ax= 'self medication' 
Ax= 'self diagnose' 
Ax= 'self diagnosis' 
Ax= 'group support' 
Ax= 'support group' 
Ax= 'peer support' 
Ax= 'expert patient' 
Ax= 'pharmacist support' 
Ax= 'pharmacist advice' 
Ax='pharmacy 
Ax= pharmacies 
Ax= 'pharmaceutical care' 
Cs=1 or2or3or4or5or6or7or8or9or10orl1 or12or13or14or15or16 
or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 
JD=2005 
JD=2006 
JD=2007 
Cs=27 or 28 or 29 
Cs=26 and 30 
National Guidehiies C/ea1inghouse 
Accessed via http: //www. guideline. gov/index. aSD 
Searched 17.4.03 
National Guide/irres C/eannghouse (> f9 recorris) 
Accessed via http: //www. quideline. qov/index. asr) 
Searched 31.08.05 
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Saved as NGC. doc 
"self care" "self manag*" "self help" "self treat*" "self administer*" "self medicat*" "self 
diagnos*" "group support*" "peer support*" "expert patient*" "pharmaceutical care" 
National Guidelines C/eannghouse (1,05reco%s) 
Accessed via http: //www. quideline. qov/search/detailedsearch. aspx 
Searched 18.04.07 
Saved as NGC180407. doc 
Keyword: "self care" or "self manag*" or "self help" or "self treat*" or "self 
administer` or "self medicat*" or "self diagnos*" or "group support*" or "peer 
support*" or "expert patient*" or "pharmaceutical care" 
Publication Date(s): 2007,2006,2005 
Nation/ Cooroinating Centre forHea/th TechnologyAssessment 
Accessed via http: //www. hta. nhsweb. nhs. uk/ 
Searched 17.4.03 
2003-2005 update - searched as part of the HTA Database. 
self care, self manage, self help, self treat, self administer, self medicat, self 
diagnos, group support, peer support, expert patient, pharmacist, pharmacy, 
pharmacies, pharmaceutical care 
2005-2007 update - searched as part of the HTA Database. 
self care, self manage, self help, self treat, self administer, self medicat, self 
diagnos, group support, peer support, expert patient, pharmacist, pharmacy, 
pharmacies, pharmaceutical care 
Health Services Technology Assessment Text (HSTAT) 
Accessed via httr: //hstat. nlm. nih. gov 
Searched 22.4.03 
Health Services Technology Assessment Text (HSTAT) (30 records) 
Accessed via http: //hstat. nlm. nih. Qov 
Searched 31.08.05 
Limited to titles only. Limit by date not available 
Saved as HSTAT. doc 
"self care" "self help" "self mang*" "self monitor*" "self treat*" "self administer*" "self 
medicat*" "group support*" "expert patient*" "peer support*" "pharmacy support*" 
"pharmacist support*" "pharmacy advice" "pharmacist advice" "pharmaceutical care" 
Health Services Technology Assessment Text (HSTAT) (34 records) 
Accessed via httD: //hstat. nlm. nih. aov 
Searched 18.04.07 
Limited to titles only. Limit by date not available 
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Saved as HSTAT180407. doc 
("self care"or"self help"or"self management"or"self monitoring"or"self 
treatment"or"self administered"or"self medicated"or"group support"or"expert 
patient"or"peer support"or"pharmacy support" or"pharmacist support"or"pharmacy 
advice"or"pharmacist advice"or"pharmaceutical care") [TITLE] AND hstat[book] 
SIGN Guidelines (Scottish Intercollegiate Guidelines Network) 
Accessed via httg: //www. siqn. ac. uk/ 
Searched 23.4.03 
SIGN Guidelines (Scottish Intercollegiate Guidelines Network) (0 records) 
Accessed via httg: //www. sign. ac. uk/ 
Searched 31.08.05 
Visual inspection of publications 
SIGN Guidelines (Scottish Intercollegiate Guidelines Network) (0 records) 
Accessed via http: //www. siqn. ac. uk/ 
Searched 18.04.07 
Visual inspection of publications 
National Institute of Clinical Excellence (published appraisals) 
Accessed via httr): //www. nice. org. uk/ 
Searched 22.4.03 
2003-2005 update - searched as part of the HTA Database. 
Self care, self help, self manag, self treat, self administer, self medicate, self 
diagnose, group support, peer support, expert patient, pharmacy, pharmacist, 
pharmacies, pharmaceutical care 
2005-2007 update - searched as part of the HTA Database. 
Self care, self help, self manag, self treat, self administer, self medicate, self 
diagnose, group support, peer support, expert patient, pharmacy, pharmacist, 
pharmacies, pharmaceutical care 
Campbe// Co//aborafion C2Regisfered Systematic Reviews fifes listing 
Accessed via http: //www. camr)bellcollaboration. org/Fralibrary. html 
Searched 23.4.03 
Campbe// Co//abocation C2 RegisfecedSysfematic Reviews fifes listing (0recores, I 
Accessed via http: //www. campbellcollaboration. or4/Fralibrarv. htmi 
Searched 31.08.05 
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No search engine. Visual inspection 
Campbell Co//abocafio17 C2 Registered Sysfemafic Reviews fifes /isfiag (Orecoc 's) 
Accessed via http: //www. campbeIIcollaboration. ora/frontend. asp#Viewing reviews 
Searched 18.04.07 
No search engine. Visual inspection 
MEDLINE (OVIDWEB) 
Accessed via httg: //gateway1. uk. ovid. com/ovidweb 
Searched 13.5.03 (1966-1994) 
MEDLINE (OVIDWEB) 
Accessed via http: //qatewayl. uk. ovid. com/ovidweb 
Searched 05.09.05 (2003-Aug 2005) 
621 Records Found 
1 self care/ or blood glucose self-monitoring/ or self administration/ 
2 self help groups/ 
3 self manag$. ti, ab. 
4 self care. ti, ab. 
5 self monitor$. ti, ab. 
6 self help. ti, ab. 
7 self treat$. ti, ab. 
8 ((self administer$ adj2 questionnaire$) or (self administer$ adj2 survey$) or (self 
administer$ adj2 interview$)). ti, ab. 
9 self administer$. ti, ab. 
10 9 not 8 
11 self medicat$. ti, ab. 
12 self diagnos$. ti, ab. 
13 (group$ adj support$). ti, ab. 
14 (peer adj support$). ti, ab. 
15 expert patient$. ti, ab. 
16 ((pharmacist$ or pharmacy or pharmacies) adj2 support$). ti, ab. 
17 ((pharmacist$ or pharmacy or pharmacies) adj assist$). ti, ab. 
18 ((pharmacist or pharmacy or pharmacies) adj2 (advice or advise)). ti, ab. 
19 pharmaceutical care. ti, ab. 
20 or/1-19 
21 economics/ 
22 exp "Costs and Cost Analysis"/ 
23 Value of Life/ 
24 economics, dental/ 
25 exp economics, hospital/ 
26 economics, medical/ 
27 economics, nursing/ 
28 economics, pharmaceutical/ 
29 or/21-28 
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30 (econom$ or cost or costs or costly or costing or price or prices or pricing or 
pharmacoeconomic$). tw. 
31 (expenditure$ not energy). tw. 
32 (value adj1 money). tw. 
33 budget$. tw. 
34 or/30-33 
35 29 or 34 
36 Ietter. pt. 
37 editorial. pt. 
38 historical article. pt. 
39 or/36-38 
40 35 not 39 
41 animal/ 
42 human/ 
43 41 not (41 and 42) 
44 40 not 43 
45 (metabolic adj cost). ti, ab, sh. 
46 ((energy or oxygen) adj cost). ti, ab, sh. 
47 44 not (45 or 46) 
48 47 and 20 
MEDLINE & MEDLINE IN-PROCESS (OVIDWEB) (638 records/ 516 after de- 
duplication) 
Accessed via http: //gateway1. uk. ovid. com/ovidweb 
Searched 17.04.07 (2005-Apr 16 2007) 
638 Records Found 
1 self care/ or blood glucose self-monitoring/ or self administration/ (21792) 
2 self help groups/ (5852) 
3 self manag$. ti, ab. (3162) 
4 self care. ti, ab. (5611) 
5 self monitor$. ti, ab. (2409) 
6 self help. ti, ab. (3002) 
7 self treat$. ti, ab. (721) 
8 self administer$. ti, ab. (12234) 
9 self medicat$. ti, ab. (1607) 
10 self diagnos$. ti, ab. (269) 
11 (group$ adj support$). ti, ab. (703) 
12 (peer adj support$). ti, ab. (586) 
13 expert patient$. ti, ab. (60) 
14 ((pharmacist$ or pharmacy or pharmacies) adj2 support$). ti, ab. (176) 
15 ((pharmacist$ or pharmacy or pharmacies) adj assist$). ti, ab. (103) 
16 ((pharmacist or pharmacy or pharmacies) adj2 (advice or advise)). ti, ab. (28) 
17 pharmaceutical care. ti, ab. (809) 
18 or/1-17 (49441) 
19 ((self administer$ adj2 questionnaire$) or (self administer$ adj2 survey$) or 
(self administer$ adj2 interview$)). ti, ab. (7294) 
20 18 not 19 (42147) 
21 economics/ (24856) 
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22 exp "Costs and Cost Analysis"/ (128397) 
23 Value of Life/ (4836) 
24 economics, dental/ (1678) 
25 exp economics, hospital/ (14634) 
26 economics, medical/ (6713) 
27 economics, nursing/ (3736) 
28 economics, pharmaceutical/ (1755) 
29 (econom$ or cost or costs or costly or costing or price or prices or pricing or 
pharmacoeconomic$). tw. (252457) 
30 (expenditure$ not energy). tw. (10562) 
31 (value adj1 money). tw. (11) 
32 budget$. tw. (11190) 
33 or/21-32 (356662) 
34 letter. pt. (596264) 
35 editorial. pt. (206441) 
36 historical article. pt. (237816) 
37 or/34-36 (1031017) 
38 33 not 37 (337012) 
39 animal/ (4050286) 
40 human/ (9679026) 
41 39 not (39 and 40) (3073984) 
42 38 not 41 (320392) 
43 (metabolic adj cost). ti, ab, sh. (439) 
44 ((energy or oxygen) adj cost). ti, ab, sh. (1937) 
45 42 not (43 or 44) (318567) 
46 20 and 45 (3248) 
47 limit 46 to yr="2005 - 2007" (638) 
EMBASE (OVIDWEB) 
Accessed via http: //qatewavl. uk. ovid. com/ovidweb 
Searched 05.09.05 (2003-Aug 2005) 
776 Records Found 
1. self care/ or blood glucose monitoring/ or drug self administration/ 
2. self medication/ 
3. self manag$. ti, ab. 
4. self care. ti, ab. 
5. self monitor$. ti, ab. 
6. self help. ti, ab. 
7. self treat$. ti, ab. 
8. ((self administer$ adj2 questionnaire$) or (self administer$ adj2 survey$) or 
(self administer$ adj2 interview$)). ti, ab. 
9. self administer$. ti, ab. 
10.9 not 8 
11. self medicat$. ti, ab. 
12. self diagnos$. ti, ab. 
13. (group$ adj support$). ti, ab. 
14. (peer adj support$). ti, ab. 
15. expert patient$. ti, ab. 
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16. ((pharmacist$ or pharmacy or pharmacies) adj2 support$). ti, ab. 
17. ((pharmacist$ or pharmacy or pharmacies) adj assist$). ti, ab. 
18. ((pharmacist or pharmacy or pharmacies) adj2 (advice or advise)). ti, ab. 
19. pharmaceutical care. ti, ab. 
20. or/1-19 
21. Health Economics/ 
22. exp Economic Evaluation/ 
23. exp Health Care Cost/ 
24. exp PHARMACOECONOMICS/ 
25. o r/21-24 
26. (econom$ or cost or costs or costly or costing or price or prices or pricing or 
pharmacoeconomic$). ti, ab. 
27. (expenditure$ not energy). ti, ab. 
28. (value adj2 money). ti, ab. 
29. budget$. ti, ab. 
30. or/26-29 
31.25or30 
32. (metabolic adj cost). ti, ab. 
33. ((energy or oxygen) adj cost). ti, ab. 
34. ((energy or oxygen) adj expenditure). ti, ab. 
35. or/32-34 
36.31 not 35 
37. editorial. pt. 
38. note. pt. 
39. letter. pt. 
40. or/37-39 
41.36 not 40 
42. (rat or rats or mouse or mice or hamster or hamsters or animal or animals or 
dogs or dog or cats or bovine or sheep). ti, ab, sh. 
43. exp animal/ 
44. Nonhuman/ 
45. or/42-44 
46. exp human/ 
47. exp human experiment/ 
48.46 or 47 
49.45 and (45 not 48) 
50.41 not 49 
51.20 and 50 
EMBASE (OVIDWEB) (692 records/ 369 after de-deuplication) 
Accessed via httD: //Qatewayl. uk. ovid. com/ovidweb 
Searched 17.04.07 (2005-2007 Week 15) 
692 Records Found 
1 self care/ or blood glucose monitoring/ or drug self administration/ (11656) 
2 self medication/ (4355) 
3 self manag$. ti, ab. (2515) 
4 self care. ti, ab. (3254) 
5 self monitor$. ti, ab. (2164) 
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6 self help. ti, ab. (2487) 
7 self treat$. ti, ab. (649) 
8 self administer$. ti, ab. (10310) 
9 self medicat$. ti, ab. (1583) 
10 self diagnos$. ti, ab. (202) 
11 (group$ adj support$). ti, ab. (549) 
12 (peer adj support$). ti, ab. (400) 
13 expert patient$. ti, ab. (49) 
14 ((pharmacist$ or pharmacy or pharmacies) adj2 support$). ti, ab. (201) 
15 ((pharmacist$ or pharmacy or pharmacies) adj assist$). ti, ab. (108) 
16 ((pharmacist or pharmacy or pharmacies) adj2 (advice or advise)). ti, ab. (44) 
17 pharmaceutical care. ti, ab. (1370) 
18 or/1-17 (34898) 
19 ((self administer$ adj2 questionnaire$) or (self administer$ adj2 survey$) or 
(self administer$ adj2 interview$)). ti, ab. (5918) 
20 18 not 19 (28980) 
21 health economics/ (9122) 
22 exp economic evaluation/ (86465) 
23 exp health care cost/ (87889) 
24 exp pharmacoeconomics/ (45594) 
25 (econom$ or cost or costs or costly or costing or price or prices or pricing or 
pharmacoeconomic$). tw. (197375) 
26 (expenditure$ not energy). tw. (8408) 
27 (value adj1 money). tw. (7) 
28 budget$. tw. (7794) 
29 or/21-28 (290198) 
30 (metabolic adj cost). ti, ab. (340) 
31 ((energy or oxygen) adj cost). ti, ab. (1566) 
32 ((energy or oxygen) adj expenditure). ti, ab. (8747) 
33 or/30-32 (10182) 
34 29 not 33 (287887) 
35 note. pt. (209771) 
36 letter. pt. (344831) 
37 editorial. pt. (176176) 
38 or/35-37 (730778) 
39 34 not 38 (249762) 
40 (rat or rats or mouse or mice or hamster or hamsters or animal or animals or 
dogs or dog or cats or bovine or sheep). ti, ab, sh. (1851048) 
41 exp animal/ (112185) 
42 nonhuman/ (2867095) 
43 or/40-42 (3184600) 
44 exp human/ (5699081) 
45 exp human experiment/ (231763) 
46 or/44-45 (5699944) 
47 43 and (43 not 46) (2645875) 
48 39 not 47 (229916) 
49 20 and 48 (3004) 
50 limit 49 to yr="2005 - 2007" (692) 
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Appendix B 
Checlr//sf usedforqua//fy assessment ofeconornic evaluations 
Study specification 
1. Was the study question clear? 
Q What was the objective of the study? How clear was it? Self- 
management interventions (SC) can be complex. 
Q What were the key costs/resources and outcomes assessed? 
2. Was a comprehensive description of the competing alternatives 
given? 
Q Can you tell who? did what? to whom? where? and how often? 
Were the care pathways clearly identified 
Q Was a comprehensive description of the interventions provided (i. e. 
the delivery needs to be described in detail in order to standardise 
the delivery and to generalise the results) 
Q Were any alternatives omitted? Is it appropriate to have a do- 
nothing alternative; could the study design prevent people self 
medicating? 
Q For SC interventions given in groups, was the effect of group 
therapy allowed for (e. g. by inclusion of the comparator arm of 
group therapy without the intervention). What was the unit of 
analysis? 
Q Were baseline utility values and/or resource use given for 
alternative treatment arms? 
3. What was the perspective of the study? 
Q Often economic studies use a health service perspective on the 
grounds that this approximates a societal perspective. In the case 
of SC evaluations, costs to patient, plus productivity changes 
should be explored. 
4. What was the study design? 
Q RCT of comparator therapies, placebo controlled RCT, controlled 
before and after, cross sectional control, before after control, case 
reports, expert opinion. 
5. What was the economic study type? 
Q Cost utility, cost-effectiveness, cost benefit, cost minimisation, cost 
consequences 
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Clinical evidence 
6. Given the type of study was the design adequate? 
Sample. 
Q How was the sample size determined? 
Q Was sample size adequate to detect differences? No statistically 
significant differences may lead to inappropriate cost minimisation 
analysis. 
Q How was the sample selected? 
Q Is there evidence to suggest that the sample is appropriate for the 
study question? Did any subjects refuse to participate? 
Q Were there any in/exclusions criteria and if so were they 
appropriate? 
Q Did studies which were RCTs have proper randomisation process? 
Contamination. 
Q Given that contamination of control groups is more likely in SC 
interventions, was contamination considered? Were attempts made 
to mitigate it? 
Q Was adherence/compliance with the intervention measured? 
Sociodemographic characteristics of study populations. 
Q Were these reported? 
Q Were the study and control groups shown to be comparable at 
baseline in terms of socio-demographic characteristics? 
Q Factors such as chronicity, previous treatment, social adjustment, 
interpersonal difficulties and social circumstances may also impact 
on the outcomes 
Compliance. Was compliance reported? 
Is the setting described? 
Q Is the area/country identified? 
Q Where did the intervention take place (home, primary care, 
hospital... ) 
Q Who delivered the intervention? 
Q How many centres were there? 
Q Was effectiveness established in a UK trial? 
Dates. 
Q Was the date of the intervention given? 
Q Were the dates for the effectiveness measures, resource use and 
price given? 
Outcome assessment 
Q Is the method described? 
Q Was assessment blinded? 
Economic analysis 
7. Were all the important and relevant costs and consequences for each 
alternative identified? 
7a Costs 
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Q Was the costing undertaken on the same sample of people as that 
used in the effectiveness study? 
Q Was the costing undertaken pro/retrospectively? 
Q Self-management interventions may have more influence on self 
medication; with these interventions, these costs should be 
included. 
Q Formal and informal care costs may also vary more markedly in SC 
interventions as the person becomes better able to cope for 
him/herself and should be measured 
7b Consequences 
Q SC interventions have been associated with improvements in 
outcomes such as empowerment, confidence etc. 
Q Were any adverse effects reported? 
Q Was quality of life measured? 
Q Appropriateness of outcome measures? 
Q Were patient preferences explored? 
8. Were costs and consequences measured accurately (and credibly) 
in appropriate physical units? (e. g. hours of nursing time, number of 
physician visits, lost work-days, gained life-years) 
8a. Costs 
Q Where were unit cost data derived from? Were they derived from the 
study? Were they UK based? If not, are these estimates good 
estimates of opportunity cost in UK? 
Q Was study powered on costs? 
Q What resource quantities and costs were reported and were they 
reported separately and how were they estimated? 
Q What direct costs were included? 
Q What productivity changes were included? Were working days really 
lost? 
Q If required, were appropriate adjustments for inflation/currency 
conversion made? 
Q Prospective data for the study? From elsewhere? 
8b. Consequences 
Q Use of outcome measures such as empowerment, motivation, 
perseverance. Have the measures been validated and are they 
reliable? Whose values were used and how many? 
Q Was the follow up period adequate? Was there loss to follow up? 
Was the outcome analysis built on intention to treat/treatment 
completers? Were the outcomes assessable within the timeframe? 
SC interventions may have little immediate impact on "hard" 
outcomes (mortality, life years gained etc);. If short follow up, is the 
link between intermediate outcome (confidence etc) and final 
outcome (e. g. QALY), well established? 
Q Direct or indirect measures of health effect? Health utility analysis? 
Analysis 
9. Was the statistical analysis appropriate given the design? 
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Q EG allowance for clustering, loss to follow up 
IOa Was sub-group analysis performed? 
10b If so were the groups pre-specified? 
Q SC interventions often study a very heterogeneous population e. g. 
with number of conditions, age group. 
11. Were costs and consequences appropriately discounted? 
Q Were discount factors applied to costs and outcomes if appropriate? 
Q Was a lower discount rate applied to outcomes if these were measured 
in volume terms rather than in value terms? 
12. Was an incremental analysis of costs and consequences of alternatives 
performed? 
Q Were the additional (incremental) costs generated by one alternative 
over another compared to the additional effects, benefits or utilities 
generated? 
13. Was allowance made for uncertainty? 
Stochastic analysis of patient-level data 
Q Were details of statistical tests and confidence intervals given for 
stochastic data? 
Q Was uncertainty around cost-effectiveness expressed (e. g. 
confidence interval around incremental cost-effectiveness ratio 
(ICER), cost-effectiveness acceptability curves). 
Q Was sensitivity analysis used to assess uncertainty in non- 
stochastic variables (e. g. unit costs, discount rates) and analytic 
decisions (e. g. methods to handle missing data)? 
Stochastic analysis of decision models 
Q Are all appropriate input parameters included with uncertainty? 
Q Is second-order uncertainty (uncertainty in means) included rather 
than first order (uncertainty between patients)? 
Q Are the probability distributions adequately detailed and 
appropriate? Was sensitivity analysis used to assess uncertainty in 
non-stochastic variables (e. g. unit costs, discount rates) and 
analytic decisions (e. g. methods to handle missing data)? 
Deterministic analysis 
Q Was the method of sensitivity analysis used specified and justified 
(e. g. univariate, threshold analysis etc)? 
Q Was the choice of variables used in the sensitivity analysis justified 
and the ranges over which the variables are varied stated? 
14. Were missing data handled adequately? 
Q As with most economic evaluations, missing data are likely to be a 
problem with SC interventions. 
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15a. Was an economic model developed? 
15b. If so was it appropriate, transparent and the methodology explicit? 
16 Study results and implications 
16a. Were limitations of the study acknowledged and biases (and 
their potential magnitude and direction) discussed? 
Qsources of funding acknowledged; declarations of competing 
interests 
16b. Were issues of generalisability discussed? 
Qdifferent country, different institutional setting, standard intervention, 
population groups. 
16c. Did the presentation and discussion of study results include all 
important issues? 
Q Were any recommendations made by the authors regarding 
policy/practice? 
Q Were specific recommendations made by the authors regarding the 
need for further research? 
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Appendix C 
C. 1 R code for/PD meta-anal sis i', Chapter 5 
rm(Iist=ls(aIl=TRUE)) 
library("R2WinBUGS") 
library("BRugs") 
setwd('C: /work/phD_stuff/') 
tData <- read. table(file= QALY5. TXT', header=TRUE) 
N. SIMS <- 15000 
N. BURNIN <-5000 
WIN. DEBUG <- FALSE 
N. CHAINS <- 2 
WIN. SOURCES <- c('GR7NSHM1 Norm. txt', 'GR7NSHM1 Log. txt', 'GR7NSHM1 LogMult. txt') 
#WIN. SOURCES <- c('GR7NSHM1Log. txt') 
nWinSource <- length(WIN. SOURCES) 
genSamps <- function(data, 
n. iter=N. SIMS+N. BURNIN, 
inits, n. burnin=N. BURNIN, 
bugs. file=winSource, 
parameters. to. save, 
winSource=winSource, 
winDebug=WIN. DEBUG){ 
sims <- bugs(data=data, 
parameters. to. save=parameters. to. save, 
model. file=bugs. file, 
n. chains=N. CHAINS, 
debug=winDebug, 
inits=inits, 
n. iter = n. iter, 
n. burnin = n. burnin, 
n. thin=1, 
program = "openbugs" 
return(sims) 
qaly <- tData$QALY 
cost <- tData$cost 
tx <- tData$tx 
study <- tData$trial_id 
nTx<-Iength(unique(tx)) 
nObs <-nrow(tData) 
nStudies <- max(study)+1 
age <- tData$age 
age <- age-mean(age, na. rm=TRUE) 
gender<-1 +tData$gender 
EQ-5D<-tData$base_EQ-5D 
EQ-5D<-EQ-5D-mean(EQ-5D) 
sei <- tData$selfeff1 
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sei <- se1-mean(sel, na. rm=TRUE) 
se2<-tData$se2 
se2 <- se2-mean(se2, na. rm=TRUE) 
qalyMean <- matrix(NA, nStudies-1, nTx) 
costMean <- matrix(NA, nStudies-1, nTx) 
for Oj in 1: nTx){ 
for (ss in 1: (nStudies-1)){ 
qalyMean[ss, jj] <- mean(qaly[tx==jj-1&study==ss], na. rm=TRUE) 
costMean[ss, jj] <- mean(cost[tx==jj-1 &study==ss], na. rm=TRUE) 
qalyMean[is. na(qalyMean)] <- 0 
costMean[is. na(qalyMean)] <- 0 
studyDummy <- study-1 
#maybe sei, note that Im rather than gim generates OLS estimates 
summary(glm(galy-tx+EQ-5D+studyDummy)) 
summary(glm(cost-tx+EQ-5D+studyDummy, gaussian(Iink = "log"))) 
summary(lm(cost-tx+EQ-5D+studyDummy)) 
#analyse effic data 
inits <- function(){Iist(qSe=rep(1, nStudies), logCostSe=rep(1, nStudies), 
ctBeta=l, qtBeta=1, df=l, ceBeta=rnorm(nStudies), qeBeta=rnorm(nStudies), 
cAlpha=rep(1000, nStudies), qAlpha=rep(1, nStudies))} 
bugsData <- Iist(cost=cost, qaly=galy, qSampMean=galyMean, nObs=nObs, tx=tx, 
nTx= nTx, study=study, EQ-5 D= EQ-5 D, n Studies= nStud ies) 
parameters. to. save <- 
c("ctBeta", "gtBeta", "cSe", "qSe", "cAlpha", "deltaCost", "deltaQaly", "postPredC", "postPredQ", "r 
esidCost", "residQaly") 
#parameters. to. save <- c("deltaCost", "deltaQaly", "df') 
#model 1 basic model with no covs or corr, normally distributed costs if norm suffix 
for (ww in 1: nWinSource){ 
rest <- 
genSamps(data=bugsData, inits=inits, parameters. to. save=parameters. to. save, winSource= 
WIN. SOURCES[ww]) 
nonTxcostl <- resl $sims. matrix[, "deltaCost"] 
qalyl <- res1$sims. matrix[, "deltaQaly"] 
ctBeta1 <- res1$sims. matrix[, "ctBeta"] 
gtBeta1 <- res1$sims. matrix[, "gtBeta"] 
txCost <- 198 
cost1 <- nonTxcostl+txCost 
ceRange <- seq(0,100000,100) 
ceac <- numeric() 
icer<-numeric() 
for (cc in seq(along=ceRange)){ 
lambda <- ceRange[cc] 
nbl <-qalyl "lambda-costl 
ceac[cc] <- mean(nbl>O) 
nbl[nbl<O]<-0 
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#nb2[nb<O]<-O 
#modelVoi[cc, ii] <- mean(nb)-mean(seNb) 
results <- rbind( 
c(mean(nonTxcostl ), quantile(nonTxcostl , c(0.025,0.975))), 
c(mean(galyl), quantile(qalyl, c(0.025,0.975))), 
c(mean(ctBeta 1), quantile(ctBeta 1, c(0.025,0.975))), 
c(mean(gtBeta1), quantile(gtBeta1, c(0.025,0.975)))) 
results <- rbind(resuIts, results[ 1, ]/results[2, ]) 
colnames(results) <- c("Mean", "2.5%", "97.5%") 
rownames(results) <- c("Cost", "QALY", "BCT", "BQT", "ICER") 
print(WIN. SOURCES[ww]) 
print(results) 
costResid <- res1$summary[(14+nObs*2): (14+nObs*3-1), 1] 
qalyResid <- resl$summary[(14+nObs"3): (14+nObs*4-1), 1] 
costPValues <- (apply(res 1 $sims. matrix[, 1 4: (14+nObs- 1)]>0,2, mean)) 
qalyPValues <- (apply(res1$sims. matrix[, (14+nObs): (14+2*nObs-1)]>0,2, mean)) 
DIC <- resl$DIC 
print(DIC) 
assign(paste("dic", ww, sep=""), DIC) 
assign(paste("results", ww, sep=""), results) 
assign(paste("galyPValues", ww, sep=""), galyPValues) 
assign(paste("costPValues", ww, sep=""), costPValues) 
assign(paste("galyResid", ww, sep=""), galyResid) 
assign(paste("costResid", ww, sep=""), costResid) 
assign(paste("ceac", ww, sep=""), ceac) 
remove(resl) 
remove(qalyl) 
remove(ctBetal) 
remove(qtBetal) 
} 
rm(list=ls(all=TRUE)) 
library("R2WinBUGS") 
libra ry("B Rugs") 
setwd('C: /work/ph D_stuff/neil3') 
tData <- read. table(file='QALY5. TXT', header=TRUE) 
#tData <- tData[tData$trial_id==1, ] 
#tData <- tData[tData$trial_id==2, ] 
N. SIMS <- 15000 
N. BURNIN <-5000 
WIN. DEBUG <- FALSE 
N. CHAINS <- 2 
WIN. SOURCES <- 
c('GR7NSHM1 Norm. txt', 'GR7NSHM1 Log. txt', 'GR7NSHM1 LogMult. txt', 'GR7NSHMITDist. txt' 
#WIN. SOURCES <- c('GR7NSHMILog. txt') 
nWinSource <- Iength(WIN. SOURCES) 
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genSamps <- function(data, 
n. iter=N. SIMS+N. BURNIN, 
inits, n. burnin=N. BURNIN, 
bugs. file=winSource, 
parameters. to. save, 
winSource=winSource, 
winDebug=WIN. DEBUG){ 
sims <- bugs(data=data, 
parameters. to. save=parameters. to. save, 
model. file=bugs. file, 
n. chains= N. CHAINS, 
debug=winDebug, 
inits=inits, 
n. iter = niter, 
n. burnin = n. burnin, 
n. thin=1, 
program = "openbugs" 
return(sims) 
qaly <- tData$QALY 
cost <- tData$cost 
tx <- tData$tx 
study <- tData$trial_id 
nTx<-Iength(unique(tx)) 
nObs <-nrow(tData) 
nStudies <- max(study)+1 
age <- tData$age 
age <- age-mean(age, na. rm=TRUE) 
gender<-1 +tData$gender 
EQ-5D<-tData$base_EQ-5D 
EQ-5D<-EQ-5D-mean(EQ-5D) 
sell <- tData$selfeffI 
sei <- se1-mean(sel, na. rm=TRUE) 
se2<-tData$se2 
se2 <- se2-mean(se2, na. rm=TRUE) 
qalyMean <- matrix(NA, nStudies-1, nTx) 
costMean <- matrix(NA, nStudies-1, nTx) 
for (jj in 1: nTx){ 
for (ss in 1: (nStudies-1)){ 
qalyMean[ss, jj] <- mean(galy[tx==jj-1 &study==ss], na. rm=TRUE) 
costMean[ss, jj] <- mean(cost[tx==jj-1&study==ss], na. rm=TRUE) 
} 
} 
qalyMean[is. na(qalyMean)] <- 0 
costMean[is. na(qalyMean)] <- 0 
studyDummy <- study-1 
#maybe sei, note that Im rather than glm generates OLS estimates 
summary(glm(qaly-tx+EQ-5D+studyDummy)) 
summary(glm(cost-tx+EQ-5D+studyDummy, gaussian(Iink ='log"))) 
summary(lm(cost-tx+EQ-5D+studyDummy)) 
#analyse effic data 
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inits <- function(){Iist(gSe=rep(1, nStudies), logCostSe=rep(1, nStudies), 
ctBeta=l, gtBeta=1, df=1, ceBeta=rnorm(nStudies), qeBeta=rnorm(nStudies), 
cAlpha=rep(1000, nStudies), qAlpha=rep(1, nStudies))} 
bugsData <- Iist(cost=cost, galy=qaly, gSampMean=qalyMean, nObs=nObs, tx=tx, 
nTx=nTx, study=study, EQ-5D=EQ-5D, nStudies=nStudies) 
parameters. to. save <- 
c("ctBeta", "gtBeta", "cSe", "qSe", "cAlpha", "deltaCost", "deltaQa ly", "postPredC", "postPredQ", "r 
esidCost", "residQaly") 
#parameters. to. save <- c("deltaCost", "deltaQaly", "df') 
#model 1 basic model with no covs or corr, normally distributed costs if norm suffix 
for (ww in 1: nWinSource[4]){ 
rest <- 
genSamps(data=bugsData, inits=in its, parameters. to. save=parameters. to. save, winSource= 
WIN. SOURCES[ww]) 
nonTxcostl <- resl $sims. matrix[, "deltaCost"] 
qalyl <- resl $sims. matrix[, "deltaQaly"] 
ctBetal <- res 1 $sims. matrix[, "ctBeta"] 
gtBeta1 <- res 1$sims. matrix[, "gtBeta"] 
txCost <- 198 
costl <- nonTxcostl +txCost 
ceRange <- seq(0,100000,100) 
ceac <- numeric() 
icer<-numeric() 
for (cc in seq(along=ceRange)){ 
lambda <- ceRange[cc] 
nbl <-qalyl *lambda-costl 
ceac[cc] <- mean(nbl >0) 
nbl[nbl<0]<-0 
#nb2[nb<0]<-0 
#modelVoi[cc, ii] <- mean(nb)-mean(seNb) 
} 
results <- rbind( 
c(mean(nonTxcostl ), quantile(nonTxcostl , c(0.025,0.975))), 
c(mean(galyl ), quantile(galyl , c(0.025,0.975))), 
c(mean(ctBeta 1), quantile(ctBeta 1, c(0.025,0.975))), 
c(mean(gtBetal ), quantile(gtBetal , c(0.025,0.975)))) 
results <- rbind(resuIts, resuIts[ 1, ]/results[2, ]) 
colnames(results) <- c("Mean", "2.5%", "97.5%") 
rownames(results) <- c("Cost", "QALY", "BCT", "BQT", "ICER") 
print(WIN. SOURCES[ww]) 
print(results) 
costResid <- resl$summary[(14+nObs*2): (14+nObs*3-1), 1] 
qalyResid <- res1$summary[(14+nObs*3): (14+nObs*4-1), 1 ] 
costPValues <- (apply(res1$sims. matrix[, 14: (14+nObs-1)]>0,2, mean)) 
qalyPValues <- (apply(res1$sims. matrix[, (14+nObs): (14+2*nObs-1)]>0,2, mean)) 
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DIC <- resl$DIC 
print(DIC) 
assign(paste("dic", ww, sep=""), DIC) 
assign(paste("results", ww, sep=""), results) 
assign(paste("galyPValues", ww, sep=""), galyPValues) 
assign(paste("costPValues", ww, sep=""), costPValues) 
assign(paste("galyResid", ww, sep=""), galyResid) 
assign(paste("costResid", ww, sep=""), costResid) 
assign(paste("ceac", ww, sep=), ceac) 
remove(resl) 
remove(qalyl) 
remove(ctBetal) 
remove(qtBetal) 
} 
layout(1) 
plot(0,0, xlim=range(ceRange)/1000, ylim=c(0,1), xlab="Cost-effectiveness Threshold 
(£1000, s)", ylab="Probability EPP 
cost-effective", bty="l", type="n") 
for (ww in 1: nWinSource){ 
lines(ceRange/1000, get(paste("ceac", ww, sep="")), col=ww, lwd=6, lty=ww) 
} 
legend (locator(1), WIN. SOURCES, col= 1: nWinSource, Ity=1) 
layout(cbind((1: nWinSource`2)-1,1: nWinSource*2)) 
for (ww in 1: nWinSource){ 
plot(cost, get(paste("costResid", ww, sep=)), pch=19, ylab="Actual - Predicted 
Cost", xlab="Cost", main=WIN. SOURCES[ww]) 
plot(1: length(get(paste("costPValues", ww, sep=))), sort(get(paste("costPValues", ww, sep="" 
))), xlab=" ", ylab=" ") 
} 
plot(galy, qalyResid, pch=I9, ylab="Actual - Predicted Qalys", xlab="Qalys", main=winSource) 
plot(1: length(galyPValues), sort(galyPValues), main=winSource) 
layout( cbind(c(1,3), c(2,4)) ) 
hist(cost[study==1 &tx==0], xlim=c(0,25000)) 
hist(cost[study== 1 &tx==1 ], xlim=c(0,25000)) 
hist(cost[study==2&tx==O], xlim=c(0,10000)) 
hist(cost[study==2&tx== 1 ], xlim=c(0,10000)) 
hist(qaly[study== 1 &tx==0], xlim=c(0,1)) 
hist(qaly[study==1 &tx==1 ], xlim=c(0,1)) 
hist(galy[study==2&tx==0], xlim=c(0,1)) 
h ist(galy[study==2&tx==1 ], xlim=c(0,1)) 
C. 2 WinBUGS code for IPD meta analysis in Chapter 5 
C. 2.1 Normally distributed costs 
Model{ 
for(ii in 1: nObs){ 
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#MODEL 1: TRIAL BASED ANALYSIS 
cMean[ii] <- cAlpha[study[ii]] + ctBeta*tx[ii] + ceBeta[study[ii]]*EQ-5D[ii] 
cc[ii] <- corrBeta[study[ii], tx[ii]+1] * (galy[ii] - gSampMean[study[ii], tx[ii]+1]) 
IogCMean[ii] <- Iog(cMean[ii])-0.5*cVar[study[ii]] 
cost[ii] - dnorm(cMean[ii], cPrec[study[ii]]) #trial c mean and precision 
galy[ii] - dnorm (gMean[ii], qPrec[study[ii]]) #trial q mean, precision 
gMean[ii] <- qAlpha[study[ii]] + gtBeta*tx[ii] + qeBeta[study[ii]]*EQ-5D[ii] 
residCost[ii] <- cost[ii] - cMean[ii] 
residQaly[ii] <- galy[ii] - qMean[ii] 
#we have a value for each individual, the predictive posterior gives a distribution of predicted 
estimates given all covs etc and we #can see how the actual observed value 
newC[ii] - dnorm(cMean[ii], cPrec[study[ii]]) 
newQ[ii] - dnorm(qMean[ii], qPrec[study[ii]]) 
postPredC[ii] <- cost[ii] - newC[ii] 
postPredQ[ii] <- qaly[ii] - newQ[ii] 
df - dunif(1,10) 
for (ss in 1: nStudies) 
for (tt in 1: nTx) { 
corrBeta[ss, tt] - dunif(-5,5) 
#psi[ss, tt] <- corrBeta[ss, tt]*sgrt(qvar[ss])/sqrt(cvar[ss]) 
ceBeta[ss]- dnorm (0,1. OE-12) 
geBeta[ss]- dnorm (0,1. OE-12) 
cAlpha[ss] - dnorm (0,1. OE-12) 
qAlpha[ss] - dnorm (0,1. OE-12) 
seAlpha[ss] - dnorm (0,1. OE-12) 
gSe[ss] - dunif (0,5) 
qVar[ss] <- pow(qSe[ss], 2) 
qPrec[ss] <-1/gVar[ss] 
IogCostSe[ss] - dunif (-5,10) 
cSe[ss] <- exp(IogCostSe[ss]) 
cVar[ss] <- pow(cSe[ss], 2) 
cPrec[ss]<-1 /cVar[ss] 
sepSe[ss] - dunif (0,10) 
sePrec[ss]<-pow(sepSe[ss], -2) 
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deltaCost <- ctBeta 
deltaQaly <- qtBeta 
ctBeta- dnorm (0,1. OE-12) 
qtBeta- dnorm (0,1. OE-12) 
C. 2.2 Log normal costs 
Model{ 
for(ii in 1: nObs){ 
#MODEL 1: TRIAL BASED ANALYSIS 
cMean[ii] <- cAlpha[study[ii]] + ctBeta*tx[ii] + ceBeta[study[ii]]*EQ-5D[ii] 
cc[ii] <- corrBeta[study[ii], tx[ii]+1] * (qaly[ii] - gSampMean[study[ii], tx[ii]+1]) 
IogCMean[ii] <- Iog(cMean[ii])-0.5*cVar[study[ii]] 
cost[ii] - dlnorm(IogCMean[ii], cPrec[study[ii]]) #trial c mean and precision 
qaly[ii] - dnorm(qMean[ii], qPrec[study[ii]]) #trial q mean, precision 
qMean[ii] <- qAlpha[study[ii]] + gtBeta*tx[ii] + geBeta[study[ii]]*EQ-5D[ii] 
residCost[ii] <- cost[ii] - cMean[ii] 
residQaly[ii] <- qaly[ii] - qMean[ii] 
#we have a value for each individual, the predictive posterior gives a distribution of predicted 
estimates given all covs etc and we #can see how the actual observed value 
newC[ii] - dlnorm(logCMean[ii], cPrec[study[ii]]) 
newQ[ii] - dnorm(gMean[ii], qPrec[study[ii]]) 
postPredC[ii] <- cost[ii] - newC[ii] 
postPredQ[ii] <- qaly[ii] - newQ[ii] 
} 
df - dunif(1,10) 
for (ss in 1: nStudies) { 
for (tt in 1: nTx) { 
corrBeta[ss, tt] - dunif(-5,5) 
# psi[ss, tt] <- corrBeta[ss, tt]*sgrt(qvar[ss])/sgrt(cvar[ss]) 
} 
ceBeta[ss]- dnorm (0,1. OE-12) 
geBeta[ss]- dnorm (0,1. OE-12) 
cAlpha[ss] - dnorm (0,1. OE-12) 
gAlpha[ss] - dnorm (0,1. OE-12) 
seAlpha[ss] - dnorm (0,1. OE-12) 
qSe[ss] - dunif (0,5) 
gVar[ss] <- pow(gSe[ss], 2) 
qPrec[ss] <-1/gVar[ss] 
IogCostSe[ss] - dunif (-5,10) 
cSe[ss] <- exp(IogCostSe[ss]) 
cVar[ss] <- pow(cSe[ss], 2) 
cPrec[ss]<-1 /cVar[ss] 
sepSe[ss] - dunif (0,10) 
sePrec[ss]<-pow(sepSe[ss], -2) 
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deltaCost <- ctBeta 
deltaQaly <- qtBeta 
ctBeta- dnorm (0,1. OE-12) 
qtBeta- dnorm (0,1. OE-12) 
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Appendix D 
Search strategy for populating the models in Chapter 6 
MEDLINE and MEDLINE In Process 
MEDLINE(R) In-Process & Other Non-Indexed Citations and Ovid MEDLINE(R) 
1950 to Present 
Searched via OVID 02/07/07 
1 exp self efficacy/ (4419) 
2 self efficacy. ti, ab. (5014) 
3 or/1-2 (7493) 
4 exp quality-adjusted life year/ (2952) 
5 "quality-adjusted life year$". ti, ab. (2114) 
6 "quality adjusted life year$". ti, ab. (2114) 
7 QALY. ti, ab. (1388) 
8 or/4-7 (4100) 
9 utility. ti, ab. (58358) 
10 3 and 8 (13) 
11 3 and 9 (133) 
12 10 or 11 (144) 
13 limit 12 to english language (142) 
14 limit 13 to yr="1990 - 2007" (138) 
Results file: checrd on rentedfs/CHE/gerry/self efficacy medline 138. txt 
EMBASE 
EMBASE 1980 to 2007 Week 26 
Searched via OVID 02/07/07 
1 self efficacy. ti, ab. (3887) 
2 exp quality-adjusted life year/ (3063) 
3 "quality-adjusted life year$". ti, ab. (1974) 
4 "quality, adjusted life year$". ti, ab. (1974) 
5 QALY. ti, ab. (1293) 
6 or/2-5 (3890) 
7 utility. ti, ab. (53311) 
81 and 6 (2) 
91 and 7 (85) 
10 8 or 9 (87) 
11 limit 10 to (english language and yr="1990 - 2007") (82) 
Results file: checrd on rentedfs/CHE/gerry/self efficacy embase 82. txt 
HMIC 
HMIC Health Management Information Consortium May 2007 
Searched via OVID 02/07/07 
1 self efficacy. ti, ab. (104) 
2 exp quality-adjusted life years/ (153) 
3 "quality-adjusted life year$". ti, ab. (304) 
4 "quality adjusted life year$". ti, ab. (304) 
5 QALY. ti, ab. (215) 
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6 or/2-5 (417) 
7 utility. ti, ab. (747) 
81 and 6 (1) 
91 and7(1) 
10 8 or 9 (2) 
11 limit 10 to yr="1990 - 2007" (2) 
Results file: checrd on rentedfs/CHE/ gerry/self efficacy hmic 2. txt 
Cochrane Central Register of Clinical Trials (CENTRAL) 
Searched via Wiley 02/07/07 
#1 (self efficacy): ti, ab, kw 3462 
#2 (utility): ti, ab, kw 2967 
#3 (QALY): ti, ab, kw 172 
#4 "quality adjusted life year": ti, ab, kw 129 
#5 (#3 OR #4) 240 
#6 (#1 AND #2) 43 
#7 (#1 AND #5) 0 
#8 (#6 OR #7), from 1990 to 2007 39 
Of 39 results in entire Cochrane Library- 37 are from CENTRAL. 
Results file: checrd on rentedfs/CHE/gerry/self efficacy central 37. txt 
Results 
Database Results After dedupe Custom 4 
MEDLINE/ MEDLINE In 
Process 
138 137 Medline and Medline 
In Process 02/07/07 
EMBASE 82 13 EMBASE 02/07/07 
HMIC 2 0 HMIC 02/07/07 
CENTRAL 37 23 CENTRAL 02/07/07 
Total 259 173 
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Appendix E 
E. 1 R code for alternative models used in Chapter 6 
library('R2WinBUGS") 
Iibrary('BRugs") 
setwd('z: /gar2/') 
tData <- read. table(file='QALY5. TXT', header=TRUE) 
#tData <-tData[tData$trial_id==1, ] 
aggStudy <- c(1,2,3,4,5,6,7,8) 
aggSe2 <- c(0.5,0.310,1.41,0.57,0.63,0.44,1.14,0.206) 
aggSeSD <- c(2.4,1.67,2.53,3.45,3.81,4.36,3.11,2.69) 
aggN <- c(489,430,177,148,954,327,286,780) 
aggNobs <- Iength(aggStudy) 
N. SIMS <- 15000 
N. BURNIN <-5000 
WIN. DEBUG <- FALSE 
N. CHAINS <- 2 
genSamps <- function(data, 
n. iter=N. SIMS+N. BURNIN, 
inits, n. burnin=N. BURNIN, 
bugs. file=WI N. SOURCE, 
parameters. to. save, 
winSource=WIN. SOURCE, 
winDebug=WIN. DEBUG){ 
sims <- bugs(data=data, 
parameters. to. save=parameters. to. save, 
model. file=bugs. file, 
n. chains= N. CHAINS, 
debug=winDebug, 
inits=inits, 
miter = niter, 
n. burnin = n. burnin, 
n. thin=1, 
program='openbugs' 
return(sims) 
qaly <- tData$QALY 
cost <- tData$cost 
tx <- tData$tx 
study <- tData$trial_id 
nTx<-Iength(unique(tx)) 
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nObs <-nrow(tData) 
nStudies <- max(study)+1 
age <- tData$age 
age <- age-mean(age, na. rm=TRUE) 
gender<-1 +tData$gender 
EQ-5D<-tData$base_EQ-5D 
EQ-5 D<-EQ-5 D-mean (EQ-5 D) 
sei <- tData$selfeff1 
sei <- se1-mean(se1, na. rm=TRUE) 
se2<-tData$se2 
se2 <- se2-mean(se2, na. rm=TRUE) 
qalyMean <- matrix(NA, nStudies-1, nTx) 
costMean <- matrix(NA, nStudies-1, nTx) 
for (jj in 1: nTx){ 
for (ss in 1: (nStudies-1)){ 
qalyMean[ss, jj] <- mean(galy[tx==jj-1&study==ss], na. rm=TRUE) 
costMean[ss, jj] <- mean(cost[tx==jj-1 &study==ss], na. rm=TRUE) 
qalyMean[is. na(qalyMean)] <- 0 
costMean[is. na(qalyMean)] <- 0 
studyDummy <- study-1 
#maybe sei 
qalyReg <- summary(glm(galy-tx+EQ-5D*studyDummy+studyDummy)) 
costReg <- summary(gIm(cost_tx+EQ-5D*studyDummy+studyDummy)) 
icer <-(costReg$coeff[2,1 ]+250)/galyReg$coeff[2,1 ] 
#analyse effic data 
inits <- function (){Iist(gSe=rep(1, nStudies), logCostSe=rep(1, nStudies), csBeta=O, qsBeta=O, 
Si Alpha=rep(1, nStudies), s2Alpha=rep(1, nStudies), s1 pSe=rep(1, nStudies), s2pSe=rep(1, nSt 
udies), 
ctBeta=1, gtBeta=1, ceBeta=rnorm(nStud ies), geBeta=rnorm(nStud ies), s2tBeta=1, 
cAlpha=rnorm(nStudies, 1 000,20), qAlpha=rnorm(nStudies, 1,0.2))) 
#analyse effic data 
#inits <- function(){Iist(qSe=runif(nStudies, 0,1), IogCostSe=runif(nStudies, -1,1), 
ctBeta=rnorm(1), qtBeta=rnorm(1), cAlpha=rnorm(nStudies), qAlpha=rnorm(nStudies))} 
bugsData <- Iist(cost=cost, galy=galy, nObs=nObs, tx=tx, 
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nTx=nTx, study=study, sel =se1, se2=se2, EQ-5D=EQ- 
5D, gender=gender, nStudies=nStudies, mixed= 0) 
AggBugsData <- Iist(cost=cost, qaly=qaly, nObs=nObs, tx=tx, 
nTx=nTx, sel =sel, se2=se2, EQ-5D=EQ- 
5D, gender=gender, study=study, nStudies=nStudies, 
aggNobs=aggNobs, aggSe2=aggSe2, aggSeSD=aggSeSD, aggN=aggN, mixed=0) 
parameters. to. save <- 
c("deltaCost", "deltaQaly", "ctBeta", "gtBeta", "csBeta", "gsBeta", "s2tBeta", "cSe", "qSe", "cAlpha" 
#parameters. to. save <- c("deltaCost", "deltaQaly") 
#model1 Direct 
WIN. SOURCE <-'GR7NSHM1. txt' 
rest <- genSamps(data=bugsData, inits=inits, parameters. to. save=parameters. to. save) 
#model 2 Indirect 
WIN. SOURCE <-'GR7NSHM2. txt' 
bugsData$mixed<-O 
res2 <- genSamps(data=bugsData, inits=inits, parameters. to. save=parameters. to. save) 
#model 3 Mixed 
WIN. SOURCE <-'GR7NSHM2. txt' 
bugsData$mixed<-1 
res3 <- gen Sam ps(data=bug sData, in its= in its, parameters. to. save= pa rameters. to. save) 
#model 2 Indirect + Agg 
WIN. SOURCE <-'GR7NSHM2Agg. txt' 
AggBugsData$mixed<-O 
res2Agg <- 
genSamps(data=AggBugsData, inits=inits, parameters. to. save=parameters. to. save) 
#model 3 Mixed + Agg 
WIN-SOURCE <-'GR7NSHM2Agg. txt' 
AggBugsData$mixed<-1 
res3Agg <- 
genSamps(data=AggBugsData, inits=inits, parameters. to. save=parameters. to. save) 
#save. image("C: \\work\\phd_stuffl\new. RData") 
save. image("C: \\work\\phd_stuff\\finished models oct 2007\\new. RData") 
ncostl <- res1$sims. matrix[, "deltaCost"] 
ncost2 <- res2$sims. matrix[, "deltaCost"] 
ncost3 <- res3$sims. matrix[, "deltaCost"] 
ncost2agg <- res2Agg$sims. matrix[, "deltaCost"] 
ncost3agg <- res3Agg$sims. matrix[, "deltaCost"] 
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qalyl <- res1$sims. matrix[, "deltaQaly"] 
qaly2 <- res2$sims. matrix[, "deltaQaly"] 
qaly3 <- res3$sims. matrix[, "deltaQaly"] 
qaly2agg <- res2Agg$sims. matrix[, "deltaQaly"] 
qaly3agg <- res3Agg $sims. matrix[, "deltaQaly"] 
ctBetal <- res1$sims. matrix[, "ctBeta"] 
ctBeta2 <- res2$sims. matrix[, "ctBeta"] 
ctBeta3 <- res3$sims. matrix[, "ctBeta"] 
ctBeta2agg <- res2Agg$sims. matrix[, "ctBeta"] 
ctBeta3agg <- res3Agg$sims. matrix[, "ctBeta"] 
qtBetal <- res1$sims. matrix[, "gtBeta"] 
qtBeta2 <- res2$sims. matrix[, "qtBeta"] 
qtBeta3 <- res3$sims. matrix[, "gtBeta"] 
qtBeta2agg <- res2Agg$sims. matrix[, "qtBeta"] 
qtBeta3agg <- res3Agg$sims. matrix[, "gtBeta"] 
csBetal <- res 1 $si ms. matrix[, "cs Beta"] 
csBeta2 <- res2$si ms. matrix[, "cs Beta"] 
csBeta3 <- res3$sims. matrix[, "csBeta"] 
csBeta2agg <- res2Agg$sims. matrix[, "csBeta"] 
csBeta3agg <- res3Agg$sims. matrix[, "csBeta"] 
gsBeta1 <- res1$sims. matrix[, "gsBeta"] 
qsBeta2 <- res2$sims. matrix[, "gsBeta"] 
qsBeta3 <- res3$sims. matrix[, "gsBeta"] 
qsBeta2agg <- res2Agg$sims. matrix[, "gsBeta"] 
qsBeta3agg <- res3Agg$sims. matrix[, "gsBeta"] 
stBeta 1 <- res1$sims. matrix[, "s2tBeta"] 
stBeta2 <- res2$sims. matrix[, "s2tBeta"] 
stBeta3 <- res3$sims. matrix[, "s2tBeta"] 
stBeta2agg <- res2Agg$sims. matrix[, "s2tBeta"] 
stBeta3agg <- res3Agg$sims. matrix[, "s2tBeta"] 
#intCost <- rnorm(N. SIMS, 250,50) 
intCost <- 198 
cost1 <- ncostl+intCost 
cost2 <- ncost2+intCost 
cost3 <- ncost3+intCost 
cost2agg <- ncost2agg+intCost 
cost3agg <- ncost3agg+intCost 
ceRange <- seq(0,100000,100) 
ceac1 <- numeric() 
ceac2 <- numeric() 
ceac3 <- numeric() 
ceac2agg <- numeric() 
ceac3agg <- numeric() 
icer<-numeric() 
evpil <- numeric() 
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evpi2 <- numeric() 
evpi3 <- numeric() 
evpi2agg <- numeric() 
evpi3agg <- numeric() 
for (cc in seq(along=ceRange)){ 
lambda <- ceRange[cc] 
nbl <-qalyl *lambda-costl 
nb2<-galy2*Iambda-cost2 
nb3<-galy3*Iambda-cost3 
nb2agg<-galy2agg*Iambda-cost2agg 
nb3agg<-galy3agg*Iambda-cost3agg 
ceacl[cc] <- mean(nbl>O) 
ceac2[cc] <- mean(nb2>0) 
ceac3[cc] <- mean(nb3>0) 
ceac2agg[cc] <- mean(nb2agg>O) 
ceac3agg[cc] <- mean(nb3agg>O) 
evpil[cc] <- sum(nbl[nbl>O]/N. SIMS)-max(O, sum(nbl/N. SIMS)) 
evpi2[cc] <- sum(nb2[nb2>0]/N. SI MS)-max(O, sum(nb2/N. SI MS)) 
evpi3[cc] <- sum(nb3[nb3>0]/N. SIMS)-max(O, sum(nb3/N. SIMS)) 
evpi2agg[cc] <- sum(nb2agg[nb2agg>O]/N. SIMS)-max(O, sum(nb2agg/N. SIMS)) 
evpi3agg[cc] <- sum(nb3agg[nb3agg>O]/N. SIMS)-max(O, sum(nb3agg/N. SIMS)) 
#nbl [nbl <O]<-0 
#nb2[nb<O]<-O 
#modelVoi[cc, ii] <- mean(nb)-mean(seNb) 
plot(O, O, xlim=range(ceRange)/1000, ylim=c(0,1), xlab="Cost-effectiveness Threshold 
(£1000, s)", ylab='Probability EPP 
cost-effective", bty="I", type="n") 
lines(ceRange/1000, ceacl, col=1, Iwd=6, lty=1) 
Tines(ceRange/1000, ceac2, col=2, Iwd=6, lty=2) 
Tines(ceRange/1000, ceac3, col=3, lwd=6, lty=3) 
legend (locator(1), legend=c("Direct', "Joint"), Ity=c(1,3), bty="n", Iwd=4, col=c(1,3), cex=1.2) 
text(locator(1), "Indirect", cex=1.2) 
par(cex=1.2) 
plot(O, O, xlim=range(ceRange/1000), ylim=c(0,1), xlab="Cost-effectiveness Threshold 
(£I000, s)", ylab="Probability EPP cost-effective", bty="I", type="n") 
Tines(ceRange/1000, ceac2, co1=2, Iwd=6, Ity=1) 
Iines(ceRange/1000, ceac2agg, col=2, Iwd=6, Ity=2) 
Tines(ceRange/1000, ceac3, col=4, Iwd=6, Ity=1) 
Iines(ceRange/1000, ceac3agg, col=4, Iwd=6, Ity=2) 
Tines(ceRange/1000, ceacl, coI=1, Iwd=6, Ity=1) 
text(Iocator(1), "Joint + Add", cex=1.2, pos=2) 
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text(locator(1), "Joint", cex=1.2, pos=4) 
text(locator(1), "Direct", cex=1.2, pos=4) 
text(Iocator(1), "Indirect + Add", cex=1.2, pos=4) 
text(Iocator(1), "I ndirect", cex=1.2, pos=4) 
plot(0,0, xlim=range(ceRange/1000), ylim=c(0,150), xlab="Cost-Effectiveness Threshold 
(El 000, s)", yl a b="EV P I", bty="I", type="n") 
lines(ceRange/1000, evpil , col=1, lwd=6, Ity=1) lines(ceRange/1000, evpi2, col=2, lwd=6, lty=1) 
lines(ceRange/1000, evpi2agg, col=2, iwd=6, lty=3) 
lines(ceRange/1000, evpi3, col=4, lwd=6, lty=1) 
Iines(ceRange/1000, evpi3agg, col=4, Iwd=6, Ity=3) 
# legend(locator(1), legend =c("Direct", "Indirect", "Indirect + Agg", "Joint", "Joint + Agg"), 
# bty="n", Iwd=4, col=c(1,2,2,3,3), Ity=c(1,1,3,1,3), cex=1.2) 
text(Iocator(1), "Joint + Add", cex=1.2, pos=2) 
text(Iocator(1), "Joint", cex=1.2, pos=4) 
text(Iocator(I ), "Direct", cex=1.2, pos=4) 
text(Iocator(1), "Indirect + Add", cex=1.2, pos=2) 
text(Iocator(1), "I ndirect", cex=1.2, pos=4) 
results <- rbind( 
c(mean(cost 1), quantile(costl, c(0.025,0.975)), 
mean(cost2), quantile(cost2, c(0.025,0.975)), 
mean(cost3), quantile(cost3, c(0.025,0.975)), 
mean(cost2agg), quantile(cost2agg, c(0.025,0.975)), 
mean(cost3agg), quantile(cost3agg, c(0.025,0.975))), 
c(mean(galyl ), quantile(galyl , c(0.025,0.975)), 
mean(galy2), quantile(galy2, c(0.025,0.975)), 
mean(galy3), quantile(galy3, c(0.025,0.975)), 
mean(galy2agg), quantile(galy2agg, c(0.025,0.975)), 
mean(galy3agg), quantile(galy3agg, c(0.025,0.975))), 
c(mean(ctBeta 1), quantile(ctBeta 1, c(0.025,0.975)), 
mean(ctBeta2), quantile(ctBeta2, c(0.025,0.975)), 
mean(ctBeta3), quantile(ctBeta3, c(0.025,0.975)), 
mean(ctBeta2agg), quantile(ctBeta2agg, c(0.025,0.975)), 
mean(ctBeta3agg), quantile(ctBeta3agg, c(0.025,0.975))), 
c(mean(gtBeta 1), quantile(gtBeta 1, c(0.025,0.975)), 
mean(gtBeta2), quantile(gtBeta2, c(0.025,0.975)), 
mean(gtBeta3), quantile(gtBeta3, c(0.025,0.975)), 
mean(gtBeta2agg), quantile(gtBeta2agg, c(0.025,0.975)), 
mean (gtBeta3agg), quantile(gtBeta3agg, c(0.025,0.975))), 
c(mean(csBetal ), quantile(csBetal , c(0.025,0.975)), 
mean (csBeta2), quantile(csBeta2, c(0.025,0.975)), 
mean(csBeta3), quantile(csBeta3, c(0.025,0.975)), 
mean(csBeta2agg), quantile(csBeta2agg, c(0.025,0.975)), 
mean (csBeta3agg), quantile(csBeta3agg, c(0.025,0.975))), 
c(mean(gsBetal ), quantile(gsBetal , c(0.025,0.975)), 
mean(gsBeta2), quantile(gsBeta2, c(0.025,0.975)), 
mean(gsBeta3), quantile(gsBeta3, c(0.025,0.975)), 
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mean(gsBeta2agg), quantile(gsBeta2agg, c(0.025,0.975)), 
mean(gsBeta3agg), quantile(gsBeta3agg, c(0.025,0.975))), 
c(mean(stBeta 1), quantile(stBeta 1, c(0.025,0.975)), 
mean(stBeta2), quantile(stBeta2, c(0.025,0.975)), 
mean (stBeta3), quantile(stBeta3, c(0.025,0.975)), 
mean(stBeta2agg), quantile(stBeta2agg, c(0.025,0.975)), 
mean(stBeta3agg), quantile(stBeta3agg, c(0.025,0.975)))) 
results[ 1, ]<-round(resuIts[ 1, ], 0) 
results[2, ]<-round(results[2, ], 3) 
results[3, ]<-round(results[3, ], O) 
results[4, ]<-round(results[4, ], 3) 
results[5, ]<-round(results[5, ], O) 
results[6, ]<-round(results[6, ], 3) 
results <- rbi nd(results, resu Its[ 1, ]/results[2, ]) 
colnames(results) <- 
c("Direct", "2.5%", "97.5%", "Indirect", "2.5%", "97.5%", "Joint", "2.5%", "97.5%", "Indirect+Agg", "2 
. 5%", "97.5%", "Joint+Agg", "2.5%", "97.5%") 
rownames(results) <- c("Cost", "QALY', 'BCT", "BQT", 'BCS", 'BQS", 'BST", "lCER") 
layout(1) 
par(new=FALSE) 
plot(galyl, cost l, ylab="lnc. Cost", xlab="lnc. Qaly", ylim=c(0,400), xlim=c(- 
0.02,0.02), bty="n", main="Direct Analysis") 
par(new=TRUE) 
curve(30000*x, ylim=c(0,400), xlim=c(-0.02,0.02), ylab=" ", xlab=" ", bty="n", Iwd=3, col="grey") 
abline(h=O, Iwd=l) 
abline(v=O, Iwd=1) 
par(new=FALSE) 
plot(galy2, cost2, ylab="Inc. Cost", xlab="lnc. Qaly", ylim=c(0,400), xlim=c(- 
0.02,0.02), bty="n", main="indirect Analysis") 
par(new=TRUE) 
curve(30000"x, ylim=c(0,400), xlim=c(-0.02,0.02), ylab=" ", xlab=" ", bty="n", Iwd=3, col="grey") 
abline(h=O, Iwd=l) 
abline(v=0, lwd=1) 
par(new=FALSE) 
plot(galy3, cost3, ylab="Inc. Cost", xlab="inc. Qaly", ylim=c(0,400), xlim=c(- 
0.02,0.02), bty="n", main="Joint Analysis") 
par(new=TRUE) 
curve(30000''x, ylim=c(0,400), xlim=c(-0.02,0.02), ylab=" ", xlab=" ", bty="n", Iwd=3, col="grey") 
abline(h=O, Iwd=l) 
abline(v=0, lwd=1) 
par(new=FALSE) 
plot(galy3agg, cost3agg, ylab="Inc. Cost", xlab="Inc. Qaly", ylim=c(0,400), xlim=c(- 
0.02,0.02), bty="n", main="Joint Analysis") 
par(new=TRUE) 
curve(30000*x, ylim=c(0,400), xlim=c(-0.02,0.02), ylab=" ", xlab=" ", bty="n", Iwd=3, col="grey") 
abline(h=O, Iwd=l) 
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abline(v=O, Iwd=1) 
E. 2 WinBUGS code for evidence synthesis in Chapter 6 
E. 2.1 Direct Model 
Model{ 
for(ii in 1: nObs){ 
#MODEL 1: TRIAL BASED ANALYSIS 
cMean[ii] <- cAlpha[study[ii]] + ctBeta*tx[ii] + ceBeta[study[ii]]*EQ-5D[ii] + 
corrBeta[study[ii], tx[ii]+1] * galy[ii] 
IogCMean[ii] <- Iog(cMean[ii])-0.5*cVar[study[ii]] 
cost[ii] - dlnorm(IogCMean[ii], cPrec[study[ii]]) #trial c mean and precision 
galy[ii] - dnorm(qMean[ii], qPrec[study[ii]]) #trial q mean, precision 
qMean[ii] <- qAlpha[study[ii]] + qtBeta*tx[ii] + geBeta[study[ii]]*EQ-5D[ii] 
sei [ii]-dnorm(0,0.01) 
se2[ii]-dnorm(0,0.01) 
gender[ii] - dnorm(0,0.01) 
) 
dummyl <- mixed 
csBeta -dunif(0,0) 
qsBeta -dunif(0,0) 
s2tBeta -dunif(1,1) 
for (ss in I: nStudies) 
for (tt in 1: nTx) { 
corrBeta[ss, tt] - dnorm (0,1. OE-3) 
# psi[ss, tt] <- corrBeta[ss, tt]*sgrt(qvar[ss])/sgrt(cvar[ss]) 
ceBeta[ss]- dnorm (0,1. OE-12) 
qeBeta[ss]- dnorm (0,1. OE-12) 
cAlpha[ss] - dnorm (0,1. OE-12) 
gAlpha[ss] - dnorm (0,1. OE-12) 
seAlpha[ss] - dnorm (0,1. OE-12) 
slAlpha[ss]- dnorm (0,1. OE-12) 
s2Alpha[ss]- dnorm (0,1. OE-12) 
s1pSe[ss] - dunif (0,10) 
s2pSe[ss] - dunif (0,10) 
gSe[ss] - dunif (0,5) 
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qVar[ss] <- pow(qSe[ss], 2) 
qPrec[ss] <-1/gVar[ss] 
IogCostSe[ss] - dunif (-5,10) 
cSe[ss] <- exp(IogCostSe[ss]) 
cVar[ss] <- pow(cSe[ss], 2) 
cPrec[ss]<-1/cVar[ss] 
sepSe[ss] - dunif (0,10) 
sePrec[ss]<-pow(sepSe[ss], -2) 
deltaCost <- ctBeta 
deltaQaly <- qtBeta 
ctBeta- dnorm (0,1. OE-12) 
qtBeta- dnorm (0,1. OE-12) 
E. 2.2 Indirect and Joint models 
Model{ 
for(ii in 1: nObs){ 
#MODEL 1: TRIAL BASED ANALYSIS 
cMean[ii] <- cAlpha[study[ii]] + ctBeta*tx[ii] *mixed+ corrBeta[study[ii], tx[ii]+1] * 
galy[ii] + ceBeta[study[ii]]*EQ-5D[ii]+ csBeta*se2[ii] 
logCMean[ii] <- Iog(cMean[ii])-0.5*cVar[study[ii]] 
cost[ii] - dlnorm(IogCMean[ii], cPrec[study[ii]]) #trial c mean and precision 
qaly[ii] - dnorm (gMean[ii], qPrec[study[ii]]) #trial q mean, precision 
qMean[ii] <- qAlpha[study[ii]] + qtBeta*tx[ii] *mixed+ qsBeta*se2[ii] + 
geBeta[study[ii]]*EQ-5D[ii] 
#SELF-EFFICACY IN TERMS OF TREATMENT GROUP 
#SELF-EFFICACY IN TERMS OF TREATMENT GROUP 
sei [ii]-dnorm(slAlpha[study[ii]], s1 Prec[study[ii]]) 
gender[ii] - dnorm(0,0.01) 
se2[ii]-dnorm(s2Mean[ii], s2Prec[study[ii]]) 
s2Mean[ii]<-s2Alpha[study[ii]] +s2tBeta*tx[ii] 
for (aa in I: aggNobs){ 
aggSe2[aa] - dnorm(s2tBeta, aggSeTau[aa]) 
aggSeTau[aa] <- aggN[aa]/pow(aggSeSD[aa], 2) 
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for (ss in 1: nStudies) { 
for (ft in 1: nTx) { 
corrBeta[ss, tt] - dnorm (0,1. OE-3) 
# psi[ss, tt] <- corrBeta[ss, tt]*sgrt(qvar[ss])/sqrt(cvar[ss]) 
} 
geBeta[ss]- dnorm (0,1. OE-12) 
ceBeta[ss]- dnorm (0,1. OE-12) 
slAlpha[ss]-' dnorm (0,1. OE-12) 
s2Alpha[ss]- dnorm (0,1. OE-12) 
cAlpha[ss] - dnorm (0,1. OE-12) 
gA[pha[ss] - dnorm (0,1. OE-12) 
qSe[ss] - dunif (0,5) 
qVar[ss] <- pow(qSe[ss], 2) 
qPrec[ss] <-1/gVar[ss] 
sSe[ss] - dunif (0,5) 
sVar[ss] <- pow(sSe[ss], 2) 
sPrec[ss] <-1 /sVar[ss] 
IogCostSe[ss] - dunif (-5,10) 
cSe[ss] <- exp(logCostSe[ss]) 
cVar[ss] <- pow(cSe[ss], 2) 
cPrec[ss]<-1 /cVar[ss] 
s1 pSe[ss] - dunif (0,10) 
s1 Prec[ss]<-pow(s1 pSe[ss], -2) 
s2pSe[ss] - dunif (0,10) 
s2Prec[ss]<-pow(s2pSe[ss], -2) 
deltaCost <- ctBeta*mixed+csBeta*s2tBeta 
deltaQaly <- qtBeta*mixed+qsBeta*s2tBeta 
ctBeta- dnorm (0,1. OE-12) 
qtBeta- dnorm (0,1. OE-12) 
csBeta- dnorm (0,1. OE-12) 
qsBeta- dnorm (0,1. OE-12) 
s2tBeta- dnorm (0,1. OE-12) 
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Appendix F. Discrete Choice Experiment Questionnaires 
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1I 
10 years 
NATIONAL 
PRIMARY CARE 
RESEARCH AND 
DEVELOPMENT 
CENTRE 
THE UNIVERSITY JO1 
In this questionnaire we ask you to make choices between the pairs of options (Option A and 
Option B) that are presented to you. Each option has four characteristics associated with it. 
These four characteristics are: 
" your health state 
" how confident you are in your ability to manage your condition 
" how long you have to wait for a GP appointment 
" your contact with friends and relatives 
We ask you to consider ALL these characteristics when making your decision. 
IMPORTANT 
For each question please choose the option you would prefer, NOT the option you feel best 
describes your current situation (i. e. please tick either A or B). There are no right and wrong 
answers. 
Please treat each question separately and imagine that these are choices that are actually 
available to you. 
Patient identification number 
Here is an example: 
Imagine that you can have either option A or option B, which would you choose? If you would 
prefer the option where you have moderate pain or discomfort, are not confident that you can 
manage your condition but you can have a GP appointment tomorrow and you see friends or 
relatives daily (i. e. everything in box A), then choose option A. 
However, if you would prefer the option where you have moderate pain or discomfort as well as 
having some problems with walking, but you are totally confident that you can manage your 
condition with a GP appointment in one week's time, but you rarely see friends or relatives (i. e. 
everything in box B), then choose option B. 
A 
You have 
no problems walking about 
no problems with self care 
no problems with usual activities 
moderate pain or discomfort 
no anxiety or depression 
" You are not confident you can 
manage your condition 
" You can have a GP appointment 
tomorrow 
" You see your friends or relatives 
daily 
Please tick one box: 
" You have 
some problems walking about 
no problems with self care 
no problems with usual activities 
moderate pain or discomfort 
no anxiety or depression 
" You are totally confident you can 
manage your condition 
" You can have a GP appointment in 
one week's time 
" You rarely see friends or relatives 
Choice AQ Choice BQ 
Now please turn to the next page to start filling in the questionnaire. 
B 
OR 
00 
ft 
Please choose the option (A or B) that you would prefer. Remember to imagine that these options are actually available to you. 
Question 1: If you had to choose between A and B below, which would you choose? 
ýA 
" You have 
no problems walking about 
no problems with self care 
no problems with usual activities 
moderate pain or discomfort 
no anxiety or depression 
" You are moderately confident you 
can manage your condition 
" You have a GP appointment in 
one week's time 
" You rarely see friends or relatives. 
Please tick one box: 
Choice AQ 
OR 
/B 
" You have 
some problems walking about 
no problems with self care 
no problems with usual activities 
moderate pain or discomfort 
no anxiety or depression 
" You are not confident you can 
manage your condition 
" You have a GP appointment in 
three week's time 
" You see friends or relatives daily 
Choice BQ 
Question 2: If you had to choose between A and B below, which would you choose? 
ýA 
" You have 
no problems walking about 
no problems with self care 
no problems with usual activities 
moderate pain or discomfort 
no anxiety or depression 
" You are not confident you can 
manage your condition 
" You have a GP appointment in 
one week's time 
" You see friends or relatives every 
few days 
Please tick one box: 
Choice AQ 
OR 
00 
" You have 
some problems walking about 
no problems with self care 
no problems with usual activities 
moderate pain or discomfort 
no anxiety or depression 
" You are totally confident you can 
manage your condition 
" You have a GP appointment 
tomorrow 
" You rarely see friends or relatives 
Choice B F-I 
Please choose the option (A or B) that you would prefer. Remember to imagine that these options are actually available to you. 
Question 3: If you had to choose between A and B below, which would you choose? 
ýA 
" You have 
some problems walking about 
no problems with self care 
no problems with usual activities 
moderate pain or discomfort 
no anxiety or depression 
" You are totally confident you can 
manage your condition 
" You have a GP appointment in 
one week's time 
" You see friends or relatives every 
few days 
Please tick one box: 
OR 
4 
" You have 
some problems walking about 
some problems with self care 
no problems with usual activities 
moderate pain or discomfort 
moderate anxiety or depression 
" You are moderately confident you 
can manage your condition 
" You have a GP appointment in 
three week's time 
" You rarely see friends or relatives. 
Choice AQ Choice BQ 
Question 4: If you had to choose between A and B below, which would you choose? 
A 
" You have 
some problems walking about 
no problems with self care 
no problems with usual activities 
moderate pain or discomfort 
no anxiety or depression 
" You are moderately confident you 
can manage your condition 
" You have a GP appointment in 
three week's time 
" You see friends or relatives daily 
Please tick one box: 
Choice AQ 
OR 
00 
" You have 
some problems walking about 
some problems with self care 
no problems with usual activities 
moderate pain or discomfort 
moderate anxiety or depression 
" You are not confident you can 
manage your condition 
" You have a GP appointment 
tomorrow 
" You see friends or relatives every 
few days 
Choice BQ 
Please choose the option (A or B) that you would prefer. Remember to imagine that these options are actually available to you. 
Question 5: If you had to choose between A and B below, which would you choose? 
IA 
" You have 
no problems walking about 
no problems with self care 
no problems with usual activities 
moderate pain or discomfort 
no anxiety or depression 
" You are totally confident you can 
manage your condition 
" You have a GP appointment 
tomorrow 
" You see friends or relatives daily 
Please tick one box: 
Choice AQ 
OR 
B 
" You have 
some problems walking about 
no problems with self care 
no problems with usual activities 
moderate pain or discomfort 
no anxiety or depression 
" You are moderately confident you 
can manage your condition 
" You have a GP appointment in 
one week's time 
" You see friends or relatives every 
few days 
Choice BQ 
Question 6: If you had to choose between A and B below, which would you choose? 
rA 
" You have 
some problems walking about 
no problems with self care 
no problems with usual activities 
moderate pain or discomfort 
no anxiety or depression 
" You are not confident you can 
manage your condition 
" You have a GP appointment 
tomorrow 
" You rarely see friends or relatives 
Please tick one box: 
Choice AQ 
OR 
00 
" You have 
some problems walking about 
some problems with self care 
no problems with usual activities 
moderate pain or discomfort 
moderate anxiety or depression 
" You are totally confident you can 
manage your condition 
" You have a GP appointment in one 
week's time 
" You see friends or relatives daily 
Choice BQ 
Please choose the option (A or B) that you would prefer. Remember to imagine that these options are actually available to you. 
Question 7: If you had to choose between A and B below, which would you choose? 
ýA 
" You have 
some problems walking about 
some problems with self care 
no problems with usual activities 
moderate pain or discomfort 
moderate anxiety or depression 
" You are totally confident you can 
manage your condition 
" You have a GP appointment in 
three week's time 
" You rarely see friends or relatives 
Please tick one box: 
Choice AQ 
/B 
" You have 
no problems walking about 
no problems with self care 
no problems with usual activities 
moderate pain or discomfort 
no anxiety or depression 
" You are moderately confident you 
can manage your condition 
" You have a GP appointment 
tomorrow 
" You see friends or relatives daily 
Choice BQ 
Question 8: If you had to choose between A and B below, which would you choose? 
ýA 
" You have 
some problems walking about 
some problems with self care 
no problems with usual activities 
moderate pain or discomfort 
moderate anxiety or depression 
" You are moderately confident you 
can manage your condition 
" You have a GP appointment 
tomorrow 
" You see friends or relatives every 
few days 
Please tick one box: 
Choice AQ 
OR 
OR 
00 
ft 
" You have 
no problems walking about 
no problems with self care 
no problems with usual activities 
moderate pain or discomfort 
no anxiety or depression 
" You are not confident you can 
manage your condition 
" You have a GP appointment in one 
week's time 
" You rarely see friends or relatives 
Choice BQ 
Please choose the option (A or B) that you would prefer. Remember to imagine that these options are actually available to you. 
Question 9: If you had to choose between A and B below, which would you choose? 
ýA 
" You have 
some problems walking about 
some problems with self care 
no problems with usual activities 
moderate pain or discomfort 
moderate anxiety or depression 
" You are not confident you can 
manage your condition 
" You have a GP appointment in 
one week's time 
" You see friends or relatives daily 
Please tick one box: 
Choice AQ 
OR 
/B 
" You have 
no problems walking about 
no problems with self care 
no problems with usual activities 
moderate pain or discomfort 
no anxiety or depression 
" You are totally confident you can 
manage your condition 
" You have a GP appointment in 
three week's time 
" You see friends or relatives every 
few days 
Choice BQ 
Question 10: If you had to choose between A and B below, which would you choose? 
ýA 
" You have 
some problems walking about 
no problems with self care 
no problems with usual activities 
moderate pain or discomfort 
no anxiety or depression 
" You are totally confident you can 
manage your condition 
" You have a GP appointment in 
one week's time 
" You see friends or relatives every 
few days 
Please tick one box: 
Choice AQ 
OR 
%g 
" You have 
some problems walking about 
some problems with self care 
no problems with usual activities 
moderate pain or discomfort 
moderate anxiety or depression 
" You are moderately confident you 
can manage your condition 
" You have a GP appointment in 
three week's time 
" You rarely see friends or relatives 
Choice B 
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In this questionnaire we ask you to make choices between the pairs of options (Option A and 
Option B) that are presented to you. Each option has four characteristics associated with it. 
These four characteristics are: 
" your health state 
" how confident you are in your ability to manage your condition 
" how long you have to wait for a GP appointment 
" your contact with friends and relatives 
We ask you to consider ALL these characteristics when making your decision. 
For each question please choose the option you would prefer, NOT the option you feel best 
describes your current situation (i. e. please tick either A or B). There are no right and wrong 
Please treat each question separately and imagine that these are choices that are actually 
available to you. 
Patient identification number 
Here is an example: 
Imagine that you can have either option A or option B, which would you choose? If you would 
prefer the option where you have moderate pain or discomfort, are not confident that you can 
manage your condition but you can have a GP appointment tomorrow and you see friends or 
relatives daily (i. e. everything in box A), then choose option A. 
However, if you would prefer the option where you have moderate pain or discomfort as well as 
having some problems with walking, but you are totally confident that you can manage your 
condition with a GP appointment in one week's time, but you rarely see friends or relatives (i. e. 
everything in box B), then choose option B. 
A 
You have 
no problems walking about 
no problems with self care 
no problems with usual activities 
moderate pain or discomfort 
no anxiety or depression 
" You are not confident you can 
manage your condition 
" You can have a GP appointment 
tomorrow 
" You see your friends or relatives 
daily 
Please tick one box: 
Choice AQ 
B 
OR 
" You have 
some problems walking about 
no problems with self care 
no problems with usual activities 
moderate pain or discomfort 
no anxiety or depression 
" You are totally confident you can 
manage your condition 
You can have a GP appointment in 
one week's time 
" You rarely see friends or relatives 
Choice BQ 
Now please turn to the next page to start filling in the questionnaire. 
09 
AM 
Please choose the option (A or B) that you would prefer. Remember to imagine that these options are actually available to you. 
Question 1: If you had to choose between A and B below, which would you choose? 
ýA 
" You have 
no problems walking about 
no problems with self care 
no problems with usual activities 
moderate pain or discomfort 
no anxiety or depression 
" You are totally confident you can 
manage your condition 
" You can have a GP appointment in 
one week's time 
" You rarely see your friends or 
relatives 
Please tick one box: 
Choice A r-I 
OR 
ýB 
" You have 
some problems walking about 
no problems with self care 
no problems with usual activities 
moderate pain or discomfort 
no anxiety or depression 
" You are moderately confident you 
can manage your condition 
" You can have a GP appointment in 
three week's time 
" You see friends or relatives daily 
Choice BQ 
Question 2: If you had to choose between A and B below, which would you choose? 
ýA 
" You have 
no problems walking about 
no problems with self care 
no problems with usual activities 
moderate pain or discomfort 
no anxiety or depression 
" You are totally confident you can 
manage your condition 
" You can have a GP appointment in 
one week's time 
" You see friends or relatives every 
few days 
Please tick one box: 
Choice AQ 
OR 
00 
ft 
/B 
" You have 
some problems walking about 
no problems with self care 
no problems with usual activities 
moderate pain or discomfort 
no anxiety or depression 
" You are moderately confident you 
can manage your condition 
" You can have a GP appointment 
tomorrow 
" You rarely see your friends or 
relatives 
Choice BQ 
Please choose the option (A or B) that you would prefer. Remember to imagine that these options are actually available to you. 
Question 3: If you had to choose between A and B below, which would you choose? 
ýA 
" You have 
no problems walking about 
no problems with self care 
no problems with usual activities 
moderate pain or discomfort 
no anxiety or depression 
" You are moderately confident you 
can manage your condition 
" You can have a GP appointment 
tomorrow 
" You rarely see your friends or 
relatives 
Please tick one box: 
OR 
ýB 
" You have 
some problems walking about 
no problems with self care 
no problems with usual activities 
moderate pain or discomfort 
no anxiety or depression 
" You are not confident you can 
manage your condition 
" You can have a GP appointment in 
one week's time 
" You see friends or relatives daily 
Choice AQ Choice BQ 
Question 4: If you had to choose between A and B below, which would you choose? 
ýA 
" You have 
no problems walking about 
no problems with self care 
no problems with usual activities 
moderate pain or discomfort 
no anxiety or depression 
" You are moderately confident you 
can manage your condition 
" You can have a GP appointment in 
one week's time 
" You see friends or relatives every 
few days 
Please tick one box: 
Choice AQ 
OR 
00 
AM 
ýB 
" You have 
some problems walking about 
no problems with self care 
no problems with usual activities 
moderate pain or discomfort 
no anxiety or depression 
" You are not confident you can 
manage your condition 
" You can have a GP appointment in 
three week's time 
" You rarely see your friends or 
relatives 
Choice BQ 
Please choose the option (A or B) that you would prefer. Remember to imagine that these options are actually available to you. 
Question 5: If you had to choose between A and B below, which would you choose? 
ýA 
" You have 
no problems walking about 
no problems with self care 
no problems with usual activities 
moderate pain or discomfort 
no anxiety or depression 
" You are moderately confident you 
can manage your condition 
" You can have a GP appointment in 
three week's time 
" You see friends or relatives daily 
Please tick one box: 
OR 
Choice AQ Choice BQ 
Question 6: If you had to choose between A and B below, which would you choose? 
ýA 
" You have 
no problems walking about 
no problems with self care 
no problems with usual activities 
moderate pain or discomfort 
no anxiety or depression 
" You are not confident you can 
manage your condition 
" You can have a GP appointment 
tomorrow 
" You see friends or relatives every 
few days 
Please tick one box: 
Choice AQ 
OR 
ýB 
" You have 
some problems walking about 
no problems with self care 
no problems with usual activities 
moderate pain or discomfort 
no anxiety or depression 
" You are not confident you can 
manage your condition 
" You can have a GP appointment 
tomorrow 
" You see friends or relatives every 
few days 
/B 
" You have 
some problems walking about 
no problems with self care 
no problems with usual activities 
moderate pain or discomfort 
no anxiety or depression 
" You are totally confident you can 
manage your condition 
" You can have a GP appointment in 
one week's time 
" You rarely see your friends or 
relatives 
Choice B F-I 
00 
Please choose the option (A or B) that you would prefer. Remember to imagine that these options are actually available to you. 
Question 7: If you had to choose between A and B below, which would you choose? 
ýA 
" You have 
no problems walking about 
no problems with self care 
no problems with usual activities 
moderate pain or discomfort 
no anxiety or depression 
" You are not confident you can 
manage your condition 
" You can have a GP appointment in 
one week's time 
" You see friends or relatives daily 
Please tick one box: 
OR 
Choice AQ Choice BQ 
Question 8: If you had to choose between A and B below, which would you choose? 
ýA 
" You have 
no problems walking about 
no problems with self care 
no problems with usual activities 
moderate pain or discomfort 
no anxiety or depression 
" You are not confident you can 
manage your condition 
" You can have a GP appointment in 
three week's time 
" You rarely see your friends or 
relatives 
Please tick one box: 
Choice AQ 
OR 
/B 
" You have 
some problems walking about 
no problems with self care 
no problems with usual activities 
moderate pain or discomfort 
no anxiety or depression 
" You are totally confident you can 
manage your condition 
" You can have a GP appointment in 
three week's time 
" You see friends or relatives every 
few days 
/B 
" You have 
some problems walking about 
no problems with self care 
no problems with usual activities 
moderate pain or discomfort 
no anxiety or depression 
" You are totally confident you can 
manage your condition 
" You can have a GP appointment 
tomorrow 
" You see friends or relatives daily 
Choice BQ 
00 
Please choose the option (A or B) that you would prefer. Remember to imagine that these options are actually available to you. 
Question 9: If you had to choose between A and B below, which would you choose? 
ýA 
" You have 
some problems walking about 
no problems with self care 
no problems with usual activities 
moderate pain or discomfort 
no anxiety or depression 
" You are totally confident you can 
manage your condition 
" You can have a GP appointment 
tomorrow 
" You see friends or relatives every 
few days 
Please tick one box: 
OR 
4B 
" You have 
some problems walking about 
some problems with self care 
no problems with usual activities 
moderate pain or discomfort 
moderate anxiety or depression 
" You are moderately confident you 
can manage your condition 
" You can have a GP appointment in 
one week's time 
" You rarely see your friends or 
relatives 
Choice AQ Choice BQ 
Question 10: If you had to choose between A and B below, which would you choose? 
ýA 
" You have 
some problems walking about 
no problems with self care 
no problems with usual activities 
moderate pain or discomfort 
no anxiety or depression 
" You are totally confident you can 
manage your condition 
" You can have a GP appointment in 
one week's time 
" You see friends or relatives daily 
Please tick one box: 
Choice AQ 
OR 
00 
ft 
/B 
" You have 
some problems walking about 
some problems with self care 
no problems with usual activities 
moderate pain or discomfort 
moderate anxiety or depression 
" You are moderately confident you 
can manage your condition 
" You can have a GP appointment in 
three week's time 
" You see friends or relatives every 
few days 
Choice BQ 
Please choose the option (A or B) that you would prefer. Remember to imagine that these options are actually available to you. 
Question 11: If you had to choose between A and B below, which would you choose? 
ýA 
" You have 
some problems walking about 
no problems with self care 
no problems with usual activities 
moderate pain or discomfort 
no anxiety or depression 
" You are totally confident you can 
manage your condition 
" You can have a GP appointment in 
three week's time 
" You rarely see your friends or 
relatives 
Please tick one box: 
OR 
/B 
" You have 
some problems walking about 
some problems with self care 
no problems with usual activities 
moderate pain or discomfort 
moderate anxiety or depression 
" You are moderately confident you 
can manage your condition 
" You can have a GP appointment 
tomorrow 
" You see friends or relatives daily 
Choice AQ Choice BQ 
Question 12: If you had to choose between A and B below, which would you choose? 
ýA 
" You have 
no problems walking about 
no problems with self care 
no problems with usual activities 
moderate pain or discomfort 
no anxiety or depression 
" You are totally confident you can 
manage your condition 
" You can have a GP appointment 
tomorrow 
" You see friends or relatives daily 
Please tick one box: 
Choice AQ 
OR 
00 
" You have 
some problems walking about 
no problems with self care 
no problems with usual activities 
moderate pain or discomfort 
no anxiety or depression 
" You are moderately confident you 
can manage your condition 
" You can have a GP appointment in 
one week's time 
" You see friends or relatives every 
few days 
Choice BQ 
Please choose the option (A or B) that you would prefer. Remember to imagine that these options are actually available to you. 
Question 13: If you had to choose between A and B below, which would you choose? 
ýA 
" You have 
some problems walking about 
no problems with self care 
no problems with usual activities 
moderate pain or discomfort 
no anxiety or depression 
" You are moderately confident you 
can manage your condition 
" You can have a GP appointment 
tomorrow 
" You see friends or relatives daily 
Please tick one box: 
OR 
Choice AQ Choice BQ 
Question 14: If you had to choose between A and B below, which would you choose? 
ýA 
" You have 
some problems walking about 
no problems with self care 
no problems with usual activities 
moderate pain or discomfort 
no anxiety or depression 
" You are moderately confident you 
can manage your condition 
" You can have a GP appointment in 
one week's time 
" You rarely see your friends or 
relatives 
Please tick one box: 
Choice AQ 
OR 
ýB 
" You have 
some problems walking about 
some problems with self care 
no problems with usual activities 
moderate pain or discomfort 
moderate anxiety or depression 
" You are not confident you can 
manage your condition 
" You can have a GP appointment in 
one week's time 
" You see friends or relatives every 
few days 
I/-- B 
" You have 
some problems walking about 
some problems with self care 
no problems with usual activities 
moderate pain or discomfort 
moderate anxiety or depression 
" You are not confident you can 
manage your condition 
" You can have a GP appointment in 
three week's time 
" You see friends or relatives daily 
Choice BQ 
00 
AM 
Please choose the option (A or B) that you would prefer. Remember to imagine that these options are actually available to you. 
Question 15: If you had to choose between A and B below, which would you choose? 
ýA 
" You have 
some problems walking about 
no problems with self care 
no problems with usual activities 
moderate pain or discomfort 
no anxiety or depression 
" You are moderately confident you 
can manage your condition 
" You can have a GP appointment in 
three week's time 
" You see friends or relatives every 
few days 
4 
" You have 
some problems walking about 
some problems with self care 
no problems with usual activities 
moderate pain or discomfort 
moderate anxiety or depression 
" You are not confident you can 
manage your condition 
" You can have a GP appointment 
tomorrow 
" You rarely see your friends or 
relatives 
Please tick one box: 
IA 
Choice AQ Choice BQ 
Question 16: If you had to choose between A and B below, which would you choose? 
" You have 
some problems walking about 
no problems with self care 
no problems with usual activities 
moderate pain or discomfort 
no anxiety or depression 
" You are not confident you can 
manage your condition 
" You can have a GP appointment 
tomorrow 
" You rarely see your friends or 
relatives 
Please tick one box: 
Choice AQ 
OR 
OR 
00 
min 
4B 
" You have 
some problems walking about 
some problems with self care 
no problems with usual activities 
moderate pain or discomfort 
moderate anxiety or depression 
" You are totally confident you can 
manage your condition 
" You can have a GP appointment in 
one week's time 
" You see friends or relatives daily 
Choice BQ 
Please choose the option (A or B) that you would prefer. Remember to imagine that these options are actually available to you. 
Question 17: If you had to choose between A and B below, which would you choose? 
ýA 
" You have 
some problems walking about 
no problems with self care 
no problems with usual activities 
moderate pain or discomfort 
no anxiety or depression 
" You are not confident you can 
manage your condition 
" You can have a GP appointment in 
one week's time 
" You see friends or relatives every 
few days 
Please tick one box: 
OR 
Choice AQ Choice BQ 
Question 18: If you had to choose between A and B below, which would you choose? 
(A 
" You have 
some problems walking about 
no problems with self care 
no problems with usual activities 
moderate pain or discomfort 
no anxiety or depression 
" You are not confident you can 
manage your condition 
" You can have a GP appointment 
in three week's time 
" You see friends or relatives daily 
Please tick one box: 
Choice AQ 
OR 
4 
" You have 
some problems walking about 
some problems with self care 
no problems with usual activities 
moderate pain or discomfort 
moderate anxiety or depression 
" You are totally confident you can 
manage your condition 
" You can have a GP appointment in 
three week's time 
" You rarely see your friends or 
relatives 
/B 
" You have 
some problems walking about 
some problems with self care 
no problems with usual activities 
moderate pain or discomfort 
moderate anxiety or depression 
" You are totally confident you can 
manage your condition 
" You can have a GP appointment 
tomorrow 
" You see friends or relatives every 
few days 
Choice BQ 
Äý 
Please choose the option (A or B) that you would prefer. Remember to imagine that these options are actually available to you. 
Question 19: If you had to choose between A and B below, which would you choose? 
ýA 
" You have 
some problems walking about 
some problems with self care 
no problems with usual activities 
moderate pain or discomfort 
moderate anxiety or depression 
" You are totally confident you can 
manage your condition 
" You can have a GP appointment 
tomorrow 
" You rarely see your friends or 
relatives 
Please tick one box: 
OR 
Choice AQ Choice BQ 
Question 20: If you had to choose between A and B below, which would you choose? 
ýA 
" You have 
some problems walking about 
some problems with self care 
no problems with usual activities 
moderate pain or discomfort 
moderate anxiety or depression 
" You are totally confident you can 
manage your condition 
" You can have a GP appointment in 
one week's time 
" You see friends or relatives every 
few days 
Please tick one box: 
Choice AQ 
OR 
ýB 
" You have 
no problems walking about 
no problems with self care 
no problems with usual activities 
moderate pain or discomfort 
no anxiety or depression 
" You are moderately confident you 
can manage your condition 
" You can have a GP appointment in 
one week's time 
" You see friends or relatives daily 
/B 
" You have 
no problems walking about 
no problems with self care 
no problems with usual activities 
moderate pain or discomfort 
no anxiety or depression 
" You are moderately confident you 
can manage your condition 
" You can have a GP appointment in 
three week's time 
" You rarely see your friends or 
relatives 
Choice BQ 
00 
ki IR 
Please choose the option (A or B) that you would prefer. Remember to imagine that these options are actually available to you. 
Question 21: If you had to choose between A and B below, which would you choose? 
ýA 
" You have 
some problems walking about 
some problems with self care 
no problems with usual activities 
moderate pain or discomfort 
moderate anxiety or depression 
" You are totally confident you can 
manage your condition 
" You can have a GP appointment in 
three week's time 
" You see friends or relatives daily 
Please tick one box: 
/B 
" You have 
no problems walking about 
no problems with self care 
no problems with usual activities 
moderate pain or discomfort 
no anxiety or depression 
" You are moderately confident you 
can manage your condition 
" You can have a GP appointment 
tomorrow 
" You see friends or relatives every 
few days 
Choice AQ Choice BQ 
Question 22: If you had to choose between A and B below, which would you choose? 
ýA 
" You have 
some problems walking about 
some problems with self care 
no problems with usual activities 
moderate pain or discomfort 
moderate anxiety or depression 
" You are moderately confident you 
can manage your condition 
" You can have a GP appointment 
tomorrow 
" You see friends or relatives every 
few days 
Please tick one box: 
Choice AQ 
OR 
ýB 
OR 
00 
811IN 
" You have 
no problems walking about 
no problems with self care 
no problems with usual activities 
moderate pain or discomfort 
no anxiety or depression 
" You are not confident you can 
manage your condition 
" You can have a GP appointment in 
one week's time 
" You rarely see your friends or 
relatives 
Choice BQ 
Please choose the option (A or B) that you would prefer. Remember to imagine that these options are actually available to you. 
Question 23: If you had to choose between A and B below, which would you choose? 
1/1, A 
" You have 
some problems walking about 
some problems with self care 
no problems with usual activities 
moderate pain or discomfort 
moderate anxiety or depression 
" You are moderately confident you 
can manage your condition 
" You can have a GP appointment in 
one week's time 
" You see friends or relatives daily 
Please tick one box: 
ýB 
" You have 
no problems walking about 
no problems with self care 
no problems with usual activities 
moderate pain or discomfort 
no anxiety or depression 
" You are not confident you can 
manage your condition 
" You can have a GP appointment in 
three week's time 
" You see friends or relatives every 
few days 
Choice AQ Choice BQ 
Question 24: If you had to choose between A and B below, which would you choose? 
ýA 
" You have 
some problems walking about 
some problems with self care 
no problems with usual activities 
moderate pain or discomfort 
moderate anxiety or depression 
" You are moderately confident you 
can manage your condition 
" You can have a GP appointment in 
three week's time 
" You rarely see your friends or 
relatives 
Please tick one box: 
Choice AQ 
OR 
OR 
00 
MIR 
ýB 
" You have 
no problems walking about 
no problems with self care 
no problems with usual activities 
moderate pain or discomfort 
no anxiety or depression 
" You are not confident you can 
manage your condition 
" You can have a GP appointment 
tomorrow 
" You see friends or relatives daily 
Choice BQ 
Please choose the option (A or B) that you would prefer. Remember to imagine that these options are actually available to you. 
Question 25: If you had to choose between A and B below, which would you choose? 
ýA 
" You have 
some problems walking about 
some problems with self care 
no problems with usual activities 
moderate pain or discomfort 
moderate anxiety or depression 
" You are not confident you can 
manage your condition 
" You can have a GP appointment 
tomorrow 
" You see friends or relatives daily 
Please tick one box: 
OR 
ýB 
" You have 
no problems walking about 
no problems with self care 
no problems with usual activities 
moderate pain or discomfort 
no anxiety or depression 
" You are totally confident you can 
manage your condition 
" You can have a GP appointment in 
one week's time 
" You see friends or relatives every 
few days 
Choice AQ Choice BQ 
Question 26: If you had to choose between A and B below, which would you choose? 
ýA 
" You have 
some problems walking about 
some problems with self care 
no problems with usual activities 
moderate pain or discomfort 
moderate anxiety or depression 
" You are not confident you can 
manage your condition 
" You can have a GP appointment in 
one week's time 
" You rarely see your friends or 
relatives 
Please tick one box: 
Choice AQ 
OR 
00 
#WIR 
/B 
" You have 
no problems walking about 
no problems with self care 
no problems with usual activities 
moderate pain or discomfort 
no anxiety or depression 
" You are totally confident you can 
manage your condition 
" You can have a GP appointment in 
three week's time 
" You see friends or relatives daily 
Choice B F1 
Please choose the option (A or B) that you would prefer. Remember to imagine that these options are actually available to you. 
Question 27: If you had to choose between A and B below, which would you choose? 
(A 
" You have 
some problems walking about 
some problems with self care 
no problems with usual activities 
moderate pain or discomfort 
moderate anxiety or depression 
" You are not confident you can 
manage your condition 
" You can have a GP appointment in 
three week's time 
" You see friends or relatives every 
few days 
Please tick one box: 
OR 
/B 
" You have 
no problems walking about 
no problems with self care 
no problems with usual activities 
moderate pain or discomfort 
no anxiety or depression 
" You are totally confident you can 
manage your condition 
" You can have a GP appointment 
tomorrow 
" You rarely see your friends or 
relatives 
Choice AQ Choice BQ 
Question 28: If you had to choose between A and B below, which would you choose? 
ýA 
" You have 
no problems walking about 
no problems with self care 
no problems with usual activities 
moderate pain or discomfort 
no anxiety or depression 
" You are moderately confident you 
can manage your condition 
" You can have a GP appointment 
tomorrow 
" You rarely see your friends or 
relatives 
Please tick one box: 
OR 
(B 
" You have 
some problems walking about 
no problems with self care 
no problems with usual activities 
moderate pain or discomfort 
no anxiety or depression 
" You are not confident you can 
manage your condition 
" You can have a GP appointment in 
one week's time 
" You see friends or relatives daily 
Choice A F-I Choice BQ 
MANY THANKS FOR TAKING THE TIME TO COMPLETE THIS FORM 
"" 
Illift 
Appendix G. Patient Questionnaires for Expert Patient Programme 
evaluation 
For assistance, call the EPP evaluation team on 0161 275 7601 
Evaluation of the Expert Patient Programme 
National Primary Care Research and Development Centre, University of Manchester, in 
conjunction with the Department of Health and the Expert Patients Programme 
Dear Patient 
You recently agreed to take part in our Evaluation of the Expert Patient Programme 
(EPP). We would be very grateful if you would complete the enclosed questionnaire, and 
return it to us in the prepaid envelope provided (no stamp is required). 
Please answer ALL the questions. 
If you have any problems completing the form, please call a member of the EPP 
evaluation team on 0161 275 7601 and we will be happy to assist. 
The code number below will help us identify your questionnaire - there is no need to write 
your name or address on the form. 
All information you provide will be treated in the strictest confidence 
Many thanks for your help 
Anne Kennedy 
EPP evaluation team leader 
Patient identification number 
For assistance, call the EPP evaluation team on 0161 275 7601 
Please write in today's date below e. g. 1St May 2003 would be 01 05 03 
Day: Month: Year: II 
Your Background 
Are you: 
(please tick one box) 
Male Q 
Female Q 
Your date of birth: 
(please write in the numbers below e. g. 1St May 1960 would be 01 05 60) 
Day: m Month: Year: m 
Who do you live with (if anybody) in your current home? 
(Please tick all boxes that apply) 
Live alone Q 
Spouse / partner Q 
Parent(s) Q 
Children under 18 Q 
Children over 18 Q 
Other family Q 
Non-family Q 
For assistance, call the EPP evaluation team on 0161 275 7601 
Is your accommodation: 
(please tick one box only) 
Owner-occupied / mortgaged? Q 
Rented from local authority /Q 
housing association? 
Rented from a private landlord? Q 
Other arrangements? Q 
(please describe) 
.............................. 
Is there a car or van normally available for use by you? 
Yes Q 
No Q 
If yes, how many are normally available? 
One Q 
Two or more Q 
Which of the following best describes you? 
(Please tick one box only) 
White - British Q 
Asian or Asian British Q 
Black or Black British Q 
Chinese or Chinese British Q 
Mixed ethnicity Q 
Other Q 
For assistance, call the EPP evaluation team on 0161 275 7601 
Which of these best describes your current work situation? 
(Please tick one box only) 
In paid work 
(including self-employed) Q 
Unemployed Q 
Retired from paid work Q 
Unable to work because of Q 
long-term disability or ill health 
Looking after the family or home Q 
In full-time education or training Q 
Other El 
Which of these qualifications do you have? 
(Please tick all boxes that apply) 
1 or more 0 levels / CSE / GCSEs (any grade) Q 
1 or more A levels or AS levels Q 
Degree Q 
NVQ Q 
Other qualification (e. g. City and Guilds) Q 
No qualifications Q 
For assistance, call the EPP evaluation team on 0161 275 7601 
Your long-term health problems 
What would you say is your MAIN problem for which you are seeking help (the one 
that has the biggest effect on your day-to-day health)? 
Diabetes Q 
Arthritis Q 
Heart Disease Q 
Asthma Q 
Other Q 
(Please describe in the box below) 
How long have you had this condition? Years 
m Months m 
What other conditions do you have? 
Diabetes Q 
Arthritis Q 
Heart Disease Q 
Asthma Q 
Other Q 
(Please describe in the box below) 
In which months are your long-term condition(s) at their worst? 
(tick all that apply) 
Much the same all year Q 
January to March Q 
April to June Q 
July to September Q 
October to December Q 
For assistance, call the EPP evaluation team on 0161 275 7601 
Your health and day-to-day activities 
Your health 
In general would you say your health is... 
(please tick one box only): 
Excellent Q 
Very good Q 
Good Q 
Fair Q 
Poor Q 
Your abilities 
Please tick the one response for each question that best describes your usual abilities 
over the past 4 weeks: 
Are you able to.... 
(please tick on box) 
Dress yourself, including tying 
shoelaces and doing buttons? 
Brush/comb your hair? 
Stand up from an armless chair? 
Get in and out of bed? 
Get up from off the floor? 
Cut your food with a knife or fork? 
Lift a full cup or glass to your lips? 
Walk outdoors the length of 
a football field? 
Walk outdoors for the length of 
several football fields? 
Climb up five steps? 
Without With With Unable 
any some much to 
difficulty difficulty difficulty do 
Q Q Q Q 
Q Q Q Q 
Q Q Q Q 
Q Q Q Q 
Q Q Q Q 
Q Q Q Q 
Q Q Q Q 
Q Q Q Q 
Q Q Q Q 
Q Q Q Q 
For assistance, call the EPP evaluation team on 0161 275 7601 
Are you able to.... 
(please tick one box) 
Without With With Unable 
any some much to 
difficulty difficulty difficulty do 
Climb up one flight of stairs? Q Q Q Q 
Wash and dry your entire body? Q Q Q Q 
Get on and off the toilet? Q Q Q Q 
Take a bath? Q Q Q Q 
Reach and get down a bag 
of sugar from just above Q Q Q Q 
your head? 
Bend down (such as to pick up Q Q Q Q 
clothing from the floor)? 
Open jars which have previously Q Q Q Q 
been opened? 
Turn taps on and off? Q Q Q Q 
Run errands and shop? Q Q Q Q 
Do household chores (such as 
vacuuming, gardening, laundry Q Q Q Q 
and DIY)? 
Get to places out of walking distance Q Q Q Q 
(by car or public transport)? 
Carry a bag of groceries 
across a room? Q Q Q Q 
For assistance, call the EPP evaluation team on 0161 275 7601 
Your health and what you do 
During the past 4 weeks, how much... 
(please tick one box): 
Not 
at all 
Has your health interfered 
with your normal social activities Q 
with family, friends, neighbours, 
or groups? 
Slightly Moderately Quite 
a lot 
QQQ 
Almost 
totally 
Has your health interfered 
with your hobbies or Q 
recreational activities? 
Has your health interfered 
with your household chores? Q 
Has your health interfered Q 
with your errands and shopping? 
Pain 
QQQQ 
Q Q Q Q 
Q Q Q Q 
Please circle the one number that best describes your physical discomfort or pain on the 
average over past 4 weeks: 
None 123456789 10 11 12 13 14 15 16 17 18 19 20 As bad as you 
can imagine 
Please circle the one number that best describes your physical discomfort or pain at its 
worst over the past 4 weeks: 
None 123456789 10 11 12 13 14 15 16 17 18 19 20 As bad as you 
can imagine 
For assistance, call the EPP evaluation team on 0161 275 7601 
During the past 4 weeks, how often have you had physical discomfort or pain? 
(If you have had more than one discomfort or pain, answer by describing your feelings of 
discomfort or pain in general). 
(please tick one box only) 
Never Q 
Once or twice Q 
A few times Q 
Fairly often Q 
Very often Q 
Every day or almost every day Q 
How much bodily discomfort or pain have you generally had during the past 4 
weeks? (please tick one box only) 
None Q 
Very mild Q 
Mild Q 
Moderate Q 
Severe Q 
Very severe Q 
When you had physical discomfort or pain during the past 4 weeks, how long did it 
usually last? (If you have ha d more than one discomfort or pain, answer by describing 
your feelings of discomfort or pain in general. 
(please tick one box only) 
Didn't have any Q 
A few minutes Q 
Several minutes to an hour Q 
Several hours Q 
A day or two Q 
More than 2 days Q 
For assistance, call the EPP evaluation team on 0161 275 7601 
Your Energy 
These questions are about how you feel and how things have been with you during the 
past month. 
How much time during the past 4 weeks... 
(please tick one box only) 
None of A little Some of A good Most All 
the time of the time of the time bit of of the time of the time 
the time 
Did you feel Q Q Q Q Q Q 
worn out? 
Did you have Q Q Q Q Q Q 
a lot of energy? 
Did you feel 
tired? Q Q Q Q Q Q 
Did you have 
enough energy QQQQQQ 
to do the things 
you wanted to? 
Did you feel QQQQQQ 
full of pep? 
Your breathing 
During the past 4 weeks, how much have you been troubled by shortness of breath 
when doing your normal daily activities? 
(please tick one box only) 
Not at all Q 
Slightly Q 
Moderately Q 
Quire a bit Q 
Almost totally Q 
For assistance, call the EPP evaluation team on 0161 275 7601 
Your well being 
These questions are about how you feel and how things have been with you during the 
past month. 
How much time during the past 4 weeks... 
(please tick one box only) 
None of A little Some of A good Most All 
the time of the time of the time bit of of the time of the time 
the time 
Have you been QQQQQQ 
a very nervous 
person? 
Have you felt QQQQQQ 
downhearted 
and blue? 
Have you felt 
so down in the QQQQQQ 
dumps that 
nothing can cheer 
you up? 
Have you felt QQQQQQ 
calm and 
peaceful? 
Have you been QQQQQQ 
a happy person? 
For assistance, call the EPP evaluation team on 0161 275 7601 
Your feelings about your health 
These questions are about how you feel and how things have been with you during the 
past month. 
How many times during the past 4 weeks.... 
(please tick one box only) 
None of A little Some of A good Most All 
the time of the time of the time bit of of the time of the time 
the time 
Were you 
discouraged Q QQQQQ 
by your health 
problems? 
Were you fearful 
about your Q QQQQQ 
future health? 
Was your health Q QQQQQ 
a worry in your 
life? 
Were you 
frustrated Q QQQQQ 
by your health 
problems? 
For assistance, call the EPP evaluation team on 0161 275 7601 
Your Exercise 
During the past week (even if it was not a typical week), how much total time (for the 
entire week) did you spend on each of the following? 
(please tick one box only) 
Stretching or strengthening exercises (range of motion, using weights, etc. ) 
None Q 
Less than 30 minutes/week Q 
30-60 minutes/week Q 
1-3 hours/week Q 
More than 3 hours/week Q 
Walk for exercise 
None Q 
Less than 30 minutes/week Q 
30-60 minutes/week Q 
1-3 hours/week Q 
More than 3 hours/week Q 
Swimming or aquatic exercise 
None Q 
Less than 30 minutes/week Q 
30-60 minutes/week Q 
1-3 hours/week Q 
More than 3 hours/week Q 
Bicycling (including stationary exercise bike) 
None Q 
Less than 30 minutes/week Q 
30-60 minutes/week Q 
1-3 hours/week Q 
More than 3 hours/week Q 
For assistance, call the EPP evaluation team on 0161 275 7601 
Other aerobic exercise equipment (Stairmaster, rowing or skiing machine) 
None Q 
Less than 30 minutes/week Q 
30-60 minutes/week Q 
1-3 hours/week Q 
More than 3 hours/week Q 
Other aerobic exercise - specify: 
None Q 
Less than 30 minutes/week Q 
30-60 minutes/week Q 
1-3 hours/week Q 
More than 3 hours/week Q 
Your smoking 
Are you a current smoker? 
Yes Q 
No Q 
If yes, how many cigarettes do you smoke on a typical day? 
cigarettes per day 
For assistance, call the EPP evaluation team on 0161 275 7601 
Your Health Today 
By placing a tick in one box in each group below, please indicate which statement best 
describes your own health state today. 
(Do not tick more than one box in each group) 
Mobility 
I have no problems in walking about Q 
I have some problems in walking about Q 
I am confined to bed Q 
Self-Care 
I have no problems with self-care Q 
I have some problems washing or dressing myself Q 
I am unable to wash or dress myself Q 
Usual Activities 
I have no problems with performing my usual activities Q 
(e. g. work, study, housework, family or leisure activities) 
I have some problems with performing my usual activities Q 
I am unable to perform my usual activities Q 
Pain/Discomfort 
I have no pain or discomfort Q 
have moderate pain or discomfort I Q 
have extreme pain or discomfort I Q 
Anxiety/Depression 
I am not anxious or depressed Q 
I am moderately anxious or depressed Q 
I am extremely anxious or depressed Q 
Compared with my general level of health over the past 12 months, my health state 
today is: 
Better Q 
Much the same Q 
Worse Q 
For assistance, call the EPP evaluation team on 0161 275 7601 
" Please indicate on this scale how good or 
bad your own health is today. 
" The best health state you can imagine is 
marked 100 and the worst health state you 
can imagine is marked 0. 
" Please draw a line from the box below to 
the point on the scale that indicates how 
good or bad your health state is today. 
Your own 
health 
state 
today 
Best imaginable 
health state 
100 
9 7.0 
8: 0 
7.0 
6! 0 
510 
4.0 
3ý0 
200 
1.0 
0 
Worst imaginable 
health state 
14 
For assistance, call the EPP evaluation team on 0161 275 7601 
Your confidence in doing activities 
We would like to know how confident you are in doing certain activities. 
For each of the following questions, please circle the number that corresponds to 
your confidence that you can do the tasks regularly at the present time. 
How confident are you that you can..... 
Having an illness often means doing different tasks and activities to manage your 
condition. How confident are you that you can do all the things necessary to 
manage your condition on a regular basis? 
Not at all 123456789 10 Totally 
confident confident 
Judge when the changes in your illness mean you should visit a doctor? 
Not at all 123456789 10 Totally 
confident confident 
Do the different tasks and activities needed to manage your health condition so 
as to reduce your need to see a doctor? 
Not at all 123456789 10 Totally 
confident confident 
Reduce the emotional distress caused by your health condition so that it does not 
affect your everyday life? 
Not at all 123456789 10 Totally 
confident confident 
Do things other than just taking medication to reduce how much your illness 
affects your everyday life? 
Not at all 123456789 10 Totally 
confident confident 
15 
For assistance, call the EPP evaluation team on 0161 275 7601 
How confident are you that you can..... 
Reduce your physical discomfort or pain? 
Not at all 123456789 10 Totally 
confident confident 
Keep the fatigue caused by your disease from interfering with the things you want 
to do? 
Not at all 123456789 10 Totally 
confident confident 
Keep the physical discomfort or pain of your disease from interfering with the 
things you want to do? 
Not at all 123456789 10 Totally 
confident confident 
Keep any other symptoms or health problems you have from interfering with the 
things you want to do? 
Not at all 123456789 10 Totally 
confident confident 
Control any symptoms or health problems you have so that they don't interfere 
with the things you want to do? 
Not at all 123456789 10 Totally 
confident confident 
16 
For assistance, call the EPP evaluation team on 0161 275 7601 
How confident are you that you can..... 
Do gentle exercises for muscle strength and flexibility three to four times per 
week (range of motion, using weights, etc)? 
Not at all 123456789 10 Totally 
confident confident 
Do an aerobic exercise such as walking, swimming, or bicycling three to four 
times each week? 
Not at all 123456789 10 Totally 
confident confident 
Exercise without making your symptoms worse? 
Not at all 123456789 10 Totally 
confident confident 
17 
For assistance, call the EPP evaluation team on 0161 275 7601 
How confident are you that you can..... 
Keep from getting discouraged when nothing you do seems to make any 
difference? 
Not at all 123456789 10 Totally 
confident confident 
Keep from feeling sad or down in the dumps? 
Not at all 123456789 10 Totally 
confident confident 
Keep yourself from feeling lonely 
Not at all 123456789 10 Totally 
confident confident 
Do something to make yourself feel better when you are feeling lonely? 
Not at all 123456789 10 Totally 
confident confident 
Do something to make yourself feel better when you are feeling discouraged? 
Not at all 123456789 10 Totally 
confident confident 
Do something to make yourself feel better when you feel sad or down in the 
dumps? 
Not at all 123456789 10 Totally 
confident confident 
18 
For assistance, call the EPP evaluation team on 0161 275 7601 
Your quality of life 
This part of the questionnaire is designed to help us get a full picture of the quality of 
your life. We want you to tell us how satisfied or dissatisfied you are with a number 
of areas of your life. 
Life in General 
How do you feel about your life as a whole, today? 
(Please tick one box only) 
Terrible Q 
Displeased Q 
Mostly dissatisfied Q 
Mixed Q 
Mostly satisfied Q 
Pleased Q 
Delighted Q 
Your Life Opportunities 
In the past year, have there been times when you wanted to improve any of the 
following aspects of your life but were unable to? 
(Please tick all boxes that apply) 
Work or education Q Living situation Q 
Finances Q Family life Q 
Leisure Q Safety Q 
Social life Q Health Q 
Your work and education 
If working: How do you feel about your job? 
(Please tick one box only) 
Terrible Q 
Displeased Q 
Mostly dissatisfied Q 
Mixed Q 
Mostly satisfied Q 
Pleased Q 
Delighted Q 
19 
For assistance, call the EPP evaluation team on 0161 275 7601 
If not working: How do you feel about not working? 
(Please tick one box only) 
Terrible Q 
Displeased Q 
Mostly dissatisfied Q 
Mixed Q 
Mostly satisfied Q 
Pleased Q 
Delighted Q 
Your finances 
How frequently (if at all) do you find it difficult to meet the cost of household 
bills? 
(Please tick one box only ) 
All of the time Q 
Most of the time Q 
Some of the time Q 
Seldom Q 
Never Q 
How do you feel about your financial situation? 
(Please tick one box only) 
Terrible Q 
Displeased Q 
Mostly dissatisfied Q 
Mixed Q 
Mostly satisfied Q 
Pleased Q 
Delighted Q 
Your leisure 
How do you feel about your leisure activities? 
(Please tick one box only) 
Terrible Q 
Displeased Q 
Mostly dissatisfied Q 
Mixed Q 
Mostly satisfied Q 
Pleased Q 
Delighted Q 
20 
For assistance, call the EPP evaluation team on 0161 275 7601 
Your social life 
How do you feel about the number of friends you have? 
(Please tick one box only) 
Terrible Q 
Displeased Q 
Mostly dissatisfied Q 
Mixed Q 
Mostly satisfied Q 
Pleased Q 
Delighted Q 
How do you feel about the quality of your friendship(s)? 
(Please tick one box only) 
Terrible Q 
Displeased Q 
Mostly dissatisfied Q 
Mixed Q 
Mostly satisfied Q 
Pleased Q 
Delighted Q 
Your living situation 
How do you feel about your accommodation? 
(Please mark one box only) 
Terrible Q 
Displeased Q 
Mostly dissatisfied Q 
Mixed Q 
Mostly satisfied Q 
Pleased Q 
Delighted Q 
21 
For assistance, call the EPP evaluation team on 0161 275 7601 
If living with other people: How do you feel about the people that you live with? 
(Please mark one box only) 
Terrible Q 
Displeased Q 
Mostly dissatisfied Q 
Mixed Q 
Mostly satisfied Q 
Pleased Q 
Delighted Q 
If living alone: How do you feel about living alone? 
(Please mark one box only) 
Terrible Q 
Displeased Q 
Mostly dissatisfied Q 
Mixed Q 
Mostly satisfied Q 
Pleased Q 
Delighted Q 
Your family 
How often do you have contact with a relative (not including those who live with 
you) either face to face or by telephone? 
(Please tick one box only) 
Not at all Q 
Daily Q 
At least weekly Q 
At least monthly Q 
At least 3 monthly Q 
At least yearly Q 
Less than yearly Q 
How do you feel about your relationship with your family? 
(Please tick one box only) 
Terrible Q 
Displeased Q 
Mostly dissatisfied Q 
Mixed Q 
Mostly satisfied Q 
Pleased Q 
Delighted Q 
22 
For assistance, call the EPP evaluation team on 0161 275 7601 
Your safety 
In the past year, have you been a victim of violence? 
Yes Q 
No Q 
How do you feel about your personal safety? 
(Please tick one box only) 
Terrible Q 
Displeased Q 
Mostly dissatisfied Q 
Mixed Q 
Mostly satisfied Q 
Pleased Q 
Delighted Q 
Your health 
How do you feel about your health? 
(Please tick one box only) 
Terrible Q 
Displeased Q 
Mostly dissatisfied Q 
Mixed Q 
Mostly satisfied Q 
Pleased Q 
Delighted Q 
How do you feel about your present mental health (nerves)? 
(Please mark one box only) 
Terrible Q 
Displeased Q 
Mostly dissatisfied Q 
Mixed Q 
Mostly satisfied Q 
Pleased Q 
Delighted Q 
23 
For assistance, call the EPP evaluation team on 0161 275 7601 
Life overall 
How do you feel about your life as a whole? 
(Please tick one box only) 
Terrible Q 
Displeased Q 
Mostly dissatisfied Q 
Mixed Q 
Mostly satisfied Q 
Pleased Q 
Delighted Q 
24 
For assistance, can the EPP evaluation team on 0161 275 7601 
Your clubs and associations 
Are you actively involved in any of the following clubs or associations? 
(please tick all boxes that apply) 
Sports club Q 
Neighbourhood watch scheme Q 
Sports supporter club 
Tenants' group 
Social club 
Residents' association 
Volunteers e. g. 
St Johns Ambulance 
La 
ca 
La 
u 
1: ) 
Local council Q 
Hobby or interest group Q 
Church or religious group Q 
Political party Q 
Other Q 
(give details) 
25 
For assistance, call the EPP evaluation team on 0161 275 7601 
Your visits to the doctor 
Thinking about the last visit you made to your doctor (GP or hospital doctor), do you 
agree or disagree with the following statements? 
(please tick one box only) 
Strongly Agree No opinion Disagree Strongly 
Agree Disagree 
I suggested a certain 
kind of treatment to Q Q Q Q Q 
my doctor 
I insisted on a 
particular kind of Q Q Q Q Q 
test or treatment 
for my symptoms 
I expressed doubt 
about the tests or Q Q Q Q Q 
treatment that my 
doctor recommended 
I gave my opinion on 
the pros and cons of Q Q Q Q Q 
the types of tests and 
treatment that my 
doctor ordered 
26 
For assistance, call the EPP evaluation team on 0161 275 7601 
Your self-care activities 
In which, if any, of the following ways do you currently help yourself to manage your 
condition, and how much do you do so? 
(please tick one box only) 
Not at all A fair amount A great deal 
Diet Q Q Q 
Alternative/ 
complementary Q Q Q 
products 
Complementary Q Q Q 
therapy 
Exercise Q Q Q 
Relaxation Q Q Q 
Looking for Q Q Q 
information 
27 
For assistance, call the EPP evaluation team on 0161 275 7601 
Do you belong to any patient support groups? 
Yes Q 
No Q 
If YES, which ones? 
28 
For assistance, call the EPP evaluation team on 0161 275 7601 
Your use of hospital services 
Have you had any overnight stays in hospital during the last 6 months? 
Yes Q 
No Q 
Have you attended a day hospital during the last 6 months? 
Yes Q 
No Q 
Have you had any outpatient appointments during the last 6 months? 
Yes Q 
No Q 
Have you attended an Accident & Emergency department during the last 6 
months? 
Yes Q 
No Q 
Have you attended hospital for day case surgery during the last 6 months? 
Yes Q 
No Q 
29 
For assistance, call the EPP evaluation team on 0161 275 7601 
Your use of services outside the hospital 
Please estimate the total number of contacts for each of the service below, during 
the last 6 months (please enter '0' if a particular service was not used): 
General Practitioner (at the surgery) m 
General Practitioner (at your home) m 
Practice Nurse (at GP surgery) m 
Occupational Therapist (at home) m 
District Nurse (at home) m 
Meals on Wheels 
m 
Physiotherapist (at home) m 
Other (please specify) m 
Other (please specify) 
m 
30 
For assistance, call the EPP evaluation team on 0161 275 7601 
Your help from carers 
Have you used any help (e. g. tasks around the home, shopping) from a carer (e. g. 
relative, friend) in last 6 months? 
Yes Q 
No Q 
If YES, please estimate how many hours of care you have received over the last 6 
months 
hours 
31 
For assistance, call the EPP evaluation team on 0161 275 7601 
Your use of day services 
Have you used any day facilities (e. g. day centre, drop in centre, social club) 
during the last 6 months? Please include any private or voluntary services. 
Yes Q 
No Q 
If YES, please state 
" the type of service 
" who provides the service 
" the approximate number of times you attended 
" how long you spent there each time you attended 
TYPE OF 
SERVICE 
(e. g. day centre) 
SERVICE-PROVIDING 
AGENCY (e. g. Health 
Authority, Social 
Services, Voluntary) 
HOW MANY 
TIMES DID YOU 
ATTEND? 
HOW LONG 
YOU WERE 
THERE EACH 
TIME ? 
Drop & VI, c da - VO-it VIZa. vy 
ovi clvv 
3 60 aitiu, ti' 
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For assistance, call the EPP evaluation team on 0161 275 7601 
Your use of medication 
Have you taken any prescribed any medication over the last 6 months? 
Yes Q 
No Q 
If YES, please list the relevant medications administered during this period. 
Name of 
medication 
How 
many 
tablets do 
you take? 
How often do 
you take the 
tablets? 
What is 
the 
dose? 
How long have 
you been 
taking the 
tablets? 
t? ºopcý vtcýýc>i 2 TwLce ci, 51 ty 6 11 LOJI vt 
lýýtýct ei't 1 Whe11 5olliq VOCC, k. 
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For assistance, call the EPP evaluation team on 0161 275 7601 
Other costs you might have to pay 
Have you had to pay for any prescription medication or over the counter drugs during 
the last 6 months? 
Yes Q 
No Q 
If YES, approximately how much have you had to pay during the last 6 months? 
Em Have you had to make any other payments as a result of your illness: e. g. improvements 
to your home? 
Yes Q 
No Q 
If YES, approximately how much have you had to pay during the last 6 months? 
Em 
34 
For assistance, call the EPP evaluation team on 0161 275 7601 
Your work and your health 
Are you in current employment? 
Yes Q 
No Q 
If YES, please answer the following questions 
If NO, please turn the page 
How many hours do you work on average per week? 
m 
hours 
Have you had to take any days off from work over the last 6 months as a result of your 
illness? 
Yes Q 
No Q 
If YES, please estimate the number of days of work you have missed as a result of your 
illness during this period 
days 
Have you lost any earnings over the last 6 months as a result of your illness? 
Yes Q 
No Q 
If YES, please estimate the percentage of your normal earnings you have lost 
during this period 
I 
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For assistance, call the EPP evaluation team on 0161 275 7601 
If you are not currently in paid employment, have you been employed for any period 
during the last 6 months? 
Yes Q 
No Q 
If YES, please describe any previous employment in this period and the duration of 
employment during the period (e. g. 1 month, 2 weeks etc. )? 
Please describe your first job 
Duration of employment (months or weeks) 
Please describe your second job if applicable 
Duration of employment (months or weeks) 
Have you given up any leisure time in the last 6 months as a result of your illness? 
Yes Q 
No Q 
If YES, please estimate the number of hours lost during this period 
hours 
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For assistance, call the EPP evaluation team on 0161 275 7601 
Your views about which group you would prefer to be in 
When you return this questionnaire, we will randomise you to either go on an EPP course 
immediately or to wait for six months before going on a course. 
We would like to know whether you have strong views about which group you would like 
to be in 
Please circle the number on the scale below which best shows the group you would prefer 
to be in. If you don't mind when you start or are unsure please circle 5. 
Start 0123456789 10 Wait 6 
the months 
course to start 
now course 
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For assistance, call the EPP evaluation team on 0161 275 7601 
If you have any comments on the survey or any other aspects of the research, please 
write them here 
If you have any problems completing the form, please call a member of the EPP 
evaluation team on 0161 275 7601 and we will be happy to assist. 
MANY THANKS FOR YOUR HELP WITH THIS RESEARCH 
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